token,sentence_no,start,tag
After,549,0,O
at,549,6,O
least,549,9,O
one,549,15,O
week,549,19,O
following,549,24,O
the,549,34,O
initiation,549,38,O
of,549,49,O
ritonavir,549,52,O
",",549,62,O
resume,549,64,O
ADCIRCA,549,71,O
at,549,79,O
20,549,82,O
mg,549,85,O
once,549,88,O
daily,549,93,O
.,549,99,O
Avoid,550,0,O
use,550,6,O
of,550,10,O
ADCIRCA,550,13,O
during,550,21,O
the,550,28,O
initiation,550,32,O
of,550,43,O
ritonavir,550,46,O
.,550,56,O
Co-administration,551,0,O
of,551,18,O
ADCIRCA,551,21,O
in,551,29,O
Patients,551,32,O
on,551,41,O
Ritonavir,551,44,O
.,551,54,O
Co-administration,552,0,O
of,552,18,O
Ritonavir,552,21,O
in,552,31,O
Patients,552,34,O
on,552,43,O
ADCIRCA,552,46,O
.,552,54,O
In,553,0,O
patients,553,3,O
receiving,553,12,O
ritonavir,553,22,O
for,553,32,O
at,553,36,O
least,553,39,O
one,553,45,O
week,553,49,O
",",553,54,O
start,553,56,O
ADCIRCA,553,62,O
at,553,70,O
20,553,73,O
mg,553,76,O
once,553,79,O
daily,553,84,O
.,553,90,O
Stop,554,0,O
ADCIRCA,554,5,O
at,554,13,O
least,554,16,O
24,554,22,O
hours,554,25,O
prior,554,31,O
to,554,37,O
starting,554,40,O
ritonavir,554,49,O
.,554,59,O
ADCIRCA,555,0,O
is,555,8,O
contraindicated,555,11,O
in,555,27,O
patients,555,30,O
with,555,39,O
a,555,44,O
known,555,46,O
serious,555,52,O
hypersensitivity,555,60,O
to,555,77,O
tadalafil,555,80,O
(,555,90,O
ADCIRCA,555,92,O
or,555,100,O
CIALIS,555,103,O
),555,110,O
.,555,112,O
Do,556,0,O
not,556,3,O
use,556,7,O
ADCIRCA,556,11,O
in,556,19,O
patients,556,22,O
who,556,31,O
are,556,35,O
using,556,39,O
a,556,45,O
GC,556,47,O
stimulator,556,50,O
",",556,61,O
such,556,63,O
as,556,68,O
riociguat,556,71,O
.,556,81,O
Do,556,0,O
not,556,3,O
use,556,7,O
ADCIRCA,556,11,O
in,556,19,O
patients,556,22,O
who,556,31,O
are,556,35,O
using,556,39,O
a,556,45,O
GC,556,47,O
stimulator,556,50,O
",",556,61,O
such,556,63,O
as,556,68,O
riociguat,556,71,O
.,556,81,O
History,557,0,O
of,557,8,O
known,557,11,O
serious,557,17,O
hypersensitivity,557,25,O
reaction,557,42,O
to,557,51,O
ADCIRCA,557,54,O
or,557,62,O
CIALIS,557,65,O
(,557,72,O
4.3,557,74,O
),557,78,O
.,557,80,O
[,558,0,O
See,558,1,O
Warnings,558,5,O
and,558,14,O
Precautions,558,18,O
(,558,30,O
5.1,558,31,O
),558,34,O
and,558,36,O
Clinical,558,40,O
Pharmacology,558,49,O
(,558,62,O
12.2,558,63,O
),558,67,O
],558,68,O
.,558,69,O
Alcohol,559,0,O
Both,559,8,O
alcohol,559,13,O
and,559,21,O
tadalafil,559,25,O
",",559,34,O
a,559,36,O
PDE5,559,38,O
inhibitor,559,43,O
",",559,52,O
act,559,54,O
as,559,58,O
mild,559,61,O
vasodilators,559,66,O
.,559,78,O
Alpha-Blockers,560,0,O
PDE5,560,15,O
inhibitors,560,20,O
",",560,30,O
including,560,32,O
ADCIRCA,560,42,O
",",560,49,O
and,560,51,O
alphaadrenergic,560,55,O
blocking,560,71,O
agents,560,80,O
are,560,87,O
both,560,91,O
vasodilators,560,96,O
with,560,109,O
blood-pressure-lowering,560,114,B-SpecificInteraction
effects,560,138,O
.,560,145,O
Alpha-Blockers,560,0,O
PDE5,560,15,O
inhibitors,560,20,O
",",560,30,O
including,560,32,O
ADCIRCA,560,42,O
",",560,49,O
and,560,51,O
alphaadrenergic,560,55,O
blocking,560,71,O
agents,560,80,O
are,560,87,O
both,560,91,O
vasodilators,560,96,O
with,560,109,O
blood-pressure-lowering,560,114,B-SpecificInteraction
effects,560,138,O
.,560,145,O
Alpha-Blockers,560,0,O
PDE5,560,15,O
inhibitors,560,20,O
",",560,30,O
including,560,32,O
ADCIRCA,560,42,O
",",560,49,O
and,560,51,O
alphaadrenergic,560,55,O
blocking,560,71,O
agents,560,80,O
are,560,87,O
both,560,91,O
vasodilators,560,96,O
with,560,109,O
blood-pressure-lowering,560,114,B-SpecificInteraction
effects,560,138,O
.,560,145,O
Antihypertensives,561,0,O
PDE5inhibitors,561,18,O
",",561,32,O
including,561,34,O
ADCIRCA,561,44,O
",",561,51,O
are,561,53,O
mild,561,57,O
systemic,561,62,O
vasodilators,561,71,O
.,561,83,O
Aspirin,562,0,O
Tadalafil,562,8,O
(,562,18,O
10,562,19,O
mg,562,22,O
and,562,25,O
20,562,29,O
mg,562,32,O
once,562,35,O
daily,562,40,O
),562,45,O
does,562,47,O
not,562,52,O
potentiate,562,56,O
the,562,67,O
increase,562,71,O
in,562,80,O
bleeding,562,83,O
time,562,92,O
caused,562,97,O
by,562,104,O
aspirin,562,107,O
[,562,115,O
see,562,116,O
Clinical,562,120,O
Pharmacology,562,129,O
(,562,142,O
12.3,562,143,O
),562,147,O
],562,148,O
.,562,149,O
At,563,0,O
steady,563,3,O
state,563,10,O
of,563,16,O
ritonavir,563,19,O
(,563,29,O
about,563,31,O
1,563,37,O
week,563,39,O
),563,44,O
",",563,46,O
the,563,48,O
exposure,563,52,O
to,563,61,O
tadalafil,563,64,O
is,563,74,O
similar,563,77,O
as,563,85,O
in,563,88,O
the,563,91,O
absence,563,95,O
of,563,103,O
ritonavir,563,106,O
see,563,116,O
Dosage,563,120,O
and,563,127,O
Administration,563,131,O
(,563,146,O
2.3,563,148,O
),563,152,O
",",563,154,O
Warnings,563,156,O
and,563,165,O
Precautions,563,169,O
(,563,181,O
5.2,563,183,O
),563,187,O
",",563,189,O
and,563,191,O
Clinical,563,195,O
Pharmacology,563,204,O
(,563,217,O
12.3,563,219,O
),563,224,O
.,563,226,O
At,564,0,O
steady,564,3,O
state,564,10,O
of,564,16,O
ritonavir,564,19,O
(,564,29,O
about,564,30,O
1,564,36,O
week,564,38,O
),564,42,O
",",564,43,O
the,564,45,O
exposure,564,49,O
to,564,58,O
tadalafil,564,61,O
is,564,71,O
similar,564,74,O
as,564,82,O
in,564,85,O
the,564,88,O
absence,564,92,O
of,564,100,O
ritonavir,564,103,O
[,564,113,O
see,564,114,O
Dosage,564,118,O
and,564,125,O
Administration,564,129,O
(,564,144,O
2.3,564,145,O
),564,148,O
",",564,149,O
Warnings,564,151,O
and,564,160,O
Precautions,564,164,O
(,564,176,O
5.2,564,177,O
),564,180,O
",",564,181,O
and,564,183,O
Clinical,564,187,O
Pharmacology,564,196,O
(,564,209,O
12.3,564,210,O
),564,214,O
],564,215,O
.,564,216,O
Both,565,0,O
alcohol,565,5,O
and,565,13,O
tadalafil,565,17,O
",",565,27,O
a,565,29,O
PDE5,565,31,O
inhibitor,565,36,O
",",565,46,O
act,565,48,O
as,565,52,O
mild,565,55,O
vasodilators,565,60,O
.,565,73,O
Clinical,566,0,O
pharmacology,566,9,O
studies,566,22,O
have,566,30,O
been,566,35,O
conducted,566,40,O
with,566,50,O
coadministration,566,55,O
of,566,72,O
tadalafil,566,75,O
with,566,85,O
doxazosin,566,90,O
",",566,100,O
alfuzosin,566,102,O
or,566,112,O
tamsulosin,566,115,O
see,566,126,O
Warnings,566,130,O
and,566,139,O
Precautions,566,143,O
(,566,155,O
5.1,566,157,O
),566,161,O
and,566,163,O
Clinical,566,167,O
Pharmacology,566,176,O
(,566,189,O
12.2,566,191,O
),566,196,O
.,566,198,O
Clinical,567,0,O
pharmacology,567,9,O
studies,567,22,O
were,567,30,O
conducted,567,35,O
to,567,45,O
assess,567,48,O
the,567,55,O
effect,567,59,O
of,567,66,O
tadalafil,567,69,O
on,567,79,O
the,567,82,O
potentiation,567,86,O
of,567,99,O
the,567,102,O
blood,567,106,O
pressure,567,112,O
lowering,567,121,O
effects,567,130,O
of,567,138,O
selected,567,141,O
antihypertensive,567,150,O
medications,567,167,O
(,567,179,O
amlodipine,567,181,O
",",567,192,O
angiotensin,567,194,O
II,567,206,O
receptor,567,209,O
blockers,567,218,O
",",567,227,O
bendroflumethiazide,567,229,O
",",567,249,O
enalapril,567,251,O
",",567,261,O
and,567,263,O
metoprolol,567,267,O
),567,278,O
.,567,280,O
Coadministration,568,0,O
of,568,17,O
tadalafil,568,20,O
(,568,30,O
40,568,32,O
mg,568,35,O
once,568,38,O
daily,568,43,O
),568,49,O
for,568,51,O
10,568,55,O
days,568,58,O
did,568,63,O
not,568,67,O
significantly,568,71,O
alter,568,85,O
digoxin,568,91,O
pharmacokinetics,568,99,O
in,568,116,O
healthy,568,119,O
subjects,568,127,O
see,568,136,O
Clinical,568,140,O
Pharmacology,568,149,O
(,568,162,O
12.3,568,164,O
),568,169,O
.,568,171,O
Cytochrome,569,0,O
P450,569,11,O
Substrates,569,16,O
Tadalafil,569,27,O
is,569,37,O
not,569,40,O
expected,569,44,O
to,569,53,O
cause,569,56,O
clinically,569,62,O
significant,569,73,O
inhibition,569,85,O
or,569,96,O
induction,569,99,O
of,569,109,O
the,569,112,O
clearance,569,116,O
of,569,126,O
drugs,569,129,O
metabolized,569,135,O
by,569,147,O
cytochrome,569,150,O
P450,569,161,O
(,569,166,O
CYP,569,167,O
),569,170,O
isoforms,569,172,O
(,569,181,O
e.g.,569,182,O
",",569,186,O
theophylline,569,188,O
",",569,200,O
warfarin,569,202,O
",",569,210,O
midazolam,569,212,O
",",569,221,O
lovastatin,569,223,O
",",569,233,O
bosentan,569,235,O
),569,243,O
[,569,245,O
see,569,246,O
Clinical,569,250,O
Pharmacology,569,259,O
(,569,272,O
12.3,569,273,O
),569,277,O
],569,278,O
.,569,279,O
For,570,0,O
patients,570,4,O
chronically,570,13,O
taking,570,25,O
potent,570,32,O
inducers,570,39,O
of,570,48,O
CYP3A,570,51,O
",",570,57,O
such,570,59,O
as,570,64,O
rifampin,570,67,O
",",570,76,O
avoid,570,78,O
use,570,84,O
of,570,88,O
ADCIRCA,570,91,O
see,570,99,O
Warnings,570,103,O
and,570,112,O
Precautions,570,116,O
(,570,128,O
5.2,570,130,O
),570,134,O
and,570,136,O
Clinical,570,140,O
Pharmacology,570,149,O
(,570,162,O
12.3,570,164,O
),570,169,O
.,570,171,O
For,570,0,O
patients,570,4,O
chronically,570,13,O
taking,570,25,O
potent,570,32,O
inducers,570,39,O
of,570,48,O
CYP3A,570,51,O
",",570,57,O
such,570,59,O
as,570,64,O
rifampin,570,67,O
",",570,76,O
avoid,570,78,O
use,570,84,O
of,570,88,O
ADCIRCA,570,91,O
see,570,99,O
Warnings,570,103,O
and,570,112,O
Precautions,570,116,O
(,570,128,O
5.2,570,130,O
),570,134,O
and,570,136,O
Clinical,570,140,O
Pharmacology,570,149,O
(,570,162,O
12.3,570,164,O
),570,169,O
.,570,171,O
In,571,0,O
a,571,3,O
patient,571,5,O
who,571,13,O
has,571,17,O
taken,571,21,O
ADCIRCA,571,27,O
",",571,34,O
where,571,36,O
nitrate,571,42,O
administration,571,50,O
is,571,65,O
deemed,571,68,O
medically,571,75,O
necessary,571,85,O
in,571,95,O
a,571,98,O
lifethreatening,571,100,O
situation,571,116,O
",",571,125,O
at,571,127,O
least,571,130,O
48,571,136,O
hours,571,139,O
should,571,145,O
elapse,571,152,O
after,571,159,O
the,571,165,O
last,571,169,O
dose,571,174,O
of,571,179,O
ADCIRCA,571,182,O
before,571,190,O
nitrate,571,197,O
administration,571,205,O
is,571,220,O
considered,571,223,O
.,571,233,O
In,572,0,O
clinical,572,3,O
pharmacology,572,12,O
studies,572,25,O
ADCIRCA,572,33,O
potentiated,572,41,B-SpecificInteraction
the,572,41,I-SpecificInteraction
hypotensive,572,41,I-SpecificInteraction
effect,572,41,I-SpecificInteraction
of,572,76,O
nitrates,572,79,O
[,572,88,O
see,572,89,O
Clinical,572,93,O
Pharmacology,572,102,O
(,572,115,O
12.2,572,116,O
),572,120,O
],572,121,O
.,572,122,O
In,573,0,O
patients,573,3,O
taking,573,12,O
potent,573,19,O
inhibitors,573,26,O
of,573,37,O
CYP3A,573,40,O
such,573,46,O
as,573,51,O
ketoconazole,573,54,O
",",573,67,O
and,573,69,O
itraconazole,573,73,O
",",573,86,O
avoid,573,88,O
use,573,94,O
of,573,98,O
ADCIRCA,573,101,O
see,573,109,O
Warnings,573,113,O
and,573,122,O
Precautions,573,126,O
(,573,138,O
5.2,573,140,O
),573,144,O
and,573,146,O
Clinical,573,150,O
Pharmacology,573,159,O
(,573,172,O
12.3,573,174,O
),573,179,O
.,573,181,O
In,573,0,O
patients,573,3,O
taking,573,12,O
potent,573,19,O
inhibitors,573,26,O
of,573,37,O
CYP3A,573,40,O
such,573,46,O
as,573,51,O
ketoconazole,573,54,O
",",573,67,O
and,573,69,O
itraconazole,573,73,O
",",573,86,O
avoid,573,88,O
use,573,94,O
of,573,98,O
ADCIRCA,573,101,O
see,573,109,O
Warnings,573,113,O
and,573,122,O
Precautions,573,126,O
(,573,138,O
5.2,573,140,O
),573,144,O
and,573,146,O
Clinical,573,150,O
Pharmacology,573,159,O
(,573,172,O
12.3,573,174,O
),573,179,O
.,573,181,O
In,573,0,O
patients,573,3,O
taking,573,12,O
potent,573,19,O
inhibitors,573,26,O
of,573,37,O
CYP3A,573,40,O
such,573,46,O
as,573,51,O
ketoconazole,573,54,O
",",573,67,O
and,573,69,O
itraconazole,573,73,O
",",573,86,O
avoid,573,88,O
use,573,94,O
of,573,98,O
ADCIRCA,573,101,O
see,573,109,O
Warnings,573,113,O
and,573,122,O
Precautions,573,126,O
(,573,138,O
5.2,573,140,O
),573,144,O
and,573,146,O
Clinical,573,150,O
Pharmacology,573,159,O
(,573,172,O
12.3,573,174,O
),573,179,O
.,573,181,O
In,574,0,O
such,574,3,O
circumstances,574,8,O
",",574,21,O
nitrates,574,23,O
should,574,32,O
still,574,39,O
only,574,45,O
be,574,50,O
administered,574,53,O
under,574,66,O
close,574,72,O
medical,574,78,O
supervision,574,86,O
with,574,98,O
appropriate,574,103,O
hemodynamic,574,115,O
monitoring,574,127,O
.,574,137,O
Nitrates,575,0,O
Do,575,9,O
not,575,12,O
use,575,16,O
ADCIRCA,575,20,O
in,575,28,O
patients,575,31,O
who,575,40,O
are,575,44,O
using,575,48,O
any,575,54,O
form,575,58,O
of,575,63,O
organic,575,66,O
nitrate,575,74,O
[,575,82,O
see,575,83,O
Contraindications,575,87,O
(,575,105,O
4.1,575,106,O
),575,109,O
],575,110,O
.,575,111,O
Other,576,0,O
Potent,576,6,O
Inhibitors,576,13,O
of,576,24,O
CYP3A,576,27,O
Tadalafil,576,33,O
is,576,43,O
metabolized,576,46,O
predominantly,576,58,O
by,576,72,O
CYP3A,576,75,O
in,576,81,O
the,576,84,O
liver,576,88,O
.,576,93,O
P-glycoprotein,577,0,O
(,577,15,O
e.g.,577,16,O
",",577,20,O
digoxin,577,22,O
),577,29,O
Coadministration,577,31,O
of,577,48,O
tadalafil,577,51,O
(,577,61,O
40,577,62,O
mg,577,65,O
once,577,68,O
daily,577,73,O
),577,78,O
for,577,80,O
10,577,84,O
days,577,87,O
did,577,92,O
not,577,96,O
significantly,577,100,O
alter,577,114,O
digoxin,577,120,O
pharmacokinetics,577,128,O
in,577,145,O
healthy,577,148,O
subjects,577,156,O
[,577,165,O
see,577,166,O
Clinical,577,170,O
Pharmacology,577,179,O
(,577,192,O
12.3,577,193,O
),577,197,O
],577,198,O
.,577,199,O
PDE5,578,0,O
inhibitors,578,5,O
",",578,16,O
including,578,18,O
ADCIRCA,578,28,O
",",578,36,O
and,578,38,O
alpha,578,42,O
adrenergic,578,48,O
blocking,578,59,O
agents,578,68,O
are,578,75,O
both,578,79,O
vasodilators,578,84,O
with,578,97,O
blood-pressure-lowering,578,102,B-SpecificInteraction
effects,578,126,O
.,578,134,O
PDE5,578,0,O
inhibitors,578,5,O
",",578,16,O
including,578,18,O
ADCIRCA,578,28,O
",",578,36,O
and,578,38,O
alpha,578,42,O
adrenergic,578,48,O
blocking,578,59,O
agents,578,68,O
are,578,75,O
both,578,79,O
vasodilators,578,84,O
with,578,97,O
blood-pressure-lowering,578,102,B-SpecificInteraction
effects,578,126,O
.,578,134,O
PDE5,579,0,O
inhibitors,579,5,O
",",579,16,O
including,579,18,O
ADCIRCA,579,28,O
",",579,36,O
are,579,38,O
mild,579,42,O
systemic,579,47,O
vasodilators,579,56,O
.,579,69,O
Potent,580,0,O
Inducers,580,7,O
of,580,16,O
CYP3A,580,19,O
For,580,25,O
patients,580,29,O
chronically,580,38,O
taking,580,50,O
potent,580,57,O
inducers,580,64,O
of,580,73,O
CYP3A,580,76,O
",",580,81,O
such,580,83,O
as,580,88,O
rifampin,580,91,O
",",580,99,O
avoid,580,101,O
use,580,107,O
of,580,111,O
ADCIRCA,580,114,O
[,580,122,O
see,580,123,O
Warnings,580,127,O
and,580,136,O
Precautions,580,140,O
(,580,152,O
5.2,580,153,O
),580,156,O
and,580,158,O
Clinical,580,162,O
Pharmacology,580,171,O
(,580,184,O
12.3,580,185,O
),580,189,O
],580,190,O
.,580,191,O
Potent,580,0,O
Inducers,580,7,O
of,580,16,O
CYP3A,580,19,O
For,580,25,O
patients,580,29,O
chronically,580,38,O
taking,580,50,O
potent,580,57,O
inducers,580,64,O
of,580,73,O
CYP3A,580,76,O
",",580,81,O
such,580,83,O
as,580,88,O
rifampin,580,91,O
",",580,99,O
avoid,580,101,O
use,580,107,O
of,580,111,O
ADCIRCA,580,114,O
[,580,122,O
see,580,123,O
Warnings,580,127,O
and,580,136,O
Precautions,580,140,O
(,580,152,O
5.2,580,153,O
),580,156,O
and,580,158,O
Clinical,580,162,O
Pharmacology,580,171,O
(,580,184,O
12.3,580,185,O
),580,189,O
],580,190,O
.,580,191,O
Ritonavir,581,0,O
initially,581,10,O
inhibits,581,20,O
and,581,29,O
later,581,33,O
induces,581,39,O
CYP3A,581,47,O
",",581,53,O
the,581,55,O
enzyme,581,59,O
involved,581,66,O
in,581,75,O
the,581,78,O
metabolism,581,82,O
of,581,93,O
tadalafil,581,96,O
.,581,106,O
Ritonavir,581,0,O
initially,581,10,O
inhibits,581,20,O
and,581,29,O
later,581,33,O
induces,581,39,O
CYP3A,581,47,O
",",581,53,O
the,581,55,O
enzyme,581,59,O
involved,581,66,O
in,581,75,O
the,581,78,O
metabolism,581,82,O
of,581,93,O
tadalafil,581,96,O
.,581,106,O
Ritonavir,582,0,O
Ritonavir,582,10,O
initially,582,20,O
inhibits,582,30,O
and,582,39,O
later,582,43,O
induces,582,49,O
CYP3A,582,57,O
",",582,62,O
the,582,64,O
enzyme,582,68,O
involved,582,75,O
in,582,84,O
the,582,87,O
metabolism,582,91,O
of,582,102,O
tadalafil,582,105,O
.,582,114,O
Ritonavir,582,0,O
Ritonavir,582,10,O
initially,582,20,O
inhibits,582,30,O
and,582,39,O
later,582,43,O
induces,582,49,O
CYP3A,582,57,O
",",582,62,O
the,582,64,O
enzyme,582,68,O
involved,582,75,O
in,582,84,O
the,582,87,O
metabolism,582,91,O
of,582,102,O
tadalafil,582,105,O
.,582,114,O
Small,583,0,O
reductions,583,6,O
in,583,17,O
blood,583,20,O
pressure,583,26,O
occurred,583,35,O
following,583,44,O
coadministration,583,54,O
of,583,71,O
tadalafil,583,74,O
with,583,84,O
these,583,89,O
agents,583,95,O
compared,583,102,O
with,583,111,O
placebo,583,116,O
[,583,124,O
see,583,125,O
Warnings,583,129,O
and,583,138,O
Precautions,583,142,O
(,583,154,O
5.1,583,155,O
),583,158,O
and,583,160,O
Clinical,583,164,O
Pharmacology,583,173,O
(,583,186,O
12.2,583,187,O
),583,191,O
],583,192,O
.,583,193,O
Substantial,584,0,O
consumption,584,12,O
of,584,24,O
alcohol,584,27,O
(,584,35,O
e.g.,584,36,O
",",584,40,O
5,584,42,O
units,584,44,O
or,584,50,O
greater,584,53,O
),584,60,O
in,584,62,O
combination,584,65,O
with,584,77,O
ADCIRCA,584,82,O
can,584,90,O
increase,584,94,O
the,584,103,O
potential,584,107,O
for,584,117,O
orthostatic,584,121,O
signs,584,133,O
and,584,139,O
symptoms,584,143,O
",",584,151,O
including,584,153,O
increase,584,163,B-SpecificInteraction
in,584,163,I-SpecificInteraction
heart,584,163,I-SpecificInteraction
rate,584,163,I-SpecificInteraction
",",584,185,O
decrease,584,187,B-SpecificInteraction
in,584,187,I-SpecificInteraction
standing,584,187,I-SpecificInteraction
blood,584,187,I-SpecificInteraction
pressure,584,187,I-SpecificInteraction
",",584,222,O
dizziness,584,224,B-SpecificInteraction
",",584,233,O
and,584,235,O
headache,584,239,B-SpecificInteraction
.,584,247,O
Tadalafil,585,0,O
(,585,10,O
10,585,12,O
mg,585,15,O
and,585,18,O
20,585,22,O
mg,585,25,O
once,585,28,O
daily,585,33,O
),585,39,O
does,585,41,O
not,585,46,O
potentiate,585,50,O
the,585,61,O
increase,585,65,O
in,585,74,O
bleeding,585,77,O
time,585,86,O
caused,585,91,O
by,585,98,O
aspirin,585,101,O
see,585,109,O
Clinical,585,113,O
Pharmacology,585,122,O
(,585,135,O
12.3,585,137,O
),585,142,O
.,585,144,O
Tadalafil,586,0,O
(,586,10,O
10,586,12,O
mg,586,15,O
or,586,18,O
20,586,21,O
mg,586,24,O
),586,27,O
did,586,29,O
not,586,33,O
affect,586,37,O
alcohol,586,44,O
plasma,586,52,O
concentrations,586,59,O
and,586,74,O
alcohol,586,78,O
did,586,86,O
not,586,90,O
affect,586,94,O
tadalafil,586,101,O
plasma,586,111,O
concentrations,586,118,O
.,586,133,O
Tadalafil,587,0,O
(,587,10,O
10,587,11,O
mg,587,14,O
or,587,17,O
20,587,20,O
mg,587,23,O
),587,25,O
did,587,27,O
not,587,31,O
affect,587,35,O
alcohol,587,42,O
plasma,587,50,O
concentrations,587,57,O
and,587,72,O
alcohol,587,76,O
did,587,84,O
not,587,88,O
affect,587,92,O
tadalafil,587,99,O
plasma,587,109,O
concentrations,587,116,O
.,587,130,O
Tadalafil,588,0,O
is,588,10,O
not,588,13,O
expected,588,17,O
to,588,26,O
cause,588,29,O
clinically,588,35,O
significant,588,46,O
inhibition,588,58,O
or,588,69,O
induction,588,72,O
of,588,82,O
the,588,85,O
clearance,588,89,O
of,588,99,O
drugs,588,102,O
metabolized,588,108,O
by,588,120,O
cytochrome,588,123,O
P450,588,134,O
(,588,139,O
CYP,588,141,O
),588,145,O
isoforms,588,147,O
(,588,156,O
e.g.,588,158,O
",",588,163,O
theophylline,588,165,O
",",588,178,O
warfarin,588,180,O
",",588,189,O
midazolam,588,191,O
",",588,201,O
lovastatin,588,203,O
",",588,214,O
bosentan,588,216,O
),588,225,O
see,588,227,O
Clinical,588,231,O
Pharmacology,588,240,O
(,588,253,O
12.3,588,255,O
),588,260,O
.,588,262,O
When,589,0,O
mild,589,5,O
vasodilators,589,10,O
are,589,23,O
taken,589,27,O
in,589,33,O
combination,589,36,O
",",589,47,O
blood,589,49,B-SpecificInteraction
pressurelowering,589,49,I-SpecificInteraction
effects,589,72,O
of,589,80,O
each,589,83,O
individual,589,88,O
compound,589,99,O
may,589,108,O
be,589,112,O
increased,589,115,O
.,589,124,O
When,590,0,O
vasodilators,590,5,O
are,590,18,O
used,590,22,O
in,590,27,O
combination,590,30,O
",",590,41,O
an,590,43,O
additive,590,46,B-SpecificInteraction
effect,590,46,I-SpecificInteraction
on,590,46,I-SpecificInteraction
blood,590,46,I-SpecificInteraction
pressure,590,46,I-SpecificInteraction
may,590,80,O
be,590,84,O
anticipated,590,87,O
.,590,98,O
Both,591,0,O
alcohol,591,5,O
and,591,13,O
tadalafil,591,17,O
are,591,27,O
mild,591,31,O
vasodilators,591,36,O
.,591,49,O
Discuss,592,0,O
with,592,8,O
patients,592,13,O
the,592,22,O
appropriate,592,26,O
action,592,38,O
to,592,45,O
take,592,48,O
in,592,53,O
the,592,56,O
event,592,60,O
that,592,66,O
they,592,71,O
experience,592,76,O
anginal,592,87,O
chest,592,95,O
pain,592,101,O
requiring,592,106,O
nitroglycerin,592,116,O
following,592,130,O
intake,592,140,O
of,592,147,O
ADCIRCA,592,150,O
.,592,158,O
For,593,0,O
patients,593,4,O
chronically,593,13,O
taking,593,25,O
potent,593,32,O
inducers,593,39,O
of,593,48,O
CYP3A,593,51,O
",",593,57,O
such,593,59,O
as,593,64,O
rifampin,593,67,O
",",593,76,O
avoid,593,78,O
use,593,84,O
of,593,88,O
ADCIRCA,593,91,O
see,593,99,O
Drug,593,103,O
Interactions,593,108,O
(,593,121,O
7.2,593,123,O
),593,127,O
and,593,129,O
Clinical,593,133,O
Pharmacology,593,142,O
(,593,155,O
12.3,593,157,O
),593,162,O
.,593,164,O
For,593,0,O
patients,593,4,O
chronically,593,13,O
taking,593,25,O
potent,593,32,O
inducers,593,39,O
of,593,48,O
CYP3A,593,51,O
",",593,57,O
such,593,59,O
as,593,64,O
rifampin,593,67,O
",",593,76,O
avoid,593,78,O
use,593,84,O
of,593,88,O
ADCIRCA,593,91,O
see,593,99,O
Drug,593,103,O
Interactions,593,108,O
(,593,121,O
7.2,593,123,O
),593,127,O
and,593,129,O
Clinical,593,133,O
Pharmacology,593,142,O
(,593,155,O
12.3,593,157,O
),593,162,O
.,593,164,O
In,594,0,O
patients,594,3,O
taking,594,12,O
potent,594,19,O
inhibitors,594,26,O
of,594,37,O
CYP3A,594,40,O
such,594,46,O
as,594,51,O
ketoconazole,594,54,O
and,594,67,O
itraconazole,594,71,O
",",594,84,O
avoid,594,86,O
use,594,92,O
of,594,96,O
ADCIRCA,594,99,O
see,594,107,O
Drug,594,111,O
Interactions,594,116,O
(,594,129,O
7.2,594,131,O
),594,135,O
and,594,137,O
Clinical,594,141,O
Pharmacology,594,150,O
(,594,163,O
12.3,594,165,O
),594,170,O
.,594,172,O
In,594,0,O
patients,594,3,O
taking,594,12,O
potent,594,19,O
inhibitors,594,26,O
of,594,37,O
CYP3A,594,40,O
such,594,46,O
as,594,51,O
ketoconazole,594,54,O
and,594,67,O
itraconazole,594,71,O
",",594,84,O
avoid,594,86,O
use,594,92,O
of,594,96,O
ADCIRCA,594,99,O
see,594,107,O
Drug,594,111,O
Interactions,594,116,O
(,594,129,O
7.2,594,131,O
),594,135,O
and,594,137,O
Clinical,594,141,O
Pharmacology,594,150,O
(,594,163,O
12.3,594,165,O
),594,170,O
.,594,172,O
In,594,0,O
patients,594,3,O
taking,594,12,O
potent,594,19,O
inhibitors,594,26,O
of,594,37,O
CYP3A,594,40,O
such,594,46,O
as,594,51,O
ketoconazole,594,54,O
and,594,67,O
itraconazole,594,71,O
",",594,84,O
avoid,594,86,O
use,594,92,O
of,594,96,O
ADCIRCA,594,99,O
see,594,107,O
Drug,594,111,O
Interactions,594,116,O
(,594,129,O
7.2,594,131,O
),594,135,O
and,594,137,O
Clinical,594,141,O
Pharmacology,594,150,O
(,594,163,O
12.3,594,165,O
),594,170,O
.,594,172,O
Inform,595,0,O
patients,595,7,O
taking,595,16,O
ADCIRCA,595,23,O
not,595,31,O
to,595,35,O
take,595,38,O
CIALIS,595,43,O
or,595,50,O
other,595,53,O
PDE5,595,59,O
inhibitors,595,64,O
.,595,75,O
Inform,595,0,O
patients,595,7,O
taking,595,16,O
ADCIRCA,595,23,O
not,595,31,O
to,595,35,O
take,595,38,O
CIALIS,595,43,O
or,595,50,O
other,595,53,O
PDE5,595,59,O
inhibitors,595,64,O
.,595,75,O
Other,596,0,O
concomitant,596,6,O
potent,596,18,O
CYP3A,596,25,O
inhibitors,596,31,O
:,596,42,O
Avoid,596,44,O
use,596,50,O
with,596,54,O
ADCIRCA,596,59,O
.,596,67,O
PDE5,597,0,O
inhibitors,597,5,O
",",597,16,O
including,597,18,O
ADCIRCA,597,28,O
",",597,36,O
and,597,38,O
alpha,597,42,O
adrenergic,597,48,O
blocking,597,59,O
agents,597,68,O
are,597,75,O
vasodilators,597,79,O
with,597,92,O
blood,597,97,B-SpecificInteraction
pressure,597,97,I-SpecificInteraction
lowering,597,97,I-SpecificInteraction
effects,597,121,O
.,597,129,O
PDE5,597,0,O
inhibitors,597,5,O
",",597,16,O
including,597,18,O
ADCIRCA,597,28,O
",",597,36,O
and,597,38,O
alpha,597,42,O
adrenergic,597,48,O
blocking,597,59,O
agents,597,68,O
are,597,75,O
vasodilators,597,79,O
with,597,92,O
blood,597,97,B-SpecificInteraction
pressure,597,97,I-SpecificInteraction
lowering,597,97,I-SpecificInteraction
effects,597,121,O
.,597,129,O
PDE5,598,0,O
inhibitors,598,5,O
",",598,16,O
including,598,18,O
tadalafil,598,28,O
",",598,38,O
have,598,40,O
mild,598,45,O
systemic,598,50,O
vasodilatory,598,59,O
properties,598,72,O
that,598,83,O
may,598,88,O
result,598,92,O
in,598,99,O
transient,598,102,O
decreases,598,112,O
in,598,122,O
blood,598,125,O
pressure,598,131,O
.,598,140,O
Potent,599,0,O
Inducers,599,7,O
of,599,16,O
CYP3A,599,19,O
:,599,25,O
Avoid,599,27,O
use,599,33,O
of,599,37,O
ADCIRCA,599,40,O
in,599,48,O
patients,599,51,O
chronically,599,60,O
taking,599,72,O
potent,599,79,O
inducers,599,86,O
of,599,95,O
CYP3A,599,98,O
(,599,104,O
e.g.,599,106,O
",",599,111,O
rifampin,599,113,O
),599,122,O
.,599,124,O
Potent,599,0,O
Inducers,599,7,O
of,599,16,O
CYP3A,599,19,O
:,599,25,O
Avoid,599,27,O
use,599,33,O
of,599,37,O
ADCIRCA,599,40,O
in,599,48,O
patients,599,51,O
chronically,599,60,O
taking,599,72,O
potent,599,79,O
inducers,599,86,O
of,599,95,O
CYP3A,599,98,O
(,599,104,O
e.g.,599,106,O
",",599,111,O
rifampin,599,113,O
),599,122,O
.,599,124,O
Tadalafil,600,0,O
is,600,10,O
also,600,13,O
marketed,600,18,O
as,600,27,O
CIALIS,600,30,O
.,600,37,O
The,601,0,O
safety,601,4,O
and,601,11,O
efficacy,601,15,O
of,601,24,O
taking,601,27,O
ADCIRCA,601,34,O
together,601,42,O
with,601,51,O
CIALIS,601,56,O
or,601,63,O
other,601,66,O
PDE5,601,72,O
inhibitors,601,77,O
have,601,88,O
not,601,93,O
been,601,97,O
studied,601,102,O
.,601,110,O
These,602,0,O
events,602,6,O
",",602,13,O
which,602,15,O
may,602,21,O
be,602,25,O
accompanied,602,28,O
by,602,40,O
tinnitus,602,43,O
and,602,52,O
dizziness,602,56,O
",",602,66,O
have,602,68,O
been,602,73,O
reported,602,78,O
in,602,87,O
temporal,602,90,O
association,602,99,O
to,602,111,O
the,602,114,O
intake,602,118,O
of,602,125,O
PDE5,602,128,O
inhibitors,602,133,O
",",602,144,O
including,602,146,O
ADCIRCA,602,156,O
.,602,164,O
When,603,0,O
administered,603,5,O
in,603,18,O
combination,603,21,O
with,603,33,O
aspirin,603,38,O
",",603,46,O
tadalafil,603,48,O
20,603,58,O
mg,603,61,O
did,603,64,O
not,603,68,O
prolong,603,72,O
bleeding,603,80,O
time,603,89,O
",",603,94,O
relative,603,96,O
to,603,105,O
aspirin,603,108,O
alone,603,116,O
.,603,122,O
Adenocard,511,0,O
(,511,10,O
adenosine,511,12,O
injection,511,22,O
),511,32,O
is,511,34,O
a,511,37,O
respiratory,511,39,O
stimulant,511,51,O
(,511,61,O
probably,511,63,O
through,511,72,O
activation,511,80,O
of,511,91,O
carotid,511,94,O
body,511,102,O
chemoreceptors,511,107,O
),511,122,O
and,511,124,O
intravenous,511,128,O
administration,511,140,O
in,511,155,O
man,511,158,O
has,511,162,O
been,511,166,O
shown,511,171,O
to,511,177,O
increase,511,180,O
minute,511,189,O
ventilation,511,196,O
(,511,208,O
Ve,511,210,O
),511,213,O
and,511,215,O
reduce,511,219,O
arterial,511,226,O
PCO2,511,235,O
causing,511,240,O
respiratory,511,248,O
alkalosis,511,260,O
.,511,270,O
Because,512,0,O
of,512,8,O
the,512,11,O
potential,512,15,O
for,512,25,O
additive,512,29,O
or,512,38,O
synergistic,512,41,O
depressant,512,53,O
effects,512,64,O
on,512,72,O
the,512,75,O
SA,512,79,O
and,512,82,O
AV,512,86,O
nodes,512,89,O
",",512,94,O
however,512,96,O
",",512,103,O
Adenocard,512,105,O
should,512,115,O
be,512,122,O
used,512,125,O
with,512,130,O
caution,512,135,O
in,512,143,O
the,512,146,O
presence,512,150,O
of,512,159,O
these,512,162,O
agents,512,168,O
.,512,174,O
Carbamazepine,513,0,O
has,513,14,O
been,513,18,O
reported,513,23,O
to,513,32,O
increase,513,35,O
the,513,44,O
degree,513,48,O
of,513,55,O
heart,513,58,B-SpecificInteraction
block,513,58,I-SpecificInteraction
produced,513,70,O
by,513,79,O
other,513,82,O
agents,513,88,O
.,513,94,O
Digoxin,514,0,O
and,514,8,O
verapamil,514,12,O
use,514,22,O
may,514,26,O
be,514,30,O
rarely,514,33,O
associated,514,40,O
with,514,51,O
ventricular,514,56,B-SpecificInteraction
fibrillation,514,56,I-SpecificInteraction
when,514,81,O
combined,514,86,O
with,514,95,O
Adenocard,514,100,O
(,514,110,O
see,514,111,O
Warnings,514,115,O
),514,124,O
.,514,125,O
Digoxin,514,0,O
and,514,8,O
verapamil,514,12,O
use,514,22,O
may,514,26,O
be,514,30,O
rarely,514,33,O
associated,514,40,O
with,514,51,O
ventricular,514,56,B-SpecificInteraction
fibrillation,514,56,I-SpecificInteraction
when,514,81,O
combined,514,86,O
with,514,95,O
Adenocard,514,100,O
(,514,110,O
see,514,111,O
Warnings,514,115,O
),514,124,O
.,514,125,O
Intravenous,515,0,O
Adenocard,515,12,O
(,515,22,O
adenosine,515,23,O
injection,515,33,O
),515,42,O
has,515,44,O
been,515,48,O
effectively,515,53,O
administered,515,65,O
in,515,78,O
the,515,81,O
presence,515,85,O
of,515,94,O
other,515,97,O
cardioactive,515,103,O
drugs,515,116,O
",",515,121,O
such,515,123,O
as,515,128,O
quinidine,515,131,O
",",515,140,O
beta-adrenergic,515,142,O
blocking,515,158,O
agents,515,167,O
",",515,173,O
calcium,515,175,O
channel,515,183,O
blocking,515,191,O
agents,515,200,O
",",515,206,O
and,515,208,O
angiotensin,515,212,O
converting,515,224,O
enzyme,515,235,O
inhibitors,515,242,O
",",515,252,O
without,515,254,O
any,515,262,O
change,515,266,O
in,515,273,O
the,515,276,O
adverse,515,280,O
reaction,515,288,O
profile,515,297,O
.,515,304,O
The,516,0,O
use,516,4,O
of,516,8,O
Adenocard,516,11,O
in,516,21,O
patients,516,24,O
receiving,516,33,O
digitalis,516,43,O
may,516,53,O
be,516,57,O
rarely,516,60,O
associated,516,67,O
with,516,78,O
ventricular,516,83,B-SpecificInteraction
fibrillation,516,83,I-SpecificInteraction
(,516,108,O
see,516,109,O
Warnings,516,113,O
),516,122,O
.,516,123,O
Adenosine,517,0,B-SpecificInteraction
effects,517,0,I-SpecificInteraction
are,517,0,I-SpecificInteraction
potentiated,517,0,I-SpecificInteraction
by,517,34,O
dipyridamole,517,37,O
.,517,50,O
As,518,0,O
the,518,3,O
primary,518,7,O
effect,518,15,O
of,518,22,O
adenosine,518,25,O
is,518,35,O
to,518,38,O
decrease,518,41,O
conduction,518,50,O
through,518,61,O
the,518,69,O
A-V,518,73,O
node,518,77,O
",",518,82,O
higher,518,84,O
degrees,518,91,O
of,518,99,O
heart,518,102,B-SpecificInteraction
block,518,102,I-SpecificInteraction
may,518,114,O
be,518,118,O
produced,518,121,O
in,518,130,O
the,518,133,O
presence,518,137,O
of,518,146,O
carbamazepine,518,149,O
.,518,163,O
In,519,0,O
the,519,3,O
presence,519,7,O
of,519,16,O
these,519,19,O
methylxanthines,519,25,O
",",519,41,O
larger,519,43,O
doses,519,50,O
of,519,56,O
adenosine,519,59,O
may,519,69,O
be,519,73,O
required,519,76,O
or,519,85,O
adenosine,519,88,B-SpecificInteraction
may,519,88,I-SpecificInteraction
not,519,88,I-SpecificInteraction
be,519,88,I-SpecificInteraction
effective,519,88,I-SpecificInteraction
.,519,119,O
Intravenous,520,0,O
Adenocard,520,12,O
(,520,22,O
adenosine,520,24,O
injection,520,34,O
),520,44,O
has,520,46,O
been,520,50,O
effectively,520,55,O
administered,520,67,O
in,520,80,O
the,520,83,O
presence,520,87,O
of,520,96,O
other,520,99,O
cardioactive,520,105,O
drugs,520,118,O
",",520,124,O
such,520,126,O
as,520,131,O
quinidine,520,134,O
",",520,144,O
beta-adrenergic,520,146,O
blocking,520,162,O
agents,520,171,O
",",520,178,O
calcium,520,180,O
channel,520,188,O
blocking,520,196,O
agents,520,205,O
",",520,212,O
and,520,214,O
angiotensin,520,218,O
converting,520,230,O
enzyme,520,241,O
inhibitors,520,248,O
",",520,259,O
without,520,261,O
any,520,269,O
change,520,273,O
in,520,280,O
the,520,283,O
adverse,520,287,O
reaction,520,295,O
profile,520,304,O
.,520,312,O
The,521,0,O
effects,521,4,B-SpecificInteraction
of,521,4,I-SpecificInteraction
adenosine,521,4,I-SpecificInteraction
are,521,4,I-SpecificInteraction
antagonized,521,4,I-SpecificInteraction
by,521,41,O
methylxanthines,521,44,O
such,521,60,O
as,521,65,O
caffeine,521,68,O
and,521,77,O
theophylline,521,81,O
.,521,94,O
The,521,0,O
effects,521,4,B-SpecificInteraction
of,521,4,I-SpecificInteraction
adenosine,521,4,I-SpecificInteraction
are,521,4,I-SpecificInteraction
antagonized,521,4,I-SpecificInteraction
by,521,41,O
methylxanthines,521,44,O
such,521,60,O
as,521,65,O
caffeine,521,68,O
and,521,77,O
theophylline,521,81,O
.,521,94,O
The,521,0,O
effects,521,4,B-SpecificInteraction
of,521,4,I-SpecificInteraction
adenosine,521,4,I-SpecificInteraction
are,521,4,I-SpecificInteraction
antagonized,521,4,I-SpecificInteraction
by,521,41,O
methylxanthines,521,44,O
such,521,60,O
as,521,65,O
caffeine,521,68,O
and,521,77,O
theophylline,521,81,O
.,521,94,O
Thus,522,0,O
",",522,5,O
smaller,522,7,O
doses,522,15,O
of,522,21,O
adenosine,522,24,O
may,522,34,O
be,522,38,O
effective,522,41,O
in,522,51,O
the,522,54,O
presence,522,58,O
of,522,67,O
dipyridamole,522,70,O
.,522,83,O
ALDACTONE,1,0,O
in,1,10,O
a,1,13,O
dosage,1,15,O
ranging,1,22,O
from,1,30,O
25,1,35,O
mg,1,38,O
to,1,41,O
100,1,44,O
mg,1,48,O
daily,1,51,O
is,1,57,O
useful,1,60,O
in,1,67,O
treating,1,70,O
a,1,79,O
diuretic-induced,1,81,O
hypokalemia,1,98,O
",",1,110,O
when,1,112,O
oral,1,117,O
potassium,1,122,O
supplements,1,132,O
or,1,144,O
other,1,147,O
potassium-sparing,1,153,O
regimens,1,171,O
are,1,180,O
considered,1,184,O
inappropriate,1,195,O
.,1,209,O
ALDACTONE,2,0,O
may,2,10,O
also,2,14,O
be,2,19,O
given,2,22,O
with,2,28,O
diuretics,2,33,O
that,2,43,O
act,2,48,O
more,2,52,O
proximally,2,57,O
in,2,68,O
the,2,71,O
renal,2,75,O
tubule,2,81,O
or,2,88,O
with,2,91,O
other,2,96,O
antihypertensive,2,102,O
agents,2,119,O
.,2,126,O
Because,3,0,O
of,3,8,O
the,3,11,O
additive,3,15,O
effect,3,24,O
of,3,31,O
ALDACTONE,3,34,O
when,3,44,O
administered,3,49,O
concurrently,3,62,O
with,3,75,O
such,3,80,O
diuretics,3,85,O
",",3,95,O
an,3,97,O
enhanced,3,100,B-SpecificInteraction
diuresis,3,100,I-SpecificInteraction
usually,3,118,O
begins,3,126,O
on,3,133,O
the,3,136,O
first,3,140,O
day,3,146,O
of,3,150,O
combined,3,153,O
treatment,3,162,O
",",3,172,O
combined,3,174,O
therapy,3,183,O
is,3,191,O
indicated,3,194,O
when,3,204,O
more,3,209,O
rapid,3,214,O
diuresis,3,220,O
is,3,229,O
desired,3,232,O
.,3,240,O
If,4,0,O
",",4,3,O
after,4,5,O
five,4,11,O
days,4,16,O
",",4,21,O
an,4,23,O
adequate,4,26,O
diuretic,4,35,O
response,4,44,O
to,4,53,O
ALDACTONE,4,56,O
has,4,66,O
not,4,70,O
occurred,4,74,O
",",4,83,O
a,4,85,O
second,4,87,O
diuretic,4,94,O
that,4,103,O
acts,4,108,O
more,4,113,O
proximally,4,118,O
in,4,129,O
the,4,132,O
renal,4,136,O
tubule,4,142,O
may,4,149,O
be,4,153,O
added,4,156,O
to,4,162,O
the,4,165,O
regimen,4,169,O
.,4,177,O
ALDACTONE,5,0,O
is,5,10,O
contraindicated,5,13,O
for,5,29,O
patients,5,33,O
with,5,42,O
anuria,5,47,O
",",5,54,O
acute,5,56,O
renal,5,62,O
insufficiency,5,68,O
",",5,82,O
significant,5,84,O
impairment,5,96,O
of,5,107,O
renal,5,110,O
excretory,5,116,O
function,5,126,O
",",5,135,O
hyperkalemia,5,137,O
",",5,150,O
Addison,5,152,O
's,5,160,O
disease,5,163,O
",",5,171,O
and,5,173,O
with,5,177,O
concomitant,5,182,O
use,5,194,O
of,5,198,O
eplerenone,5,201,O
.,5,212,O
ALDACTONE,6,0,O
",",6,10,O
when,6,12,O
used,6,17,O
with,6,22,O
ACE,6,27,O
inhibitors,6,31,O
or,6,42,O
indomethacin,6,45,O
",",6,58,O
even,6,60,O
in,6,65,O
the,6,68,O
presence,6,72,O
of,6,81,O
a,6,84,O
diuretic,6,86,O
",",6,95,O
has,6,97,O
been,6,101,O
associated,6,106,O
with,6,117,O
severe,6,122,B-SpecificInteraction
hyperkalemia,6,122,I-SpecificInteraction
.,6,142,O
ALDACTONE,6,0,O
",",6,10,O
when,6,12,O
used,6,17,O
with,6,22,O
ACE,6,27,O
inhibitors,6,31,O
or,6,42,O
indomethacin,6,45,O
",",6,58,O
even,6,60,O
in,6,65,O
the,6,68,O
presence,6,72,O
of,6,81,O
a,6,84,O
diuretic,6,86,O
",",6,95,O
has,6,97,O
been,6,101,O
associated,6,106,O
with,6,117,O
severe,6,122,B-SpecificInteraction
hyperkalemia,6,122,I-SpecificInteraction
.,6,142,O
ALDACTONE,7,0,O
should,7,10,O
not,7,17,O
be,7,21,O
administered,7,24,O
concurrently,7,37,O
with,7,50,O
other,7,55,O
potassium-sparing,7,61,O
diuretics,7,79,O
.,7,89,O
Concomitant,8,0,O
administration,8,12,O
of,8,27,O
ALDACTONE,8,30,O
with,8,40,O
the,8,45,O
following,8,49,O
drugs,8,59,O
or,8,65,O
potassium,8,68,O
sources,8,78,O
may,8,86,O
lead,8,90,O
to,8,95,O
severe,8,98,O
hyperkalemia,8,105,O
:,8,118,O
.,8,120,O
Potassium,9,0,O
supplementation,9,10,O
",",9,26,O
either,9,28,O
in,9,35,O
the,9,38,O
form,9,42,O
of,9,47,O
medication,9,50,O
or,9,61,O
as,9,64,O
a,9,67,O
diet,9,69,O
rich,9,74,O
in,9,79,O
potassium,9,82,O
",",9,92,O
should,9,94,O
not,9,101,O
ordinarily,9,105,O
be,9,116,O
given,9,119,O
in,9,125,O
association,9,128,O
with,9,140,O
ALDACTONE,9,145,O
therapy,9,155,O
.,9,163,O
Combination,10,0,O
of,10,12,O
NSAIDs,10,15,O
",",10,21,O
e.g.,10,23,O
",",10,27,O
indomethacin,10,29,O
",",10,41,O
with,10,43,O
potassium-sparing,10,48,O
diuretics,10,66,O
has,10,76,O
been,10,80,O
associated,10,85,O
with,10,96,O
severe,10,101,B-SpecificInteraction
hyperkalemia,10,101,I-SpecificInteraction
.,10,120,O
Combination,10,0,O
of,10,12,O
NSAIDs,10,15,O
",",10,21,O
e.g.,10,23,O
",",10,27,O
indomethacin,10,29,O
",",10,41,O
with,10,43,O
potassium-sparing,10,48,O
diuretics,10,66,O
has,10,76,O
been,10,80,O
associated,10,85,O
with,10,96,O
severe,10,101,B-SpecificInteraction
hyperkalemia,10,101,I-SpecificInteraction
.,10,120,O
Concomitant,11,0,O
administration,11,12,O
may,11,27,O
lead,11,31,O
to,11,36,O
severe,11,39,O
hyperkalemia,11,46,O
.,11,58,O
Concomitant,12,0,O
administration,12,12,O
of,12,27,O
ACE,12,30,O
inhibitors,12,34,O
with,12,45,O
potassium-sparing,12,50,O
diuretics,12,68,O
has,12,78,O
been,12,82,O
associated,12,87,O
with,12,98,O
severe,12,103,B-SpecificInteraction
hyperkalemia,12,103,I-SpecificInteraction
.,12,122,O
Diuretic,13,0,O
agents,13,9,O
reduce,13,16,O
the,13,23,O
renal,13,27,O
clearance,13,33,O
of,13,43,O
lithium,13,46,O
and,13,54,O
add,13,58,O
a,13,62,O
high,13,64,O
risk,13,69,O
of,13,74,O
lithium,13,77,O
toxicity,13,85,O
.,13,93,O
In,14,0,O
some,14,3,O
patients,14,8,O
",",14,16,O
the,14,18,O
administration,14,22,O
of,14,37,O
an,14,40,O
NSAID,14,43,O
can,14,49,O
reduce,14,53,O
the,14,60,O
diuretic,14,64,O
",",14,72,O
natriuretic,14,74,O
",",14,85,O
and,14,87,O
antihypertensive,14,91,O
effect,14,108,O
of,14,115,O
loop,14,118,O
",",14,122,O
potassium-sparing,14,124,O
",",14,141,O
and,14,143,O
thiazide,14,147,O
diuretics,14,156,O
.,14,165,O
Intensified,15,0,O
electrolyte,15,12,O
depletion,15,24,O
",",15,33,O
particularly,15,35,O
hypokalemia,15,48,O
",",15,59,O
may,15,61,O
occur,15,65,O
.,15,70,O
It,16,0,O
may,16,3,O
be,16,7,O
necessary,16,10,O
to,16,20,O
reduce,16,23,O
the,16,30,O
maintenance,16,34,O
and,16,46,O
digitalization,16,50,O
doses,16,65,O
when,16,71,O
ALDACTONE,16,76,O
is,16,86,O
administered,16,89,O
",",16,101,O
and,16,103,O
the,16,107,O
patient,16,111,O
should,16,119,O
be,16,126,O
carefully,16,129,O
monitored,16,139,O
to,16,149,O
avoid,16,152,O
over-,16,158,O
or,16,164,O
under-digitalization,16,167,O
.,16,187,O
Lithium,17,0,O
generally,17,8,O
should,17,18,O
not,17,25,O
be,17,29,O
given,17,32,O
with,17,38,O
diuretics,17,43,O
.,17,52,O
Possible,18,0,O
increased,18,9,O
responsiveness,18,19,O
to,18,34,O
the,18,37,O
muscle,18,41,O
relaxant,18,48,O
may,18,57,O
result,18,61,O
.,18,67,O
Potentiation,19,0,O
of,19,13,O
orthostatic,19,16,O
hypotension,19,28,O
may,19,40,O
occur,19,44,O
.,19,49,O
Therefore,20,0,O
",",20,9,O
caution,20,11,O
should,20,19,O
be,20,26,O
exercised,20,29,O
in,20,39,O
the,20,42,O
management,20,46,O
of,20,57,O
patients,20,60,O
subjected,20,69,O
to,20,79,O
regional,20,82,O
or,20,91,O
general,20,94,O
anesthesia,20,102,O
while,20,113,O
they,20,119,O
are,20,124,O
being,20,128,O
treated,20,134,O
with,20,142,O
ALDACTONE,20,147,O
.,20,156,O
This,21,0,O
may,21,5,O
result,21,9,O
in,21,16,O
increased,21,19,O
serum,21,29,O
digoxin,21,35,O
levels,21,43,O
and,21,50,O
subsequent,21,54,O
digitalis,21,65,O
toxicity,21,75,O
.,21,83,O
A,22,0,O
dose-related,22,2,O
(,22,15,O
above,22,17,O
20,22,23,O
mg/kg/day,22,26,O
),22,36,O
incidence,22,38,O
of,22,48,O
myelocytic,22,51,O
leukemia,22,62,O
was,22,71,O
observed,22,75,O
in,22,84,O
rats,22,87,O
fed,22,92,O
daily,22,96,O
doses,22,102,O
of,22,108,O
potassium,22,111,O
canrenoate,22,121,O
(,22,132,O
a,22,134,O
compound,22,136,O
chemically,22,145,O
similar,22,156,O
to,22,164,O
ALDACTONE,22,167,O
and,22,177,O
whose,22,181,O
primary,22,187,O
metabolite,22,195,O
",",22,206,O
canrenone,22,208,O
",",22,218,O
is,22,220,O
also,22,223,O
a,22,228,O
major,22,230,O
product,22,236,O
of,22,244,O
ALDACTONE,22,247,O
in,22,257,O
man,22,260,O
),22,264,O
for,22,266,O
a,22,270,O
period,22,272,O
of,22,279,O
one,22,282,O
year,22,286,O
.,22,291,O
ALDACTONE,23,0,O
(,23,10,O
100,23,12,O
mg/kg/day,23,16,O
),23,26,O
",",23,28,O
administered,23,30,O
i.p.,23,43,O
to,23,48,O
female,23,51,O
mice,23,58,O
during,23,63,O
a,23,70,O
two-week,23,72,O
cohabitation,23,81,O
period,23,94,O
with,23,101,O
untreated,23,106,O
males,23,116,O
",",23,122,O
decreased,23,124,O
the,23,134,O
number,23,138,O
of,23,145,O
mated,23,148,O
mice,23,154,O
that,23,159,O
conceived,23,164,O
(,23,174,O
effect,23,176,O
shown,23,183,O
to,23,189,O
be,23,192,O
caused,23,195,O
by,23,202,O
an,23,205,O
inhibition,23,208,O
of,23,219,O
ovulation,23,222,O
),23,232,O
and,23,234,O
decreased,23,238,O
the,23,248,O
number,23,252,O
of,23,259,O
implanted,23,262,O
embryos,23,272,O
in,23,280,O
those,23,283,O
that,23,289,O
became,23,294,O
pregnant,23,301,O
(,23,310,O
effect,23,312,O
shown,23,319,O
to,23,325,O
be,23,328,O
caused,23,331,O
by,23,338,O
an,23,341,O
inhibition,23,344,O
of,23,355,O
implantation,23,358,O
),23,371,O
",",23,373,O
and,23,375,O
at,23,379,O
200,23,382,O
mg/kg,23,386,O
",",23,392,O
also,23,394,O
increased,23,399,O
the,23,409,O
latency,23,413,O
period,23,421,O
to,23,428,O
mating,23,431,O
.,23,438,O
ALDACTONE,24,0,O
has,24,10,O
been,24,14,O
shown,24,19,O
to,24,25,O
increase,24,28,O
the,24,37,O
half-life,24,41,O
of,24,51,O
digoxin,24,54,O
.,24,62,O
ALDACTONE,25,0,O
reduces,25,10,B-SpecificInteraction
the,25,10,I-SpecificInteraction
vascular,25,10,I-SpecificInteraction
responsiveness,25,10,I-SpecificInteraction
to,25,46,O
norepinephrine,25,49,O
.,25,64,O
Because,26,0,O
of,26,8,O
its,26,11,O
antiandrogenic,26,15,O
activity,26,30,O
and,26,39,O
the,26,43,O
requirement,26,47,O
of,26,59,O
testosterone,26,62,O
for,26,75,O
male,26,79,O
morphogenesis,26,84,O
",",26,98,O
ALDACTONE,26,100,O
may,26,110,O
have,26,114,O
the,26,119,O
potential,26,123,O
for,26,133,O
adversely,26,137,O
affecting,26,147,O
sex,26,157,O
differentiation,26,161,O
of,26,177,O
the,26,180,O
male,26,184,O
during,26,189,O
embryogenesis,26,196,O
.,26,210,O
Canrenone,27,0,O
",",27,10,O
a,27,12,O
major,27,14,O
(,27,20,O
and,27,22,O
active,27,26,O
),27,33,O
metabolite,27,35,O
of,27,46,O
ALDACTONE,27,49,O
",",27,59,O
appears,27,61,O
in,27,69,O
human,27,72,O
breast,27,78,O
milk,27,85,O
.,27,90,O
Consequently,28,0,O
",",28,13,O
no,28,15,O
potassium,28,18,O
supplement,28,28,O
should,28,39,O
ordinarily,28,46,O
be,28,57,O
given,28,60,O
with,28,66,O
ALDACTONE,28,71,O
.,28,81,O
Dilutional,29,0,B-SpecificInteraction
hyponatremia,29,0,I-SpecificInteraction
",",29,24,O
manifested,29,26,O
by,29,37,O
dryness,29,40,B-SpecificInteraction
of,29,40,I-SpecificInteraction
the,29,40,I-SpecificInteraction
mouth,29,40,I-SpecificInteraction
",",29,61,O
thirst,29,63,B-SpecificInteraction
",",29,70,O
lethargy,29,72,B-SpecificInteraction
",",29,81,O
and,29,83,O
drowsiness,29,87,B-SpecificInteraction
",",29,98,O
and,29,100,O
confirmed,29,104,O
by,29,114,O
a,29,117,O
low,29,119,B-SpecificInteraction
serum,29,119,I-SpecificInteraction
sodium,29,119,I-SpecificInteraction
level,29,119,I-SpecificInteraction
",",29,142,O
may,29,144,O
be,29,148,O
caused,29,151,O
or,29,158,O
aggravated,29,161,O
",",29,172,O
especially,29,174,O
when,29,185,O
ALDACTONE,29,190,O
is,29,200,O
administered,29,203,O
in,29,216,O
combination,29,219,O
with,29,231,O
other,29,236,O
diuretics,29,242,O
",",29,252,O
and,29,254,O
dilutional,29,258,O
hyponatremia,29,269,O
may,29,282,O
occur,29,286,O
in,29,292,O
edematous,29,295,O
patients,29,305,O
in,29,314,O
hot,29,317,O
weather,29,321,O
",",29,329,O
appropriate,29,331,O
therapy,29,343,O
is,29,351,O
water,29,354,O
restriction,29,360,O
rather,29,372,O
than,29,379,O
administration,29,384,O
of,29,399,O
sodium,29,402,O
",",29,409,O
except,29,411,O
in,29,418,O
rare,29,421,O
instances,29,426,O
when,29,436,O
the,29,441,O
hyponatremia,29,445,O
is,29,458,O
life-threatening,29,461,O
.,29,478,O
Hyperkalemic,30,0,B-SpecificInteraction
metabolic,30,0,I-SpecificInteraction
acidosis,30,0,I-SpecificInteraction
has,30,32,O
been,30,36,O
reported,30,41,O
in,30,50,O
patients,30,53,O
given,30,62,O
ALDACTONE,30,68,O
concurrently,30,78,O
with,30,91,O
cholestyramine,30,96,O
.,30,111,O
In,31,0,O
the,31,3,O
absence,31,7,O
of,31,15,O
metabolic,31,18,O
activation,31,28,O
",",31,39,O
neither,31,41,O
ALDACTONE,31,49,O
nor,31,59,O
potassium,31,63,O
canrenoate,31,73,O
has,31,84,O
been,31,88,O
shown,31,93,O
to,31,99,O
be,31,102,O
mutagenic,31,105,O
in,31,115,O
mammalian,31,118,O
tests,31,128,O
in,31,134,O
vitro,31,137,O
.,31,143,O
Neither,32,0,O
ALDACTONE,32,8,O
nor,32,18,O
potassium,32,22,O
canrenoate,32,32,O
produced,32,43,O
mutagenic,32,52,O
effects,32,62,O
in,32,70,O
tests,32,73,O
using,32,79,O
bacteria,32,85,O
or,32,94,O
yeast,32,97,O
.,32,103,O
Patients,33,0,O
who,33,9,O
receive,33,13,O
ALDACTONE,33,21,O
should,33,31,O
be,33,38,O
advised,33,41,O
to,33,49,O
avoid,33,52,O
potassium,33,58,O
supplements,33,68,O
and,33,80,O
foods,33,84,O
containing,33,90,O
high,33,101,O
levels,33,106,O
of,33,113,O
potassium,33,116,O
",",33,126,O
including,33,128,O
salt,33,138,O
substitutes,33,143,O
.,33,155,O
Several,34,0,O
reports,34,8,O
of,34,16,O
possible,34,19,O
interference,34,28,O
with,34,41,O
digoxin,34,46,O
radioimmunoassay,34,54,O
by,34,71,O
ALDACTONE,34,74,O
",",34,84,O
or,34,86,O
its,34,89,O
metabolites,34,93,O
",",34,105,O
have,34,107,O
appeared,34,112,O
in,34,121,O
the,34,124,O
literature,34,128,O
.,34,139,O
Therefore,35,0,O
",",35,10,O
when,35,12,O
ALDACTONE,35,17,O
and,35,27,O
NSAIDs,35,31,O
are,35,38,O
used,35,42,O
concomitantly,35,47,O
",",35,61,O
the,35,63,O
patient,35,67,O
should,35,75,O
be,35,82,O
observed,35,85,O
closely,35,94,O
to,35,102,O
determine,35,105,O
if,35,115,O
the,35,118,O
desired,35,122,O
effect,35,130,O
of,35,137,O
the,35,140,O
diuretic,35,144,O
is,35,153,O
obtained,35,156,O
.,35,165,O
BREVIBLOC,206,0,O
is,206,10,O
not,206,13,O
compatible,206,17,O
with,206,28,O
Sodium,206,33,O
Bicarbonate,206,40,O
(,206,52,O
5,206,54,O
%,206,56,O
),206,58,O
solution,206,60,O
(,206,69,O
limited,206,71,O
stability,206,79,O
),206,89,O
or,206,91,O
furosemide,206,94,O
(,206,105,O
precipitation,206,107,O
),206,121,O
.,206,123,O
Coadministration,207,0,O
of,207,17,O
IV,207,20,O
cardiodepressant,207,23,O
calcium-channel,207,40,O
antagonists,207,56,O
(,207,68,O
e.g.,207,70,O
verapamil,207,75,O
),207,85,O
in,207,87,O
close,207,90,O
proximity,207,96,O
to,207,106,O
BREVIBLOC,207,109,O
injection,207,119,O
(,207,129,O
4,207,131,O
",",207,133,O
7,207,135,O
),207,137,O
.,207,139,O
Hypersensitivity,208,0,O
reactions,208,17,O
",",208,27,O
including,208,29,O
anaphylaxis,208,39,O
",",208,51,O
to,208,53,O
esmolol,208,56,O
or,208,64,O
any,208,67,O
of,208,71,O
the,208,74,O
inactive,208,78,O
ingredients,208,87,O
of,208,99,O
the,208,102,O
product,208,106,O
(,208,114,O
cross-sensitivity,208,116,O
between,208,134,O
beta,208,142,O
blockers,208,147,O
is,208,156,O
possible,208,159,O
),208,168,O
.,208,170,O
IV,209,0,O
administration,209,3,O
of,209,18,O
cardiodepressant,209,21,O
calcium-channel,209,38,O
antagonists,209,54,O
(,209,66,O
e.g.,209,68,O
",",209,73,O
verapamil,209,75,O
),209,85,O
and,209,87,O
BREVIBLOC,209,91,O
in,209,101,O
close,209,104,O
proximity,209,110,O
(,209,120,O
i.e.,209,122,O
",",209,127,O
while,209,129,O
cardiac,209,135,O
effects,209,143,O
from,209,151,O
the,209,156,O
other,209,160,O
are,209,166,O
still,209,170,O
present,209,176,O
),209,184,O
",",209,186,O
fatal,209,188,O
cardiac,209,194,B-SpecificInteraction
arrests,209,194,I-SpecificInteraction
have,209,194,I-SpecificInteraction
occurred,209,194,I-SpecificInteraction
in,209,194,I-SpecificInteraction
patients,209,194,I-SpecificInteraction
receiving,209,194,I-SpecificInteraction
BREVIBLOC,209,194,I-SpecificInteraction
and,209,194,I-SpecificInteraction
intravenous,209,194,I-SpecificInteraction
verapamil,209,194,I-SpecificInteraction
.,209,194,I-SpecificInteraction
IV,209,0,O
administration,209,3,O
of,209,18,O
cardiodepressant,209,21,O
calcium-channel,209,38,O
antagonists,209,54,O
(,209,66,O
e.g.,209,68,O
",",209,73,O
verapamil,209,75,O
),209,85,O
and,209,87,O
BREVIBLOC,209,91,O
in,209,101,O
close,209,104,O
proximity,209,110,O
(,209,120,O
i.e.,209,122,O
",",209,127,O
while,209,129,O
cardiac,209,135,O
effects,209,143,O
from,209,151,O
the,209,156,O
other,209,160,O
are,209,166,O
still,209,170,O
present,209,176,O
),209,184,O
",",209,186,O
fatal,209,188,O
cardiac,209,194,B-SpecificInteraction
arrests,209,194,I-SpecificInteraction
have,209,194,I-SpecificInteraction
occurred,209,194,I-SpecificInteraction
in,209,194,I-SpecificInteraction
patients,209,194,I-SpecificInteraction
receiving,209,194,I-SpecificInteraction
BREVIBLOC,209,194,I-SpecificInteraction
and,209,194,I-SpecificInteraction
intravenous,209,194,I-SpecificInteraction
verapamil,209,194,I-SpecificInteraction
.,209,194,I-SpecificInteraction
(,210,0,O
See,210,1,O
clonidine,210,5,O
",",210,14,O
guanfacine,210,16,O
",",210,26,O
and,210,28,O
moxonidine,210,32,O
below,210,43,O
.,210,48,O
),210,49,O
Anticholinesterases,211,0,O
:,211,20,O
BREVIBLOC,211,22,O
prolonged,211,32,O
the,211,42,O
duration,211,46,O
of,211,55,O
succinylcholine-induced,211,58,O
neuromuscular,211,82,O
blockade,211,96,O
and,211,105,O
moderately,211,109,O
prolonged,211,120,O
clinical,211,130,O
duration,211,139,O
and,211,148,O
recovery,211,152,O
index,211,161,O
of,211,167,O
mivacurium,211,170,O
.,211,181,O
Antihypertensive,212,0,O
agents,212,17,O
clonidine,212,24,O
",",212,33,O
guanfacine,212,35,O
",",212,45,O
or,212,47,O
moxonidine,212,50,O
:,212,60,O
Beta,212,62,O
blockers,212,67,O
also,212,76,O
increase,212,81,O
the,212,90,O
risk,212,94,O
of,212,99,O
clonidine-,212,102,O
",",212,112,O
guanfacine-,212,114,O
",",212,125,O
or,212,127,O
moxonidine-withdrawal,212,130,O
rebound,212,152,B-SpecificInteraction
hypertension,212,152,I-SpecificInteraction
.,212,172,O
Antihypertensive,212,0,O
agents,212,17,O
clonidine,212,24,O
",",212,33,O
guanfacine,212,35,O
",",212,45,O
or,212,47,O
moxonidine,212,50,O
:,212,60,O
Beta,212,62,O
blockers,212,67,O
also,212,76,O
increase,212,81,O
the,212,90,O
risk,212,94,O
of,212,99,O
clonidine-,212,102,O
",",212,112,O
guanfacine-,212,114,O
",",212,125,O
or,212,127,O
moxonidine-withdrawal,212,130,O
rebound,212,152,B-SpecificInteraction
hypertension,212,152,I-SpecificInteraction
.,212,172,O
Antihypertensive,212,0,O
agents,212,17,O
clonidine,212,24,O
",",212,33,O
guanfacine,212,35,O
",",212,45,O
or,212,47,O
moxonidine,212,50,O
:,212,60,O
Beta,212,62,O
blockers,212,67,O
also,212,76,O
increase,212,81,O
the,212,90,O
risk,212,94,O
of,212,99,O
clonidine-,212,102,O
",",212,112,O
guanfacine-,212,114,O
",",212,125,O
or,212,127,O
moxonidine-withdrawal,212,130,O
rebound,212,152,B-SpecificInteraction
hypertension,212,152,I-SpecificInteraction
.,212,172,O
Both,213,0,O
digoxin,213,5,O
and,213,13,O
beta,213,17,O
blockers,213,22,O
slow,213,31,O
atrioventricular,213,36,O
conduction,213,53,O
and,213,64,O
decrease,213,68,O
heart,213,77,O
rate,213,83,O
.,213,87,O
BREVIBLOC,214,0,O
should,214,10,O
therefore,214,17,O
be,214,27,O
used,214,30,O
only,214,35,O
after,214,40,O
careful,214,46,O
individual,214,54,O
assessment,214,65,O
of,214,76,O
the,214,79,O
risks,214,83,O
and,214,89,O
expected,214,93,O
benefits,214,102,O
in,214,111,O
patients,214,114,O
receiving,214,123,O
drugs,214,133,O
that,214,139,O
can,214,144,O
cause,214,148,O
these,214,154,O
types,214,160,O
of,214,166,O
pharmacodynamic,214,169,O
interactions,214,185,O
",",214,198,O
including,214,200,O
but,214,210,O
not,214,214,O
limited,214,218,O
to,214,226,O
:,214,229,O
.,214,231,O
Calcium,215,0,O
channel,215,8,O
antagonists,215,16,O
:,215,28,O
In,215,30,O
patients,215,33,O
with,215,42,O
depressed,215,47,O
myocardial,215,57,O
function,215,68,O
",",215,77,O
use,215,79,O
of,215,83,O
BREVIBLOC,215,86,O
with,215,96,O
cardiodepressant,215,101,O
calcium,215,118,O
channel,215,126,O
antagonists,215,134,O
(,215,146,O
e.g.,215,148,O
",",215,153,O
verapamil,215,155,O
),215,165,O
can,215,167,O
lead,215,171,O
to,215,176,O
fatal,215,179,B-SpecificInteraction
cardiac,215,179,I-SpecificInteraction
arrests,215,179,I-SpecificInteraction
.,215,201,O
Calcium,215,0,O
channel,215,8,O
antagonists,215,16,O
:,215,28,O
In,215,30,O
patients,215,33,O
with,215,42,O
depressed,215,47,O
myocardial,215,57,O
function,215,68,O
",",215,77,O
use,215,79,O
of,215,83,O
BREVIBLOC,215,86,O
with,215,96,O
cardiodepressant,215,101,O
calcium,215,118,O
channel,215,126,O
antagonists,215,134,O
(,215,146,O
e.g.,215,148,O
",",215,153,O
verapamil,215,155,O
),215,165,O
can,215,167,O
lead,215,171,O
to,215,176,O
fatal,215,179,B-SpecificInteraction
cardiac,215,179,I-SpecificInteraction
arrests,215,179,I-SpecificInteraction
.,215,201,O
Concomitant,216,0,O
use,216,12,O
increases,216,16,O
the,216,26,O
risk,216,30,O
of,216,35,O
bradycardia,216,38,O
.,216,49,O
Concomitant,217,0,O
use,217,12,O
of,217,16,O
BREVIBLOC,217,19,O
injection,217,29,O
with,217,39,O
other,217,44,O
drugs,217,50,O
that,217,56,O
can,217,61,O
lower,217,65,B-SpecificInteraction
blood,217,65,I-SpecificInteraction
pressure,217,65,I-SpecificInteraction
",",217,86,O
reduce,217,88,B-SpecificInteraction
myocardial,217,88,I-SpecificInteraction
contractility,217,88,I-SpecificInteraction
",",217,120,O
or,217,122,O
interfere,217,125,O
with,217,135,O
sinus,217,140,O
node,217,146,O
function,217,151,O
or,217,160,O
electrical,217,163,O
impulse,217,174,O
propagation,217,182,O
in,217,194,O
the,217,197,O
myocardium,217,201,O
can,217,212,O
exaggerate,217,216,O
BREVIBLOC,217,227,O
s,217,237,O
effects,217,239,O
on,217,247,O
blood,217,250,O
pressure,217,256,O
",",217,265,O
contractility,217,267,O
",",217,281,O
and,217,283,O
impulse,217,287,O
propagation,217,295,O
.,217,307,O
Concomitant,217,0,O
use,217,12,O
of,217,16,O
BREVIBLOC,217,19,O
injection,217,29,O
with,217,39,O
other,217,44,O
drugs,217,50,O
that,217,56,O
can,217,61,O
lower,217,65,B-SpecificInteraction
blood,217,65,I-SpecificInteraction
pressure,217,65,I-SpecificInteraction
",",217,86,O
reduce,217,88,B-SpecificInteraction
myocardial,217,88,I-SpecificInteraction
contractility,217,88,I-SpecificInteraction
",",217,120,O
or,217,122,O
interfere,217,125,O
with,217,135,O
sinus,217,140,O
node,217,146,O
function,217,151,O
or,217,160,O
electrical,217,163,O
impulse,217,174,O
propagation,217,182,O
in,217,194,O
the,217,197,O
myocardium,217,201,O
can,217,212,O
exaggerate,217,216,O
BREVIBLOC,217,227,O
s,217,237,O
effects,217,239,O
on,217,247,O
blood,217,250,O
pressure,217,256,O
",",217,265,O
contractility,217,267,O
",",217,281,O
and,217,283,O
impulse,217,287,O
propagation,217,295,O
.,217,307,O
Concomitant,217,0,O
use,217,12,O
of,217,16,O
BREVIBLOC,217,19,O
injection,217,29,O
with,217,39,O
other,217,44,O
drugs,217,50,O
that,217,56,O
can,217,61,O
lower,217,65,B-SpecificInteraction
blood,217,65,I-SpecificInteraction
pressure,217,65,I-SpecificInteraction
",",217,86,O
reduce,217,88,B-SpecificInteraction
myocardial,217,88,I-SpecificInteraction
contractility,217,88,I-SpecificInteraction
",",217,120,O
or,217,122,O
interfere,217,125,O
with,217,135,O
sinus,217,140,O
node,217,146,O
function,217,151,O
or,217,160,O
electrical,217,163,O
impulse,217,174,O
propagation,217,182,O
in,217,194,O
the,217,197,O
myocardium,217,201,O
can,217,212,O
exaggerate,217,216,O
BREVIBLOC,217,227,O
s,217,237,O
effects,217,239,O
on,217,247,O
blood,217,250,O
pressure,217,256,O
",",217,265,O
contractility,217,267,O
",",217,281,O
and,217,283,O
impulse,217,287,O
propagation,217,295,O
.,217,307,O
Concomitant,217,0,O
use,217,12,O
of,217,16,O
BREVIBLOC,217,19,O
injection,217,29,O
with,217,39,O
other,217,44,O
drugs,217,50,O
that,217,56,O
can,217,61,O
lower,217,65,B-SpecificInteraction
blood,217,65,I-SpecificInteraction
pressure,217,65,I-SpecificInteraction
",",217,86,O
reduce,217,88,B-SpecificInteraction
myocardial,217,88,I-SpecificInteraction
contractility,217,88,I-SpecificInteraction
",",217,120,O
or,217,122,O
interfere,217,125,O
with,217,135,O
sinus,217,140,O
node,217,146,O
function,217,151,O
or,217,160,O
electrical,217,163,O
impulse,217,174,O
propagation,217,182,O
in,217,194,O
the,217,197,O
myocardium,217,201,O
can,217,212,O
exaggerate,217,216,O
BREVIBLOC,217,227,O
s,217,237,O
effects,217,239,O
on,217,247,O
blood,217,250,O
pressure,217,256,O
",",217,265,O
contractility,217,267,O
",",217,281,O
and,217,283,O
impulse,217,287,O
propagation,217,295,O
.,217,307,O
Digitalis,218,0,O
glycosides,218,10,O
:,218,21,O
Concomitant,218,23,O
administration,218,35,O
of,218,50,O
digoxin,218,53,O
and,218,61,O
BREVIBLOC,218,65,O
leads,218,75,O
to,218,81,O
an,218,84,O
approximate,218,87,O
10,218,99,O
%,218,102,O
to,218,104,O
20,218,107,O
%,218,110,O
increase,218,112,O
of,218,121,O
digoxin,218,124,O
blood,218,132,O
levels,218,138,O
at,218,145,O
some,218,148,O
time,218,153,O
points,218,158,O
.,218,165,O
Digitalis,219,0,O
glycosides,219,10,O
:,219,20,O
Risk,219,22,O
of,219,27,O
bradycardia,219,30,B-SpecificInteraction
(,219,42,O
7,219,43,O
),219,44,O
Anticholinesterases,219,46,O
:,219,65,O
Prolongs,219,67,B-SpecificInteraction
neuromuscular,219,67,I-SpecificInteraction
blockade,219,67,I-SpecificInteraction
(,219,99,O
7,219,100,O
),219,101,O
Antihypertensive,219,103,O
agents,219,120,O
:,219,126,O
Risk,219,128,O
of,219,133,O
rebound,219,136,B-SpecificInteraction
hypertension,219,136,I-SpecificInteraction
(,219,157,O
7,219,158,O
),219,159,O
Sympathomimetic,219,161,O
drugs,219,177,O
:,219,182,O
Dose,219,184,O
adjustment,219,189,O
needed,219,200,O
(,219,207,O
7,219,208,O
),219,209,O
Vasoconstrictive,219,211,O
and,219,228,O
positive,219,232,O
inotropic,219,241,O
effect,219,251,O
substances,219,258,O
:,219,268,O
Avoid,219,270,O
concomitant,219,276,O
use,219,288,O
(,219,292,O
7,219,293,O
),219,294,O
Digitalis,219,0,O
glycosides,219,10,O
:,219,20,O
Risk,219,22,O
of,219,27,O
bradycardia,219,30,B-SpecificInteraction
(,219,42,O
7,219,43,O
),219,44,O
Anticholinesterases,219,46,O
:,219,65,O
Prolongs,219,67,B-SpecificInteraction
neuromuscular,219,67,I-SpecificInteraction
blockade,219,67,I-SpecificInteraction
(,219,99,O
7,219,100,O
),219,101,O
Antihypertensive,219,103,O
agents,219,120,O
:,219,126,O
Risk,219,128,O
of,219,133,O
rebound,219,136,B-SpecificInteraction
hypertension,219,136,I-SpecificInteraction
(,219,157,O
7,219,158,O
),219,159,O
Sympathomimetic,219,161,O
drugs,219,177,O
:,219,182,O
Dose,219,184,O
adjustment,219,189,O
needed,219,200,O
(,219,207,O
7,219,208,O
),219,209,O
Vasoconstrictive,219,211,O
and,219,228,O
positive,219,232,O
inotropic,219,241,O
effect,219,251,O
substances,219,258,O
:,219,268,O
Avoid,219,270,O
concomitant,219,276,O
use,219,288,O
(,219,292,O
7,219,293,O
),219,294,O
Digitalis,219,0,O
glycosides,219,10,O
:,219,20,O
Risk,219,22,O
of,219,27,O
bradycardia,219,30,B-SpecificInteraction
(,219,42,O
7,219,43,O
),219,44,O
Anticholinesterases,219,46,O
:,219,65,O
Prolongs,219,67,B-SpecificInteraction
neuromuscular,219,67,I-SpecificInteraction
blockade,219,67,I-SpecificInteraction
(,219,99,O
7,219,100,O
),219,101,O
Antihypertensive,219,103,O
agents,219,120,O
:,219,126,O
Risk,219,128,O
of,219,133,O
rebound,219,136,B-SpecificInteraction
hypertension,219,136,I-SpecificInteraction
(,219,157,O
7,219,158,O
),219,159,O
Sympathomimetic,219,161,O
drugs,219,177,O
:,219,182,O
Dose,219,184,O
adjustment,219,189,O
needed,219,200,O
(,219,207,O
7,219,208,O
),219,209,O
Vasoconstrictive,219,211,O
and,219,228,O
positive,219,232,O
inotropic,219,241,O
effect,219,251,O
substances,219,258,O
:,219,268,O
Avoid,219,270,O
concomitant,219,276,O
use,219,288,O
(,219,292,O
7,219,293,O
),219,294,O
Digitalis,219,0,O
glycosides,219,10,O
:,219,20,O
Risk,219,22,O
of,219,27,O
bradycardia,219,30,B-SpecificInteraction
(,219,42,O
7,219,43,O
),219,44,O
Anticholinesterases,219,46,O
:,219,65,O
Prolongs,219,67,B-SpecificInteraction
neuromuscular,219,67,I-SpecificInteraction
blockade,219,67,I-SpecificInteraction
(,219,99,O
7,219,100,O
),219,101,O
Antihypertensive,219,103,O
agents,219,120,O
:,219,126,O
Risk,219,128,O
of,219,133,O
rebound,219,136,B-SpecificInteraction
hypertension,219,136,I-SpecificInteraction
(,219,157,O
7,219,158,O
),219,159,O
Sympathomimetic,219,161,O
drugs,219,177,O
:,219,182,O
Dose,219,184,O
adjustment,219,189,O
needed,219,200,O
(,219,207,O
7,219,208,O
),219,209,O
Vasoconstrictive,219,211,O
and,219,228,O
positive,219,232,O
inotropic,219,241,O
effect,219,251,O
substances,219,258,O
:,219,268,O
Avoid,219,270,O
concomitant,219,276,O
use,219,288,O
(,219,292,O
7,219,293,O
),219,294,O
Digitalis,219,0,O
glycosides,219,10,O
:,219,20,O
Risk,219,22,O
of,219,27,O
bradycardia,219,30,B-SpecificInteraction
(,219,42,O
7,219,43,O
),219,44,O
Anticholinesterases,219,46,O
:,219,65,O
Prolongs,219,67,B-SpecificInteraction
neuromuscular,219,67,I-SpecificInteraction
blockade,219,67,I-SpecificInteraction
(,219,99,O
7,219,100,O
),219,101,O
Antihypertensive,219,103,O
agents,219,120,O
:,219,126,O
Risk,219,128,O
of,219,133,O
rebound,219,136,B-SpecificInteraction
hypertension,219,136,I-SpecificInteraction
(,219,157,O
7,219,158,O
),219,159,O
Sympathomimetic,219,161,O
drugs,219,177,O
:,219,182,O
Dose,219,184,O
adjustment,219,189,O
needed,219,200,O
(,219,207,O
7,219,208,O
),219,209,O
Vasoconstrictive,219,211,O
and,219,228,O
positive,219,232,O
inotropic,219,241,O
effect,219,251,O
substances,219,258,O
:,219,268,O
Avoid,219,270,O
concomitant,219,276,O
use,219,288,O
(,219,292,O
7,219,293,O
),219,294,O
Digitalis,219,0,O
glycosides,219,10,O
:,219,20,O
Risk,219,22,O
of,219,27,O
bradycardia,219,30,B-SpecificInteraction
(,219,42,O
7,219,43,O
),219,44,O
Anticholinesterases,219,46,O
:,219,65,O
Prolongs,219,67,B-SpecificInteraction
neuromuscular,219,67,I-SpecificInteraction
blockade,219,67,I-SpecificInteraction
(,219,99,O
7,219,100,O
),219,101,O
Antihypertensive,219,103,O
agents,219,120,O
:,219,126,O
Risk,219,128,O
of,219,133,O
rebound,219,136,B-SpecificInteraction
hypertension,219,136,I-SpecificInteraction
(,219,157,O
7,219,158,O
),219,159,O
Sympathomimetic,219,161,O
drugs,219,177,O
:,219,182,O
Dose,219,184,O
adjustment,219,189,O
needed,219,200,O
(,219,207,O
7,219,208,O
),219,209,O
Vasoconstrictive,219,211,O
and,219,228,O
positive,219,232,O
inotropic,219,241,O
effect,219,251,O
substances,219,258,O
:,219,268,O
Avoid,219,270,O
concomitant,219,276,O
use,219,288,O
(,219,292,O
7,219,293,O
),219,294,O
Digoxin,220,0,O
does,220,8,O
not,220,13,O
affect,220,17,O
BREVIBLOC,220,24,O
pharmacokinetics,220,34,O
.,220,51,O
If,221,0,O
",",221,2,O
during,221,4,O
concomitant,221,11,O
use,221,23,O
of,221,27,O
a,221,30,O
beta,221,32,O
blocker,221,37,O
",",221,44,O
antihypertensive,221,46,O
therapy,221,63,O
needs,221,71,O
to,221,77,O
be,221,80,O
interrupted,221,83,O
or,221,95,O
discontinued,221,98,O
",",221,110,O
discontinue,221,112,O
the,221,124,O
beta,221,128,O
blocker,221,133,O
first,221,141,O
",",221,146,O
and,221,148,O
the,221,152,O
discontinuation,221,156,O
should,221,172,O
be,221,179,O
gradual,221,182,O
.,221,189,O
In,222,0,O
addition,222,3,O
",",222,11,O
with,222,13,O
some,222,18,O
drugs,222,23,O
",",222,28,O
beta,222,30,O
blockade,222,35,O
may,222,44,O
precipitate,222,48,O
increased,222,60,O
withdrawal,222,70,B-SpecificInteraction
effects,222,70,I-SpecificInteraction
.,222,88,O
Severe,223,0,O
interactions,223,7,O
with,223,20,O
such,223,25,O
drugs,223,30,O
can,223,36,O
result,223,40,O
in,223,47,O
",",223,49,O
for,223,51,O
example,223,55,O
",",223,62,O
severe,223,64,O
hypotension,223,71,O
",",223,82,O
cardiac,223,84,O
failure,223,92,O
",",223,99,O
severe,223,101,O
bradycardia,223,108,O
",",223,119,O
sinus,223,121,O
pause,223,127,O
",",223,132,O
sinoatrial,223,134,O
block,223,145,O
",",223,150,O
atrioventricular,223,152,O
block,223,169,O
",",223,174,O
and/or,223,176,O
cardiac,223,183,O
arrest,223,191,O
.,223,197,O
Sympathomimetic,224,0,O
drugs,224,16,O
:,224,22,O
Sympathomimetic,224,24,O
drugs,224,40,O
having,224,46,O
beta-adrenergic,224,53,O
agonist,224,69,O
activity,224,77,O
will,224,86,O
counteract,224,91,B-SpecificInteraction
effects,224,91,I-SpecificInteraction
of,224,91,I-SpecificInteraction
BREVIBLOC,224,91,I-SpecificInteraction
.,224,123,O
Vasoconstrictive,225,0,O
and,225,17,O
positive,225,21,O
inotropic,225,30,O
agents,225,40,O
:,225,47,O
Because,225,49,O
of,225,57,O
the,225,60,O
risk,225,64,O
of,225,69,O
reducing,225,72,B-SpecificInteraction
cardiac,225,72,I-SpecificInteraction
contractility,225,72,I-SpecificInteraction
in,225,103,O
presence,225,106,O
of,225,115,O
high,225,118,O
systemic,225,123,O
vascular,225,132,O
resistance,225,141,O
",",225,152,O
do,225,154,O
not,225,157,O
use,225,161,O
BREVIBLOC,225,165,O
to,225,175,O
control,225,178,O
tachycardia,225,186,O
in,225,198,O
patients,225,201,O
receiving,225,210,O
drugs,225,220,O
that,225,226,O
are,225,231,O
vasoconstrictive,225,235,O
and,225,252,O
have,225,256,O
positive,225,261,O
inotropic,225,270,O
effects,225,280,O
",",225,288,O
such,225,290,O
as,225,295,O
epinephrine,225,298,O
",",225,310,O
norepinephrine,225,312,O
",",225,327,O
and,225,329,O
dopamine,225,333,O
.,225,342,O
Vasoconstrictive,225,0,O
and,225,17,O
positive,225,21,O
inotropic,225,30,O
agents,225,40,O
:,225,47,O
Because,225,49,O
of,225,57,O
the,225,60,O
risk,225,64,O
of,225,69,O
reducing,225,72,B-SpecificInteraction
cardiac,225,72,I-SpecificInteraction
contractility,225,72,I-SpecificInteraction
in,225,103,O
presence,225,106,O
of,225,115,O
high,225,118,O
systemic,225,123,O
vascular,225,132,O
resistance,225,141,O
",",225,152,O
do,225,154,O
not,225,157,O
use,225,161,O
BREVIBLOC,225,165,O
to,225,175,O
control,225,178,O
tachycardia,225,186,O
in,225,198,O
patients,225,201,O
receiving,225,210,O
drugs,225,220,O
that,225,226,O
are,225,231,O
vasoconstrictive,225,235,O
and,225,252,O
have,225,256,O
positive,225,261,O
inotropic,225,270,O
effects,225,280,O
",",225,288,O
such,225,290,O
as,225,295,O
epinephrine,225,298,O
",",225,310,O
norepinephrine,225,312,O
",",225,327,O
and,225,329,O
dopamine,225,333,O
.,225,342,O
Vasoconstrictive,225,0,O
and,225,17,O
positive,225,21,O
inotropic,225,30,O
agents,225,40,O
:,225,47,O
Because,225,49,O
of,225,57,O
the,225,60,O
risk,225,64,O
of,225,69,O
reducing,225,72,B-SpecificInteraction
cardiac,225,72,I-SpecificInteraction
contractility,225,72,I-SpecificInteraction
in,225,103,O
presence,225,106,O
of,225,115,O
high,225,118,O
systemic,225,123,O
vascular,225,132,O
resistance,225,141,O
",",225,152,O
do,225,154,O
not,225,157,O
use,225,161,O
BREVIBLOC,225,165,O
to,225,175,O
control,225,178,O
tachycardia,225,186,O
in,225,198,O
patients,225,201,O
receiving,225,210,O
drugs,225,220,O
that,225,226,O
are,225,231,O
vasoconstrictive,225,235,O
and,225,252,O
have,225,256,O
positive,225,261,O
inotropic,225,270,O
effects,225,280,O
",",225,288,O
such,225,290,O
as,225,295,O
epinephrine,225,298,O
",",225,310,O
norepinephrine,225,312,O
",",225,327,O
and,225,329,O
dopamine,225,333,O
.,225,342,O
Vasoconstrictive,225,0,O
and,225,17,O
positive,225,21,O
inotropic,225,30,O
agents,225,40,O
:,225,47,O
Because,225,49,O
of,225,57,O
the,225,60,O
risk,225,64,O
of,225,69,O
reducing,225,72,B-SpecificInteraction
cardiac,225,72,I-SpecificInteraction
contractility,225,72,I-SpecificInteraction
in,225,103,O
presence,225,106,O
of,225,115,O
high,225,118,O
systemic,225,123,O
vascular,225,132,O
resistance,225,141,O
",",225,152,O
do,225,154,O
not,225,157,O
use,225,161,O
BREVIBLOC,225,165,O
to,225,175,O
control,225,178,O
tachycardia,225,186,O
in,225,198,O
patients,225,201,O
receiving,225,210,O
drugs,225,220,O
that,225,226,O
are,225,231,O
vasoconstrictive,225,235,O
and,225,252,O
have,225,256,O
positive,225,261,O
inotropic,225,270,O
effects,225,280,O
",",225,288,O
such,225,290,O
as,225,295,O
epinephrine,225,298,O
",",225,310,O
norepinephrine,225,312,O
",",225,327,O
and,225,329,O
dopamine,225,333,O
.,225,342,O
Vasoconstrictive,225,0,O
and,225,17,O
positive,225,21,O
inotropic,225,30,O
agents,225,40,O
:,225,47,O
Because,225,49,O
of,225,57,O
the,225,60,O
risk,225,64,O
of,225,69,O
reducing,225,72,B-SpecificInteraction
cardiac,225,72,I-SpecificInteraction
contractility,225,72,I-SpecificInteraction
in,225,103,O
presence,225,106,O
of,225,115,O
high,225,118,O
systemic,225,123,O
vascular,225,132,O
resistance,225,141,O
",",225,152,O
do,225,154,O
not,225,157,O
use,225,161,O
BREVIBLOC,225,165,O
to,225,175,O
control,225,178,O
tachycardia,225,186,O
in,225,198,O
patients,225,201,O
receiving,225,210,O
drugs,225,220,O
that,225,226,O
are,225,231,O
vasoconstrictive,225,235,O
and,225,252,O
have,225,256,O
positive,225,261,O
inotropic,225,270,O
effects,225,280,O
",",225,288,O
such,225,290,O
as,225,295,O
epinephrine,225,298,O
",",225,310,O
norepinephrine,225,312,O
",",225,327,O
and,225,329,O
dopamine,225,333,O
.,225,342,O
Beta,226,0,O
blockers,226,5,O
",",226,14,O
including,226,16,O
BREVIBLOC,226,26,O
",",226,36,O
have,226,38,O
been,226,43,O
associated,226,48,O
with,226,59,O
increases,226,64,O
in,226,74,O
serum,226,77,O
potassium,226,83,O
levels,226,93,O
and,226,100,O
hyperkalemia,226,104,O
.,226,117,O
Beta,227,0,O
blockers,227,5,O
",",227,14,O
including,227,16,O
BREVIBLOC,227,26,O
",",227,36,O
have,227,38,O
been,227,43,O
reported,227,48,O
to,227,57,O
cause,227,60,O
hyperkalemic,227,66,O
renal,227,79,O
tubular,227,85,O
acidosis,227,93,O
.,227,102,O
Beta,228,0,O
blockers,228,5,O
",",228,14,O
like,228,16,O
BREVIBLOC,228,21,O
injection,228,31,O
",",228,41,O
can,228,43,O
cause,228,47,O
depression,228,53,O
of,228,64,O
myocardial,228,67,O
contractility,228,78,O
and,228,92,O
may,228,96,O
precipitate,228,100,O
heart,228,112,O
failure,228,118,O
and,228,126,O
cardiogenic,228,130,O
shock,228,142,O
.,228,148,O
If,229,0,O
BREVIBLOC,229,3,O
is,229,13,O
used,229,16,O
in,229,21,O
the,229,24,O
setting,229,28,O
of,229,36,O
pheochromocytoma,229,39,O
",",229,56,O
give,229,58,O
it,229,63,O
in,229,66,O
combination,229,69,O
with,229,81,O
an,229,86,O
alpha-blocker,229,89,O
",",229,103,O
and,229,105,O
only,229,109,O
after,229,114,O
the,229,120,O
alpha-blocker,229,124,O
has,229,138,O
been,229,142,O
initiated,229,147,O
.,229,157,O
Monitor,230,0,O
serum,230,8,O
electrolytes,230,14,O
during,230,27,O
therapy,230,34,O
with,230,42,O
BREVIBLOC,230,47,O
.,230,57,O
ASPIRIN,523,0,O
DOSE,523,8,O
AND,523,13,O
BRILINTA,523,17,O
EFFECTIVENESS,523,26,O
.,523,40,O
BRILINTA,524,0,O
",",524,9,O
like,524,11,O
other,524,16,O
antiplatelet,524,22,O
agents,524,35,O
",",524,42,O
can,524,44,O
cause,524,48,O
significant,524,54,O
",",524,66,O
sometimes,524,68,O
fatal,524,78,O
bleeding,524,84,O
(,524,93,O
5.1,524,95,O
",",524,99,O
6.1,524,101,O
),524,105,O
.,524,107,O
Maintenance,525,0,O
doses,525,12,O
of,525,18,O
aspirin,525,21,O
above,525,29,O
100,525,35,O
mg,525,39,O
reduce,525,42,B-SpecificInteraction
the,525,42,I-SpecificInteraction
effectiveness,525,42,I-SpecificInteraction
of,525,42,I-SpecificInteraction
BRILINTA,525,42,I-SpecificInteraction
and,525,79,O
should,525,83,O
be,525,90,O
avoided,525,93,O
(,525,101,O
2.1,525,103,O
",",525,107,O
5.2,525,109,O
",",525,113,O
14.1,525,115,O
),525,120,O
.,525,122,O
Maintenance,526,0,O
doses,526,12,O
of,526,18,O
aspirin,526,21,O
above,526,29,O
100,526,35,O
mg,526,39,O
reduce,526,42,B-SpecificInteraction
the,526,42,I-SpecificInteraction
effectiveness,526,42,I-SpecificInteraction
of,526,42,I-SpecificInteraction
BRILINTA,526,42,I-SpecificInteraction
and,526,79,O
should,526,83,O
be,526,90,O
avoided,526,93,O
.,526,101,O
WARNING,527,0,O
:,527,8,O
(,527,10,O
A,527,12,O
),527,14,O
BLEEDING,527,16,O
RISK,527,25,O
",",527,30,O
(,527,32,O
B,527,34,O
),527,36,O
ASPIRIN,527,38,O
DOSE,527,46,O
AND,527,51,O
BRILINTA,527,55,O
EFFECTIVENESS,527,64,O
.,527,78,O
WARNING,528,0,O
:,528,8,O
(,528,10,O
A,528,12,O
),528,14,O
BLEEDING,528,16,O
RISK,528,25,O
",",528,30,O
and,528,32,O
(,528,36,O
B,528,38,O
),528,40,O
ASPIRIN,528,42,O
DOSE,528,50,O
AND,528,55,O
BRILINTA,528,59,O
EFFECTIVENESS,528,68,O
.,528,82,O
Do,529,0,O
not,529,3,O
administer,529,7,O
BRILINTA,529,18,O
with,529,27,O
another,529,32,O
oral,529,40,O
P2Y12,529,45,O
platelet,529,51,O
inhibitor,529,60,O
.,529,70,O
Use,530,0,O
BRILINTA,530,4,O
with,530,13,O
a,530,18,O
daily,530,20,O
maintenance,530,26,O
dose,530,38,O
of,530,43,O
aspirin,530,46,O
of,530,54,O
75-100,530,57,O
mg,530,64,O
.,530,67,O
Use,531,0,O
BRILINTA,531,4,O
with,531,13,O
a,531,18,O
daily,531,20,O
maintenance,531,26,O
dose,531,38,O
of,531,43,O
aspirin,531,46,O
of,531,54,O
75-100,531,57,O
mg,531,64,O
see,531,67,O
Warnings,531,71,O
and,531,80,O
Precautions,531,84,O
(,531,96,O
5.2,531,98,O
),531,102,O
and,531,104,O
Clinical,531,108,O
Studies,531,117,O
(,531,125,O
14.1,531,127,O
),531,132,O
.,531,134,O
(,532,0,O
7.1,532,1,O
",",532,4,O
7.2,532,6,O
),532,9,O
Patients,532,11,O
receiving,532,20,O
more,532,30,O
than,532,35,O
40,532,40,O
mg,532,43,O
per,532,46,O
day,532,50,O
of,532,54,O
simvastatin,532,57,O
or,532,69,O
lovastatin,532,72,O
may,532,83,O
be,532,87,O
at,532,90,O
increased,532,93,O
risk,532,103,O
of,532,108,O
statin-related,532,111,B-SpecificInteraction
adverse,532,111,I-SpecificInteraction
effects,532,111,I-SpecificInteraction
.,532,141,O
(,532,0,O
7.1,532,1,O
",",532,4,O
7.2,532,6,O
),532,9,O
Patients,532,11,O
receiving,532,20,O
more,532,30,O
than,532,35,O
40,532,40,O
mg,532,43,O
per,532,46,O
day,532,50,O
of,532,54,O
simvastatin,532,57,O
or,532,69,O
lovastatin,532,72,O
may,532,83,O
be,532,87,O
at,532,90,O
increased,532,93,O
risk,532,103,O
of,532,108,O
statin-related,532,111,B-SpecificInteraction
adverse,532,111,I-SpecificInteraction
effects,532,111,I-SpecificInteraction
.,532,141,O
(,533,0,O
7.4,533,1,O
),533,4,O
Monitor,533,6,O
digoxin,533,14,O
levels,533,22,O
with,533,29,O
initiation,533,34,O
of,533,45,O
or,533,48,O
any,533,51,O
change,533,55,O
in,533,62,O
BRILINTA,533,65,O
.,533,73,O
(,534,0,O
7.5,534,1,O
),534,4,O
Strong,534,6,O
CYP3A,534,13,O
inhibitors,534,19,O
substantially,534,30,O
increase,534,44,O
ticagrelor,534,53,O
exposure,534,64,O
and,534,73,O
so,534,77,O
increase,534,80,O
the,534,89,O
risk,534,93,O
of,534,98,O
dyspnea,534,101,B-SpecificInteraction
",",534,108,O
bleeding,534,110,B-SpecificInteraction
",",534,118,O
and,534,120,O
other,534,124,O
adverse,534,130,O
events,534,138,O
.,534,144,O
(,534,0,O
7.5,534,1,O
),534,4,O
Strong,534,6,O
CYP3A,534,13,O
inhibitors,534,19,O
substantially,534,30,O
increase,534,44,O
ticagrelor,534,53,O
exposure,534,64,O
and,534,73,O
so,534,77,O
increase,534,80,O
the,534,89,O
risk,534,93,O
of,534,98,O
dyspnea,534,101,B-SpecificInteraction
",",534,108,O
bleeding,534,110,B-SpecificInteraction
",",534,118,O
and,534,120,O
other,534,124,O
adverse,534,130,O
events,534,138,O
.,534,144,O
Avoid,535,0,O
simvastatin,535,6,O
and,535,18,O
lovastatin,535,22,O
doses,535,33,O
greater,535,39,O
than,535,47,O
40,535,52,O
mg,535,55,O
[,535,58,O
see,535,59,O
Clinical,535,63,O
Pharmacology,535,72,O
(,535,85,O
12.3,535,86,O
),535,90,O
],535,92,O
.,535,93,O
Avoid,535,0,O
simvastatin,535,6,O
and,535,18,O
lovastatin,535,22,O
doses,535,33,O
greater,535,39,O
than,535,47,O
40,535,52,O
mg,535,55,O
[,535,58,O
see,535,59,O
Clinical,535,63,O
Pharmacology,535,72,O
(,535,85,O
12.3,535,86,O
),535,90,O
],535,92,O
.,535,93,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,536,0,O
use,536,6,O
of,536,10,O
strong,536,13,O
inhibitors,536,20,O
of,536,31,O
CYP3A,536,34,O
(,536,40,O
e.g.,536,41,O
",",536,45,O
ketoconazole,536,47,O
",",536,59,O
itraconazole,536,61,O
",",536,73,O
voriconazole,536,75,O
",",536,87,O
clarithromycin,536,89,O
",",536,103,O
nefazodone,536,105,O
",",536,115,O
ritonavir,536,117,O
",",536,126,O
saquinavir,536,128,O
",",536,138,O
nelfinavir,536,140,O
",",536,150,O
indinavir,536,152,O
",",536,161,O
atazanavir,536,163,O
and,536,174,O
telithromycin,536,178,O
),536,191,O
[,536,193,O
see,536,194,O
Clinical,536,198,O
Pharmacology,536,207,O
(,536,220,O
12.3,536,221,O
),536,225,O
],536,227,O
.,536,228,O
Avoid,537,0,O
use,537,6,O
with,537,10,O
strong,537,15,O
CYP3A,537,22,O
inhibitors,537,28,O
or,537,39,O
CYP3A,537,42,O
inducers,537,48,O
.,537,56,O
Avoid,537,0,O
use,537,6,O
with,537,10,O
strong,537,15,O
CYP3A,537,22,O
inhibitors,537,28,O
or,537,39,O
CYP3A,537,42,O
inducers,537,48,O
.,537,56,O
Avoid,538,0,O
use,538,6,O
with,538,10,O
strong,538,15,O
inducers,538,22,O
of,538,31,O
CYP3A,538,34,O
(,538,40,O
e.g.,538,41,O
",",538,45,O
rifampin,538,47,O
",",538,55,O
phenytoin,538,57,O
",",538,66,O
carbamazepine,538,68,O
and,538,82,O
phenobarbital,538,86,O
),538,99,O
[,538,101,O
see,538,102,O
Clinical,538,106,O
Pharmacology,538,115,O
(,538,128,O
12.3,538,129,O
),538,133,O
],538,135,O
.,538,136,O
Avoid,538,0,O
use,538,6,O
with,538,10,O
strong,538,15,O
inducers,538,22,O
of,538,31,O
CYP3A,538,34,O
(,538,40,O
e.g.,538,41,O
",",538,45,O
rifampin,538,47,O
",",538,55,O
phenytoin,538,57,O
",",538,66,O
carbamazepine,538,68,O
and,538,82,O
phenobarbital,538,86,O
),538,99,O
[,538,101,O
see,538,102,O
Clinical,538,106,O
Pharmacology,538,115,O
(,538,128,O
12.3,538,129,O
),538,133,O
],538,135,O
.,538,136,O
Avoid,538,0,O
use,538,6,O
with,538,10,O
strong,538,15,O
inducers,538,22,O
of,538,31,O
CYP3A,538,34,O
(,538,40,O
e.g.,538,41,O
",",538,45,O
rifampin,538,47,O
",",538,55,O
phenytoin,538,57,O
",",538,66,O
carbamazepine,538,68,O
and,538,82,O
phenobarbital,538,86,O
),538,99,O
[,538,101,O
see,538,102,O
Clinical,538,106,O
Pharmacology,538,115,O
(,538,128,O
12.3,538,129,O
),538,133,O
],538,135,O
.,538,136,O
Avoid,538,0,O
use,538,6,O
with,538,10,O
strong,538,15,O
inducers,538,22,O
of,538,31,O
CYP3A,538,34,O
(,538,40,O
e.g.,538,41,O
",",538,45,O
rifampin,538,47,O
",",538,55,O
phenytoin,538,57,O
",",538,66,O
carbamazepine,538,68,O
and,538,82,O
phenobarbital,538,86,O
),538,99,O
[,538,101,O
see,538,102,O
Clinical,538,106,O
Pharmacology,538,115,O
(,538,128,O
12.3,538,129,O
),538,133,O
],538,135,O
.,538,136,O
Avoid,538,0,O
use,538,6,O
with,538,10,O
strong,538,15,O
inducers,538,22,O
of,538,31,O
CYP3A,538,34,O
(,538,40,O
e.g.,538,41,O
",",538,45,O
rifampin,538,47,O
",",538,55,O
phenytoin,538,57,O
",",538,66,O
carbamazepine,538,68,O
and,538,82,O
phenobarbital,538,86,O
),538,99,O
[,538,101,O
see,538,102,O
Clinical,538,106,O
Pharmacology,538,115,O
(,538,128,O
12.3,538,129,O
),538,133,O
],538,135,O
.,538,136,O
BRILINTA,539,0,O
increases,539,9,O
serum,539,19,O
concentrations,539,25,O
of,539,40,O
simvastatin,539,43,O
and,539,55,O
lovastatin,539,59,O
because,539,70,O
these,539,78,O
drugs,539,84,O
are,539,90,O
metabolized,539,94,O
by,539,106,O
CYP3A4,539,109,O
.,539,116,O
BRILINTA,539,0,O
increases,539,9,O
serum,539,19,O
concentrations,539,25,O
of,539,40,O
simvastatin,539,43,O
and,539,55,O
lovastatin,539,59,O
because,539,70,O
these,539,78,O
drugs,539,84,O
are,539,90,O
metabolized,539,94,O
by,539,106,O
CYP3A4,539,109,O
.,539,116,O
BRILINTA,540,0,O
inhibits,540,9,O
the,540,18,O
P-glycoprotein,540,22,O
transporter,540,37,O
;,540,48,O
monitor,540,50,O
digoxin,540,58,O
levels,540,66,O
with,540,73,O
initiation,540,78,O
of,540,89,O
or,540,92,O
change,540,95,O
in,540,102,O
BRILINTA,540,105,O
therapy,540,114,O
[,540,122,O
see,540,123,O
Clinical,540,127,O
Pharmacology,540,136,O
(,540,149,O
12.3,540,150,O
),540,154,O
],540,156,O
.,540,157,O
Strong,541,0,O
CYP3A,541,7,O
inducers,541,13,O
substantially,541,22,O
reduce,541,36,O
ticagrelor,541,43,O
exposure,541,54,O
and,541,63,O
so,541,67,O
decrease,541,70,O
the,541,79,O
efficacy,541,83,O
of,541,92,O
ticagrelor,541,95,O
.,541,106,O
Strong,542,0,O
CYP3A,542,7,O
inhibitors,542,13,O
substantially,542,24,O
increase,542,38,O
ticagrelor,542,47,O
exposure,542,58,O
and,542,67,O
so,542,71,O
increase,542,74,O
the,542,83,O
risk,542,87,O
of,542,92,O
dyspnea,542,95,O
",",542,103,O
bleeding,542,105,O
",",542,114,O
and,542,116,O
other,542,120,O
adverse,542,126,O
events,542,134,O
.,542,141,O
Use,543,0,O
of,543,4,O
BRILINTA,543,7,O
with,543,16,O
aspirin,543,21,O
maintenance,543,29,O
doses,543,41,O
above,543,47,O
100,543,53,O
mg,543,57,O
reduced,543,60,B-SpecificInteraction
the,543,60,I-SpecificInteraction
effectiveness,543,60,I-SpecificInteraction
of,543,60,I-SpecificInteraction
BRILINTA,543,60,I-SpecificInteraction
see,543,98,O
Warnings,543,102,O
and,543,111,O
Precautions,543,115,O
(,543,127,O
5.2,543,129,O
),543,133,O
and,543,135,O
Clinical,543,139,O
Studies,543,148,O
(,543,156,O
14.1,543,158,O
),543,163,O
.,543,165,O
Dyspnea,544,0,O
was,544,8,O
usually,544,12,O
mild,544,20,O
to,544,25,O
moderate,544,28,O
in,544,37,O
intensity,544,40,O
and,544,50,O
often,544,54,O
resolved,544,60,O
during,544,69,O
continued,544,76,O
treatment,544,86,O
",",544,96,O
but,544,98,O
led,544,102,O
to,544,106,O
study,544,109,O
drug,544,115,O
discontinuation,544,120,O
in,544,136,O
0.9,544,139,O
%,544,143,O
of,544,145,O
BRILINTA,544,148,O
and,544,157,O
0.1,544,161,O
%,544,165,O
of,544,167,O
clopidogrel,544,170,O
patients,544,182,O
in,544,191,O
PLATO,544,194,O
and,544,200,O
4.3,544,204,O
%,544,208,O
of,544,210,O
BRILINTA,544,213,O
60,544,222,O
mg,544,225,O
and,544,228,O
0.7,544,232,O
%,544,236,O
on,544,238,O
aspirin,544,241,O
alone,544,249,O
patients,544,255,O
in,544,264,O
PEGASUS,544,267,O
.,544,275,O
In,545,0,O
PLATO,545,3,O
the,545,9,O
use,545,13,O
of,545,17,O
BRILINTA,545,20,O
with,545,29,O
maintenance,545,34,O
doses,545,46,O
of,545,52,O
aspirin,545,55,O
above,545,63,O
100,545,69,O
mg,545,73,O
decreased,545,76,B-SpecificInteraction
the,545,76,I-SpecificInteraction
effectiveness,545,76,I-SpecificInteraction
of,545,76,I-SpecificInteraction
BRILINTA,545,76,I-SpecificInteraction
.,545,116,O
In,546,0,O
the,546,3,O
case,546,7,O
of,546,12,O
intolerable,546,15,O
dyspnea,546,27,O
requiring,546,35,O
discontinuation,546,45,O
of,546,61,O
BRILINTA,546,64,O
",",546,73,O
consider,546,75,O
prescribing,546,84,O
another,546,96,O
antiplatelet,546,104,O
agent,546,117,O
.,546,123,O
Patients,547,0,O
with,547,9,O
a,547,14,O
history,547,16,O
of,547,24,O
sick,547,27,O
sinus,547,32,O
syndrome,547,38,O
",",547,47,O
2nd,547,49,O
or,547,53,O
3rd,547,56,O
degree,547,60,O
AV,547,67,O
block,547,70,O
or,547,76,O
bradycardia-related,547,79,O
syncope,547,99,O
not,547,107,O
protected,547,111,O
by,547,121,O
a,547,124,O
pacemaker,547,126,O
were,547,136,O
excluded,547,141,O
from,547,150,O
PLATO,547,155,O
and,547,161,O
PEGASUS,547,165,O
and,547,173,O
may,547,177,O
be,547,181,O
at,547,184,O
increased,547,187,O
risk,547,197,O
of,547,202,O
developing,547,205,O
bradyarrhythmias,547,216,O
with,547,233,O
ticagrelor,547,238,O
.,547,249,O
Therefore,548,0,O
",",548,10,O
after,548,12,O
the,548,18,O
initial,548,22,O
loading,548,30,O
dose,548,38,O
of,548,43,O
aspirin,548,46,O
",",548,54,O
use,548,56,O
BRILINTA,548,60,O
with,548,69,O
a,548,74,O
maintenance,548,76,O
dose,548,88,O
of,548,93,O
aspirin,548,96,O
of,548,104,O
75-100,548,107,O
mg,548,114,O
see,548,117,O
Dosage,548,121,O
and,548,128,O
Administration,548,132,O
(,548,147,O
2.1,548,149,O
),548,153,O
and,548,155,O
Clinical,548,159,O
Studies,548,168,O
(,548,176,O
14.1,548,178,O
),548,183,O
.,548,185,O
If,93,0,O
patients,93,3,O
are,93,12,O
not,93,16,O
adequately,93,20,O
controlled,93,31,O
by,93,42,O
the,93,45,O
use,93,49,O
of,93,53,O
DEMSER,93,56,O
",",93,63,O
an,93,65,O
alpha-adrenergic,93,68,O
blocking,93,85,O
agent,93,94,O
(,93,100,O
phenoxybenzamine,93,102,O
),93,119,O
should,93,121,O
be,93,128,O
added,93,131,O
.,93,137,O
Optimally,94,0,O
effective,94,10,O
dosages,94,20,O
of,94,28,O
DEMSER,94,31,O
usually,94,38,O
are,94,46,O
between,94,50,O
2.0,94,58,O
and,94,62,O
3.0,94,66,O
g/day,94,70,O
",",94,76,O
and,94,78,O
the,94,82,O
dose,94,86,O
should,94,91,O
be,94,98,O
titrated,94,101,O
by,94,110,O
monitoring,94,113,O
clinical,94,124,O
symptoms,94,133,O
and,94,142,O
catecholamine,94,146,O
excretion,94,160,O
.,94,170,O
DEMSER,95,0,O
may,95,7,O
add,95,11,O
to,95,15,O
the,95,18,O
sedative,95,22,B-SpecificInteraction
effects,95,22,I-SpecificInteraction
of,95,39,O
alcohol,95,42,O
and,95,50,O
other,95,54,O
CNS,95,60,O
depressants,95,64,O
",",95,76,O
e.g.,95,78,O
",",95,83,O
hypnotics,95,85,O
",",95,95,O
sedatives,95,97,O
",",95,107,O
and,95,109,O
tranquilizers,95,113,O
.,95,127,O
DEMSER,95,0,O
may,95,7,O
add,95,11,O
to,95,15,O
the,95,18,O
sedative,95,22,B-SpecificInteraction
effects,95,22,I-SpecificInteraction
of,95,39,O
alcohol,95,42,O
and,95,50,O
other,95,54,O
CNS,95,60,O
depressants,95,64,O
",",95,76,O
e.g.,95,78,O
",",95,83,O
hypnotics,95,85,O
",",95,95,O
sedatives,95,97,O
",",95,107,O
and,95,109,O
tranquilizers,95,113,O
.,95,127,O
DEMSER,95,0,O
may,95,7,O
add,95,11,O
to,95,15,O
the,95,18,O
sedative,95,22,B-SpecificInteraction
effects,95,22,I-SpecificInteraction
of,95,39,O
alcohol,95,42,O
and,95,50,O
other,95,54,O
CNS,95,60,O
depressants,95,64,O
",",95,76,O
e.g.,95,78,O
",",95,83,O
hypnotics,95,85,O
",",95,95,O
sedatives,95,97,O
",",95,107,O
and,95,109,O
tranquilizers,95,113,O
.,95,127,O
DEMSER,95,0,O
may,95,7,O
add,95,11,O
to,95,15,O
the,95,18,O
sedative,95,22,B-SpecificInteraction
effects,95,22,I-SpecificInteraction
of,95,39,O
alcohol,95,42,O
and,95,50,O
other,95,54,O
CNS,95,60,O
depressants,95,64,O
",",95,76,O
e.g.,95,78,O
",",95,83,O
hypnotics,95,85,O
",",95,95,O
sedatives,95,97,O
",",95,107,O
and,95,109,O
tranquilizers,95,113,O
.,95,127,O
DEMSER,95,0,O
may,95,7,O
add,95,11,O
to,95,15,O
the,95,18,O
sedative,95,22,B-SpecificInteraction
effects,95,22,I-SpecificInteraction
of,95,39,O
alcohol,95,42,O
and,95,50,O
other,95,54,O
CNS,95,60,O
depressants,95,64,O
",",95,76,O
e.g.,95,78,O
",",95,83,O
hypnotics,95,85,O
",",95,95,O
sedatives,95,97,O
",",95,107,O
and,95,109,O
tranquilizers,95,113,O
.,95,127,O
When,96,0,O
DEMSER,96,5,O
is,96,12,O
used,96,15,O
preoperatively,96,20,O
",",96,35,O
alone,96,37,O
or,96,43,O
especially,96,46,O
in,96,57,O
combination,96,60,O
with,96,72,O
alpha-adrenergic,96,77,O
blocking,96,94,O
drugs,96,103,O
",",96,109,O
adequate,96,111,O
intravascular,96,120,O
volume,96,134,O
must,96,141,O
be,96,146,O
maintained,96,149,O
intraoperatively,96,160,O
(,96,177,O
especially,96,179,O
after,96,190,O
tumor,96,196,O
removal,96,202,O
),96,210,O
and,96,212,O
postoperatively,96,216,O
to,96,232,O
avoid,96,235,O
hypotension,96,241,B-SpecificInteraction
and,96,253,O
decreased,96,257,B-SpecificInteraction
perfusion,96,257,I-SpecificInteraction
of,96,257,I-SpecificInteraction
vital,96,257,I-SpecificInteraction
organs,96,257,I-SpecificInteraction
resulting,96,293,O
from,96,303,O
vasodilatation,96,308,B-SpecificInteraction
and,96,323,O
expanded,96,327,B-SpecificInteraction
volume,96,327,I-SpecificInteraction
capacity,96,327,I-SpecificInteraction
.,96,352,O
While,97,0,O
the,97,6,O
preoperative,97,10,O
use,97,23,O
of,97,27,O
DEMSER,97,30,O
in,97,37,O
patients,97,40,O
with,97,49,O
pheochromocytoma,97,54,O
is,97,71,O
thought,97,74,O
to,97,82,O
decrease,97,85,O
intraoperative,97,94,O
problems,97,109,O
with,97,118,O
blood,97,123,O
pressure,97,129,O
control,97,138,O
",",97,146,O
DEMSER,97,148,O
does,97,155,O
not,97,160,O
eliminate,97,164,O
the,97,174,O
danger,97,178,O
of,97,185,O
hypertensive,97,188,O
crises,97,201,O
or,97,208,O
arrhythmias,97,211,O
during,97,223,O
manipulation,97,230,O
of,97,243,O
the,97,246,O
tumor,97,250,O
",",97,256,O
and,97,258,O
the,97,262,O
alpha-adrenergic,97,266,O
blocking,97,283,O
drug,97,292,O
",",97,297,O
phentolamine,97,299,O
",",97,312,O
may,97,314,O
be,97,318,O
needed,97,321,O
.,97,328,O
(,98,0,O
See,98,1,O
WARNINGS,98,5,O
and,98,14,O
PRECAUTIONS,98,18,O
",",98,29,O
Information,98,31,O
for,98,43,O
Patients,98,47,O
.,98,56,O
),98,57,O
Caution,99,0,O
should,99,8,O
be,99,15,O
observed,99,18,O
in,99,27,O
administering,99,30,O
DEMSER,99,44,O
to,99,51,O
patients,99,54,O
receiving,99,63,O
phenothiazines,99,73,O
or,99,88,O
haloperidol,99,91,O
because,99,103,O
the,99,111,O
extrapyramidal,99,115,B-SpecificInteraction
effects,99,115,I-SpecificInteraction
of,99,138,O
these,99,141,O
drugs,99,147,O
can,99,153,O
be,99,157,O
expected,99,160,O
to,99,169,O
be,99,172,O
potentiated,99,175,O
by,99,187,O
inhibition,99,190,O
of,99,201,O
catecholamine,99,204,O
synthesis,99,218,O
.,99,228,O
Caution,99,0,O
should,99,8,O
be,99,15,O
observed,99,18,O
in,99,27,O
administering,99,30,O
DEMSER,99,44,O
to,99,51,O
patients,99,54,O
receiving,99,63,O
phenothiazines,99,73,O
or,99,88,O
haloperidol,99,91,O
because,99,103,O
the,99,111,O
extrapyramidal,99,115,B-SpecificInteraction
effects,99,115,I-SpecificInteraction
of,99,138,O
these,99,141,O
drugs,99,147,O
can,99,153,O
be,99,157,O
expected,99,160,O
to,99,169,O
be,99,172,O
potentiated,99,175,O
by,99,187,O
inhibition,99,190,O
of,99,201,O
catecholamine,99,204,O
synthesis,99,218,O
.,99,228,O
Concurrent,100,0,O
use,100,11,O
of,100,15,O
DEMSER,100,18,O
with,100,25,O
alcohol,100,30,O
or,100,38,O
other,100,41,O
CNS,100,47,O
depressants,100,51,O
can,100,63,O
increase,100,67,O
their,100,76,O
sedative,100,82,B-SpecificInteraction
effects,100,82,I-SpecificInteraction
.,100,99,O
Concurrent,100,0,O
use,100,11,O
of,100,15,O
DEMSER,100,18,O
with,100,25,O
alcohol,100,30,O
or,100,38,O
other,100,41,O
CNS,100,47,O
depressants,100,51,O
can,100,63,O
increase,100,67,O
their,100,76,O
sedative,100,82,B-SpecificInteraction
effects,100,82,I-SpecificInteraction
.,100,99,O
DEMSER,101,0,O
may,101,7,O
have,101,11,O
additive,101,16,O
sedative,101,25,B-SpecificInteraction
effects,101,25,I-SpecificInteraction
with,101,42,O
alcohol,101,47,O
and,101,55,O
other,101,59,O
CNS,101,65,O
depressants,101,69,O
",",101,81,O
e.g.,101,83,O
",",101,88,O
hypnotics,101,90,O
",",101,100,O
sedatives,101,102,O
",",101,112,O
and,101,114,O
tranquilizers,101,118,O
.,101,132,O
DEMSER,101,0,O
may,101,7,O
have,101,11,O
additive,101,16,O
sedative,101,25,B-SpecificInteraction
effects,101,25,I-SpecificInteraction
with,101,42,O
alcohol,101,47,O
and,101,55,O
other,101,59,O
CNS,101,65,O
depressants,101,69,O
",",101,81,O
e.g.,101,83,O
",",101,88,O
hypnotics,101,90,O
",",101,100,O
sedatives,101,102,O
",",101,112,O
and,101,114,O
tranquilizers,101,118,O
.,101,132,O
DEMSER,101,0,O
may,101,7,O
have,101,11,O
additive,101,16,O
sedative,101,25,B-SpecificInteraction
effects,101,25,I-SpecificInteraction
with,101,42,O
alcohol,101,47,O
and,101,55,O
other,101,59,O
CNS,101,65,O
depressants,101,69,O
",",101,81,O
e.g.,101,83,O
",",101,88,O
hypnotics,101,90,O
",",101,100,O
sedatives,101,102,O
",",101,112,O
and,101,114,O
tranquilizers,101,118,O
.,101,132,O
DEMSER,101,0,O
may,101,7,O
have,101,11,O
additive,101,16,O
sedative,101,25,B-SpecificInteraction
effects,101,25,I-SpecificInteraction
with,101,42,O
alcohol,101,47,O
and,101,55,O
other,101,59,O
CNS,101,65,O
depressants,101,69,O
",",101,81,O
e.g.,101,83,O
",",101,88,O
hypnotics,101,90,O
",",101,100,O
sedatives,101,102,O
",",101,112,O
and,101,114,O
tranquilizers,101,118,O
.,101,132,O
DEMSER,101,0,O
may,101,7,O
have,101,11,O
additive,101,16,O
sedative,101,25,B-SpecificInteraction
effects,101,25,I-SpecificInteraction
with,101,42,O
alcohol,101,47,O
and,101,55,O
other,101,59,O
CNS,101,65,O
depressants,101,69,O
",",101,81,O
e.g.,101,83,O
",",101,88,O
hypnotics,101,90,O
",",101,100,O
sedatives,101,102,O
",",101,112,O
and,101,114,O
tranquilizers,101,118,O
.,101,132,O
Diovan,245,0,O
may,245,7,O
be,245,11,O
administered,245,14,O
with,245,27,O
other,245,32,O
antihypertensive,245,38,O
agents,245,55,O
.,245,62,O
Diovan,246,0,O
may,246,7,O
be,246,11,O
given,246,14,O
with,246,20,O
other,246,25,O
standard,246,31,O
post-myocardial,246,40,O
infarction,246,56,O
treatment,246,67,O
",",246,77,O
including,246,79,O
thrombolytics,246,89,O
",",246,103,O
aspirin,246,105,O
",",246,113,O
beta-blockers,246,115,O
",",246,129,O
and,246,131,O
statins,246,135,O
.,246,143,O
Do,247,0,O
not,247,3,O
coadminister,247,7,O
aliskiren,247,20,O
with,247,30,O
Diovan,247,35,O
in,247,42,O
patients,247,45,O
with,247,54,O
diabetes,247,59,O
see,247,68,O
Drug,247,72,O
Interactions,247,77,O
(,247,90,O
7,247,92,O
),247,94,O
.,247,96,O
Known,248,0,O
hypersensitivity,248,6,O
to,248,23,O
any,248,26,O
component,248,30,O
",",248,40,O
Do,248,42,O
not,248,45,O
coadminister,248,49,O
aliskiren,248,62,O
with,248,72,O
Diovan,248,77,O
in,248,84,O
patients,248,87,O
with,248,96,O
diabetes,248,101,O
(,248,110,O
4,248,112,O
),248,114,O
.,248,116,O
Avoid,249,0,O
use,249,6,O
of,249,10,O
aliskiren,249,13,O
with,249,23,O
Diovan,249,28,O
in,249,35,O
patients,249,38,O
with,249,47,O
renal,249,52,O
impairment,249,58,O
(,249,69,O
GFR,249,71,O
60,249,75,O
mL/min,249,78,O
),249,85,O
.,249,87,O
Blood,250,0,O
Urea,250,6,O
Nitrogen,250,11,O
(,250,20,O
BUN,250,21,O
),250,24,O
:,250,25,O
In,250,27,O
heart,250,30,O
failure,250,36,O
trials,250,44,O
",",250,50,O
greater,250,52,O
than,250,60,O
50,250,65,O
%,250,67,O
increases,250,69,O
in,250,79,O
BUN,250,82,O
were,250,86,O
observed,250,91,O
in,250,100,O
16.6,250,103,O
%,250,107,O
of,250,109,O
Diovan-treated,250,112,O
patients,250,127,O
compared,250,136,O
to,250,145,O
6.3,250,148,O
%,250,151,O
of,250,153,O
placebo-treated,250,156,O
patients,250,172,O
.,250,180,O
Closely,251,0,O
monitor,251,8,O
blood,251,16,O
pressure,251,22,O
",",251,31,O
renal,251,33,O
function,251,39,O
and,251,48,O
electrolytes,251,52,O
in,251,65,O
patients,251,68,O
on,251,77,O
Diovan,251,80,O
and,251,87,O
other,251,91,O
agents,251,97,O
that,251,104,O
affect,251,109,O
the,251,116,O
RAS,251,120,O
.,251,124,O
Coadministration,252,0,O
of,252,17,O
inhibitors,252,20,O
of,252,31,O
the,252,34,O
uptake,252,38,O
transporter,252,45,O
(,252,57,O
rifampin,252,59,O
",",252,68,O
cyclosporine,252,70,O
),252,83,O
or,252,85,O
efflux,252,88,O
transporter,252,95,O
(,252,107,O
ritonavir,252,109,O
),252,119,O
may,252,121,O
increase,252,125,O
the,252,134,O
systemic,252,138,O
exposure,252,147,O
to,252,156,O
valsartan,252,159,O
.,252,169,O
Coadministration,252,0,O
of,252,17,O
inhibitors,252,20,O
of,252,31,O
the,252,34,O
uptake,252,38,O
transporter,252,45,O
(,252,57,O
rifampin,252,59,O
",",252,68,O
cyclosporine,252,70,O
),252,83,O
or,252,85,O
efflux,252,88,O
transporter,252,95,O
(,252,107,O
ritonavir,252,109,O
),252,119,O
may,252,121,O
increase,252,125,O
the,252,134,O
systemic,252,138,O
exposure,252,147,O
to,252,156,O
valsartan,252,159,O
.,252,169,O
Coadministration,252,0,O
of,252,17,O
inhibitors,252,20,O
of,252,31,O
the,252,34,O
uptake,252,38,O
transporter,252,45,O
(,252,57,O
rifampin,252,59,O
",",252,68,O
cyclosporine,252,70,O
),252,83,O
or,252,85,O
efflux,252,88,O
transporter,252,95,O
(,252,107,O
ritonavir,252,109,O
),252,119,O
may,252,121,O
increase,252,125,O
the,252,134,O
systemic,252,138,O
exposure,252,147,O
to,252,156,O
valsartan,252,159,O
.,252,169,O
Coadministration,252,0,O
of,252,17,O
inhibitors,252,20,O
of,252,31,O
the,252,34,O
uptake,252,38,O
transporter,252,45,O
(,252,57,O
rifampin,252,59,O
",",252,68,O
cyclosporine,252,70,O
),252,83,O
or,252,85,O
efflux,252,88,O
transporter,252,95,O
(,252,107,O
ritonavir,252,109,O
),252,119,O
may,252,121,O
increase,252,125,O
the,252,134,O
systemic,252,138,O
exposure,252,147,O
to,252,156,O
valsartan,252,159,O
.,252,169,O
Coadministration,252,0,O
of,252,17,O
inhibitors,252,20,O
of,252,31,O
the,252,34,O
uptake,252,38,O
transporter,252,45,O
(,252,57,O
rifampin,252,59,O
",",252,68,O
cyclosporine,252,70,O
),252,83,O
or,252,85,O
efflux,252,88,O
transporter,252,95,O
(,252,107,O
ritonavir,252,109,O
),252,119,O
may,252,121,O
increase,252,125,O
the,252,134,O
systemic,252,138,O
exposure,252,147,O
to,252,156,O
valsartan,252,159,O
.,252,169,O
Coadministration,253,0,O
of,253,17,O
valsartan,253,20,O
and,253,30,O
warfarin,253,34,O
did,253,43,O
not,253,47,O
change,253,51,O
the,253,58,O
pharmacokinetics,253,62,O
of,253,79,O
valsartan,253,82,O
or,253,92,O
the,253,95,O
time-course,253,99,O
of,253,111,O
the,253,114,O
anticoagulant,253,118,O
properties,253,132,O
of,253,143,O
warfarin,253,146,O
.,253,155,O
Creatinine,254,0,O
:,254,10,O
Minor,254,12,O
elevations,254,18,O
in,254,29,O
creatinine,254,32,O
occurred,254,43,O
in,254,52,O
0.8,254,55,O
%,254,58,O
of,254,60,O
patients,254,63,O
taking,254,72,O
Diovan,254,79,O
and,254,86,O
0.6,254,90,O
%,254,93,O
given,254,95,O
placebo,254,101,O
in,254,109,O
controlled,254,112,O
clinical,254,123,O
trials,254,132,O
of,254,139,O
hypertensive,254,142,O
patients,254,155,O
.,254,163,O
CYP,255,0,O
450,255,4,O
Interactions,255,8,O
:,255,20,O
In,255,22,O
vitro,255,25,O
metabolism,255,31,O
studies,255,42,O
indicate,255,50,O
that,255,59,O
CYP,255,64,O
450,255,68,O
mediated,255,72,O
drug,255,81,O
interactions,255,86,O
between,255,99,O
valsartan,255,107,O
and,255,117,O
coadministered,255,121,O
drugs,255,136,O
are,255,142,O
unlikely,255,146,O
because,255,155,O
of,255,163,O
the,255,166,O
low,255,170,O
extent,255,174,O
of,255,181,O
metabolism,255,184,O
[,255,195,O
see,255,196,O
Clinical,255,200,O
Pharmacology,255,209,O
(,255,222,O
12.3,255,223,O
),255,227,O
],255,228,O
.,255,229,O
Do,256,0,O
not,256,3,O
coadminister,256,7,O
aliskiren,256,20,O
with,256,30,O
Diovan,256,35,O
in,256,42,O
patients,256,45,O
with,256,54,O
diabetes,256,59,O
.,256,68,O
Dual,257,0,O
Blockade,257,5,O
of,257,14,O
the,257,17,O
Renin-Angiotensin,257,21,O
System,257,39,O
(,257,46,O
RAS,257,47,O
),257,50,O
:,257,51,O
Dual,257,53,O
blockade,257,58,O
of,257,67,O
the,257,70,O
RAS,257,74,O
with,257,78,O
angiotensin,257,83,O
receptor,257,95,O
blockers,257,104,O
",",257,112,O
ACE,257,114,O
inhibitors,257,118,O
",",257,128,O
or,257,130,O
aliskiren,257,133,O
is,257,143,O
associated,257,146,O
with,257,157,O
increased,257,162,O
risks,257,172,O
of,257,178,O
hypotension,257,181,B-SpecificInteraction
",",257,192,O
hyperkalemia,257,194,B-SpecificInteraction
",",257,206,O
and,257,208,O
changes,257,212,B-SpecificInteraction
in,257,212,I-SpecificInteraction
renal,257,212,I-SpecificInteraction
function,257,212,I-SpecificInteraction
(,257,238,O
including,257,239,O
acute,257,249,O
renal,257,255,O
failure,257,261,O
),257,268,O
compared,257,270,O
to,257,279,O
monotherapy,257,282,O
.,257,293,O
Dual,257,0,O
Blockade,257,5,O
of,257,14,O
the,257,17,O
Renin-Angiotensin,257,21,O
System,257,39,O
(,257,46,O
RAS,257,47,O
),257,50,O
:,257,51,O
Dual,257,53,O
blockade,257,58,O
of,257,67,O
the,257,70,O
RAS,257,74,O
with,257,78,O
angiotensin,257,83,O
receptor,257,95,O
blockers,257,104,O
",",257,112,O
ACE,257,114,O
inhibitors,257,118,O
",",257,128,O
or,257,130,O
aliskiren,257,133,O
is,257,143,O
associated,257,146,O
with,257,157,O
increased,257,162,O
risks,257,172,O
of,257,178,O
hypotension,257,181,B-SpecificInteraction
",",257,192,O
hyperkalemia,257,194,B-SpecificInteraction
",",257,206,O
and,257,208,O
changes,257,212,B-SpecificInteraction
in,257,212,I-SpecificInteraction
renal,257,212,I-SpecificInteraction
function,257,212,I-SpecificInteraction
(,257,238,O
including,257,239,O
acute,257,249,O
renal,257,255,O
failure,257,261,O
),257,268,O
compared,257,270,O
to,257,279,O
monotherapy,257,282,O
.,257,293,O
Dual,257,0,O
Blockade,257,5,O
of,257,14,O
the,257,17,O
Renin-Angiotensin,257,21,O
System,257,39,O
(,257,46,O
RAS,257,47,O
),257,50,O
:,257,51,O
Dual,257,53,O
blockade,257,58,O
of,257,67,O
the,257,70,O
RAS,257,74,O
with,257,78,O
angiotensin,257,83,O
receptor,257,95,O
blockers,257,104,O
",",257,112,O
ACE,257,114,O
inhibitors,257,118,O
",",257,128,O
or,257,130,O
aliskiren,257,133,O
is,257,143,O
associated,257,146,O
with,257,157,O
increased,257,162,O
risks,257,172,O
of,257,178,O
hypotension,257,181,B-SpecificInteraction
",",257,192,O
hyperkalemia,257,194,B-SpecificInteraction
",",257,206,O
and,257,208,O
changes,257,212,B-SpecificInteraction
in,257,212,I-SpecificInteraction
renal,257,212,I-SpecificInteraction
function,257,212,I-SpecificInteraction
(,257,238,O
including,257,239,O
acute,257,249,O
renal,257,255,O
failure,257,261,O
),257,268,O
compared,257,270,O
to,257,279,O
monotherapy,257,282,O
.,257,293,O
Hemoglobin,258,0,O
and,258,11,O
Hematocrit,258,15,O
:,258,25,O
Greater,258,27,O
than,258,35,O
20,258,40,O
%,258,42,O
decreases,258,44,O
in,258,54,O
hemoglobin,258,57,O
and,258,68,O
hematocrit,258,72,O
were,258,83,O
observed,258,88,O
in,258,97,O
0.4,258,100,O
%,258,103,O
and,258,105,O
0.8,258,109,O
%,258,112,O
",",258,113,O
respectively,258,115,O
",",258,127,O
of,258,129,O
Diovan,258,132,O
patients,258,139,O
",",258,147,O
compared,258,149,O
with,258,158,O
0.1,258,163,O
%,258,166,O
and,258,168,O
0.1,258,172,O
%,258,175,O
in,258,177,O
placebo-treated,258,180,O
patients,258,196,O
.,258,204,O
If,259,0,O
co-medication,259,3,O
is,259,17,O
considered,259,20,O
necessary,259,31,O
",",259,40,O
monitoring,259,42,O
of,259,53,O
serum,259,56,O
potassium,259,62,O
is,259,72,O
advisable,259,75,O
.,259,84,O
In,260,0,O
general,260,3,O
",",260,10,O
avoid,260,12,O
combined,260,18,O
use,260,27,O
of,260,31,O
RAS,260,34,O
inhibitors,260,38,O
.,260,48,O
In,261,0,O
heart,261,3,O
failure,261,9,O
patients,261,17,O
",",261,25,O
greater,261,27,O
than,261,35,O
20,261,40,O
%,261,42,O
increases,261,44,O
in,261,54,O
serum,261,57,O
potassium,261,63,O
were,261,73,O
observed,261,78,O
in,261,87,O
10.0,261,90,O
%,261,94,O
of,261,96,O
Diovan-treated,261,99,O
patients,261,114,O
compared,261,123,O
to,261,132,O
5.1,261,135,O
%,261,138,O
of,261,140,O
placebo-treated,261,143,O
patients,261,159,O
.,261,167,O
In,262,0,O
heart,262,3,O
failure,262,9,O
trials,262,17,O
",",262,23,O
greater,262,25,O
than,262,33,O
50,262,38,O
%,262,40,O
increases,262,42,O
in,262,52,O
creatinine,262,55,O
were,262,66,O
observed,262,71,O
in,262,80,O
3.9,262,83,O
%,262,86,O
of,262,88,O
Diovan-treated,262,91,O
patients,262,106,O
compared,262,115,O
to,262,124,O
0.9,262,127,O
%,262,130,O
of,262,132,O
placebo-treated,262,135,O
patients,262,151,O
.,262,159,O
In,263,0,O
post-myocardial,263,3,O
infarction,263,19,O
patients,263,30,O
",",263,39,O
doubling,263,41,O
of,263,50,O
serum,263,53,O
creatinine,263,59,O
was,263,70,O
observed,263,74,O
in,263,83,O
4.2,263,86,O
%,263,90,O
of,263,92,O
valsartan-treated,263,95,O
patients,263,113,O
and,263,122,O
3.4,263,126,O
%,263,130,O
of,263,132,O
captopril-treated,263,135,O
patients,263,153,O
.,263,162,O
Lithium,264,0,O
:,264,8,O
Increases,264,10,O
in,264,20,O
serum,264,23,O
lithium,264,29,O
concentrations,264,37,O
and,264,52,O
lithium,264,56,O
toxicity,264,64,O
have,264,73,O
been,264,78,O
reported,264,83,O
during,264,92,O
concomitant,264,99,O
administration,264,111,O
of,264,126,O
lithium,264,129,O
with,264,137,O
angiotensin,264,142,O
II,264,154,O
receptor,264,157,O
antagonists,264,166,O
",",264,178,O
including,264,180,O
Diovan,264,190,O
.,264,197,O
Liver,265,0,O
Function,265,6,O
Tests,265,15,O
:,265,20,O
Occasional,265,22,O
elevations,265,33,O
(,265,44,O
greater,265,45,O
than,265,53,O
150,265,58,O
%,265,61,O
),265,62,O
of,265,64,O
liver,265,67,O
chemistries,265,73,O
occurred,265,85,O
in,265,94,O
Diovan-treated,265,97,O
patients,265,112,O
.,265,120,O
Monitor,266,0,O
renal,266,8,O
function,266,14,O
periodically,266,23,O
in,266,36,O
patients,266,39,O
receiving,266,48,O
valsartan,266,58,O
and,266,68,O
NSAID,266,72,O
therapy,266,78,O
.,266,86,O
Monitor,267,0,O
serum,267,8,O
lithium,267,14,O
levels,267,22,O
during,267,29,O
concomitant,267,36,O
use,267,48,O
.,267,51,O
Most,268,0,O
patients,268,5,O
receiving,268,14,O
the,268,24,O
combination,268,28,O
of,268,40,O
two,268,43,O
RAS,268,47,O
inhibitors,268,51,O
do,268,62,O
not,268,65,O
obtain,268,69,O
any,268,76,O
additional,268,80,O
benefit,268,91,O
compared,268,99,O
to,268,108,O
monotherapy,268,111,O
[,268,123,O
see,268,124,O
Clinical,268,128,O
Studies,268,137,O
(,268,145,O
14.3,268,146,O
),268,150,O
],268,151,O
.,268,152,O
Neutropenia,269,0,O
:,269,11,O
Neutropenia,269,13,O
was,269,25,O
observed,269,29,O
in,269,38,O
1.9,269,41,O
%,269,44,O
of,269,46,O
patients,269,49,O
treated,269,58,O
with,269,66,O
Diovan,269,71,O
and,269,78,O
0.8,269,82,O
%,269,85,O
of,269,87,O
patients,269,90,O
treated,269,99,O
with,269,107,O
placebo,269,112,O
.,269,119,O
No,270,0,O
clinically,270,3,O
significant,270,14,O
pharmacokinetic,270,26,O
interactions,270,42,O
were,270,55,O
observed,270,60,O
when,270,69,O
Diovan,270,74,O
(,270,81,O
valsartan,270,83,O
),270,93,O
was,270,95,O
coadministered,270,99,O
with,270,114,O
amlodipine,270,119,O
",",270,130,O
atenolol,270,132,O
",",270,141,O
cimetidine,270,143,O
",",270,154,O
digoxin,270,156,O
",",270,164,O
furosemide,270,166,O
",",270,177,O
glyburide,270,179,O
",",270,189,O
hydrochlorothiazide,270,191,O
",",270,211,O
or,270,213,O
indomethacin,270,216,O
.,270,229,O
Non-Steroidal,271,0,O
Anti-Inflammatory,271,14,O
Agents,271,32,O
including,271,39,O
Selective,271,49,O
Cyclooxygenase-2,271,59,O
Inhibitors,271,76,O
(,271,87,O
COX-2,271,89,O
Inhibitors,271,95,O
),271,106,O
:,271,108,O
In,271,110,O
patients,271,113,O
who,271,122,O
are,271,126,O
elderly,271,130,O
",",271,138,O
volume-depleted,271,140,O
(,271,156,O
including,271,158,O
those,271,168,O
on,271,174,O
diuretic,271,177,O
therapy,271,186,O
),271,194,O
",",271,196,O
or,271,198,O
with,271,201,O
compromised,271,206,O
renal,271,218,O
function,271,224,O
",",271,233,O
coadministration,271,235,O
of,271,252,O
NSAIDs,271,255,O
",",271,262,O
including,271,264,O
selective,271,274,O
COX-2,271,284,O
inhibitors,271,290,O
",",271,301,O
with,271,303,O
angiotensin,271,308,O
II,271,320,O
receptor,271,323,O
antagonists,271,332,O
",",271,344,O
including,271,346,O
valsartan,271,356,O
",",271,366,O
may,271,368,O
result,271,372,O
in,271,379,O
deterioration,271,382,B-SpecificInteraction
of,271,382,I-SpecificInteraction
renal,271,382,I-SpecificInteraction
function,271,382,I-SpecificInteraction
",",271,414,O
including,271,416,O
possible,271,426,O
acute,271,435,B-SpecificInteraction
renal,271,435,I-SpecificInteraction
failure,271,435,I-SpecificInteraction
.,271,455,O
Non-Steroidal,271,0,O
Anti-Inflammatory,271,14,O
Agents,271,32,O
including,271,39,O
Selective,271,49,O
Cyclooxygenase-2,271,59,O
Inhibitors,271,76,O
(,271,87,O
COX-2,271,89,O
Inhibitors,271,95,O
),271,106,O
:,271,108,O
In,271,110,O
patients,271,113,O
who,271,122,O
are,271,126,O
elderly,271,130,O
",",271,138,O
volume-depleted,271,140,O
(,271,156,O
including,271,158,O
those,271,168,O
on,271,174,O
diuretic,271,177,O
therapy,271,186,O
),271,194,O
",",271,196,O
or,271,198,O
with,271,201,O
compromised,271,206,O
renal,271,218,O
function,271,224,O
",",271,233,O
coadministration,271,235,O
of,271,252,O
NSAIDs,271,255,O
",",271,262,O
including,271,264,O
selective,271,274,O
COX-2,271,284,O
inhibitors,271,290,O
",",271,301,O
with,271,303,O
angiotensin,271,308,O
II,271,320,O
receptor,271,323,O
antagonists,271,332,O
",",271,344,O
including,271,346,O
valsartan,271,356,O
",",271,366,O
may,271,368,O
result,271,372,O
in,271,379,O
deterioration,271,382,B-SpecificInteraction
of,271,382,I-SpecificInteraction
renal,271,382,I-SpecificInteraction
function,271,382,I-SpecificInteraction
",",271,414,O
including,271,416,O
possible,271,426,O
acute,271,435,B-SpecificInteraction
renal,271,435,I-SpecificInteraction
failure,271,435,I-SpecificInteraction
.,271,455,O
Non-Steroidal,271,0,O
Anti-Inflammatory,271,14,O
Agents,271,32,O
including,271,39,O
Selective,271,49,O
Cyclooxygenase-2,271,59,O
Inhibitors,271,76,O
(,271,87,O
COX-2,271,89,O
Inhibitors,271,95,O
),271,106,O
:,271,108,O
In,271,110,O
patients,271,113,O
who,271,122,O
are,271,126,O
elderly,271,130,O
",",271,138,O
volume-depleted,271,140,O
(,271,156,O
including,271,158,O
those,271,168,O
on,271,174,O
diuretic,271,177,O
therapy,271,186,O
),271,194,O
",",271,196,O
or,271,198,O
with,271,201,O
compromised,271,206,O
renal,271,218,O
function,271,224,O
",",271,233,O
coadministration,271,235,O
of,271,252,O
NSAIDs,271,255,O
",",271,262,O
including,271,264,O
selective,271,274,O
COX-2,271,284,O
inhibitors,271,290,O
",",271,301,O
with,271,303,O
angiotensin,271,308,O
II,271,320,O
receptor,271,323,O
antagonists,271,332,O
",",271,344,O
including,271,346,O
valsartan,271,356,O
",",271,366,O
may,271,368,O
result,271,372,O
in,271,379,O
deterioration,271,382,B-SpecificInteraction
of,271,382,I-SpecificInteraction
renal,271,382,I-SpecificInteraction
function,271,382,I-SpecificInteraction
",",271,414,O
including,271,416,O
possible,271,426,O
acute,271,435,B-SpecificInteraction
renal,271,435,I-SpecificInteraction
failure,271,435,I-SpecificInteraction
.,271,455,O
Non-Steroidal,271,0,O
Anti-Inflammatory,271,14,O
Agents,271,32,O
including,271,39,O
Selective,271,49,O
Cyclooxygenase-2,271,59,O
Inhibitors,271,76,O
(,271,87,O
COX-2,271,89,O
Inhibitors,271,95,O
),271,106,O
:,271,108,O
In,271,110,O
patients,271,113,O
who,271,122,O
are,271,126,O
elderly,271,130,O
",",271,138,O
volume-depleted,271,140,O
(,271,156,O
including,271,158,O
those,271,168,O
on,271,174,O
diuretic,271,177,O
therapy,271,186,O
),271,194,O
",",271,196,O
or,271,198,O
with,271,201,O
compromised,271,206,O
renal,271,218,O
function,271,224,O
",",271,233,O
coadministration,271,235,O
of,271,252,O
NSAIDs,271,255,O
",",271,262,O
including,271,264,O
selective,271,274,O
COX-2,271,284,O
inhibitors,271,290,O
",",271,301,O
with,271,303,O
angiotensin,271,308,O
II,271,320,O
receptor,271,323,O
antagonists,271,332,O
",",271,344,O
including,271,346,O
valsartan,271,356,O
",",271,366,O
may,271,368,O
result,271,372,O
in,271,379,O
deterioration,271,382,B-SpecificInteraction
of,271,382,I-SpecificInteraction
renal,271,382,I-SpecificInteraction
function,271,382,I-SpecificInteraction
",",271,414,O
including,271,416,O
possible,271,426,O
acute,271,435,B-SpecificInteraction
renal,271,435,I-SpecificInteraction
failure,271,435,I-SpecificInteraction
.,271,455,O
One,272,0,O
valsartan,272,4,O
patient,272,14,O
discontinued,272,22,O
treatment,272,35,O
for,272,45,O
microcytic,272,49,O
anemia,272,60,O
.,272,66,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium,273,0,O
:,273,10,O
Concomitant,273,12,O
use,273,24,O
of,273,28,O
valsartan,273,31,O
with,273,41,O
other,273,46,O
agents,273,52,O
that,273,59,O
block,273,64,O
the,273,70,O
renin-angiotensin,273,74,O
system,273,92,O
",",273,99,O
potassium-sparing,273,101,O
diuretics,273,119,O
(,273,129,O
e.g.,273,131,O
",",273,136,O
spironolactone,273,138,O
",",273,153,O
triamterene,273,155,O
",",273,167,O
amiloride,273,169,O
),273,179,O
",",273,181,O
potassium,273,183,O
supplements,273,193,O
",",273,205,O
salt,273,207,O
substitutes,273,212,O
containing,273,224,O
potassium,273,235,O
or,273,245,O
other,273,248,O
drugs,273,254,O
that,273,260,O
may,273,265,O
increase,273,269,O
potassium,273,278,O
levels,273,288,O
(,273,295,O
e.g.,273,297,O
",",273,302,O
heparin,273,304,O
),273,312,O
may,273,314,O
lead,273,318,O
to,273,323,O
increases,273,326,B-SpecificInteraction
in,273,326,I-SpecificInteraction
serum,273,326,I-SpecificInteraction
potassium,273,326,I-SpecificInteraction
and,273,355,O
in,273,359,O
heart,273,362,O
failure,273,368,O
patients,273,376,O
to,273,385,O
increases,273,388,B-SpecificInteraction
in,273,388,I-SpecificInteraction
serum,273,388,I-SpecificInteraction
creatinine,273,388,I-SpecificInteraction
.,273,418,O
Potassium-sparing,274,0,O
diuretics,274,18,O
",",274,27,O
potassium,274,29,O
supplements,274,39,O
or,274,51,O
salt,274,54,O
substitutes,274,59,O
may,274,71,O
lead,274,75,O
to,274,80,O
increases,274,83,B-SpecificInteraction
in,274,83,I-SpecificInteraction
serum,274,83,I-SpecificInteraction
potassium,274,83,I-SpecificInteraction
",",274,111,O
and,274,113,O
in,274,117,O
heart,274,120,O
failure,274,126,O
patients,274,134,O
",",274,142,O
increases,274,144,B-SpecificInteraction
in,274,144,I-SpecificInteraction
serum,274,144,I-SpecificInteraction
creatinine,274,144,I-SpecificInteraction
(,274,174,O
7,274,175,O
),274,176,O
NSAID,274,178,O
use,274,184,O
may,274,188,O
lead,274,192,O
to,274,197,O
increased,274,200,O
risk,274,210,O
of,274,215,O
renal,274,218,B-SpecificInteraction
impairment,274,218,I-SpecificInteraction
and,274,235,O
loss,274,239,B-SpecificInteraction
of,274,239,I-SpecificInteraction
antihypertensive,274,239,I-SpecificInteraction
effect,274,239,I-SpecificInteraction
(,274,271,O
7,274,272,O
),274,273,O
Dual,274,275,O
inhibition,274,280,O
of,274,291,O
the,274,294,O
renin-angiotensin,274,298,O
system,274,316,O
:,274,322,O
Increased,274,324,O
risk,274,334,O
of,274,339,O
renal,274,342,O
impairment,274,348,O
",",274,358,O
hypotension,274,360,O
",",274,371,O
and,274,373,O
hyperkalemia,274,377,O
(,274,390,O
7,274,391,O
),274,392,O
Lithium,274,394,O
:,274,401,O
Increases,274,403,O
in,274,413,O
serum,274,416,O
lithium,274,422,O
concentrations,274,430,O
and,274,445,O
lithium,274,449,O
toxicity,274,457,O
(,274,466,O
7,274,467,O
),274,468,O
In,274,470,O
controlled,274,473,O
clinical,274,484,O
trials,274,493,O
",",274,499,O
clinically,274,501,O
important,274,512,O
changes,274,522,O
in,274,530,O
standard,274,533,O
laboratory,274,542,O
parameters,274,553,O
were,274,564,O
rarely,274,569,O
associated,274,576,O
with,274,587,O
administration,274,592,O
of,274,607,O
Diovan,274,610,O
.,274,616,O
Potassium-sparing,274,0,O
diuretics,274,18,O
",",274,27,O
potassium,274,29,O
supplements,274,39,O
or,274,51,O
salt,274,54,O
substitutes,274,59,O
may,274,71,O
lead,274,75,O
to,274,80,O
increases,274,83,B-SpecificInteraction
in,274,83,I-SpecificInteraction
serum,274,83,I-SpecificInteraction
potassium,274,83,I-SpecificInteraction
",",274,111,O
and,274,113,O
in,274,117,O
heart,274,120,O
failure,274,126,O
patients,274,134,O
",",274,142,O
increases,274,144,B-SpecificInteraction
in,274,144,I-SpecificInteraction
serum,274,144,I-SpecificInteraction
creatinine,274,144,I-SpecificInteraction
(,274,174,O
7,274,175,O
),274,176,O
NSAID,274,178,O
use,274,184,O
may,274,188,O
lead,274,192,O
to,274,197,O
increased,274,200,O
risk,274,210,O
of,274,215,O
renal,274,218,B-SpecificInteraction
impairment,274,218,I-SpecificInteraction
and,274,235,O
loss,274,239,B-SpecificInteraction
of,274,239,I-SpecificInteraction
antihypertensive,274,239,I-SpecificInteraction
effect,274,239,I-SpecificInteraction
(,274,271,O
7,274,272,O
),274,273,O
Dual,274,275,O
inhibition,274,280,O
of,274,291,O
the,274,294,O
renin-angiotensin,274,298,O
system,274,316,O
:,274,322,O
Increased,274,324,O
risk,274,334,O
of,274,339,O
renal,274,342,O
impairment,274,348,O
",",274,358,O
hypotension,274,360,O
",",274,371,O
and,274,373,O
hyperkalemia,274,377,O
(,274,390,O
7,274,391,O
),274,392,O
Lithium,274,394,O
:,274,401,O
Increases,274,403,O
in,274,413,O
serum,274,416,O
lithium,274,422,O
concentrations,274,430,O
and,274,445,O
lithium,274,449,O
toxicity,274,457,O
(,274,466,O
7,274,467,O
),274,468,O
In,274,470,O
controlled,274,473,O
clinical,274,484,O
trials,274,493,O
",",274,499,O
clinically,274,501,O
important,274,512,O
changes,274,522,O
in,274,530,O
standard,274,533,O
laboratory,274,542,O
parameters,274,553,O
were,274,564,O
rarely,274,569,O
associated,274,576,O
with,274,587,O
administration,274,592,O
of,274,607,O
Diovan,274,610,O
.,274,616,O
Potassium-sparing,274,0,O
diuretics,274,18,O
",",274,27,O
potassium,274,29,O
supplements,274,39,O
or,274,51,O
salt,274,54,O
substitutes,274,59,O
may,274,71,O
lead,274,75,O
to,274,80,O
increases,274,83,B-SpecificInteraction
in,274,83,I-SpecificInteraction
serum,274,83,I-SpecificInteraction
potassium,274,83,I-SpecificInteraction
",",274,111,O
and,274,113,O
in,274,117,O
heart,274,120,O
failure,274,126,O
patients,274,134,O
",",274,142,O
increases,274,144,B-SpecificInteraction
in,274,144,I-SpecificInteraction
serum,274,144,I-SpecificInteraction
creatinine,274,144,I-SpecificInteraction
(,274,174,O
7,274,175,O
),274,176,O
NSAID,274,178,O
use,274,184,O
may,274,188,O
lead,274,192,O
to,274,197,O
increased,274,200,O
risk,274,210,O
of,274,215,O
renal,274,218,B-SpecificInteraction
impairment,274,218,I-SpecificInteraction
and,274,235,O
loss,274,239,B-SpecificInteraction
of,274,239,I-SpecificInteraction
antihypertensive,274,239,I-SpecificInteraction
effect,274,239,I-SpecificInteraction
(,274,271,O
7,274,272,O
),274,273,O
Dual,274,275,O
inhibition,274,280,O
of,274,291,O
the,274,294,O
renin-angiotensin,274,298,O
system,274,316,O
:,274,322,O
Increased,274,324,O
risk,274,334,O
of,274,339,O
renal,274,342,O
impairment,274,348,O
",",274,358,O
hypotension,274,360,O
",",274,371,O
and,274,373,O
hyperkalemia,274,377,O
(,274,390,O
7,274,391,O
),274,392,O
Lithium,274,394,O
:,274,401,O
Increases,274,403,O
in,274,413,O
serum,274,416,O
lithium,274,422,O
concentrations,274,430,O
and,274,445,O
lithium,274,449,O
toxicity,274,457,O
(,274,466,O
7,274,467,O
),274,468,O
In,274,470,O
controlled,274,473,O
clinical,274,484,O
trials,274,493,O
",",274,499,O
clinically,274,501,O
important,274,512,O
changes,274,522,O
in,274,530,O
standard,274,533,O
laboratory,274,542,O
parameters,274,553,O
were,274,564,O
rarely,274,569,O
associated,274,576,O
with,274,587,O
administration,274,592,O
of,274,607,O
Diovan,274,610,O
.,274,616,O
Potassium-sparing,274,0,O
diuretics,274,18,O
",",274,27,O
potassium,274,29,O
supplements,274,39,O
or,274,51,O
salt,274,54,O
substitutes,274,59,O
may,274,71,O
lead,274,75,O
to,274,80,O
increases,274,83,B-SpecificInteraction
in,274,83,I-SpecificInteraction
serum,274,83,I-SpecificInteraction
potassium,274,83,I-SpecificInteraction
",",274,111,O
and,274,113,O
in,274,117,O
heart,274,120,O
failure,274,126,O
patients,274,134,O
",",274,142,O
increases,274,144,B-SpecificInteraction
in,274,144,I-SpecificInteraction
serum,274,144,I-SpecificInteraction
creatinine,274,144,I-SpecificInteraction
(,274,174,O
7,274,175,O
),274,176,O
NSAID,274,178,O
use,274,184,O
may,274,188,O
lead,274,192,O
to,274,197,O
increased,274,200,O
risk,274,210,O
of,274,215,O
renal,274,218,B-SpecificInteraction
impairment,274,218,I-SpecificInteraction
and,274,235,O
loss,274,239,B-SpecificInteraction
of,274,239,I-SpecificInteraction
antihypertensive,274,239,I-SpecificInteraction
effect,274,239,I-SpecificInteraction
(,274,271,O
7,274,272,O
),274,273,O
Dual,274,275,O
inhibition,274,280,O
of,274,291,O
the,274,294,O
renin-angiotensin,274,298,O
system,274,316,O
:,274,322,O
Increased,274,324,O
risk,274,334,O
of,274,339,O
renal,274,342,O
impairment,274,348,O
",",274,358,O
hypotension,274,360,O
",",274,371,O
and,274,373,O
hyperkalemia,274,377,O
(,274,390,O
7,274,391,O
),274,392,O
Lithium,274,394,O
:,274,401,O
Increases,274,403,O
in,274,413,O
serum,274,416,O
lithium,274,422,O
concentrations,274,430,O
and,274,445,O
lithium,274,449,O
toxicity,274,457,O
(,274,466,O
7,274,467,O
),274,468,O
In,274,470,O
controlled,274,473,O
clinical,274,484,O
trials,274,493,O
",",274,499,O
clinically,274,501,O
important,274,512,O
changes,274,522,O
in,274,530,O
standard,274,533,O
laboratory,274,542,O
parameters,274,553,O
were,274,564,O
rarely,274,569,O
associated,274,576,O
with,274,587,O
administration,274,592,O
of,274,607,O
Diovan,274,610,O
.,274,616,O
Potassium-sparing,274,0,O
diuretics,274,18,O
",",274,27,O
potassium,274,29,O
supplements,274,39,O
or,274,51,O
salt,274,54,O
substitutes,274,59,O
may,274,71,O
lead,274,75,O
to,274,80,O
increases,274,83,B-SpecificInteraction
in,274,83,I-SpecificInteraction
serum,274,83,I-SpecificInteraction
potassium,274,83,I-SpecificInteraction
",",274,111,O
and,274,113,O
in,274,117,O
heart,274,120,O
failure,274,126,O
patients,274,134,O
",",274,142,O
increases,274,144,B-SpecificInteraction
in,274,144,I-SpecificInteraction
serum,274,144,I-SpecificInteraction
creatinine,274,144,I-SpecificInteraction
(,274,174,O
7,274,175,O
),274,176,O
NSAID,274,178,O
use,274,184,O
may,274,188,O
lead,274,192,O
to,274,197,O
increased,274,200,O
risk,274,210,O
of,274,215,O
renal,274,218,B-SpecificInteraction
impairment,274,218,I-SpecificInteraction
and,274,235,O
loss,274,239,B-SpecificInteraction
of,274,239,I-SpecificInteraction
antihypertensive,274,239,I-SpecificInteraction
effect,274,239,I-SpecificInteraction
(,274,271,O
7,274,272,O
),274,273,O
Dual,274,275,O
inhibition,274,280,O
of,274,291,O
the,274,294,O
renin-angiotensin,274,298,O
system,274,316,O
:,274,322,O
Increased,274,324,O
risk,274,334,O
of,274,339,O
renal,274,342,O
impairment,274,348,O
",",274,358,O
hypotension,274,360,O
",",274,371,O
and,274,373,O
hyperkalemia,274,377,O
(,274,390,O
7,274,391,O
),274,392,O
Lithium,274,394,O
:,274,401,O
Increases,274,403,O
in,274,413,O
serum,274,416,O
lithium,274,422,O
concentrations,274,430,O
and,274,445,O
lithium,274,449,O
toxicity,274,457,O
(,274,466,O
7,274,467,O
),274,468,O
In,274,470,O
controlled,274,473,O
clinical,274,484,O
trials,274,493,O
",",274,499,O
clinically,274,501,O
important,274,512,O
changes,274,522,O
in,274,530,O
standard,274,533,O
laboratory,274,542,O
parameters,274,553,O
were,274,564,O
rarely,274,569,O
associated,274,576,O
with,274,587,O
administration,274,592,O
of,274,607,O
Diovan,274,610,O
.,274,616,O
Potassium-sparing,274,0,O
diuretics,274,18,O
",",274,27,O
potassium,274,29,O
supplements,274,39,O
or,274,51,O
salt,274,54,O
substitutes,274,59,O
may,274,71,O
lead,274,75,O
to,274,80,O
increases,274,83,B-SpecificInteraction
in,274,83,I-SpecificInteraction
serum,274,83,I-SpecificInteraction
potassium,274,83,I-SpecificInteraction
",",274,111,O
and,274,113,O
in,274,117,O
heart,274,120,O
failure,274,126,O
patients,274,134,O
",",274,142,O
increases,274,144,B-SpecificInteraction
in,274,144,I-SpecificInteraction
serum,274,144,I-SpecificInteraction
creatinine,274,144,I-SpecificInteraction
(,274,174,O
7,274,175,O
),274,176,O
NSAID,274,178,O
use,274,184,O
may,274,188,O
lead,274,192,O
to,274,197,O
increased,274,200,O
risk,274,210,O
of,274,215,O
renal,274,218,B-SpecificInteraction
impairment,274,218,I-SpecificInteraction
and,274,235,O
loss,274,239,B-SpecificInteraction
of,274,239,I-SpecificInteraction
antihypertensive,274,239,I-SpecificInteraction
effect,274,239,I-SpecificInteraction
(,274,271,O
7,274,272,O
),274,273,O
Dual,274,275,O
inhibition,274,280,O
of,274,291,O
the,274,294,O
renin-angiotensin,274,298,O
system,274,316,O
:,274,322,O
Increased,274,324,O
risk,274,334,O
of,274,339,O
renal,274,342,O
impairment,274,348,O
",",274,358,O
hypotension,274,360,O
",",274,371,O
and,274,373,O
hyperkalemia,274,377,O
(,274,390,O
7,274,391,O
),274,392,O
Lithium,274,394,O
:,274,401,O
Increases,274,403,O
in,274,413,O
serum,274,416,O
lithium,274,422,O
concentrations,274,430,O
and,274,445,O
lithium,274,449,O
toxicity,274,457,O
(,274,466,O
7,274,467,O
),274,468,O
In,274,470,O
controlled,274,473,O
clinical,274,484,O
trials,274,493,O
",",274,499,O
clinically,274,501,O
important,274,512,O
changes,274,522,O
in,274,530,O
standard,274,533,O
laboratory,274,542,O
parameters,274,553,O
were,274,564,O
rarely,274,569,O
associated,274,576,O
with,274,587,O
administration,274,592,O
of,274,607,O
Diovan,274,610,O
.,274,616,O
Potassium-sparing,274,0,O
diuretics,274,18,O
",",274,27,O
potassium,274,29,O
supplements,274,39,O
or,274,51,O
salt,274,54,O
substitutes,274,59,O
may,274,71,O
lead,274,75,O
to,274,80,O
increases,274,83,B-SpecificInteraction
in,274,83,I-SpecificInteraction
serum,274,83,I-SpecificInteraction
potassium,274,83,I-SpecificInteraction
",",274,111,O
and,274,113,O
in,274,117,O
heart,274,120,O
failure,274,126,O
patients,274,134,O
",",274,142,O
increases,274,144,B-SpecificInteraction
in,274,144,I-SpecificInteraction
serum,274,144,I-SpecificInteraction
creatinine,274,144,I-SpecificInteraction
(,274,174,O
7,274,175,O
),274,176,O
NSAID,274,178,O
use,274,184,O
may,274,188,O
lead,274,192,O
to,274,197,O
increased,274,200,O
risk,274,210,O
of,274,215,O
renal,274,218,B-SpecificInteraction
impairment,274,218,I-SpecificInteraction
and,274,235,O
loss,274,239,B-SpecificInteraction
of,274,239,I-SpecificInteraction
antihypertensive,274,239,I-SpecificInteraction
effect,274,239,I-SpecificInteraction
(,274,271,O
7,274,272,O
),274,273,O
Dual,274,275,O
inhibition,274,280,O
of,274,291,O
the,274,294,O
renin-angiotensin,274,298,O
system,274,316,O
:,274,322,O
Increased,274,324,O
risk,274,334,O
of,274,339,O
renal,274,342,O
impairment,274,348,O
",",274,358,O
hypotension,274,360,O
",",274,371,O
and,274,373,O
hyperkalemia,274,377,O
(,274,390,O
7,274,391,O
),274,392,O
Lithium,274,394,O
:,274,401,O
Increases,274,403,O
in,274,413,O
serum,274,416,O
lithium,274,422,O
concentrations,274,430,O
and,274,445,O
lithium,274,449,O
toxicity,274,457,O
(,274,466,O
7,274,467,O
),274,468,O
In,274,470,O
controlled,274,473,O
clinical,274,484,O
trials,274,493,O
",",274,499,O
clinically,274,501,O
important,274,512,O
changes,274,522,O
in,274,530,O
standard,274,533,O
laboratory,274,542,O
parameters,274,553,O
were,274,564,O
rarely,274,569,O
associated,274,576,O
with,274,587,O
administration,274,592,O
of,274,607,O
Diovan,274,610,O
.,274,616,O
Potassium-sparing,274,0,O
diuretics,274,18,O
",",274,27,O
potassium,274,29,O
supplements,274,39,O
or,274,51,O
salt,274,54,O
substitutes,274,59,O
may,274,71,O
lead,274,75,O
to,274,80,O
increases,274,83,B-SpecificInteraction
in,274,83,I-SpecificInteraction
serum,274,83,I-SpecificInteraction
potassium,274,83,I-SpecificInteraction
",",274,111,O
and,274,113,O
in,274,117,O
heart,274,120,O
failure,274,126,O
patients,274,134,O
",",274,142,O
increases,274,144,B-SpecificInteraction
in,274,144,I-SpecificInteraction
serum,274,144,I-SpecificInteraction
creatinine,274,144,I-SpecificInteraction
(,274,174,O
7,274,175,O
),274,176,O
NSAID,274,178,O
use,274,184,O
may,274,188,O
lead,274,192,O
to,274,197,O
increased,274,200,O
risk,274,210,O
of,274,215,O
renal,274,218,B-SpecificInteraction
impairment,274,218,I-SpecificInteraction
and,274,235,O
loss,274,239,B-SpecificInteraction
of,274,239,I-SpecificInteraction
antihypertensive,274,239,I-SpecificInteraction
effect,274,239,I-SpecificInteraction
(,274,271,O
7,274,272,O
),274,273,O
Dual,274,275,O
inhibition,274,280,O
of,274,291,O
the,274,294,O
renin-angiotensin,274,298,O
system,274,316,O
:,274,322,O
Increased,274,324,O
risk,274,334,O
of,274,339,O
renal,274,342,O
impairment,274,348,O
",",274,358,O
hypotension,274,360,O
",",274,371,O
and,274,373,O
hyperkalemia,274,377,O
(,274,390,O
7,274,391,O
),274,392,O
Lithium,274,394,O
:,274,401,O
Increases,274,403,O
in,274,413,O
serum,274,416,O
lithium,274,422,O
concentrations,274,430,O
and,274,445,O
lithium,274,449,O
toxicity,274,457,O
(,274,466,O
7,274,467,O
),274,468,O
In,274,470,O
controlled,274,473,O
clinical,274,484,O
trials,274,493,O
",",274,499,O
clinically,274,501,O
important,274,512,O
changes,274,522,O
in,274,530,O
standard,274,533,O
laboratory,274,542,O
parameters,274,553,O
were,274,564,O
rarely,274,569,O
associated,274,576,O
with,274,587,O
administration,274,592,O
of,274,607,O
Diovan,274,610,O
.,274,616,O
Serum,275,0,O
Potassium,275,6,O
:,275,15,O
In,275,17,O
hypertensive,275,20,O
patients,275,33,O
",",275,41,O
greater,275,43,O
than,275,51,O
20,275,56,O
%,275,58,O
increases,275,60,O
in,275,70,O
serum,275,73,O
potassium,275,79,O
were,275,89,O
observed,275,94,O
in,275,103,O
4.4,275,106,O
%,275,109,O
of,275,111,O
Diovan-treated,275,114,O
patients,275,129,O
compared,275,138,O
to,275,147,O
2.9,275,150,O
%,275,153,O
of,275,155,O
placebo-treated,275,158,O
patients,275,174,O
.,275,182,O
The,276,0,O
antihypertensive,276,4,O
effect,276,21,O
of,276,28,O
angiotensin,276,31,O
II,276,43,O
receptor,276,46,O
antagonists,276,55,O
",",276,67,O
including,276,69,O
valsartan,276,79,O
",",276,89,O
may,276,91,O
be,276,95,O
attenuated,276,98,O
by,276,109,O
NSAIDs,276,112,O
including,276,119,O
selective,276,129,O
COX-2,276,139,O
inhibitors,276,145,O
.,276,156,O
The,276,0,O
antihypertensive,276,4,O
effect,276,21,O
of,276,28,O
angiotensin,276,31,O
II,276,43,O
receptor,276,46,O
antagonists,276,55,O
",",276,67,O
including,276,69,O
valsartan,276,79,O
",",276,89,O
may,276,91,O
be,276,95,O
attenuated,276,98,O
by,276,109,O
NSAIDs,276,112,O
including,276,119,O
selective,276,129,O
COX-2,276,139,O
inhibitors,276,145,O
.,276,156,O
The,277,0,O
valsartan-atenolol,277,4,O
combination,277,23,O
was,277,35,O
more,277,39,O
antihypertensive,277,44,O
than,277,61,O
either,277,66,O
component,277,73,O
",",277,83,O
but,277,85,O
it,277,89,O
did,277,92,O
not,277,96,O
lower,277,100,O
the,277,106,O
heart,277,110,O
rate,277,116,O
more,277,121,O
than,277,126,O
atenolol,277,131,O
alone,277,140,O
.,277,146,O
Three,278,0,O
patients,278,6,O
(,278,15,O
<,278,16,O
0.1,278,17,O
%,278,20,O
),278,21,O
treated,278,23,O
with,278,31,O
valsartan,278,36,O
discontinued,278,46,O
treatment,278,59,O
for,278,69,O
elevated,278,73,O
liver,278,82,O
chemistries,278,88,O
.,278,99,O
Transporters,279,0,O
:,279,12,O
The,279,14,O
results,279,18,O
from,279,26,O
an,279,31,O
in,279,34,O
vitro,279,37,O
study,279,43,O
with,279,49,O
human,279,54,O
liver,279,60,O
tissue,279,66,O
indicate,279,73,O
that,279,82,O
valsartan,279,87,O
is,279,97,O
a,279,100,O
substrate,279,102,O
of,279,112,O
the,279,115,O
hepatic,279,119,O
uptake,279,127,O
transporter,279,134,O
OATP1B1,279,146,O
and,279,154,O
the,279,158,O
hepatic,279,162,O
efflux,279,170,O
transporter,279,177,O
MRP2,279,189,O
.,279,193,O
In,280,0,O
the,280,3,O
VALsartan,280,7,O
In,280,17,O
Acute,280,20,O
myocardial,280,26,O
iNfarcTion,280,37,O
trial,280,48,O
(,280,54,O
VALIANT,280,56,O
),280,64,O
",",280,66,O
hypotension,280,68,O
in,280,80,O
post-myocardial,280,83,O
infarction,280,99,O
patients,280,110,O
led,280,119,O
to,280,123,O
permanent,280,126,O
discontinuation,280,136,O
of,280,152,O
therapy,280,155,O
in,280,163,O
1.4,280,166,O
%,280,170,O
of,280,172,O
valsartan-treated,280,175,O
patients,280,193,O
and,280,202,O
0.8,280,206,O
%,280,210,O
of,280,212,O
captopril-treated,280,215,O
patients,280,233,O
.,280,242,O
Alcohol,400,0,O
",",400,7,O
Barbiturates,400,9,O
",",400,21,O
or,400,23,O
Narcotics-,400,26,O
potentiation,400,37,O
of,400,50,O
orthostatic,400,53,O
hypotension,400,65,O
may,400,77,O
occur,400,81,O
.,400,86,O
Antidiabetic,401,0,O
Drugs,401,13,O
(,401,19,O
Oral,401,20,O
Agents,401,25,O
and,401,32,O
Insulin,401,36,O
),401,43,O
-,401,44,O
dosage,401,46,O
adjustment,401,53,O
of,401,64,O
the,401,67,O
antidiabetic,401,71,O
drug,401,84,O
may,401,89,O
be,401,93,O
required,401,96,O
.,401,104,O
Cholestyramine,402,0,O
and,402,15,O
Colestipol,402,19,O
Resins-,402,30,O
Both,402,38,O
cholestyramine,402,43,O
and,402,58,O
colestipol,402,62,O
resins,402,73,O
have,402,80,O
the,402,85,O
potential,402,89,O
of,402,99,O
binding,402,102,O
thiazide,402,110,O
diuretics,402,119,O
and,402,129,O
reducing,402,133,O
diuretic,402,142,O
absorption,402,151,O
from,402,162,O
the,402,167,O
gastrointestinal,402,171,O
tract,402,188,O
.,402,193,O
Cholestyramine,402,0,O
and,402,15,O
Colestipol,402,19,O
Resins-,402,30,O
Both,402,38,O
cholestyramine,402,43,O
and,402,58,O
colestipol,402,62,O
resins,402,73,O
have,402,80,O
the,402,85,O
potential,402,89,O
of,402,99,O
binding,402,102,O
thiazide,402,110,O
diuretics,402,119,O
and,402,129,O
reducing,402,133,O
diuretic,402,142,O
absorption,402,151,O
from,402,162,O
the,402,167,O
gastrointestinal,402,171,O
tract,402,188,O
.,402,193,O
Corticosteroids,403,0,O
",",403,15,O
ACTH-,403,17,O
intensified,403,23,O
electrolyte,403,35,O
depletion,403,47,O
",",403,56,O
particularly,403,58,O
hypokalemia,403,71,O
.,403,82,O
Diuretic,404,0,O
agents,404,9,O
reduce,404,16,O
the,404,23,O
renal,404,27,O
clearance,404,33,O
of,404,43,O
lithium,404,46,O
and,404,54,O
add,404,58,O
a,404,62,O
high,404,64,O
risk,404,69,O
of,404,74,O
lithium,404,77,O
toxicity,404,85,O
.,404,93,O
Drug,405,0,O
Interactions,405,5,O
When,405,18,O
given,405,23,O
concurrently,405,29,O
the,405,42,O
following,405,46,O
drugs,405,56,O
may,405,62,O
interact,405,66,O
with,405,75,O
thiazide,405,80,O
diuretics,405,89,O
.,405,98,O
In,406,0,O
some,406,3,O
patients,406,8,O
with,406,17,O
compromised,406,22,O
renal,406,34,O
function,406,40,O
(,406,49,O
e.g.,406,50,O
",",406,54,O
elderly,406,56,O
patients,406,64,O
or,406,73,O
patients,406,76,O
who,406,85,O
are,406,89,O
volume-depleted,406,93,O
",",406,108,O
including,406,110,O
those,406,120,O
on,406,126,O
diuretic,406,129,O
therapy,406,138,O
),406,145,O
who,406,147,O
are,406,151,O
being,406,155,O
treated,406,161,O
with,406,169,O
non-steroidal,406,174,O
anti-inflammatory,406,188,O
drugs,406,206,O
",",406,211,O
including,406,213,O
selective,406,223,O
COX-2,406,233,O
inhibitors,406,239,O
",",406,249,O
the,406,251,O
co-administration,406,255,O
of,406,273,O
angiotensin,406,276,O
II,406,288,O
receptor,406,291,O
antagonists,406,300,O
or,406,312,O
ACE,406,315,O
inhibitors,406,319,O
may,406,330,O
result,406,334,O
in,406,341,O
a,406,344,O
further,406,346,O
deterioration,406,354,B-SpecificInteraction
of,406,354,I-SpecificInteraction
renal,406,354,I-SpecificInteraction
function,406,354,I-SpecificInteraction
",",406,385,O
including,406,387,O
possible,406,397,O
acute,406,406,B-SpecificInteraction
renal,406,406,I-SpecificInteraction
failure,406,406,I-SpecificInteraction
.,406,425,O
In,406,0,O
some,406,3,O
patients,406,8,O
with,406,17,O
compromised,406,22,O
renal,406,34,O
function,406,40,O
(,406,49,O
e.g.,406,50,O
",",406,54,O
elderly,406,56,O
patients,406,64,O
or,406,73,O
patients,406,76,O
who,406,85,O
are,406,89,O
volume-depleted,406,93,O
",",406,108,O
including,406,110,O
those,406,120,O
on,406,126,O
diuretic,406,129,O
therapy,406,138,O
),406,145,O
who,406,147,O
are,406,151,O
being,406,155,O
treated,406,161,O
with,406,169,O
non-steroidal,406,174,O
anti-inflammatory,406,188,O
drugs,406,206,O
",",406,211,O
including,406,213,O
selective,406,223,O
COX-2,406,233,O
inhibitors,406,239,O
",",406,249,O
the,406,251,O
co-administration,406,255,O
of,406,273,O
angiotensin,406,276,O
II,406,288,O
receptor,406,291,O
antagonists,406,300,O
or,406,312,O
ACE,406,315,O
inhibitors,406,319,O
may,406,330,O
result,406,334,O
in,406,341,O
a,406,344,O
further,406,346,O
deterioration,406,354,B-SpecificInteraction
of,406,354,I-SpecificInteraction
renal,406,354,I-SpecificInteraction
function,406,354,I-SpecificInteraction
",",406,385,O
including,406,387,O
possible,406,397,O
acute,406,406,B-SpecificInteraction
renal,406,406,I-SpecificInteraction
failure,406,406,I-SpecificInteraction
.,406,425,O
Lithium,407,0,O
-,407,8,O
generally,407,10,O
should,407,20,O
not,407,27,O
be,407,31,O
given,407,34,O
with,407,40,O
diuretics,407,45,O
.,407,54,O
Non-steroidal,408,0,O
Anti-inflammatory,408,14,O
Drugs,408,32,O
Including,408,38,O
Selective,408,48,O
Cyclooxygenase-2,408,58,O
(,408,75,O
COX-2,408,76,O
),408,81,O
Inhibitors-,408,83,O
In,408,95,O
some,408,98,O
patients,408,103,O
",",408,111,O
the,408,113,O
administration,408,117,O
of,408,132,O
a,408,135,O
non-steroidal,408,137,O
anti-inflammatory,408,151,O
agent,408,169,O
including,408,175,O
a,408,185,O
selective,408,187,O
COX-2,408,197,O
inhibitor,408,203,O
can,408,213,O
reduce,408,217,O
the,408,224,O
diuretic,408,228,O
",",408,236,O
natriuretic,408,238,O
",",408,249,O
and,408,251,O
antihypertensive,408,255,O
effects,408,272,O
of,408,280,O
loop,408,283,O
",",408,287,O
potassium-sparing,408,289,O
and,408,307,O
thiazide,408,311,O
diuretics,408,320,O
.,408,329,O
Non-steroidal,408,0,O
Anti-inflammatory,408,14,O
Drugs,408,32,O
Including,408,38,O
Selective,408,48,O
Cyclooxygenase-2,408,58,O
(,408,75,O
COX-2,408,76,O
),408,81,O
Inhibitors-,408,83,O
In,408,95,O
some,408,98,O
patients,408,103,O
",",408,111,O
the,408,113,O
administration,408,117,O
of,408,132,O
a,408,135,O
non-steroidal,408,137,O
anti-inflammatory,408,151,O
agent,408,169,O
including,408,175,O
a,408,185,O
selective,408,187,O
COX-2,408,197,O
inhibitor,408,203,O
can,408,213,O
reduce,408,217,O
the,408,224,O
diuretic,408,228,O
",",408,236,O
natriuretic,408,238,O
",",408,249,O
and,408,251,O
antihypertensive,408,255,O
effects,408,272,O
of,408,280,O
loop,408,283,O
",",408,287,O
potassium-sparing,408,289,O
and,408,307,O
thiazide,408,311,O
diuretics,408,320,O
.,408,329,O
Other,409,0,O
Antihypertensive,409,6,O
Drugs-,409,23,O
additive,409,30,O
effect,409,39,O
or,409,46,O
potentiation,409,49,O
.,409,61,O
Pressor,410,0,O
Amines,410,8,O
(,410,15,O
e.g.,410,16,O
",",410,20,O
Norepinephrine,410,22,O
),410,36,O
-,410,37,O
possible,410,39,O
decreased,410,48,O
response,410,58,O
to,410,67,O
pressor,410,70,O
amines,410,78,O
but,410,85,O
not,410,89,O
sufficient,410,93,O
to,410,104,O
preclude,410,107,O
their,410,116,O
use,410,122,O
.,410,125,O
Pressor,410,0,O
Amines,410,8,O
(,410,15,O
e.g.,410,16,O
",",410,20,O
Norepinephrine,410,22,O
),410,36,O
-,410,37,O
possible,410,39,O
decreased,410,48,O
response,410,58,O
to,410,67,O
pressor,410,70,O
amines,410,78,O
but,410,85,O
not,410,89,O
sufficient,410,93,O
to,410,104,O
preclude,410,107,O
their,410,116,O
use,410,122,O
.,410,125,O
Refer,411,0,O
to,411,6,O
the,411,9,O
package,411,13,O
insert,411,21,O
for,411,28,O
lithium,411,32,O
preparations,411,40,O
before,411,53,O
use,411,60,O
of,411,64,O
such,411,67,O
preparations,411,72,O
with,411,85,O
DIURIL,411,90,O
.,411,96,O
Skeletal,412,0,O
Muscle,412,9,O
Relaxants,412,16,O
",",412,25,O
Nondepolarizing,412,27,O
(,412,43,O
e.g.,412,44,O
",",412,48,O
Tubocurarine,412,50,O
),412,62,O
-,412,63,O
possible,412,65,O
increased,412,74,B-SpecificInteraction
responsiveness,412,74,I-SpecificInteraction
to,412,74,I-SpecificInteraction
the,412,74,I-SpecificInteraction
muscle,412,74,I-SpecificInteraction
relaxant,412,74,I-SpecificInteraction
.,412,121,O
Skeletal,412,0,O
Muscle,412,9,O
Relaxants,412,16,O
",",412,25,O
Nondepolarizing,412,27,O
(,412,43,O
e.g.,412,44,O
",",412,48,O
Tubocurarine,412,50,O
),412,62,O
-,412,63,O
possible,412,65,O
increased,412,74,B-SpecificInteraction
responsiveness,412,74,I-SpecificInteraction
to,412,74,I-SpecificInteraction
the,412,74,I-SpecificInteraction
muscle,412,74,I-SpecificInteraction
relaxant,412,74,I-SpecificInteraction
.,412,121,O
Therefore,413,0,O
",",413,9,O
the,413,11,O
combination,413,15,O
should,413,27,O
be,413,34,O
administered,413,37,O
with,413,50,O
caution,413,55,O
",",413,62,O
especially,413,64,O
in,413,75,O
the,413,78,O
elderly,413,82,O
.,413,89,O
These,414,0,O
interactions,414,6,O
should,414,19,O
be,414,26,O
considered,414,29,O
in,414,40,O
patients,414,43,O
taking,414,52,O
NSAIDs,414,59,O
including,414,66,O
selective,414,76,O
COX-2,414,86,O
inhibitors,414,92,O
concomitantly,414,103,O
with,414,117,O
diuretics,414,122,O
and,414,132,O
angiotensin,414,136,O
II,414,148,O
antagonists,414,151,O
or,414,163,O
ACE,414,166,O
inhibitors,414,170,O
.,414,180,O
These,414,0,O
interactions,414,6,O
should,414,19,O
be,414,26,O
considered,414,29,O
in,414,40,O
patients,414,43,O
taking,414,52,O
NSAIDs,414,59,O
including,414,66,O
selective,414,76,O
COX-2,414,86,O
inhibitors,414,92,O
concomitantly,414,103,O
with,414,117,O
diuretics,414,122,O
and,414,132,O
angiotensin,414,136,O
II,414,148,O
antagonists,414,151,O
or,414,163,O
ACE,414,166,O
inhibitors,414,170,O
.,414,180,O
It,415,0,O
is,415,3,O
not,415,6,O
known,415,10,O
whether,415,16,O
chlorothiazide,415,24,O
can,415,39,O
cause,415,43,O
fetal,415,49,O
harm,415,55,O
when,415,60,O
administered,415,65,O
to,415,78,O
a,415,81,O
pregnant,415,83,O
woman,415,92,O
",",415,98,O
however,415,100,O
",",415,108,O
thiazides,415,110,O
cross,415,120,O
the,415,126,O
placental,415,130,O
barrier,415,140,O
and,415,148,O
appear,415,152,O
in,415,159,O
cord,415,162,O
blood,415,167,O
.,415,173,O
Therefore,416,0,O
",",416,10,O
when,416,12,O
DIURIL,416,17,O
and,416,24,O
non-steroidal,416,28,O
anti-inflammatory,416,42,O
agents,416,60,O
or,416,67,O
selective,416,70,O
COX-2,416,80,O
inhibitors,416,86,O
are,416,97,O
used,416,101,O
concomitantly,416,106,O
",",416,120,O
the,416,122,O
patient,416,126,O
should,416,134,O
be,416,141,O
observed,416,144,O
closely,416,153,O
to,416,161,O
determine,416,164,O
if,416,174,O
the,416,177,O
desired,416,181,O
effect,416,189,O
of,416,196,O
the,416,199,O
diuretic,416,203,O
is,416,212,O
obtained,416,215,O
.,416,224,O
Do,281,0,O
not,281,3,O
administer,281,7,O
Dobutamine,281,18,O
Hydrochloride,281,29,O
in,281,43,O
5,281,46,O
%,281,48,O
Dextrose,281,52,O
Injection,281,61,O
simultaneously,281,71,O
with,281,86,O
solutions,281,91,O
containing,281,101,O
sodium,281,112,O
bicarbonate,281,119,O
or,281,131,O
strong,281,134,O
alkaline,281,141,O
solutions,281,150,O
.,281,160,O
Do,281,0,O
not,281,3,O
administer,281,7,O
Dobutamine,281,18,O
Hydrochloride,281,29,O
in,281,43,O
5,281,46,O
%,281,48,O
Dextrose,281,52,O
Injection,281,61,O
simultaneously,281,71,O
with,281,86,O
solutions,281,91,O
containing,281,101,O
sodium,281,112,O
bicarbonate,281,119,O
or,281,131,O
strong,281,134,O
alkaline,281,141,O
solutions,281,150,O
.,281,160,O
Dobutamine,282,0,O
Hydrochloride,282,11,O
in,282,25,O
5,282,28,O
%,282,30,O
Dextrose,282,34,O
Injection,282,43,O
solutions,282,53,O
may,282,63,O
exhibit,282,67,O
a,282,75,O
pink,282,77,O
color,282,82,O
that,282,88,O
",",282,93,O
if,282,95,O
present,282,98,O
",",282,106,O
will,282,108,O
increase,282,113,O
with,282,122,O
time,282,127,O
.,282,132,O
Dobutamine,283,0,O
Hydrochloride,283,11,O
in,283,25,O
5,283,28,O
%,283,30,O
Dextrose,283,34,O
Injection,283,43,O
contains,283,53,O
sodium,283,62,O
bisulfite,283,69,O
",",283,79,O
a,283,81,O
sulfite,283,83,O
that,283,91,O
may,283,96,O
cause,283,100,O
allergic-type,283,106,O
reactions,283,120,O
",",283,130,O
including,283,132,O
anaphylactic,283,142,O
symptoms,283,155,O
and,283,164,O
life-threatening,283,168,O
or,283,185,O
less,283,188,O
severe,283,193,O
asthmatic,283,200,O
episodes,283,210,O
",",283,219,O
in,283,221,O
certain,283,224,O
susceptible,283,232,O
people,283,244,O
.,283,251,O
In,284,0,O
patients,284,3,O
who,284,12,O
have,284,16,O
atrial,284,21,O
fibrillation,284,28,O
with,284,41,O
rapid,284,46,O
ventricular,284,52,O
response,284,64,O
",",284,73,O
a,284,75,O
digitalis,284,77,O
preparation,284,87,O
should,284,99,O
be,284,106,O
used,284,109,O
prior,284,114,O
to,284,120,O
institution,284,123,O
of,284,135,O
therapy,284,138,O
with,284,146,O
Dobutamine,284,151,O
in,284,162,O
D5W,284,165,O
.,284,169,O
During,285,0,O
the,285,7,O
administration,285,11,O
of,285,26,O
Dobutamine,285,29,O
Hydrochloride,285,40,O
in,285,54,O
5,285,57,O
%,285,59,O
Dextrose,285,63,O
Injection,285,72,O
",",285,82,O
as,285,84,O
with,285,87,O
any,285,92,O
adrenergic,285,96,O
agent,285,107,O
",",285,113,O
ECG,285,115,O
and,285,119,O
blood,285,123,O
pressure,285,129,O
should,285,138,O
be,285,145,O
continuously,285,148,O
monitored,285,161,O
.,285,171,O
Hypovolemia,286,0,O
should,286,12,O
be,286,19,O
corrected,286,22,O
with,286,32,O
suitable,286,37,O
volume,286,46,O
expanders,286,53,O
before,286,63,O
treatment,286,70,O
with,286,80,O
dobutamine,286,85,O
is,286,96,O
instituted,286,99,O
.,286,110,O
In,287,0,O
premature,287,3,O
neonates,287,13,O
",",287,22,O
however,287,24,O
",",287,32,O
dobutamine,287,34,O
is,287,45,O
less,287,48,O
effective,287,53,O
than,287,63,O
dopamine,287,68,O
in,287,77,O
raising,287,80,O
systemic,287,88,O
blood,287,97,O
pressure,287,103,O
without,287,112,O
causing,287,120,O
undue,287,128,O
tachycardia,287,134,O
",",287,146,O
and,287,148,O
dobutamine,287,152,O
has,287,163,O
not,287,167,O
been,287,171,O
shown,287,176,O
to,287,182,O
provide,287,185,O
any,287,193,O
added,287,197,O
benefit,287,203,O
when,287,211,O
given,287,216,O
to,287,222,O
such,287,225,O
infants,287,230,O
already,287,238,O
receiving,287,246,O
optimal,287,256,O
infusions,287,264,O
of,287,274,O
dopamine,287,277,O
.,287,286,O
Preliminary,288,0,O
studies,288,12,O
indicate,288,20,O
that,288,29,O
the,288,34,O
concomitant,288,38,O
use,288,50,O
of,288,54,O
dobutamine,288,57,O
and,288,68,O
nitroprusside,288,72,O
results,288,86,O
in,288,94,O
a,288,97,O
higher,288,99,B-SpecificInteraction
cardiac,288,99,I-SpecificInteraction
output,288,99,I-SpecificInteraction
and,288,121,O
",",288,125,O
usually,288,127,O
",",288,135,O
a,288,137,O
lower,288,139,B-SpecificInteraction
pulmonary,288,139,I-SpecificInteraction
wedge,288,139,I-SpecificInteraction
pressure,288,139,I-SpecificInteraction
than,288,170,O
when,288,175,O
either,288,180,O
drug,288,187,O
is,288,192,O
used,288,195,O
alone,288,200,O
.,288,206,O
There,289,0,O
was,289,6,O
no,289,10,O
evidence,289,13,O
of,289,22,O
drug,289,25,O
interactions,289,30,O
in,289,43,O
clinical,289,46,O
studies,289,55,O
in,289,63,O
which,289,66,O
dobutamine,289,72,O
was,289,83,O
administered,289,87,O
concurrently,289,100,O
with,289,113,O
other,289,118,O
drugs,289,124,O
",",289,130,O
including,289,132,O
digitalis,289,142,O
preparations,289,152,O
",",289,165,O
furosemide,289,167,O
",",289,178,O
spironolactone,289,180,O
",",289,195,O
lidocaine,289,197,O
",",289,207,O
glyceryl,289,209,O
trinitrate,289,218,O
",",289,229,O
isosorbide,289,231,O
dinitrate,289,242,O
",",289,252,O
morphine,289,254,O
",",289,263,O
atropine,289,265,O
",",289,274,O
heparin,289,276,O
",",289,284,O
protamine,289,286,O
",",289,296,O
potassium,289,298,O
chloride,289,308,O
",",289,317,O
folic,289,319,O
acid,289,325,O
",",289,330,O
and,289,332,O
acetaminophen,289,336,O
.,289,350,O
Edarbi,351,0,O
may,351,7,O
be,351,11,O
administered,351,14,O
with,351,27,O
other,351,32,O
antihypertensive,351,38,O
agents,351,55,O
.,351,62,O
If,352,0,O
blood,352,3,O
pressure,352,9,O
is,352,18,O
not,352,21,O
controlled,352,25,O
with,352,36,O
Edarbi,352,41,O
alone,352,48,O
",",352,54,O
additional,352,56,O
blood,352,67,O
pressure,352,73,O
reduction,352,82,O
can,352,92,O
be,352,96,O
achieved,352,99,O
by,352,108,O
taking,352,111,O
Edarbi,352,118,O
with,352,125,O
other,352,130,O
antihypertensive,352,136,O
agents,352,153,O
.,352,160,O
Do,353,0,O
not,353,3,O
coadminister,353,7,O
aliskiren,353,20,O
with,353,30,O
Edarbi,353,35,O
in,353,42,O
patients,353,45,O
with,353,54,O
diabetes,353,59,O
.,353,68,O
Do,354,0,O
not,354,3,O
coadminister,354,7,O
aliskiren,354,20,O
with,354,30,O
Edarbi,354,35,O
in,354,42,O
patients,354,45,O
with,354,54,O
diabetes,354,59,O
see,354,68,O
Drug,354,72,O
Interactions,354,77,O
(,354,90,O
7,354,92,O
),354,94,O
.,354,96,O
Avoid,355,0,O
use,355,6,O
of,355,10,O
aliskiren,355,13,O
with,355,23,O
Edarbi,355,28,O
in,355,35,O
patients,355,38,O
with,355,47,O
renal,355,52,O
impairment,355,58,O
(,355,69,O
GFR,355,71,O
60,355,75,O
mL/min,355,78,O
),355,85,O
.,355,87,O
Closely,356,0,O
monitor,356,8,O
blood,356,16,O
pressure,356,22,O
",",356,31,O
renal,356,33,O
function,356,39,O
and,356,48,O
electrolytes,356,52,O
in,356,65,O
patients,356,68,O
on,356,77,O
Edarbi,356,80,O
and,356,87,O
other,356,91,O
agents,356,97,O
that,356,104,O
affect,356,109,O
the,356,116,O
RAS,356,120,O
.,356,124,O
Dual,357,0,O
Blockade,357,5,O
of,357,14,O
the,357,17,O
Renin-Angiotensin,357,21,O
System,357,39,O
(,357,46,O
RAS,357,47,O
),357,50,O
Dual,357,52,O
blockade,357,57,O
of,357,66,O
the,357,69,O
RAS,357,73,O
with,357,77,O
angiotensin,357,82,O
receptor,357,94,O
blockers,357,103,O
",",357,111,O
ACE,357,113,O
inhibitors,357,117,O
",",357,127,O
or,357,129,O
aliskiren,357,132,O
is,357,142,O
associated,357,145,O
with,357,156,O
increased,357,161,O
risks,357,171,O
of,357,177,O
hypotension,357,180,B-SpecificInteraction
",",357,191,O
hyperkalemia,357,193,B-SpecificInteraction
",",357,205,O
and,357,207,O
changes,357,211,B-SpecificInteraction
in,357,211,I-SpecificInteraction
renal,357,211,I-SpecificInteraction
function,357,211,I-SpecificInteraction
(,357,237,O
including,357,238,O
acute,357,248,B-SpecificInteraction
renal,357,248,I-SpecificInteraction
failure,357,248,I-SpecificInteraction
),357,267,O
compared,357,269,O
to,357,278,O
monotherapy,357,281,O
.,357,292,O
Dual,357,0,O
Blockade,357,5,O
of,357,14,O
the,357,17,O
Renin-Angiotensin,357,21,O
System,357,39,O
(,357,46,O
RAS,357,47,O
),357,50,O
Dual,357,52,O
blockade,357,57,O
of,357,66,O
the,357,69,O
RAS,357,73,O
with,357,77,O
angiotensin,357,82,O
receptor,357,94,O
blockers,357,103,O
",",357,111,O
ACE,357,113,O
inhibitors,357,117,O
",",357,127,O
or,357,129,O
aliskiren,357,132,O
is,357,142,O
associated,357,145,O
with,357,156,O
increased,357,161,O
risks,357,171,O
of,357,177,O
hypotension,357,180,B-SpecificInteraction
",",357,191,O
hyperkalemia,357,193,B-SpecificInteraction
",",357,205,O
and,357,207,O
changes,357,211,B-SpecificInteraction
in,357,211,I-SpecificInteraction
renal,357,211,I-SpecificInteraction
function,357,211,I-SpecificInteraction
(,357,237,O
including,357,238,O
acute,357,248,B-SpecificInteraction
renal,357,248,I-SpecificInteraction
failure,357,248,I-SpecificInteraction
),357,267,O
compared,357,269,O
to,357,278,O
monotherapy,357,281,O
.,357,292,O
Dual,358,0,O
inhibition,358,5,O
of,358,16,O
the,358,19,O
renin-angiotensin,358,23,O
system,358,41,O
:,358,47,O
Increased,358,49,O
risk,358,59,O
of,358,64,O
renal,358,67,O
impairment,358,73,O
",",358,83,O
hypotension,358,85,O
",",358,96,O
and,358,98,O
hyperkalemia,358,102,O
.,358,114,O
In,359,0,O
patients,359,3,O
who,359,12,O
are,359,16,O
elderly,359,20,O
",",359,28,O
volume-depleted,359,30,O
(,359,46,O
including,359,48,O
those,359,58,O
on,359,64,O
diuretic,359,67,O
therapy,359,76,O
),359,84,O
",",359,86,O
or,359,88,O
who,359,91,O
have,359,95,O
compromised,359,100,O
renal,359,112,O
function,359,118,O
",",359,127,O
coadministration,359,129,O
of,359,146,O
NSAIDs,359,149,O
",",359,156,O
including,359,158,O
selective,359,168,O
COX-2,359,178,O
inhibitors,359,184,O
",",359,195,O
with,359,197,O
angiotensin,359,202,O
II,359,214,O
receptor,359,217,O
antagonists,359,226,O
",",359,238,O
including,359,240,O
azilsartan,359,250,O
",",359,261,O
may,359,263,O
result,359,267,O
in,359,274,O
deterioration,359,277,B-SpecificInteraction
of,359,277,I-SpecificInteraction
renal,359,277,I-SpecificInteraction
function,359,277,I-SpecificInteraction
",",359,309,O
including,359,311,O
possible,359,321,O
acute,359,330,B-SpecificInteraction
renal,359,330,I-SpecificInteraction
failure,359,330,I-SpecificInteraction
.,359,350,O
In,359,0,O
patients,359,3,O
who,359,12,O
are,359,16,O
elderly,359,20,O
",",359,28,O
volume-depleted,359,30,O
(,359,46,O
including,359,48,O
those,359,58,O
on,359,64,O
diuretic,359,67,O
therapy,359,76,O
),359,84,O
",",359,86,O
or,359,88,O
who,359,91,O
have,359,95,O
compromised,359,100,O
renal,359,112,O
function,359,118,O
",",359,127,O
coadministration,359,129,O
of,359,146,O
NSAIDs,359,149,O
",",359,156,O
including,359,158,O
selective,359,168,O
COX-2,359,178,O
inhibitors,359,184,O
",",359,195,O
with,359,197,O
angiotensin,359,202,O
II,359,214,O
receptor,359,217,O
antagonists,359,226,O
",",359,238,O
including,359,240,O
azilsartan,359,250,O
",",359,261,O
may,359,263,O
result,359,267,O
in,359,274,O
deterioration,359,277,B-SpecificInteraction
of,359,277,I-SpecificInteraction
renal,359,277,I-SpecificInteraction
function,359,277,I-SpecificInteraction
",",359,309,O
including,359,311,O
possible,359,321,O
acute,359,330,B-SpecificInteraction
renal,359,330,I-SpecificInteraction
failure,359,330,I-SpecificInteraction
.,359,350,O
Monitor,360,0,O
renal,360,8,O
function,360,14,O
periodically,360,23,O
in,360,36,O
patients,360,39,O
receiving,360,48,O
azilsartan,360,58,O
and,360,69,O
NSAID,360,73,O
therapy,360,79,O
.,360,87,O
No,361,0,O
clinically,361,3,O
significant,361,14,O
drug,361,26,O
interactions,361,31,O
have,361,44,O
been,361,49,O
observed,361,54,O
in,361,63,O
studies,361,66,O
of,361,74,O
azilsartan,361,77,O
medoxomil,361,88,O
or,361,98,O
azilsartan,361,101,O
given,361,112,O
with,361,118,O
amlodipine,361,123,O
",",361,134,O
antacids,361,136,O
",",361,145,O
chlorthalidone,361,147,O
",",361,162,O
digoxin,361,164,O
",",361,172,O
fluconazole,361,174,O
",",361,186,O
glyburide,361,188,O
",",361,198,O
ketoconazole,361,200,O
",",361,213,O
metformin,361,215,O
",",361,225,O
pioglitazone,361,227,O
",",361,240,O
and,361,242,O
warfarin,361,246,O
.,361,255,O
Non-steroidal,362,0,O
Anti-Inflammatory,362,14,O
Agents,362,32,O
",",362,38,O
including,362,40,O
Selective,362,50,O
Cyclooxygenase-2,362,60,O
Inhibitors,362,77,O
(,362,88,O
COX-2,362,89,O
Inhibitors,362,95,O
),362,105,O
In,362,107,O
patients,362,110,O
who,362,119,O
are,362,123,O
elderly,362,127,O
",",362,134,O
volume-depleted,362,136,O
(,362,152,O
including,362,153,O
those,362,163,O
on,362,169,O
diuretic,362,172,O
therapy,362,181,O
),362,188,O
",",362,189,O
or,362,191,O
who,362,194,O
have,362,198,O
compromised,362,203,O
renal,362,215,O
function,362,221,O
",",362,229,O
coadministration,362,231,O
of,362,248,O
NSAIDs,362,251,O
",",362,257,O
including,362,259,O
selective,362,269,O
COX-2,362,279,O
inhibitors,362,285,O
",",362,295,O
with,362,297,O
angiotensin,362,302,O
II,362,314,O
receptor,362,317,O
antagonists,362,326,O
",",362,337,O
including,362,339,O
azilsartan,362,349,O
",",362,359,O
may,362,361,O
result,362,365,O
in,362,372,O
deterioration,362,375,B-SpecificInteraction
of,362,375,I-SpecificInteraction
renal,362,375,I-SpecificInteraction
function,362,375,I-SpecificInteraction
",",362,406,O
including,362,408,O
possible,362,418,O
acute,362,427,B-SpecificInteraction
renal,362,427,I-SpecificInteraction
failure,362,427,I-SpecificInteraction
.,362,446,O
Non-steroidal,362,0,O
Anti-Inflammatory,362,14,O
Agents,362,32,O
",",362,38,O
including,362,40,O
Selective,362,50,O
Cyclooxygenase-2,362,60,O
Inhibitors,362,77,O
(,362,88,O
COX-2,362,89,O
Inhibitors,362,95,O
),362,105,O
In,362,107,O
patients,362,110,O
who,362,119,O
are,362,123,O
elderly,362,127,O
",",362,134,O
volume-depleted,362,136,O
(,362,152,O
including,362,153,O
those,362,163,O
on,362,169,O
diuretic,362,172,O
therapy,362,181,O
),362,188,O
",",362,189,O
or,362,191,O
who,362,194,O
have,362,198,O
compromised,362,203,O
renal,362,215,O
function,362,221,O
",",362,229,O
coadministration,362,231,O
of,362,248,O
NSAIDs,362,251,O
",",362,257,O
including,362,259,O
selective,362,269,O
COX-2,362,279,O
inhibitors,362,285,O
",",362,295,O
with,362,297,O
angiotensin,362,302,O
II,362,314,O
receptor,362,317,O
antagonists,362,326,O
",",362,337,O
including,362,339,O
azilsartan,362,349,O
",",362,359,O
may,362,361,O
result,362,365,O
in,362,372,O
deterioration,362,375,B-SpecificInteraction
of,362,375,I-SpecificInteraction
renal,362,375,I-SpecificInteraction
function,362,375,I-SpecificInteraction
",",362,406,O
including,362,408,O
possible,362,418,O
acute,362,427,B-SpecificInteraction
renal,362,427,I-SpecificInteraction
failure,362,427,I-SpecificInteraction
.,362,446,O
Non-steroidal,362,0,O
Anti-Inflammatory,362,14,O
Agents,362,32,O
",",362,38,O
including,362,40,O
Selective,362,50,O
Cyclooxygenase-2,362,60,O
Inhibitors,362,77,O
(,362,88,O
COX-2,362,89,O
Inhibitors,362,95,O
),362,105,O
In,362,107,O
patients,362,110,O
who,362,119,O
are,362,123,O
elderly,362,127,O
",",362,134,O
volume-depleted,362,136,O
(,362,152,O
including,362,153,O
those,362,163,O
on,362,169,O
diuretic,362,172,O
therapy,362,181,O
),362,188,O
",",362,189,O
or,362,191,O
who,362,194,O
have,362,198,O
compromised,362,203,O
renal,362,215,O
function,362,221,O
",",362,229,O
coadministration,362,231,O
of,362,248,O
NSAIDs,362,251,O
",",362,257,O
including,362,259,O
selective,362,269,O
COX-2,362,279,O
inhibitors,362,285,O
",",362,295,O
with,362,297,O
angiotensin,362,302,O
II,362,314,O
receptor,362,317,O
antagonists,362,326,O
",",362,337,O
including,362,339,O
azilsartan,362,349,O
",",362,359,O
may,362,361,O
result,362,365,O
in,362,372,O
deterioration,362,375,B-SpecificInteraction
of,362,375,I-SpecificInteraction
renal,362,375,I-SpecificInteraction
function,362,375,I-SpecificInteraction
",",362,406,O
including,362,408,O
possible,362,418,O
acute,362,427,B-SpecificInteraction
renal,362,427,I-SpecificInteraction
failure,362,427,I-SpecificInteraction
.,362,446,O
Non-steroidal,362,0,O
Anti-Inflammatory,362,14,O
Agents,362,32,O
",",362,38,O
including,362,40,O
Selective,362,50,O
Cyclooxygenase-2,362,60,O
Inhibitors,362,77,O
(,362,88,O
COX-2,362,89,O
Inhibitors,362,95,O
),362,105,O
In,362,107,O
patients,362,110,O
who,362,119,O
are,362,123,O
elderly,362,127,O
",",362,134,O
volume-depleted,362,136,O
(,362,152,O
including,362,153,O
those,362,163,O
on,362,169,O
diuretic,362,172,O
therapy,362,181,O
),362,188,O
",",362,189,O
or,362,191,O
who,362,194,O
have,362,198,O
compromised,362,203,O
renal,362,215,O
function,362,221,O
",",362,229,O
coadministration,362,231,O
of,362,248,O
NSAIDs,362,251,O
",",362,257,O
including,362,259,O
selective,362,269,O
COX-2,362,279,O
inhibitors,362,285,O
",",362,295,O
with,362,297,O
angiotensin,362,302,O
II,362,314,O
receptor,362,317,O
antagonists,362,326,O
",",362,337,O
including,362,339,O
azilsartan,362,349,O
",",362,359,O
may,362,361,O
result,362,365,O
in,362,372,O
deterioration,362,375,B-SpecificInteraction
of,362,375,I-SpecificInteraction
renal,362,375,I-SpecificInteraction
function,362,375,I-SpecificInteraction
",",362,406,O
including,362,408,O
possible,362,418,O
acute,362,427,B-SpecificInteraction
renal,362,427,I-SpecificInteraction
failure,362,427,I-SpecificInteraction
.,362,446,O
The,363,0,O
antihypertensive,363,4,O
effect,363,21,O
of,363,28,O
angiotensin,363,31,O
II,363,43,O
receptor,363,46,O
antagonists,363,55,O
",",363,67,O
including,363,69,O
azilsartan,363,79,O
",",363,90,O
may,363,92,O
be,363,96,O
attenuated,363,99,O
by,363,110,O
NSAIDs,363,113,O
",",363,120,O
including,363,122,O
selective,363,132,O
COX-2,363,142,O
inhibitors,363,148,O
.,363,159,O
The,363,0,O
antihypertensive,363,4,O
effect,363,21,O
of,363,28,O
angiotensin,363,31,O
II,363,43,O
receptor,363,46,O
antagonists,363,55,O
",",363,67,O
including,363,69,O
azilsartan,363,79,O
",",363,90,O
may,363,92,O
be,363,96,O
attenuated,363,99,O
by,363,110,O
NSAIDs,363,113,O
",",363,120,O
including,363,122,O
selective,363,132,O
COX-2,363,142,O
inhibitors,363,148,O
.,363,159,O
Therefore,364,0,O
",",364,9,O
Edarbi,364,11,O
may,364,18,O
be,364,22,O
used,364,25,O
concomitantly,364,30,O
with,364,44,O
these,364,49,O
medications,364,55,O
.,364,66,O
In,365,0,O
patients,365,3,O
with,365,12,O
an,365,17,O
activated,365,20,O
renin-angiotensin,365,30,O
system,365,48,O
",",365,55,O
such,365,57,O
as,365,62,O
volume,365,65,O
-,365,72,O
and/or,365,74,O
salt-depleted,365,81,O
patients,365,95,O
(,365,104,O
e.g.,365,106,O
",",365,111,O
those,365,113,O
being,365,119,O
treated,365,125,O
with,365,133,O
high,365,138,O
doses,365,143,O
of,365,149,O
diuretics,365,152,O
),365,162,O
",",365,164,O
symptomatic,365,166,O
hypotension,365,178,O
may,365,190,O
occur,365,194,O
after,365,200,O
initiation,365,206,O
of,365,217,O
treatment,365,220,O
with,365,230,O
Edarbi,365,235,O
.,365,242,O
Before,231,0,O
infusion,231,7,O
of,231,16,O
INTEGRILIN,231,19,O
",",231,30,O
the,231,32,O
following,231,36,O
laboratory,231,46,O
tests,231,57,O
should,231,63,O
be,231,70,O
performed,231,73,O
to,231,83,O
identify,231,86,O
pre-existing,231,95,O
hemostatic,231,108,O
abnormalities,231,119,O
:,231,133,O
hematocrit,231,135,O
or,231,146,O
hemoglobin,231,149,O
",",231,160,O
platelet,231,162,O
count,231,171,O
",",231,177,O
serum,231,179,O
creatinine,231,185,O
",",231,196,O
and,231,198,O
PT/aPTT,231,202,O
.,231,210,O
Do,232,0,O
not,232,3,O
administer,232,7,O
INTEGRILIN,232,18,O
through,232,29,O
the,232,37,O
same,232,41,O
intravenous,232,46,O
line,232,58,O
as,232,63,O
furosemide,232,66,O
.,232,77,O
INTEGRILIN,233,0,O
should,233,11,O
be,233,18,O
given,233,21,O
concomitantly,233,27,O
with,233,41,O
heparin,233,46,O
dosed,233,54,O
to,233,60,O
achieve,233,63,O
the,233,71,O
following,233,75,O
parameters,233,85,O
:,233,96,O
.,233,98,O
INTEGRILIN,234,0,O
should,234,11,O
be,234,18,O
given,234,21,O
concomitantly,234,27,O
with,234,41,O
heparin,234,46,O
to,234,54,O
achieve,234,57,O
a,234,65,O
target,234,67,O
ACT,234,74,O
of,234,78,O
200,234,81,O
to,234,85,O
300,234,88,O
seconds,234,92,O
.,234,100,O
May,235,0,O
administer,235,4,O
INTEGRILIN,235,15,O
in,235,26,O
the,235,29,O
same,235,33,O
intravenous,235,38,O
line,235,50,O
as,235,55,O
alteplase,235,58,O
",",235,68,O
atropine,235,70,O
",",235,79,O
dobutamine,235,81,O
",",235,92,O
heparin,235,94,O
",",235,102,O
lidocaine,235,104,O
",",235,114,O
meperidine,235,116,O
",",235,127,O
metoprolol,235,129,O
",",235,140,O
midazolam,235,142,O
",",235,152,O
morphine,235,154,O
",",235,163,O
nitroglycerin,235,165,O
",",235,179,O
or,235,181,O
verapamil,235,184,O
.,235,194,O
May,236,0,O
administer,236,4,O
INTEGRILIN,236,15,O
in,236,26,O
the,236,29,O
same,236,33,O
IV,236,38,O
line,236,41,O
with,236,46,O
0.9,236,51,O
%,236,55,O
NaCl,236,57,O
or,236,62,O
0.9,236,65,O
%,236,69,O
NaCl/5,236,71,O
%,236,78,O
dextrose,236,80,O
.,236,89,O
(,237,0,O
7.1,237,1,O
),237,4,O
Coadministration,237,6,O
of,237,23,O
antiplatelet,237,26,O
agents,237,39,O
",",237,45,O
thrombolytics,237,47,O
",",237,60,O
heparin,237,62,O
",",237,69,O
aspirin,237,71,O
",",237,78,O
and,237,80,O
chronic,237,84,O
NSAID,237,92,O
use,237,98,O
increases,237,102,B-SpecificInteraction
the,237,102,I-SpecificInteraction
risk,237,102,I-SpecificInteraction
of,237,102,I-SpecificInteraction
bleeding,237,102,I-SpecificInteraction
(,237,0,O
7.1,237,1,O
),237,4,O
Coadministration,237,6,O
of,237,23,O
antiplatelet,237,26,O
agents,237,39,O
",",237,45,O
thrombolytics,237,47,O
",",237,60,O
heparin,237,62,O
",",237,69,O
aspirin,237,71,O
",",237,78,O
and,237,80,O
chronic,237,84,O
NSAID,237,92,O
use,237,98,O
increases,237,102,B-SpecificInteraction
the,237,102,I-SpecificInteraction
risk,237,102,I-SpecificInteraction
of,237,102,I-SpecificInteraction
bleeding,237,102,I-SpecificInteraction
(,237,0,O
7.1,237,1,O
),237,4,O
Coadministration,237,6,O
of,237,23,O
antiplatelet,237,26,O
agents,237,39,O
",",237,45,O
thrombolytics,237,47,O
",",237,60,O
heparin,237,62,O
",",237,69,O
aspirin,237,71,O
",",237,78,O
and,237,80,O
chronic,237,84,O
NSAID,237,92,O
use,237,98,O
increases,237,102,B-SpecificInteraction
the,237,102,I-SpecificInteraction
risk,237,102,I-SpecificInteraction
of,237,102,I-SpecificInteraction
bleeding,237,102,I-SpecificInteraction
(,237,0,O
7.1,237,1,O
),237,4,O
Coadministration,237,6,O
of,237,23,O
antiplatelet,237,26,O
agents,237,39,O
",",237,45,O
thrombolytics,237,47,O
",",237,60,O
heparin,237,62,O
",",237,69,O
aspirin,237,71,O
",",237,78,O
and,237,80,O
chronic,237,84,O
NSAID,237,92,O
use,237,98,O
increases,237,102,B-SpecificInteraction
the,237,102,I-SpecificInteraction
risk,237,102,I-SpecificInteraction
of,237,102,I-SpecificInteraction
bleeding,237,102,I-SpecificInteraction
(,237,0,O
7.1,237,1,O
),237,4,O
Coadministration,237,6,O
of,237,23,O
antiplatelet,237,26,O
agents,237,39,O
",",237,45,O
thrombolytics,237,47,O
",",237,60,O
heparin,237,62,O
",",237,69,O
aspirin,237,71,O
",",237,78,O
and,237,80,O
chronic,237,84,O
NSAID,237,92,O
use,237,98,O
increases,237,102,B-SpecificInteraction
the,237,102,I-SpecificInteraction
risk,237,102,I-SpecificInteraction
of,237,102,I-SpecificInteraction
bleeding,237,102,I-SpecificInteraction
Avoid,238,0,O
concomitant,238,6,O
use,238,18,O
with,238,22,O
other,238,27,O
glycoprotein,238,33,O
(,238,46,O
GP,238,47,O
),238,49,O
IIb/IIIa,238,51,O
inhibitors,238,60,O
.,238,70,O
Coadministration,239,0,O
of,239,17,O
antiplatelet,239,20,O
agents,239,33,O
",",239,39,O
thrombolytics,239,41,O
",",239,54,O
heparin,239,56,O
",",239,63,O
aspirin,239,65,O
",",239,72,O
and,239,74,O
chronic,239,78,O
NSAID,239,86,O
use,239,92,O
increases,239,96,O
the,239,106,O
risk,239,110,O
of,239,115,O
bleeding,239,118,B-SpecificInteraction
.,239,126,O
Coadministration,239,0,O
of,239,17,O
antiplatelet,239,20,O
agents,239,33,O
",",239,39,O
thrombolytics,239,41,O
",",239,54,O
heparin,239,56,O
",",239,63,O
aspirin,239,65,O
",",239,72,O
and,239,74,O
chronic,239,78,O
NSAID,239,86,O
use,239,92,O
increases,239,96,O
the,239,106,O
risk,239,110,O
of,239,115,O
bleeding,239,118,B-SpecificInteraction
.,239,126,O
Coadministration,239,0,O
of,239,17,O
antiplatelet,239,20,O
agents,239,33,O
",",239,39,O
thrombolytics,239,41,O
",",239,54,O
heparin,239,56,O
",",239,63,O
aspirin,239,65,O
",",239,72,O
and,239,74,O
chronic,239,78,O
NSAID,239,86,O
use,239,92,O
increases,239,96,O
the,239,106,O
risk,239,110,O
of,239,115,O
bleeding,239,118,B-SpecificInteraction
.,239,126,O
Coadministration,239,0,O
of,239,17,O
antiplatelet,239,20,O
agents,239,33,O
",",239,39,O
thrombolytics,239,41,O
",",239,54,O
heparin,239,56,O
",",239,63,O
aspirin,239,65,O
",",239,72,O
and,239,74,O
chronic,239,78,O
NSAID,239,86,O
use,239,92,O
increases,239,96,O
the,239,106,O
risk,239,110,O
of,239,115,O
bleeding,239,118,B-SpecificInteraction
.,239,126,O
Concomitant,240,0,O
treatment,240,12,O
with,240,22,O
other,240,27,O
inhibitors,240,33,O
of,240,44,O
platelet,240,47,O
receptor,240,56,O
GP,240,65,O
IIb/IIIa,240,68,O
should,240,77,O
be,240,84,O
avoided,240,87,O
.,240,94,O
If,241,0,O
bleeding,241,3,O
at,241,12,O
access,241,15,O
site,241,22,O
can,241,27,O
not,241,31,O
be,241,35,O
controlled,241,38,O
with,241,49,O
pressure,241,54,O
",",241,63,O
infusion,241,65,O
of,241,74,O
INTEGRILIN,241,77,O
and,241,88,O
heparin,241,92,O
should,241,100,O
be,241,107,O
discontinued,241,110,O
immediately,241,123,O
.,241,135,O
In,242,0,O
any,242,3,O
case,242,7,O
",",242,12,O
both,242,14,O
heparin,242,19,O
and,242,27,O
INTEGRILIN,242,31,O
should,242,42,O
be,242,49,O
discontinued,242,52,O
and,242,65,O
sheath,242,69,O
hemostasis,242,76,O
should,242,87,O
be,242,94,O
achieved,242,97,O
at,242,106,O
least,242,109,O
2,242,115,O
to,242,117,O
4,242,120,O
hours,242,122,O
before,242,128,O
hospital,242,135,O
discharge,242,144,O
.,242,154,O
In,243,0,O
the,243,3,O
event,243,7,O
of,243,13,O
acute,243,16,O
profound,243,22,O
thrombocytopenia,243,31,O
or,243,48,O
a,243,51,O
confirmed,243,53,O
platelet,243,63,O
decrease,243,72,O
to,243,81,O
"100,000",243,84,O
/,243,92,O
mm3,243,94,O
",",243,98,O
discontinue,243,100,O
INTEGRILIN,243,112,O
and,243,123,O
heparin,243,127,O
(,243,135,O
unfractionated,243,137,O
or,243,152,O
low-molecular,243,155,O
weight,243,169,O
),243,176,O
.,243,178,O
Thrombocytopenia,244,0,O
:,244,17,O
Discontinue,244,19,O
INTEGRILIN,244,31,O
and,244,42,O
heparin,244,46,O
.,244,54,O
As,471,0,O
the,471,3,O
blood,471,7,B-SpecificInteraction
pressure,471,7,I-SpecificInteraction
falls,471,7,I-SpecificInteraction
under,471,28,O
the,471,34,O
potentiating,471,38,O
effect,471,51,O
of,471,58,O
LASIX,471,61,O
",",471,67,O
a,471,69,O
further,471,71,O
reduction,471,79,O
in,471,89,O
dosage,471,92,O
or,471,99,O
even,471,102,O
discontinuation,471,107,O
of,471,123,O
other,471,126,O
antihypertensive,471,132,O
drugs,471,149,O
may,471,155,O
be,471,159,O
necessary,471,162,O
.,471,172,O
Changes,472,0,B-SpecificInteraction
in,472,0,I-SpecificInteraction
blood,472,0,I-SpecificInteraction
pressure,472,0,I-SpecificInteraction
must,472,26,O
be,472,31,O
carefully,472,34,O
monitored,472,44,O
when,472,54,O
LASIX,472,59,O
is,472,65,O
used,472,68,O
with,472,73,O
other,472,78,O
antihypertensive,472,84,O
drugs,472,101,O
",",472,107,O
especially,472,109,O
during,472,120,O
initial,472,127,O
therapy,472,135,O
.,472,143,O
Reports,473,0,O
usually,473,8,O
indicate,473,16,O
that,473,25,O
LASIX,473,30,O
ototoxicity,473,36,B-SpecificInteraction
is,473,48,O
associated,473,51,O
with,473,62,O
rapid,473,67,O
injection,473,73,O
",",473,83,O
severe,473,85,O
renal,473,92,O
impairment,473,98,O
",",473,109,O
the,473,111,O
use,473,115,O
of,473,119,O
higher,473,122,O
than,473,129,O
recommended,473,134,O
doses,473,146,O
",",473,152,O
hypoproteinemia,473,154,O
or,473,170,O
concomitant,473,173,O
therapy,473,185,O
with,473,193,O
aminoglycoside,473,198,O
antibiotics,473,213,O
",",473,225,O
ethacrynic,473,227,O
acid,473,238,O
",",473,243,O
or,473,245,O
other,473,248,O
ototoxic,473,254,O
drugs,473,263,O
.,473,269,O
Reports,473,0,O
usually,473,8,O
indicate,473,16,O
that,473,25,O
LASIX,473,30,O
ototoxicity,473,36,B-SpecificInteraction
is,473,48,O
associated,473,51,O
with,473,62,O
rapid,473,67,O
injection,473,73,O
",",473,83,O
severe,473,85,O
renal,473,92,O
impairment,473,98,O
",",473,109,O
the,473,111,O
use,473,115,O
of,473,119,O
higher,473,122,O
than,473,129,O
recommended,473,134,O
doses,473,146,O
",",473,152,O
hypoproteinemia,473,154,O
or,473,170,O
concomitant,473,173,O
therapy,473,185,O
with,473,193,O
aminoglycoside,473,198,O
antibiotics,473,213,O
",",473,225,O
ethacrynic,473,227,O
acid,473,238,O
",",473,243,O
or,473,245,O
other,473,248,O
ototoxic,473,254,O
drugs,473,263,O
.,473,269,O
Reports,473,0,O
usually,473,8,O
indicate,473,16,O
that,473,25,O
LASIX,473,30,O
ototoxicity,473,36,B-SpecificInteraction
is,473,48,O
associated,473,51,O
with,473,62,O
rapid,473,67,O
injection,473,73,O
",",473,83,O
severe,473,85,O
renal,473,92,O
impairment,473,98,O
",",473,109,O
the,473,111,O
use,473,115,O
of,473,119,O
higher,473,122,O
than,473,129,O
recommended,473,134,O
doses,473,146,O
",",473,152,O
hypoproteinemia,473,154,O
or,473,170,O
concomitant,473,173,O
therapy,473,185,O
with,473,193,O
aminoglycoside,473,198,O
antibiotics,473,213,O
",",473,225,O
ethacrynic,473,227,O
acid,473,238,O
",",473,243,O
or,473,245,O
other,473,248,O
ototoxic,473,254,O
drugs,473,263,O
.,473,269,O
Except,474,0,O
in,474,7,O
life-threatening,474,10,O
situations,474,27,O
",",474,37,O
avoid,474,39,O
this,474,45,O
combination,474,50,O
.,474,61,O
High-dose,475,0,O
treatment,475,10,O
of,475,20,O
both,475,23,O
LASIX,475,28,O
and,475,34,O
these,475,38,O
other,475,44,O
drugs,475,50,O
may,475,56,O
result,475,60,O
in,475,67,O
elevated,475,70,O
serum,475,79,O
levels,475,85,O
of,475,92,O
these,475,95,O
drugs,475,101,O
and,475,107,O
may,475,111,O
potentiate,475,115,O
their,475,126,O
toxicity,475,132,O
as,475,141,O
well,475,144,O
as,475,149,O
the,475,152,O
toxicity,475,156,O
of,475,165,O
LASIX,475,168,O
.,475,173,O
However,476,0,O
",",476,7,O
norepinephrine,476,9,O
may,476,24,O
still,476,28,O
be,476,34,O
used,476,37,O
effectively,476,42,O
.,476,53,O
Indomethacin,477,0,O
may,477,13,O
also,477,17,O
affect,477,22,O
plasma,477,29,O
renin,477,36,O
levels,477,42,O
",",477,48,O
aldosterone,477,50,O
excretion,477,62,O
",",477,71,O
and,477,73,O
renin,477,77,O
profile,477,83,O
evaluation,477,91,O
.,477,101,O
Lithium,478,0,O
generally,478,8,O
should,478,18,O
not,478,25,O
be,478,29,O
given,478,32,O
with,478,38,O
diuretics,478,43,O
because,478,53,O
they,478,61,O
reduce,478,66,O
lithium,478,73,O
's,478,80,O
renal,478,83,O
clearance,478,89,O
and,478,99,O
add,478,103,O
a,478,107,O
high,478,109,O
risk,478,114,O
of,478,119,O
lithium,478,122,O
toxicity,478,130,O
.,478,138,O
Potentiation,479,0,B-SpecificInteraction
occurs,479,13,O
with,479,20,O
ganglionic,479,25,O
or,479,36,O
peripheral,479,39,O
adrenergic,479,50,O
blocking,479,61,O
drugs,479,70,O
.,479,75,O
Potentiation,479,0,B-SpecificInteraction
occurs,479,13,O
with,479,20,O
ganglionic,479,25,O
or,479,36,O
peripheral,479,39,O
adrenergic,479,50,O
blocking,479,61,O
drugs,479,70,O
.,479,75,O
An,480,0,O
interruption,480,3,O
or,480,16,O
reduction,480,19,O
in,480,29,O
the,480,32,O
dosage,480,36,O
of,480,43,O
LASIX,480,46,O
",",480,52,O
angiotensin,480,54,O
converting,480,66,O
enzyme,480,77,O
inhibitors,480,84,O
",",480,95,O
or,480,97,O
angiotensin,480,100,O
receptor,480,112,O
blockers,480,121,O
may,480,130,O
be,480,134,O
necessary,480,137,O
.,480,147,O
As,481,0,O
with,481,3,O
any,481,8,O
effective,481,12,O
diuretic,481,22,O
",",481,31,O
electrolyte,481,33,O
depletion,481,45,O
may,481,55,O
occur,481,59,O
during,481,65,O
LASIX,481,72,O
therapy,481,78,O
",",481,86,O
especially,481,88,O
in,481,99,O
patients,481,102,O
receiving,481,111,O
higher,481,121,O
doses,481,128,O
and,481,134,O
a,481,138,O
restricted,481,140,O
salt,481,151,O
intake,481,156,O
.,481,163,O
Concomitant,482,0,O
use,482,12,O
of,482,16,O
cyclosporine,482,19,O
and,482,32,O
LASIX,482,36,O
is,482,42,O
associated,482,45,O
with,482,56,O
increased,482,61,O
risk,482,71,O
of,482,76,O
gouty,482,79,B-SpecificInteraction
arthritis,482,79,I-SpecificInteraction
secondary,482,95,O
to,482,105,O
LASIX-induced,482,108,O
hyperurecemia,482,122,B-SpecificInteraction
and,482,136,O
cyclosporine,482,140,O
impairment,482,153,B-SpecificInteraction
of,482,153,I-SpecificInteraction
renal,482,153,I-SpecificInteraction
urate,482,153,I-SpecificInteraction
excretion,482,153,I-SpecificInteraction
.,482,189,O
Conversely,483,0,O
",",483,11,O
LASIX,483,13,O
may,483,19,O
decrease,483,23,O
renal,483,32,O
elimination,483,38,O
of,483,50,O
other,483,53,O
drugs,483,59,O
that,483,65,O
undergo,483,70,O
tubular,483,78,O
secretion,483,86,O
.,483,96,O
Hypokalemia,484,0,B-SpecificInteraction
may,484,12,O
develop,484,16,O
with,484,24,O
LASIX,484,29,O
",",484,35,O
especially,484,37,O
with,484,48,O
brisk,484,53,O
diuresis,484,59,O
",",484,68,O
inadequate,484,70,O
oral,484,81,O
electrolyte,484,86,O
intake,484,98,O
",",484,105,O
when,484,107,O
cirrhosis,484,112,O
is,484,122,O
present,484,125,O
",",484,133,O
or,484,135,O
during,484,138,O
concomitant,484,145,O
use,484,157,O
of,484,161,O
corticosteroids,484,164,O
",",484,180,O
ACTH,484,182,O
",",484,187,O
licorice,484,189,O
in,484,198,O
large,484,201,O
amounts,484,207,O
",",484,215,O
or,484,217,O
prolonged,484,220,O
use,484,230,O
of,484,234,O
laxatives,484,237,O
.,484,247,O
Hypokalemia,484,0,B-SpecificInteraction
may,484,12,O
develop,484,16,O
with,484,24,O
LASIX,484,29,O
",",484,35,O
especially,484,37,O
with,484,48,O
brisk,484,53,O
diuresis,484,59,O
",",484,68,O
inadequate,484,70,O
oral,484,81,O
electrolyte,484,86,O
intake,484,98,O
",",484,105,O
when,484,107,O
cirrhosis,484,112,O
is,484,122,O
present,484,125,O
",",484,133,O
or,484,135,O
during,484,138,O
concomitant,484,145,O
use,484,157,O
of,484,161,O
corticosteroids,484,164,O
",",484,180,O
ACTH,484,182,O
",",484,187,O
licorice,484,189,O
in,484,198,O
large,484,201,O
amounts,484,207,O
",",484,215,O
or,484,217,O
prolonged,484,220,O
use,484,230,O
of,484,234,O
laxatives,484,237,O
.,484,247,O
Hypokalemia,484,0,B-SpecificInteraction
may,484,12,O
develop,484,16,O
with,484,24,O
LASIX,484,29,O
",",484,35,O
especially,484,37,O
with,484,48,O
brisk,484,53,O
diuresis,484,59,O
",",484,68,O
inadequate,484,70,O
oral,484,81,O
electrolyte,484,86,O
intake,484,98,O
",",484,105,O
when,484,107,O
cirrhosis,484,112,O
is,484,122,O
present,484,125,O
",",484,133,O
or,484,135,O
during,484,138,O
concomitant,484,145,O
use,484,157,O
of,484,161,O
corticosteroids,484,164,O
",",484,180,O
ACTH,484,182,O
",",484,187,O
licorice,484,189,O
in,484,198,O
large,484,201,O
amounts,484,207,O
",",484,215,O
or,484,217,O
prolonged,484,220,O
use,484,230,O
of,484,234,O
laxatives,484,237,O
.,484,247,O
Hypokalemia,484,0,B-SpecificInteraction
may,484,12,O
develop,484,16,O
with,484,24,O
LASIX,484,29,O
",",484,35,O
especially,484,37,O
with,484,48,O
brisk,484,53,O
diuresis,484,59,O
",",484,68,O
inadequate,484,70,O
oral,484,81,O
electrolyte,484,86,O
intake,484,98,O
",",484,105,O
when,484,107,O
cirrhosis,484,112,O
is,484,122,O
present,484,125,O
",",484,133,O
or,484,135,O
during,484,138,O
concomitant,484,145,O
use,484,157,O
of,484,161,O
corticosteroids,484,164,O
",",484,180,O
ACTH,484,182,O
",",484,187,O
licorice,484,189,O
in,484,198,O
large,484,201,O
amounts,484,207,O
",",484,215,O
or,484,217,O
prolonged,484,220,O
use,484,230,O
of,484,234,O
laxatives,484,237,O
.,484,247,O
In,485,0,O
addition,485,3,O
",",485,12,O
nephrotoxicity,485,14,B-SpecificInteraction
of,485,29,O
nephrotoxic,485,32,O
drugs,485,44,O
such,485,50,O
as,485,55,O
cisplatin,485,58,O
may,485,68,O
be,485,72,O
enhanced,485,75,O
if,485,84,O
LASIX,485,87,O
is,485,93,O
not,485,96,O
given,485,100,O
in,485,106,O
lower,485,109,O
doses,485,115,O
and,485,121,O
with,485,125,O
positive,485,130,O
fluid,485,139,O
balance,485,145,O
when,485,153,O
used,485,158,O
to,485,163,O
achieve,485,166,O
forced,485,174,O
diuresis,485,181,O
during,485,190,O
cisplatin,485,197,O
treatment,485,207,O
.,485,217,O
In,485,0,O
addition,485,3,O
",",485,12,O
nephrotoxicity,485,14,B-SpecificInteraction
of,485,29,O
nephrotoxic,485,32,O
drugs,485,44,O
such,485,50,O
as,485,55,O
cisplatin,485,58,O
may,485,68,O
be,485,72,O
enhanced,485,75,O
if,485,84,O
LASIX,485,87,O
is,485,93,O
not,485,96,O
given,485,100,O
in,485,106,O
lower,485,109,O
doses,485,115,O
and,485,121,O
with,485,125,O
positive,485,130,O
fluid,485,139,O
balance,485,145,O
when,485,153,O
used,485,158,O
to,485,163,O
achieve,485,166,O
forced,485,174,O
diuresis,485,181,O
during,485,190,O
cisplatin,485,197,O
treatment,485,207,O
.,485,217,O
In,486,0,O
isolated,486,3,O
cases,486,12,O
",",486,18,O
intravenous,486,20,O
administration,486,32,O
of,486,47,O
LASIX,486,50,O
within,486,56,O
24,486,63,O
hours,486,66,O
of,486,72,O
taking,486,75,O
chloral,486,82,O
hydrate,486,90,O
may,486,98,O
lead,486,102,O
to,486,107,O
flushing,486,110,B-SpecificInteraction
",",486,119,O
sweating,486,121,B-SpecificInteraction
attacks,486,121,I-SpecificInteraction
",",486,138,O
restlessness,486,140,B-SpecificInteraction
",",486,153,O
nausea,486,155,B-SpecificInteraction
",",486,162,O
increase,486,164,B-SpecificInteraction
in,486,164,I-SpecificInteraction
blood,486,164,I-SpecificInteraction
pressure,486,164,I-SpecificInteraction
and,486,191,O
tachycardia,486,195,B-SpecificInteraction
.,486,207,O
LASIX,487,0,O
(,487,6,O
furosemide,487,8,O
),487,19,O
produced,487,21,O
no,487,30,O
impairment,487,33,O
of,487,44,O
fertility,487,47,O
in,487,57,O
male,487,60,O
or,487,65,O
female,487,68,O
rats,487,75,O
",",487,80,O
at,487,82,O
100,487,85,O
mg/kg/day,487,89,O
(,487,99,O
the,487,101,O
maximum,487,105,O
effective,487,113,O
diuretic,487,123,O
dose,487,132,O
in,487,137,O
the,487,140,O
rat,487,144,O
and,487,148,O
8,487,152,O
times,487,154,O
the,487,160,O
maximal,487,164,O
human,487,172,O
dose,487,178,O
of,487,183,O
600,487,186,O
mg/day,487,190,O
),487,197,O
.,487,199,O
LASIX,488,0,O
can,488,6,O
increase,488,10,O
the,488,19,O
risk,488,23,O
of,488,28,O
cephalosporin-induced,488,31,O
nephrotoxicity,488,53,B-SpecificInteraction
even,488,68,O
in,488,73,O
the,488,76,O
setting,488,80,O
of,488,88,O
minor,488,91,O
or,488,97,O
transient,488,100,O
renal,488,110,O
impairment,488,116,O
.,488,127,O
LASIX,489,0,O
combined,489,6,O
with,489,15,O
angiotensin,489,20,O
converting,489,32,O
enzyme,489,43,O
inhibitors,489,50,O
or,489,61,O
angiotensin,489,64,O
II,489,76,O
receptor,489,79,O
blockers,489,88,O
may,489,97,O
lead,489,101,O
to,489,106,O
severe,489,109,O
hypotension,489,116,B-SpecificInteraction
and,489,128,O
deterioration,489,132,B-SpecificInteraction
in,489,132,I-SpecificInteraction
renal,489,132,I-SpecificInteraction
function,489,132,I-SpecificInteraction
",",489,164,O
including,489,166,O
renal,489,176,B-SpecificInteraction
failure,489,176,I-SpecificInteraction
.,489,190,O
LASIX,489,0,O
combined,489,6,O
with,489,15,O
angiotensin,489,20,O
converting,489,32,O
enzyme,489,43,O
inhibitors,489,50,O
or,489,61,O
angiotensin,489,64,O
II,489,76,O
receptor,489,79,O
blockers,489,88,O
may,489,97,O
lead,489,101,O
to,489,106,O
severe,489,109,O
hypotension,489,116,B-SpecificInteraction
and,489,128,O
deterioration,489,132,B-SpecificInteraction
in,489,132,I-SpecificInteraction
renal,489,132,I-SpecificInteraction
function,489,132,I-SpecificInteraction
",",489,164,O
including,489,166,O
renal,489,176,B-SpecificInteraction
failure,489,176,I-SpecificInteraction
.,489,190,O
LASIX,490,0,O
has,490,6,O
a,490,10,O
tendency,490,12,O
to,490,21,O
antagonize,490,24,B-SpecificInteraction
the,490,24,I-SpecificInteraction
skeletal,490,24,I-SpecificInteraction
muscle,490,24,I-SpecificInteraction
relaxing,490,24,I-SpecificInteraction
effect,490,24,I-SpecificInteraction
of,490,71,O
tubocurarine,490,74,O
and,490,87,O
may,490,91,O
potentiate,490,95,B-SpecificInteraction
the,490,95,I-SpecificInteraction
action,490,95,I-SpecificInteraction
of,490,95,I-SpecificInteraction
succinylcholine,490,95,I-SpecificInteraction
.,490,136,O
LASIX,490,0,O
has,490,6,O
a,490,10,O
tendency,490,12,O
to,490,21,O
antagonize,490,24,B-SpecificInteraction
the,490,24,I-SpecificInteraction
skeletal,490,24,I-SpecificInteraction
muscle,490,24,I-SpecificInteraction
relaxing,490,24,I-SpecificInteraction
effect,490,24,I-SpecificInteraction
of,490,71,O
tubocurarine,490,74,O
and,490,87,O
may,490,91,O
potentiate,490,95,B-SpecificInteraction
the,490,95,I-SpecificInteraction
action,490,95,I-SpecificInteraction
of,490,95,I-SpecificInteraction
succinylcholine,490,95,I-SpecificInteraction
.,490,136,O
LASIX,491,0,O
may,491,6,O
decrease,491,10,B-SpecificInteraction
arterial,491,10,I-SpecificInteraction
responsiveness,491,10,I-SpecificInteraction
to,491,43,O
norepinephrine,491,46,O
.,491,61,O
LASIX,492,0,O
may,492,6,O
increase,492,10,O
the,492,19,O
ototoxic,492,23,B-SpecificInteraction
potential,492,23,I-SpecificInteraction
of,492,42,O
aminoglycoside,492,45,O
antibiotics,492,60,O
",",492,72,O
especially,492,74,O
in,492,85,O
the,492,88,O
presence,492,92,O
of,492,101,O
impaired,492,104,O
renal,492,113,O
function,492,119,O
.,492,128,O
LASIX,493,0,O
may,493,6,O
lower,493,10,O
serum,493,16,O
levels,493,22,O
of,493,29,O
calcium,493,32,O
(,493,40,O
rarely,493,42,O
cases,493,49,O
of,493,55,O
tetany,493,58,O
have,493,65,O
been,493,70,O
reported,493,75,O
),493,84,O
and,493,86,O
magnesium,493,90,O
.,493,100,O
LASIX,494,0,O
should,494,6,O
not,494,13,O
be,494,17,O
used,494,20,O
concomitantly,494,25,O
with,494,39,O
ethacrynic,494,44,O
acid,494,55,O
because,494,60,O
of,494,68,O
the,494,71,O
possibility,494,75,O
of,494,87,O
ototoxicity,494,90,B-SpecificInteraction
.,494,102,O
Literature,495,0,O
reports,495,11,O
indicate,495,19,O
that,495,28,O
coadministration,495,33,O
of,495,50,O
indomethacin,495,53,O
may,495,66,O
reduce,495,70,O
the,495,77,O
natriuretic,495,81,O
and,495,93,O
antihypertensive,495,97,O
effects,495,114,O
of,495,122,O
LASIX,495,125,O
(,495,131,O
furosemide,495,133,O
),495,144,O
in,495,146,O
some,495,149,O
patients,495,154,O
by,495,163,O
inhibiting,495,166,O
prostaglandin,495,177,O
synthesis,495,191,O
.,495,201,O
Methotrexate,496,0,O
and,496,13,O
other,496,17,O
drugs,496,23,O
that,496,29,O
",",496,34,O
like,496,36,O
LASIX,496,41,O
",",496,47,O
undergo,496,49,O
significant,496,57,O
renal,496,69,O
tubular,496,75,O
secretion,496,83,O
may,496,93,O
reduce,496,97,B-SpecificInteraction
the,496,97,I-SpecificInteraction
effect,496,97,I-SpecificInteraction
of,496,97,I-SpecificInteraction
LASIX,496,97,I-SpecificInteraction
.,496,124,O
Methotrexate,496,0,O
and,496,13,O
other,496,17,O
drugs,496,23,O
that,496,29,O
",",496,34,O
like,496,36,O
LASIX,496,41,O
",",496,47,O
undergo,496,49,O
significant,496,57,O
renal,496,69,O
tubular,496,75,O
secretion,496,83,O
may,496,93,O
reduce,496,97,B-SpecificInteraction
the,496,97,I-SpecificInteraction
effect,496,97,I-SpecificInteraction
of,496,97,I-SpecificInteraction
LASIX,496,97,I-SpecificInteraction
.,496,124,O
One,497,0,O
study,497,4,O
in,497,10,O
six,497,13,O
subjects,497,17,O
demonstrated,497,26,O
that,497,39,O
the,497,44,O
combination,497,48,O
of,497,60,O
furosemide,497,63,O
and,497,74,O
acetylsalicylic,497,78,O
acid,497,94,O
temporarily,497,99,O
reduced,497,111,B-SpecificInteraction
creatinine,497,111,I-SpecificInteraction
clearance,497,111,I-SpecificInteraction
in,497,140,O
patients,497,143,O
with,497,152,O
chronic,497,157,O
renal,497,165,O
insufficiency,497,171,O
.,497,185,O
Patients,498,0,O
allergic,498,9,O
to,498,18,O
sulfonamides,498,21,O
may,498,34,O
also,498,38,O
be,498,43,O
allergic,498,46,O
to,498,55,O
LASIX,498,58,O
.,498,64,O
Patients,499,0,O
receiving,499,9,O
both,499,19,O
drugs,499,24,O
should,499,30,O
be,499,37,O
observed,499,40,O
closely,499,49,O
to,499,57,O
determine,499,60,O
if,499,70,O
the,499,73,O
desired,499,77,O
diuretic,499,85,O
and/or,499,94,O
antihypertensive,499,101,O
effect,499,118,O
of,499,125,O
LASIX,499,128,O
is,499,134,O
achieved,499,137,O
.,499,146,O
Patients,500,0,O
receiving,500,9,O
both,500,19,O
indomethacin,500,24,O
and,500,37,O
LASIX,500,41,O
should,500,47,O
be,500,54,O
observed,500,57,O
closely,500,66,O
to,500,74,O
determine,500,77,O
if,500,87,O
the,500,90,O
desired,500,94,O
diuretic,500,102,O
and/or,500,111,O
antihypertensive,500,118,O
effect,500,135,O
of,500,142,O
LASIX,500,145,O
is,500,151,O
achieved,500,154,O
.,500,163,O
Patients,501,0,O
receiving,501,9,O
high,501,19,O
doses,501,24,O
of,501,30,O
salicylates,501,33,O
concomitantly,501,45,O
with,501,59,O
LASIX,501,64,O
",",501,70,O
as,501,72,O
in,501,75,O
rheumatic,501,78,O
disease,501,88,O
",",501,96,O
may,501,98,O
experience,501,102,O
salicylate,501,113,O
toxicity,501,124,O
at,501,133,O
lower,501,136,O
doses,501,142,O
because,501,148,O
of,501,156,O
competitive,501,159,O
renal,501,171,O
excretory,501,177,O
sites,501,187,O
.,501,193,O
Patients,502,0,O
receiving,502,9,O
LASIX,502,19,O
should,502,25,O
be,502,32,O
advised,502,35,O
that,502,43,O
they,502,48,O
may,502,53,O
experience,502,57,O
symptoms,502,68,O
from,502,77,O
excessive,502,82,O
fluid,502,92,O
and/or,502,98,O
electrolyte,502,105,O
losses,502,117,O
.,502,124,O
Phenytoin,503,0,O
interferes,503,10,B-SpecificInteraction
directly,503,10,I-SpecificInteraction
with,503,10,I-SpecificInteraction
renal,503,10,I-SpecificInteraction
action,503,10,I-SpecificInteraction
of,503,10,I-SpecificInteraction
LASIX,503,10,I-SpecificInteraction
.,503,57,O
Serum,504,0,O
electrolytes,504,6,O
(,504,19,O
particularly,504,21,O
potassium,504,34,O
),504,44,O
",",504,46,O
CO2,504,48,O
",",504,52,O
creatinine,504,54,O
and,504,65,O
BUN,504,69,O
should,504,73,O
be,504,80,O
determined,504,83,O
frequently,504,94,O
during,504,105,O
the,504,112,O
first,504,116,O
few,504,122,O
months,504,126,O
of,504,133,O
LASIX,504,136,O
therapy,504,142,O
and,504,150,O
periodically,504,154,O
thereafter,504,167,O
.,504,178,O
Simultaneous,505,0,O
administration,505,13,O
of,505,28,O
sucralfate,505,31,O
and,505,42,O
LASIX,505,46,O
tablets,505,52,O
may,505,60,O
reduce,505,64,O
the,505,71,O
natriuretic,505,75,O
and,505,87,O
antihypertensive,505,91,O
effects,505,108,O
of,505,116,O
LASIX,505,119,O
.,505,125,O
The,506,0,O
intake,506,4,O
of,506,11,O
LASIX,506,14,O
and,506,20,O
sucralfate,506,24,O
should,506,35,O
be,506,42,O
separated,506,45,O
by,506,55,O
at,506,58,O
least,506,61,O
two,506,67,O
hours,506,71,O
.,506,77,O
There,507,0,O
are,507,6,O
case,507,10,O
reports,507,15,O
of,507,23,O
patients,507,26,O
who,507,35,O
developed,507,39,O
increased,507,49,B-SpecificInteraction
BUN,507,49,I-SpecificInteraction
",",507,49,I-SpecificInteraction
serum,507,49,I-SpecificInteraction
creatinine,507,49,I-SpecificInteraction
and,507,82,O
serum,507,86,O
potassium,507,92,O
levels,507,102,O
",",507,109,O
and,507,111,O
weight,507,115,B-SpecificInteraction
gain,507,115,I-SpecificInteraction
when,507,127,O
furosemide,507,132,O
was,507,143,O
used,507,147,O
in,507,152,O
conjunction,507,155,O
with,507,167,O
NSAIDs,507,172,O
.,507,179,O
There,508,0,O
is,508,6,O
a,508,9,O
risk,508,11,O
of,508,16,O
ototoxic,508,19,B-SpecificInteraction
effects,508,19,I-SpecificInteraction
if,508,36,O
cisplatin,508,39,O
and,508,49,O
LASIX,508,53,O
are,508,59,O
given,508,63,O
concomitantly,508,69,O
.,508,83,O
There,509,0,O
is,509,6,O
evidence,509,9,O
that,509,18,O
treatment,509,23,O
with,509,33,O
phenytoin,509,38,O
leads,509,48,O
to,509,54,O
decrease,509,57,O
intestinal,509,66,O
absorption,509,77,O
of,509,88,O
LASIX,509,91,O
",",509,97,O
and,509,99,O
consequently,509,103,O
to,509,116,O
lower,509,119,O
peak,509,125,O
serum,509,130,O
furosemide,509,136,O
concentrations,509,147,O
.,509,162,O
Use,510,0,O
of,510,4,O
LASIX,510,7,O
concomitantly,510,13,O
with,510,27,O
chloral,510,32,O
hydrate,510,40,O
is,510,48,O
",",510,51,O
therefore,510,53,O
",",510,63,O
not,510,65,O
recommended,510,69,O
.,510,81,O
NEXTERONE,426,0,O
Premixed,426,10,O
Injection,426,19,O
is,426,29,O
available,426,32,O
in,426,42,O
GALAXY,426,45,O
containers,426,52,O
as,426,63,O
a,426,66,O
single-use,426,68,O
",",426,79,O
ready-to-use,426,81,O
",",426,94,O
iso-osmotic,426,96,O
solution,426,108,O
in,426,117,O
dextrose,426,120,O
for,426,129,O
intravenous,426,133,O
administration,426,145,O
.,426,160,O
Known,427,0,O
hypersensitivity,427,6,O
to,427,23,O
any,427,26,O
of,427,30,O
the,427,33,O
components,427,37,O
of,427,48,O
NEXTERONE,427,51,O
",",427,61,O
including,427,63,O
iodine,427,73,O
.,427,80,O
Known,428,0,O
hypersensitivity,428,6,O
to,428,23,O
any,428,26,O
of,428,30,O
the,428,33,O
components,428,37,O
of,428,48,O
NEXTERONE,428,51,O
Premixed,428,61,O
Injection,428,70,O
",",428,80,O
including,428,82,O
iodine,428,92,O
.,428,99,O
Amiodarone,429,0,O
and,429,11,O
DEA,429,15,O
are,429,19,O
inhibitors,429,23,O
of,429,34,O
P-glycoprotein,429,37,O
and,429,52,O
certain,429,56,O
CYP450,429,64,O
enzymes,429,71,O
",",429,79,O
including,429,81,O
CYP1A2,429,91,O
",",429,98,O
CYP2C9,429,100,O
",",429,107,O
CYP2D6,429,109,O
and,429,116,O
CYP3A,429,120,O
see,429,126,O
Clinical,429,130,O
Pharmacology,429,139,O
(,429,152,O
12.3,429,154,O
),429,159,O
.,429,161,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,430,0,O
has,430,11,O
the,430,15,O
potential,430,19,O
for,430,29,O
interactions,430,33,O
with,430,46,O
drugs,430,51,O
or,430,57,O
substances,430,60,O
that,430,71,O
may,430,76,O
be,430,80,O
substrates,430,83,O
",",430,94,O
inhibitors,430,96,O
or,430,107,O
inducers,430,110,O
of,430,119,O
CYP450,430,122,O
enzymes,430,129,O
(,430,137,O
e.g.,430,139,O
",",430,144,O
inhibitors,430,146,O
such,430,157,O
as,430,162,O
protease,430,165,O
inhibitors,430,174,O
",",430,185,O
grapefruit,430,187,O
juice,430,198,O
",",430,204,O
certain,430,206,O
fluoroquinolone,430,214,O
and,430,230,O
macrolide,430,234,O
antibiotics,430,244,O
",",430,256,O
azole,430,258,O
antifungals,430,264,O
and,430,276,O
inducers,430,280,O
such,430,289,O
as,430,294,O
St.,430,297,O
John,430,303,O
s,430,308,O
Wort,430,310,O
),430,315,O
or,430,317,O
P-glycoprotein,430,320,O
.,430,335,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,431,0,O
is,431,11,O
a,431,14,O
substrate,431,16,O
for,431,26,O
CYP3A,431,30,O
and,431,36,O
CYP2C8,431,40,O
",",431,46,O
so,431,48,O
inhibitors,431,51,O
and,431,62,O
inducers,431,66,O
affect,431,75,O
amiodarone,431,82,O
exposure,431,93,O
(,431,102,O
7,431,103,O
),431,104,O
Amiodarone,431,106,O
inhibits,431,117,O
p-glycoprotein,431,126,O
and,431,141,O
CYP1A2,431,145,O
",",431,151,O
CYP2C9,431,153,O
",",431,159,O
CYP2D6,431,161,O
",",431,167,O
and,431,169,O
CYP3A,431,173,O
",",431,178,O
increasing,431,180,O
exposure,431,191,O
to,431,200,O
other,431,203,O
drugs,431,209,O
(,431,215,O
7,431,216,O
),431,217,O
Drugs,431,219,O
prolonging,431,225,O
the,431,236,O
QT,431,240,O
interval,431,243,O
:,431,251,O
Co-administration,431,253,O
of,431,271,O
drugs,431,274,O
prolonging,431,280,O
the,431,291,O
QT,431,295,O
interval,431,298,O
(,431,307,O
such,431,308,O
as,431,313,O
class,431,316,O
I,431,322,O
and,431,324,O
III,431,328,O
antiarrhythmics,431,332,O
",",431,347,O
lithium,431,349,O
",",431,356,O
certain,431,358,O
phenothiazines,431,366,O
",",431,380,O
tricyclic,431,382,O
antidepressants,431,392,O
",",431,407,O
certain,431,409,O
fluoroquinolone,431,417,O
and,431,433,O
macrolide,431,437,O
antibiotics,431,447,O
",",431,458,O
azole,431,460,O
antifungals,431,466,O
",",431,477,O
halogenated,431,479,O
inhalation,431,491,O
anesthetic,431,502,O
agents,431,513,O
),431,519,O
increases,431,521,O
the,431,531,O
risk,431,535,O
of,431,540,O
Torsade,431,543,B-SpecificInteraction
de,431,543,I-SpecificInteraction
Pointes,431,543,I-SpecificInteraction
.,431,561,O
Amiodarone,432,0,O
is,432,11,O
metabolized,432,14,O
to,432,26,O
the,432,29,O
active,432,33,O
metabolite,432,40,O
desethylamiodarone,432,51,O
(,432,70,O
DEA,432,72,O
),432,76,O
by,432,78,O
the,432,81,O
cytochrome,432,85,O
P450,432,96,O
(,432,101,O
CYP450,432,103,O
),432,110,O
enzyme,432,112,O
group,432,119,O
",",432,125,O
specifically,432,127,O
CYP3A,432,140,O
and,432,146,O
CYP2C8,432,150,O
.,432,157,O
Antiarrhythmics,433,0,O
:,433,16,O
The,433,18,O
metabolism,433,22,O
of,433,33,O
quinidine,433,36,O
",",433,46,O
procainamide,433,48,O
",",433,61,O
flecainide,433,63,O
can,433,74,O
be,433,78,O
inhibited,433,81,O
by,433,91,O
amiodarone,433,94,O
.,433,105,O
Antiarrhythmics,433,0,O
:,433,16,O
The,433,18,O
metabolism,433,22,O
of,433,33,O
quinidine,433,36,O
",",433,46,O
procainamide,433,48,O
",",433,61,O
flecainide,433,63,O
can,433,74,O
be,433,78,O
inhibited,433,81,O
by,433,91,O
amiodarone,433,94,O
.,433,105,O
Antiarrhythmics,433,0,O
:,433,16,O
The,433,18,O
metabolism,433,22,O
of,433,33,O
quinidine,433,36,O
",",433,46,O
procainamide,433,48,O
",",433,61,O
flecainide,433,63,O
can,433,74,O
be,433,78,O
inhibited,433,81,O
by,433,91,O
amiodarone,433,94,O
.,433,105,O
Anticoagulants,434,0,O
:,434,15,O
Potentiation,434,17,DB-SpecificInteraction
of,434,30,O
warfarin,434,33,O
-,434,42,O
type,434,44,O
(,434,49,O
CYP2C9,434,51,O
and,434,58,O
CYP3A,434,62,O
substrate,434,68,O
),434,78,O
anticoagulant,434,80,O
response,434,94,O
is,434,103,O
almost,434,106,O
always,434,113,O
seen,434,120,O
in,434,125,O
patients,434,128,O
receiving,434,137,O
amiodarone,434,147,O
and,434,158,O
can,434,162,O
result,434,166,O
in,434,173,O
serious,434,176,O
or,434,184,O
fatal,434,187,O
bleeding,434,193,B-SpecificInteraction
.,434,202,O
Anticoagulants,434,0,O
:,434,15,O
Potentiation,434,17,DB-SpecificInteraction
of,434,30,O
warfarin,434,33,O
-,434,42,O
type,434,44,O
(,434,49,O
CYP2C9,434,51,O
and,434,58,O
CYP3A,434,62,O
substrate,434,68,O
),434,78,O
anticoagulant,434,80,O
response,434,94,O
is,434,103,O
almost,434,106,O
always,434,113,O
seen,434,120,O
in,434,125,O
patients,434,128,O
receiving,434,137,O
amiodarone,434,147,O
and,434,158,O
can,434,162,O
result,434,166,O
in,434,173,O
serious,434,176,O
or,434,184,O
fatal,434,187,O
bleeding,434,193,B-SpecificInteraction
.,434,202,O
Anticoagulants,434,0,O
:,434,15,O
Potentiation,434,17,DB-SpecificInteraction
of,434,30,O
warfarin,434,33,O
-,434,42,O
type,434,44,O
(,434,49,O
CYP2C9,434,51,O
and,434,58,O
CYP3A,434,62,O
substrate,434,68,O
),434,78,O
anticoagulant,434,80,O
response,434,94,O
is,434,103,O
almost,434,106,O
always,434,113,O
seen,434,120,O
in,434,125,O
patients,434,128,O
receiving,434,137,O
amiodarone,434,147,O
and,434,158,O
can,434,162,O
result,434,166,O
in,434,173,O
serious,434,176,O
or,434,184,O
fatal,434,187,O
bleeding,434,193,B-SpecificInteraction
.,434,202,O
Anticoagulants,435,0,O
:,435,14,O
Potentiation,435,16,DB-SpecificInteraction
of,435,29,O
warfarin-type,435,32,O
(,435,46,O
CYP2C9,435,47,O
and,435,54,O
CYP3A,435,58,O
substrate,435,64,O
),435,73,O
anticoagulant,435,75,O
response,435,89,O
is,435,98,O
almost,435,101,O
always,435,108,O
seen,435,115,O
in,435,120,O
patients,435,123,O
receiving,435,132,O
amiodarone,435,142,O
and,435,153,O
can,435,157,O
result,435,161,O
in,435,168,O
serious,435,171,O
or,435,179,O
fatal,435,182,O
bleeding,435,188,B-SpecificInteraction
.,435,196,O
Bradycardia,436,0,O
generally,436,12,O
occurred,436,22,O
within,436,31,O
hours,436,38,O
to,436,44,O
days,436,47,O
",",436,51,O
but,436,53,O
in,436,57,O
some,436,60,O
cases,436,65,O
up,436,71,O
to,436,74,O
2,436,77,O
weeks,436,79,O
after,436,85,O
initiating,436,91,O
antiviral,436,102,O
treatment,436,112,O
.,436,121,O
Bradycardia,437,0,O
generally,437,12,O
resolved,437,22,O
after,437,31,O
discontinuation,437,37,O
of,437,53,O
antiviral,437,56,O
treatment,437,66,O
.,437,75,O
Cyclosporine,438,0,O
(,438,13,O
CYP3A,438,15,O
substrate,438,21,O
),438,31,O
administered,438,33,O
in,438,46,O
combination,438,49,O
with,438,61,O
oral,438,66,O
amiodarone,438,71,O
has,438,82,O
been,438,86,O
reported,438,91,O
to,438,100,O
produce,438,103,O
persistently,438,111,O
elevated,438,124,O
plasma,438,133,O
concentrations,438,140,O
of,438,155,O
cyclosporine,438,158,O
resulting,438,171,O
in,438,181,O
elevated,438,184,B-SpecificInteraction
creatinine,438,184,I-SpecificInteraction
",",438,204,O
despite,438,206,O
reduction,438,214,O
in,438,224,O
dose,438,227,O
of,438,232,O
cyclosporine,438,235,O
.,438,248,O
Cyclosporine,438,0,O
(,438,13,O
CYP3A,438,15,O
substrate,438,21,O
),438,31,O
administered,438,33,O
in,438,46,O
combination,438,49,O
with,438,61,O
oral,438,66,O
amiodarone,438,71,O
has,438,82,O
been,438,86,O
reported,438,91,O
to,438,100,O
produce,438,103,O
persistently,438,111,O
elevated,438,124,O
plasma,438,133,O
concentrations,438,140,O
of,438,155,O
cyclosporine,438,158,O
resulting,438,171,O
in,438,181,O
elevated,438,184,B-SpecificInteraction
creatinine,438,184,I-SpecificInteraction
",",438,204,O
despite,438,206,O
reduction,438,214,O
in,438,224,O
dose,438,227,O
of,438,232,O
cyclosporine,438,235,O
.,438,248,O
Cyclosporine,438,0,O
(,438,13,O
CYP3A,438,15,O
substrate,438,21,O
),438,31,O
administered,438,33,O
in,438,46,O
combination,438,49,O
with,438,61,O
oral,438,66,O
amiodarone,438,71,O
has,438,82,O
been,438,86,O
reported,438,91,O
to,438,100,O
produce,438,103,O
persistently,438,111,O
elevated,438,124,O
plasma,438,133,O
concentrations,438,140,O
of,438,155,O
cyclosporine,438,158,O
resulting,438,171,O
in,438,181,O
elevated,438,184,B-SpecificInteraction
creatinine,438,184,I-SpecificInteraction
",",438,204,O
despite,438,206,O
reduction,438,214,O
in,438,224,O
dose,438,227,O
of,438,232,O
cyclosporine,438,235,O
.,438,248,O
Cyclosporine,438,0,O
(,438,13,O
CYP3A,438,15,O
substrate,438,21,O
),438,31,O
administered,438,33,O
in,438,46,O
combination,438,49,O
with,438,61,O
oral,438,66,O
amiodarone,438,71,O
has,438,82,O
been,438,86,O
reported,438,91,O
to,438,100,O
produce,438,103,O
persistently,438,111,O
elevated,438,124,O
plasma,438,133,O
concentrations,438,140,O
of,438,155,O
cyclosporine,438,158,O
resulting,438,171,O
in,438,181,O
elevated,438,184,B-SpecificInteraction
creatinine,438,184,I-SpecificInteraction
",",438,204,O
despite,438,206,O
reduction,438,214,O
in,438,224,O
dose,438,227,O
of,438,232,O
cyclosporine,438,235,O
.,438,248,O
Cyclosporine,439,0,O
(,439,13,O
CYP3A,439,14,O
substrate,439,20,O
),439,29,O
administered,439,31,O
in,439,44,O
combination,439,47,O
with,439,59,O
oral,439,64,O
amiodarone,439,69,O
has,439,80,O
been,439,84,O
reported,439,89,O
to,439,98,O
produce,439,101,O
persistently,439,109,O
elevated,439,122,O
plasma,439,131,O
concentrations,439,138,O
of,439,153,O
cyclosporine,439,156,O
resulting,439,169,O
in,439,179,O
elevated,439,182,B-SpecificInteraction
creatinine,439,182,I-SpecificInteraction
",",439,201,O
despite,439,203,O
reduction,439,211,O
in,439,221,O
dose,439,224,O
of,439,229,O
cyclosporine,439,232,O
.,439,244,O
Cyclosporine,439,0,O
(,439,13,O
CYP3A,439,14,O
substrate,439,20,O
),439,29,O
administered,439,31,O
in,439,44,O
combination,439,47,O
with,439,59,O
oral,439,64,O
amiodarone,439,69,O
has,439,80,O
been,439,84,O
reported,439,89,O
to,439,98,O
produce,439,101,O
persistently,439,109,O
elevated,439,122,O
plasma,439,131,O
concentrations,439,138,O
of,439,153,O
cyclosporine,439,156,O
resulting,439,169,O
in,439,179,O
elevated,439,182,B-SpecificInteraction
creatinine,439,182,I-SpecificInteraction
",",439,201,O
despite,439,203,O
reduction,439,211,O
in,439,221,O
dose,439,224,O
of,439,229,O
cyclosporine,439,232,O
.,439,244,O
Cyclosporine,439,0,O
(,439,13,O
CYP3A,439,14,O
substrate,439,20,O
),439,29,O
administered,439,31,O
in,439,44,O
combination,439,47,O
with,439,59,O
oral,439,64,O
amiodarone,439,69,O
has,439,80,O
been,439,84,O
reported,439,89,O
to,439,98,O
produce,439,101,O
persistently,439,109,O
elevated,439,122,O
plasma,439,131,O
concentrations,439,138,O
of,439,153,O
cyclosporine,439,156,O
resulting,439,169,O
in,439,179,O
elevated,439,182,B-SpecificInteraction
creatinine,439,182,I-SpecificInteraction
",",439,201,O
despite,439,203,O
reduction,439,211,O
in,439,221,O
dose,439,224,O
of,439,229,O
cyclosporine,439,232,O
.,439,244,O
Cyclosporine,439,0,O
(,439,13,O
CYP3A,439,14,O
substrate,439,20,O
),439,29,O
administered,439,31,O
in,439,44,O
combination,439,47,O
with,439,59,O
oral,439,64,O
amiodarone,439,69,O
has,439,80,O
been,439,84,O
reported,439,89,O
to,439,98,O
produce,439,101,O
persistently,439,109,O
elevated,439,122,O
plasma,439,131,O
concentrations,439,138,O
of,439,153,O
cyclosporine,439,156,O
resulting,439,169,O
in,439,179,O
elevated,439,182,B-SpecificInteraction
creatinine,439,182,I-SpecificInteraction
",",439,201,O
despite,439,203,O
reduction,439,211,O
in,439,221,O
dose,439,224,O
of,439,229,O
cyclosporine,439,232,O
.,439,244,O
Digoxin,440,0,O
:,440,8,O
In,440,10,O
patients,440,13,O
receiving,440,22,O
digoxin,440,32,O
therapy,440,40,O
",",440,48,O
administration,440,50,O
of,440,65,O
oral,440,68,O
amiodarone,440,73,O
results,440,84,O
in,440,92,O
an,440,95,O
increase,440,98,O
in,440,107,O
serum,440,110,O
digoxin,440,116,O
concentration,440,124,O
.,440,138,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
Drugs,441,0,O
that,441,6,O
slow,441,11,O
heart,441,16,O
rate,441,22,O
:,441,27,O
Concomitant,441,29,O
use,441,41,O
of,441,45,O
drugs,441,48,O
with,441,54,O
depressant,441,59,O
effects,441,70,DI-SpecificInteraction
on,441,78,O
the,441,81,O
sinus,441,85,O
and,441,91,O
AV,441,95,O
node,441,98,O
(,441,103,O
e.g.,441,105,O
",",441,110,O
digoxin,441,112,O
",",441,120,O
beta,441,122,O
blockers,441,127,O
",",441,136,O
verapamil,441,138,O
",",441,148,O
diltiazem,441,150,O
",",441,160,O
ivabradine,441,162,O
",",441,173,O
clonidine,441,175,O
),441,185,O
can,441,187,O
potentiate,441,191,O
the,441,202,O
electrophysiologic,441,206,DB-SpecificInteraction
and,441,225,O
hemodynamic,441,229,B-SpecificInteraction
effects,441,229,I-SpecificInteraction
of,441,249,O
amiodarone,441,252,O
",",441,263,O
resulting,441,265,O
in,441,275,O
bradycardia,441,278,B-SpecificInteraction
",",441,290,O
sinus,441,292,B-SpecificInteraction
arrest,441,292,I-SpecificInteraction
",",441,305,O
and,441,307,O
AV,441,311,B-SpecificInteraction
block,441,311,I-SpecificInteraction
.,441,320,O
During,442,0,O
transfer,442,7,O
to,442,16,O
oral,442,19,O
amiodarone,442,24,O
",",442,34,O
reduce,442,36,O
the,442,43,O
dose,442,47,O
levels,442,52,O
of,442,59,O
previously,442,62,O
administered,442,73,O
agents,442,86,O
by,442,93,O
30,442,96,O
to,442,99,O
50,442,102,O
%,442,104,O
several,442,106,O
days,442,114,O
after,442,119,O
the,442,125,O
addition,442,129,O
of,442,138,O
oral,442,141,O
amiodarone,442,146,O
.,442,156,O
Effect,443,0,O
of,443,7,O
amiodarone,443,10,O
on,443,21,O
other,443,24,O
drugs,443,30,O
Amiodarone,443,36,O
and,443,47,O
DEA,443,51,O
are,443,55,O
inhibitors,443,59,O
of,443,70,O
P-glycoprotein,443,73,O
and,443,88,O
certain,443,92,O
CYP450,443,100,O
enzymes,443,107,O
",",443,114,O
including,443,116,O
CYP1A2,443,126,O
",",443,132,O
CYP2C9,443,134,O
",",443,140,O
CYP2D6,443,142,O
and,443,149,O
CYP3A,443,153,O
[,443,159,O
see,443,160,O
Clinical,443,164,O
Pharmacology,443,173,O
(,443,186,O
12.3,443,187,O
),443,191,O
],443,192,O
.,443,193,O
Effect,444,0,O
of,444,7,O
other,444,10,O
drugs,444,16,O
on,444,22,O
amiodarone,444,25,O
Amiodarone,444,36,O
is,444,47,O
metabolized,444,50,O
to,444,62,O
the,444,65,O
active,444,69,O
metabolite,444,76,O
desethylamiodarone,444,87,O
(,444,106,O
DEA,444,107,O
),444,110,O
by,444,112,O
the,444,115,O
cytochrome,444,119,O
P450,444,130,O
(,444,135,O
CYP450,444,136,O
),444,142,O
enzyme,444,144,O
group,444,151,O
",",444,156,O
specifically,444,158,O
CYP3A,444,171,O
and,444,177,O
CYP2C8,444,181,O
.,444,187,O
HMG-CoA,445,0,O
Reductase,445,8,O
Inhibitors,445,18,O
:,445,29,O
Limit,445,31,O
the,445,37,O
dose,445,41,O
of,445,46,O
simvastatin,445,49,O
in,445,61,O
patients,445,64,O
on,445,73,O
amiodarone,445,76,O
to,445,87,O
20,445,90,O
mg,445,93,O
daily,445,96,O
.,445,102,O
HMG-CoA,445,0,O
Reductase,445,8,O
Inhibitors,445,18,O
:,445,29,O
Limit,445,31,O
the,445,37,O
dose,445,41,O
of,445,46,O
simvastatin,445,49,O
in,445,61,O
patients,445,64,O
on,445,73,O
amiodarone,445,76,O
to,445,87,O
20,445,90,O
mg,445,93,O
daily,445,96,O
.,445,102,O
If,446,0,O
digitalis,446,3,O
treatment,446,13,O
is,446,23,O
continued,446,26,O
",",446,35,O
monitor,446,37,O
serum,446,45,O
levels,446,51,O
closely,446,58,O
and,446,66,O
observe,446,70,O
patients,446,78,O
for,446,87,O
clinical,446,91,O
evidence,446,100,O
of,446,109,O
toxicity,446,112,O
[,446,121,O
see,446,122,O
Clinical,446,126,O
Pharmacology,446,135,O
(,446,148,O
12.3,446,149,O
),446,153,O
],446,154,O
.,446,155,O
In,447,0,O
general,447,3,O
",",447,10,O
avoid,447,12,O
concomitant,447,18,O
use,447,30,O
of,447,34,O
drugs,447,37,O
that,447,43,O
prolong,447,48,O
the,447,56,O
QT,447,60,O
interval,447,63,O
[,447,72,O
see,447,73,O
Warnings,447,77,O
and,447,86,O
Precautions,447,90,O
(,447,102,O
5.4,447,103,O
),447,106,O
],447,107,O
.,447,108,O
In,448,0,O
general,448,3,O
",",448,10,O
initiate,448,12,O
any,448,21,O
added,448,25,O
antiarrhythmic,448,31,O
drug,448,46,O
at,448,51,O
a,448,54,O
lower,448,56,O
than,448,62,O
usual,448,67,O
dose,448,73,O
and,448,78,O
monitor,448,82,O
the,448,90,O
patient,448,94,O
carefully,448,102,O
.,448,111,O
In,449,0,O
view,449,3,O
of,449,8,O
the,449,11,O
long,449,15,O
and,449,20,O
variable,449,24,O
half-life,449,33,O
of,449,43,O
amiodarone,449,46,O
",",449,56,O
potential,449,58,O
for,449,68,O
drug,449,72,O
interactions,449,77,O
exists,449,90,O
not,449,97,O
only,449,101,O
with,449,106,O
concomitant,449,111,O
medication,449,123,O
but,449,134,O
also,449,138,O
with,449,143,O
drugs,449,148,O
administered,449,154,O
after,449,167,O
discontinuation,449,173,O
of,449,189,O
amiodarone,449,192,O
[,449,203,O
see,449,204,O
Clinical,449,208,O
Pharmacology,449,217,O
(,449,230,O
12.3,449,231,O
),449,235,O
],449,236,O
.,449,237,O
Increased,450,0,O
steady-state,450,10,O
levels,450,23,O
of,450,30,O
phenytoin,450,33,O
during,450,43,O
concomitant,450,50,O
therapy,450,62,O
with,450,70,O
amiodarone,450,75,O
have,450,86,O
been,450,91,O
reported,450,96,O
.,450,104,O
Limit,451,0,O
the,451,6,O
daily,451,10,O
dose,451,16,O
of,451,21,O
lovastatin,451,24,O
to,451,35,O
40,451,38,O
mg.,451,41,O
Lower,451,45,O
starting,451,51,O
and,451,60,O
maintenance,451,64,O
doses,451,76,O
of,451,82,O
other,451,85,O
CYP3A4,451,91,O
substrates,451,98,O
(,451,109,O
e.g.,451,110,O
",",451,114,O
atorvastatin,451,116,O
),451,128,O
may,451,130,O
be,451,134,O
required,451,137,O
as,451,146,O
amiodarone,451,149,O
may,451,160,O
increase,451,164,O
the,451,173,O
plasma,451,177,O
concentration,451,184,O
of,451,198,O
these,451,201,O
drugs,451,207,O
.,451,212,O
Limit,451,0,O
the,451,6,O
daily,451,10,O
dose,451,16,O
of,451,21,O
lovastatin,451,24,O
to,451,35,O
40,451,38,O
mg.,451,41,O
Lower,451,45,O
starting,451,51,O
and,451,60,O
maintenance,451,64,O
doses,451,76,O
of,451,82,O
other,451,85,O
CYP3A4,451,91,O
substrates,451,98,O
(,451,109,O
e.g.,451,110,O
",",451,114,O
atorvastatin,451,116,O
),451,128,O
may,451,130,O
be,451,134,O
required,451,137,O
as,451,146,O
amiodarone,451,149,O
may,451,160,O
increase,451,164,O
the,451,173,O
plasma,451,177,O
concentration,451,184,O
of,451,198,O
these,451,201,O
drugs,451,207,O
.,451,212,O
Limit,451,0,O
the,451,6,O
daily,451,10,O
dose,451,16,O
of,451,21,O
lovastatin,451,24,O
to,451,35,O
40,451,38,O
mg.,451,41,O
Lower,451,45,O
starting,451,51,O
and,451,60,O
maintenance,451,64,O
doses,451,76,O
of,451,82,O
other,451,85,O
CYP3A4,451,91,O
substrates,451,98,O
(,451,109,O
e.g.,451,110,O
",",451,114,O
atorvastatin,451,116,O
),451,128,O
may,451,130,O
be,451,134,O
required,451,137,O
as,451,146,O
amiodarone,451,149,O
may,451,160,O
increase,451,164,O
the,451,173,O
plasma,451,177,O
concentration,451,184,O
of,451,198,O
these,451,201,O
drugs,451,207,O
.,451,212,O
Lower,452,0,O
starting,452,6,O
and,452,15,O
maintenance,452,19,O
doses,452,31,O
of,452,37,O
other,452,40,O
CYP3A4,452,46,O
substrates,452,53,O
(,452,64,O
e.g.,452,66,O
",",452,71,O
atorvastatin,452,73,O
),452,86,O
may,452,88,O
be,452,92,O
required,452,95,O
as,452,104,O
amiodarone,452,107,O
may,452,118,O
increase,452,122,O
the,452,131,O
plasma,452,135,O
concentration,452,142,O
of,452,156,O
these,452,159,O
drugs,452,165,O
.,452,171,O
Lower,452,0,O
starting,452,6,O
and,452,15,O
maintenance,452,19,O
doses,452,31,O
of,452,37,O
other,452,40,O
CYP3A4,452,46,O
substrates,452,53,O
(,452,64,O
e.g.,452,66,O
",",452,71,O
atorvastatin,452,73,O
),452,86,O
may,452,88,O
be,452,92,O
required,452,95,O
as,452,104,O
amiodarone,452,107,O
may,452,118,O
increase,452,122,O
the,452,131,O
plasma,452,135,O
concentration,452,142,O
of,452,156,O
these,452,159,O
drugs,452,165,O
.,452,171,O
Monitor,453,0,O
cyclosporine,453,8,O
drug,453,21,O
levels,453,26,O
and,453,33,O
renal,453,37,O
function,453,43,O
in,453,52,O
patients,453,55,O
taking,453,64,O
both,453,71,O
drugs,453,76,O
.,453,81,O
Monitor,454,0,O
heart,454,8,O
rate,454,14,O
in,454,19,O
patients,454,22,O
on,454,31,O
amiodarone,454,34,O
and,454,45,O
concomitant,454,49,O
drugs,454,61,O
that,454,67,O
slow,454,72,B-SpecificInteraction
heart,454,72,I-SpecificInteraction
rate,454,72,I-SpecificInteraction
.,454,87,O
Monitor,454,0,O
heart,454,8,O
rate,454,14,O
in,454,19,O
patients,454,22,O
on,454,31,O
amiodarone,454,34,O
and,454,45,O
concomitant,454,49,O
drugs,454,61,O
that,454,67,O
slow,454,72,B-SpecificInteraction
heart,454,72,I-SpecificInteraction
rate,454,72,I-SpecificInteraction
.,454,87,O
Monitor,455,0,O
heart,455,8,O
rate,455,14,O
in,455,19,O
patients,455,22,O
taking,455,31,O
or,455,38,O
recently,455,41,O
discontinuing,455,50,O
amiodarone,455,64,O
when,455,75,O
starting,455,80,O
antiviral,455,89,O
treatment,455,99,O
.,455,109,O
Monitor,456,0,O
phenytoin,456,8,O
levels,456,18,O
in,456,25,O
patients,456,28,O
taking,456,37,O
both,456,44,O
drugs,456,49,O
.,456,54,O
Patients,457,0,O
should,457,9,O
avoid,457,16,O
grapefruit,457,22,O
juice,457,33,O
beverages,457,39,O
while,457,49,O
taking,457,55,O
amiodarone,457,62,O
because,457,73,O
exposure,457,81,O
to,457,90,O
amiodarone,457,93,O
is,457,104,O
significantly,457,107,O
increased,457,121,O
[,457,131,O
see,457,132,O
Clinical,457,136,O
Pharmacology,457,145,O
(,457,158,O
12.3,457,159,O
),457,163,O
],457,164,O
.,457,165,O
Postmarketing,458,0,O
cases,458,14,O
of,458,20,O
symptomatic,458,23,O
bradycardia,458,35,B-SpecificInteraction
",",458,47,O
some,458,49,O
requiring,458,54,O
pacemaker,458,64,O
insertion,458,74,O
and,458,84,O
at,458,88,O
least,458,91,O
one,458,97,O
fatal,458,101,O
",",458,107,O
have,458,109,O
been,458,114,O
reported,458,119,O
when,458,128,O
ledipasvir/sofosbuvir,458,133,O
or,458,155,O
sofosbuvir,458,158,O
with,458,169,O
simeprevir,458,174,O
were,458,185,O
initiated,458,190,O
in,458,200,O
patients,458,203,O
on,458,212,O
amiodarone,458,215,O
.,458,226,O
Postmarketing,458,0,O
cases,458,14,O
of,458,20,O
symptomatic,458,23,O
bradycardia,458,35,B-SpecificInteraction
",",458,47,O
some,458,49,O
requiring,458,54,O
pacemaker,458,64,O
insertion,458,74,O
and,458,84,O
at,458,88,O
least,458,91,O
one,458,97,O
fatal,458,101,O
",",458,107,O
have,458,109,O
been,458,114,O
reported,458,119,O
when,458,128,O
ledipasvir/sofosbuvir,458,133,O
or,458,155,O
sofosbuvir,458,158,O
with,458,169,O
simeprevir,458,174,O
were,458,185,O
initiated,458,190,O
in,458,200,O
patients,458,203,O
on,458,212,O
amiodarone,458,215,O
.,458,226,O
Postmarketing,458,0,O
cases,458,14,O
of,458,20,O
symptomatic,458,23,O
bradycardia,458,35,B-SpecificInteraction
",",458,47,O
some,458,49,O
requiring,458,54,O
pacemaker,458,64,O
insertion,458,74,O
and,458,84,O
at,458,88,O
least,458,91,O
one,458,97,O
fatal,458,101,O
",",458,107,O
have,458,109,O
been,458,114,O
reported,458,119,O
when,458,128,O
ledipasvir/sofosbuvir,458,133,O
or,458,155,O
sofosbuvir,458,158,O
with,458,169,O
simeprevir,458,174,O
were,458,185,O
initiated,458,190,O
in,458,200,O
patients,458,203,O
on,458,212,O
amiodarone,458,215,O
.,458,226,O
Reduce,459,0,O
dose,459,7,O
of,459,12,O
digoxin,459,15,O
by,459,23,O
half,459,26,O
or,459,31,O
discontinue,459,34,O
digoxin,459,46,O
.,459,53,O
Review,460,0,O
the,460,7,O
continued,460,11,O
need,460,21,O
for,460,26,O
the,460,30,O
other,460,34,O
antiarrhythmic,460,40,O
agent,460,55,O
after,460,61,O
the,460,67,O
effects,460,71,O
of,460,79,O
amiodarone,460,82,O
have,460,93,O
been,460,98,O
established,460,103,O
",",460,115,O
and,460,117,O
attempt,460,121,O
discontinuation,460,129,O
see,460,145,O
Clinical,460,149,O
Pharmacology,460,158,O
(,460,171,O
12.3,460,173,O
),460,178,O
.,460,180,O
Since,461,0,O
the,461,6,O
concomitant,461,10,O
administration,461,22,O
of,461,37,O
warfarin,461,40,O
with,461,49,O
amiodarone,461,54,O
increases,461,65,B-SpecificInteraction
the,461,65,I-SpecificInteraction
INR,461,65,I-SpecificInteraction
by,461,83,O
100,461,86,O
%,461,90,O
after,461,92,O
3,461,98,O
to,461,100,O
4,461,103,O
days,461,105,O
",",461,110,O
reduce,461,112,O
the,461,119,O
dose,461,123,O
of,461,128,O
the,461,131,O
anticoagulant,461,135,O
by,461,149,O
one-third,461,152,O
to,461,162,O
one-half,461,165,O
",",461,174,O
and,461,176,O
monitor,461,180,O
INR,461,188,O
closely,461,192,O
.,461,200,O
The,462,0,O
mechanism,462,4,O
for,462,14,O
this,462,18,O
effect,462,23,O
is,462,30,O
unknown,462,33,O
.,462,40,O
Amiodarone,463,0,O
inhibits,463,11,O
peripheral,463,20,O
conversion,463,31,O
of,463,42,O
thyroxine,463,45,O
(,463,55,O
T4,463,57,O
),463,60,O
to,463,62,O
triiodothyronine,463,65,O
(,463,82,O
T3,463,84,O
),463,87,O
and,463,89,O
may,463,93,O
cause,463,97,O
increased,463,103,O
T4,463,113,O
levels,463,116,O
",",463,123,O
decreased,463,125,O
T3,463,135,O
levels,463,138,O
",",463,145,O
and,463,147,O
increased,463,151,O
levels,463,161,O
of,463,168,O
inactive,463,171,O
reverse,463,180,O
T3,463,188,O
(,463,191,O
rT3,463,193,O
),463,197,O
in,463,199,O
clinically,463,202,O
euthyroid,463,213,O
patients,463,223,O
.,463,232,O
Amiodarone,463,0,O
inhibits,463,11,O
peripheral,463,20,O
conversion,463,31,O
of,463,42,O
thyroxine,463,45,O
(,463,55,O
T4,463,57,O
),463,60,O
to,463,62,O
triiodothyronine,463,65,O
(,463,82,O
T3,463,84,O
),463,87,O
and,463,89,O
may,463,93,O
cause,463,97,O
increased,463,103,O
T4,463,113,O
levels,463,116,O
",",463,123,O
decreased,463,125,O
T3,463,135,O
levels,463,138,O
",",463,145,O
and,463,147,O
increased,463,151,O
levels,463,161,O
of,463,168,O
inactive,463,171,O
reverse,463,180,O
T3,463,188,O
(,463,191,O
rT3,463,193,O
),463,197,O
in,463,199,O
clinically,463,202,O
euthyroid,463,213,O
patients,463,223,O
.,463,232,O
Amiodarone,464,0,O
is,464,11,O
also,464,14,O
a,464,19,O
potential,464,21,O
source,464,31,O
of,464,38,O
large,464,41,O
amounts,464,47,O
of,464,55,O
inorganic,464,58,O
iodine,464,68,O
and,464,75,O
can,464,79,O
cause,464,83,O
either,464,89,O
hypothyroidism,464,96,O
or,464,111,O
hyperthyroidism,464,114,O
.,464,130,O
Because,465,0,O
of,465,8,O
the,465,11,O
long,465,15,O
half-life,465,20,O
of,465,30,O
amiodarone,465,33,O
and,465,44,O
its,465,48,O
metabolite,465,52,O
desethylamiodarone,465,63,O
",",465,82,O
the,465,84,O
potential,465,88,O
for,465,98,O
adverse,465,102,O
reactions,465,110,O
or,465,120,O
interactions,465,123,O
",",465,136,O
as,465,138,O
well,465,141,O
as,465,146,O
observed,465,149,O
adverse,465,158,O
effects,465,166,O
",",465,174,O
can,465,176,O
persist,465,180,O
following,465,188,O
amiodarone,465,198,O
withdrawal,465,209,O
.,465,220,O
Like,466,0,O
all,466,5,O
antiarrhythmic,466,9,O
agents,466,24,O
",",466,31,O
NEXTERONE,466,33,O
may,466,43,O
cause,466,47,O
a,466,53,O
worsening,466,55,O
of,466,65,O
existing,466,68,O
arrhythmias,466,77,O
or,466,89,O
precipitate,466,92,O
a,466,104,O
new,466,106,O
arrhythmia,466,110,O
",",466,121,O
sometimes,466,123,O
leading,466,133,O
to,466,141,O
fatal,466,144,O
outcomes,466,150,O
see,466,159,O
Adverse,466,163,O
Reactions,466,171,O
(,466,181,O
6.2,466,183,O
),466,187,O
.,466,189,O
Manage,467,0,O
hypothyroidism,467,7,O
by,467,22,O
reducing,467,25,O
the,467,34,O
dose,467,38,O
of,467,43,O
or,467,46,O
discontinuing,467,49,O
NEXTERONE,467,63,O
and,467,73,O
considering,467,77,O
the,467,89,O
need,467,93,O
for,467,98,O
thyroid,467,102,O
hormone,467,110,O
supplement,467,118,O
.,467,129,O
Perform,468,0,O
close,468,8,O
perioperative,468,14,O
monitoring,468,28,O
in,468,39,O
patients,468,42,O
undergoing,468,51,O
general,468,62,O
anesthesia,468,70,O
who,468,81,O
are,468,85,O
on,468,89,O
amiodarone,468,92,O
therapy,468,103,O
as,468,111,O
they,468,114,O
may,468,119,O
be,468,123,O
more,468,126,O
sensitive,468,131,O
to,468,141,O
the,468,144,O
myocardial,468,148,B-SpecificInteraction
depressant,468,148,I-SpecificInteraction
and,468,170,O
conduction,468,174,B-SpecificInteraction
defects,468,174,I-SpecificInteraction
of,468,193,O
halogenated,468,196,O
inhalational,468,208,O
anesthetics,468,221,O
.,468,233,O
Reserve,469,0,O
the,469,8,O
combination,469,12,O
of,469,24,O
amiodarone,469,27,O
with,469,38,O
other,469,43,O
antiarrhythmic,469,49,O
therapies,469,64,O
that,469,74,O
prolong,469,79,O
the,469,87,O
QTc,469,91,O
to,469,95,O
patients,469,98,O
with,469,107,O
life-threatening,469,112,O
ventricular,469,129,O
arrhythmias,469,141,O
who,469,153,O
are,469,157,O
incompletely,469,161,O
responsive,469,174,O
to,469,185,O
a,469,188,O
single,469,190,O
agent,469,197,O
.,469,203,O
Since,470,0,O
NEXTERONE,470,6,O
contains,470,16,O
dextrose,470,25,O
",",470,34,O
patients,470,36,O
with,470,45,O
allergy,470,50,O
to,470,58,O
corn,470,61,O
or,470,66,O
corn,470,69,O
products,470,74,O
are,470,83,O
at,470,87,O
risk,470,90,O
for,470,95,O
allergic,470,99,O
reaction,470,108,O
.,470,117,O
After,67,0,O
an,67,6,O
initial,67,9,O
priming,67,17,O
of,67,25,O
10,67,28,O
sprays,67,31,O
",",67,38,O
each,67,40,O
metered,67,45,O
spray,67,53,O
of,67,59,O
NitroMist,67,62,O
delivers,67,72,O
33,67,81,O
mg,67,84,O
of,67,87,O
solution,67,90,O
containing,67,99,O
400,67,110,O
mcg,67,114,O
of,67,118,O
nitroglycerin,67,121,O
.,67,135,O
Administration,68,0,O
of,68,15,O
NitroMist,68,18,O
is,68,28,O
contraindicated,68,31,O
in,68,47,O
patients,68,50,O
who,68,59,O
are,68,63,O
using,68,67,O
a,68,73,O
selective,68,75,O
inhibitor,68,85,O
of,68,95,O
cyclic,68,98,O
guanosine,68,105,O
monophosphate,68,115,O
(,68,129,O
cGMP,68,131,O
),68,136,O
-,68,138,O
specific,68,140,O
phosphodiesterase,68,149,O
type,68,167,O
5,68,172,O
(,68,174,O
PDE5,68,176,O
),68,181,O
",",68,183,O
as,68,185,O
PDE5,68,188,O
inhibitors,68,193,O
such,68,204,O
as,68,209,O
sildenafil,68,212,O
",",68,223,O
vardenafil,68,225,O
",",68,236,O
and,68,238,O
tadalafil,68,242,O
have,68,252,O
been,68,257,O
shown,68,262,O
to,68,268,O
potentiate,68,271,O
the,68,282,O
hypotensive,68,286,B-SpecificInteraction
effects,68,286,I-SpecificInteraction
of,68,306,O
organic,68,309,O
nitrates,68,317,O
see,68,326,O
DRUG,68,330,O
INTERACTIONS,68,335,O
(,68,348,O
7.1,68,350,O
),68,354,O
.,68,356,O
Administration,68,0,O
of,68,15,O
NitroMist,68,18,O
is,68,28,O
contraindicated,68,31,O
in,68,47,O
patients,68,50,O
who,68,59,O
are,68,63,O
using,68,67,O
a,68,73,O
selective,68,75,O
inhibitor,68,85,O
of,68,95,O
cyclic,68,98,O
guanosine,68,105,O
monophosphate,68,115,O
(,68,129,O
cGMP,68,131,O
),68,136,O
-,68,138,O
specific,68,140,O
phosphodiesterase,68,149,O
type,68,167,O
5,68,172,O
(,68,174,O
PDE5,68,176,O
),68,181,O
",",68,183,O
as,68,185,O
PDE5,68,188,O
inhibitors,68,193,O
such,68,204,O
as,68,209,O
sildenafil,68,212,O
",",68,223,O
vardenafil,68,225,O
",",68,236,O
and,68,238,O
tadalafil,68,242,O
have,68,252,O
been,68,257,O
shown,68,262,O
to,68,268,O
potentiate,68,271,O
the,68,282,O
hypotensive,68,286,B-SpecificInteraction
effects,68,286,I-SpecificInteraction
of,68,306,O
organic,68,309,O
nitrates,68,317,O
see,68,326,O
DRUG,68,330,O
INTERACTIONS,68,335,O
(,68,348,O
7.1,68,350,O
),68,354,O
.,68,356,O
Administration,68,0,O
of,68,15,O
NitroMist,68,18,O
is,68,28,O
contraindicated,68,31,O
in,68,47,O
patients,68,50,O
who,68,59,O
are,68,63,O
using,68,67,O
a,68,73,O
selective,68,75,O
inhibitor,68,85,O
of,68,95,O
cyclic,68,98,O
guanosine,68,105,O
monophosphate,68,115,O
(,68,129,O
cGMP,68,131,O
),68,136,O
-,68,138,O
specific,68,140,O
phosphodiesterase,68,149,O
type,68,167,O
5,68,172,O
(,68,174,O
PDE5,68,176,O
),68,181,O
",",68,183,O
as,68,185,O
PDE5,68,188,O
inhibitors,68,193,O
such,68,204,O
as,68,209,O
sildenafil,68,212,O
",",68,223,O
vardenafil,68,225,O
",",68,236,O
and,68,238,O
tadalafil,68,242,O
have,68,252,O
been,68,257,O
shown,68,262,O
to,68,268,O
potentiate,68,271,O
the,68,282,O
hypotensive,68,286,B-SpecificInteraction
effects,68,286,I-SpecificInteraction
of,68,306,O
organic,68,309,O
nitrates,68,317,O
see,68,326,O
DRUG,68,330,O
INTERACTIONS,68,335,O
(,68,348,O
7.1,68,350,O
),68,354,O
.,68,356,O
Administration,68,0,O
of,68,15,O
NitroMist,68,18,O
is,68,28,O
contraindicated,68,31,O
in,68,47,O
patients,68,50,O
who,68,59,O
are,68,63,O
using,68,67,O
a,68,73,O
selective,68,75,O
inhibitor,68,85,O
of,68,95,O
cyclic,68,98,O
guanosine,68,105,O
monophosphate,68,115,O
(,68,129,O
cGMP,68,131,O
),68,136,O
-,68,138,O
specific,68,140,O
phosphodiesterase,68,149,O
type,68,167,O
5,68,172,O
(,68,174,O
PDE5,68,176,O
),68,181,O
",",68,183,O
as,68,185,O
PDE5,68,188,O
inhibitors,68,193,O
such,68,204,O
as,68,209,O
sildenafil,68,212,O
",",68,223,O
vardenafil,68,225,O
",",68,236,O
and,68,238,O
tadalafil,68,242,O
have,68,252,O
been,68,257,O
shown,68,262,O
to,68,268,O
potentiate,68,271,O
the,68,282,O
hypotensive,68,286,B-SpecificInteraction
effects,68,286,I-SpecificInteraction
of,68,306,O
organic,68,309,O
nitrates,68,317,O
see,68,326,O
DRUG,68,330,O
INTERACTIONS,68,335,O
(,68,348,O
7.1,68,350,O
),68,354,O
.,68,356,O
(,69,0,O
7.5,69,1,O
),69,4,O
Ergotamine,69,6,O
:,69,16,O
increased,69,18,O
bioavailability,69,28,O
of,69,44,O
ergotamine,69,47,O
.,69,57,O
(,70,0,O
7.6,70,1,O
),70,4,O
Administration,70,6,O
of,70,21,O
NitroMist,70,24,O
is,70,34,O
contraindicated,70,37,O
in,70,53,O
patients,70,56,O
who,70,65,O
are,70,69,O
using,70,73,O
a,70,79,O
selective,70,81,O
inhibitor,70,91,O
of,70,101,O
cyclic,70,104,O
guanosine,70,111,O
monophosphate,70,121,O
(,70,135,O
cGMP,70,136,O
),70,140,O
-specific,70,141,O
phosphodiesterase,70,151,O
type5,70,169,O
(,70,175,O
PDE5,70,176,O
),70,180,O
.,70,181,O
Activated,71,0,O
partial,71,10,O
thromboplastin,71,18,O
times,71,33,O
(,71,39,O
APTT,71,41,O
),71,46,O
should,71,48,O
be,71,55,O
monitored,71,58,O
in,71,68,O
patients,71,71,O
receiving,71,80,O
heparin,71,90,O
and,71,98,O
intravenous,71,102,O
nitroglycerin,71,114,O
.,71,128,O
Activated,72,0,O
partial,72,10,O
thromboplastin,72,18,O
times,72,33,O
(,72,39,O
APTT,72,40,O
),72,44,O
should,72,46,O
be,72,53,O
monitored,72,56,O
in,72,66,O
patients,72,69,O
receiving,72,78,O
heparin,72,88,O
and,72,96,O
intravenous,72,100,O
nitroglycerin,72,112,O
.,72,125,O
Appropriate,73,0,O
supportive,73,12,O
care,73,23,O
for,73,28,O
the,73,32,O
severe,73,36,O
hypotension,73,43,O
has,73,55,O
not,73,59,O
been,73,63,O
studied,73,68,O
",",73,75,O
but,73,77,O
it,73,81,O
seems,73,84,O
reasonable,73,90,O
to,73,101,O
treat,73,104,O
this,73,110,O
as,73,115,O
a,73,118,O
nitrate,73,120,O
overdose,73,128,O
",",73,136,O
with,73,138,O
elevation,73,143,O
of,73,153,O
the,73,156,O
extremities,73,160,O
and,73,172,O
with,73,176,O
central,73,181,O
volume,73,189,O
expansion,73,196,O
.,73,205,O
Aspirin,74,0,O
:,74,8,O
increased,74,10,O
nitroglycerin,74,20,O
levels,74,34,O
(,74,41,O
7.3,74,43,O
),74,47,O
.,74,49,O
Coadministration,75,0,O
of,75,17,O
aspirin,75,20,O
and,75,28,O
nitroglycerin,75,32,O
has,75,46,O
been,75,50,O
reported,75,55,O
to,75,64,O
result,75,67,O
in,75,74,O
increased,75,77,O
nitroglycerin,75,87,O
maximum,75,101,O
concentrations,75,109,O
by,75,124,O
as,75,127,O
much,75,130,O
as,75,135,O
67,75,138,O
%,75,141,O
and,75,143,O
AUC,75,147,O
by,75,151,O
73,75,154,O
%,75,157,O
when,75,159,O
administered,75,164,O
as,75,177,O
a,75,180,O
single,75,182,O
dose,75,189,O
.,75,194,O
Coadministration,75,0,O
of,75,17,O
aspirin,75,20,O
and,75,28,O
nitroglycerin,75,32,O
has,75,46,O
been,75,50,O
reported,75,55,O
to,75,64,O
result,75,67,O
in,75,74,O
increased,75,77,O
nitroglycerin,75,87,O
maximum,75,101,O
concentrations,75,109,O
by,75,124,O
as,75,127,O
much,75,130,O
as,75,135,O
67,75,138,O
%,75,141,O
and,75,143,O
AUC,75,147,O
by,75,151,O
73,75,154,O
%,75,157,O
when,75,159,O
administered,75,164,O
as,75,177,O
a,75,180,O
single,75,182,O
dose,75,189,O
.,75,194,O
Ergotamine,76,0,O
is,76,11,O
known,76,14,O
to,76,20,O
precipitate,76,23,O
angina,76,35,O
pectoris,76,42,O
.,76,50,O
If,77,0,O
labetolol,77,3,O
is,77,13,O
used,77,16,O
with,77,21,O
nitroglycerin,77,26,O
in,77,40,O
patients,77,43,O
with,77,52,O
angina,77,57,O
pectoris,77,64,O
",",77,73,O
additional,77,75,O
hypotensive,77,86,B-SpecificInteraction
effects,77,86,I-SpecificInteraction
may,77,106,O
occur,77,110,O
.,77,116,O
Intravenous,78,0,O
administration,78,12,O
of,78,27,O
nitroglycerin,78,30,O
decreases,78,44,O
the,78,54,O
thrombolytic,78,58,O
effect,78,71,O
of,78,78,O
tissue-type,78,81,O
plasminogen,78,93,O
activator,78,105,O
(,78,115,O
t-PA,78,117,O
),78,122,O
.,78,124,O
Intravenous,79,0,O
nitroglycerin,79,12,O
reduces,79,26,B-SpecificInteraction
the,79,26,I-SpecificInteraction
anticoagulant,79,26,I-SpecificInteraction
effect,79,26,I-SpecificInteraction
of,79,59,O
heparin,79,62,O
.,79,70,O
It,80,0,O
is,80,3,O
not,80,6,O
known,80,10,O
if,80,16,O
this,80,19,O
effect,80,24,O
occurs,80,31,O
following,80,38,O
single,80,48,O
nitroglycerin,80,55,O
doses,80,69,O
.,80,74,O
Labetolol,81,0,O
blunts,81,10,O
the,81,17,O
reflex,81,21,O
tachycardia,81,28,O
produced,81,40,O
by,81,49,O
nitroglycerin,81,52,O
without,81,66,O
preventing,81,74,O
its,81,85,O
hypotensive,81,89,O
effects,81,101,O
.,81,109,O
Marked,82,0,B-SpecificInteraction
orthostatic,82,0,I-SpecificInteraction
hypotension,82,0,I-SpecificInteraction
has,82,31,O
been,82,35,O
reported,82,40,O
when,82,49,O
calcium,82,54,O
channel,82,62,O
blockers,82,70,O
and,82,79,O
organic,82,83,O
nitrates,82,91,O
were,82,100,O
used,82,105,O
concomitantly,82,110,O
.,82,123,O
Oral,83,0,O
administration,83,5,O
of,83,20,O
nitroglycerin,83,23,O
markedly,83,37,O
decreases,83,46,O
the,83,56,O
first-pass,83,60,O
metabolism,83,71,O
of,83,82,O
dihydroergotamine,83,85,O
and,83,103,O
subsequently,83,107,O
increases,83,120,O
its,83,130,O
oral,83,134,O
bioavailability,83,139,O
.,83,155,O
Patients,84,0,O
receiving,84,9,O
antihypertensive,84,19,O
drugs,84,36,O
",",84,41,O
beta-adrenergic,84,43,O
blockers,84,59,O
",",84,67,O
and,84,69,O
nitrates,84,73,O
should,84,82,O
be,84,89,O
observed,84,92,O
for,84,101,O
possible,84,105,O
additive,84,114,O
hypotensive,84,123,B-SpecificInteraction
effects,84,123,I-SpecificInteraction
.,84,142,O
Patients,84,0,O
receiving,84,9,O
antihypertensive,84,19,O
drugs,84,36,O
",",84,41,O
beta-adrenergic,84,43,O
blockers,84,59,O
",",84,67,O
and,84,69,O
nitrates,84,73,O
should,84,82,O
be,84,89,O
observed,84,92,O
for,84,101,O
possible,84,105,O
additive,84,114,O
hypotensive,84,123,B-SpecificInteraction
effects,84,123,I-SpecificInteraction
.,84,142,O
Patients,84,0,O
receiving,84,9,O
antihypertensive,84,19,O
drugs,84,36,O
",",84,41,O
beta-adrenergic,84,43,O
blockers,84,59,O
",",84,67,O
and,84,69,O
nitrates,84,73,O
should,84,82,O
be,84,89,O
observed,84,92,O
for,84,101,O
possible,84,105,O
additive,84,114,O
hypotensive,84,123,B-SpecificInteraction
effects,84,123,I-SpecificInteraction
.,84,142,O
PDE5,85,0,O
inhibitors,85,5,O
such,85,16,O
as,85,21,O
sildenafil,85,24,O
",",85,34,O
vardenafil,85,36,O
",",85,46,O
and,85,48,O
tadalafil,85,52,O
have,85,62,O
been,85,67,O
shown,85,72,O
to,85,78,O
potentiate,85,81,O
the,85,92,O
hypotensive,85,96,B-SpecificInteraction
effects,85,96,I-SpecificInteraction
of,85,116,O
organic,85,119,O
nitrates,85,127,O
.,85,135,O
PDE5,85,0,O
inhibitors,85,5,O
such,85,16,O
as,85,21,O
sildenafil,85,24,O
",",85,34,O
vardenafil,85,36,O
",",85,46,O
and,85,48,O
tadalafil,85,52,O
have,85,62,O
been,85,67,O
shown,85,72,O
to,85,78,O
potentiate,85,81,O
the,85,92,O
hypotensive,85,96,B-SpecificInteraction
effects,85,96,I-SpecificInteraction
of,85,116,O
organic,85,119,O
nitrates,85,127,O
.,85,135,O
PDE5,85,0,O
inhibitors,85,5,O
such,85,16,O
as,85,21,O
sildenafil,85,24,O
",",85,34,O
vardenafil,85,36,O
",",85,46,O
and,85,48,O
tadalafil,85,52,O
have,85,62,O
been,85,67,O
shown,85,72,O
to,85,78,O
potentiate,85,81,O
the,85,92,O
hypotensive,85,96,B-SpecificInteraction
effects,85,96,I-SpecificInteraction
of,85,116,O
organic,85,119,O
nitrates,85,127,O
.,85,135,O
PDE5,85,0,O
inhibitors,85,5,O
such,85,16,O
as,85,21,O
sildenafil,85,24,O
",",85,34,O
vardenafil,85,36,O
",",85,46,O
and,85,48,O
tadalafil,85,52,O
have,85,62,O
been,85,67,O
shown,85,72,O
to,85,78,O
potentiate,85,81,O
the,85,92,O
hypotensive,85,96,B-SpecificInteraction
effects,85,96,I-SpecificInteraction
of,85,116,O
organic,85,119,O
nitrates,85,127,O
.,85,135,O
PDE5,86,0,O
inhibitors,86,5,O
:,86,15,O
Concomitant,86,17,O
use,86,29,O
contraindicated,86,33,O
(,86,49,O
4.1,86,50,O
",",86,53,O
7.1,86,55,O
),86,58,O
Antihypertensives,86,60,O
:,86,77,O
Possible,86,79,O
additive,86,88,B-SpecificInteraction
hypotensive,86,88,I-SpecificInteraction
effects,86,88,I-SpecificInteraction
(,86,117,O
7.2,86,118,O
),86,121,O
Aspirin,86,123,O
:,86,130,O
increased,86,132,O
nitroglycerin,86,142,O
levels,86,156,O
(,86,163,O
7.3,86,164,O
),86,167,O
Tissue-type,86,169,O
plasminogen,86,181,O
activator,86,193,O
(,86,203,O
t-PA,86,204,O
),86,208,O
:,86,209,O
decreased,86,211,B-SpecificInteraction
thrombolytic,86,211,I-SpecificInteraction
effect,86,211,I-SpecificInteraction
(,86,241,O
7.4,86,242,O
),86,245,O
Heparin,86,247,O
:,86,254,O
anticoagulant,86,256,O
effect,86,270,O
of,86,277,O
heparin,86,280,O
may,86,288,O
be,86,292,O
reduced,86,295,O
.,86,302,O
PDE5,86,0,O
inhibitors,86,5,O
:,86,15,O
Concomitant,86,17,O
use,86,29,O
contraindicated,86,33,O
(,86,49,O
4.1,86,50,O
",",86,53,O
7.1,86,55,O
),86,58,O
Antihypertensives,86,60,O
:,86,77,O
Possible,86,79,O
additive,86,88,B-SpecificInteraction
hypotensive,86,88,I-SpecificInteraction
effects,86,88,I-SpecificInteraction
(,86,117,O
7.2,86,118,O
),86,121,O
Aspirin,86,123,O
:,86,130,O
increased,86,132,O
nitroglycerin,86,142,O
levels,86,156,O
(,86,163,O
7.3,86,164,O
),86,167,O
Tissue-type,86,169,O
plasminogen,86,181,O
activator,86,193,O
(,86,203,O
t-PA,86,204,O
),86,208,O
:,86,209,O
decreased,86,211,B-SpecificInteraction
thrombolytic,86,211,I-SpecificInteraction
effect,86,211,I-SpecificInteraction
(,86,241,O
7.4,86,242,O
),86,245,O
Heparin,86,247,O
:,86,254,O
anticoagulant,86,256,O
effect,86,270,O
of,86,277,O
heparin,86,280,O
may,86,288,O
be,86,292,O
reduced,86,295,O
.,86,302,O
PDE5,86,0,O
inhibitors,86,5,O
:,86,15,O
Concomitant,86,17,O
use,86,29,O
contraindicated,86,33,O
(,86,49,O
4.1,86,50,O
",",86,53,O
7.1,86,55,O
),86,58,O
Antihypertensives,86,60,O
:,86,77,O
Possible,86,79,O
additive,86,88,B-SpecificInteraction
hypotensive,86,88,I-SpecificInteraction
effects,86,88,I-SpecificInteraction
(,86,117,O
7.2,86,118,O
),86,121,O
Aspirin,86,123,O
:,86,130,O
increased,86,132,O
nitroglycerin,86,142,O
levels,86,156,O
(,86,163,O
7.3,86,164,O
),86,167,O
Tissue-type,86,169,O
plasminogen,86,181,O
activator,86,193,O
(,86,203,O
t-PA,86,204,O
),86,208,O
:,86,209,O
decreased,86,211,B-SpecificInteraction
thrombolytic,86,211,I-SpecificInteraction
effect,86,211,I-SpecificInteraction
(,86,241,O
7.4,86,242,O
),86,245,O
Heparin,86,247,O
:,86,254,O
anticoagulant,86,256,O
effect,86,270,O
of,86,277,O
heparin,86,280,O
may,86,288,O
be,86,292,O
reduced,86,295,O
.,86,302,O
PDE5,86,0,O
inhibitors,86,5,O
:,86,15,O
Concomitant,86,17,O
use,86,29,O
contraindicated,86,33,O
(,86,49,O
4.1,86,50,O
",",86,53,O
7.1,86,55,O
),86,58,O
Antihypertensives,86,60,O
:,86,77,O
Possible,86,79,O
additive,86,88,B-SpecificInteraction
hypotensive,86,88,I-SpecificInteraction
effects,86,88,I-SpecificInteraction
(,86,117,O
7.2,86,118,O
),86,121,O
Aspirin,86,123,O
:,86,130,O
increased,86,132,O
nitroglycerin,86,142,O
levels,86,156,O
(,86,163,O
7.3,86,164,O
),86,167,O
Tissue-type,86,169,O
plasminogen,86,181,O
activator,86,193,O
(,86,203,O
t-PA,86,204,O
),86,208,O
:,86,209,O
decreased,86,211,B-SpecificInteraction
thrombolytic,86,211,I-SpecificInteraction
effect,86,211,I-SpecificInteraction
(,86,241,O
7.4,86,242,O
),86,245,O
Heparin,86,247,O
:,86,254,O
anticoagulant,86,256,O
effect,86,270,O
of,86,277,O
heparin,86,280,O
may,86,288,O
be,86,292,O
reduced,86,295,O
.,86,302,O
PDE5,86,0,O
inhibitors,86,5,O
:,86,15,O
Concomitant,86,17,O
use,86,29,O
contraindicated,86,33,O
(,86,49,O
4.1,86,50,O
",",86,53,O
7.1,86,55,O
),86,58,O
Antihypertensives,86,60,O
:,86,77,O
Possible,86,79,O
additive,86,88,B-SpecificInteraction
hypotensive,86,88,I-SpecificInteraction
effects,86,88,I-SpecificInteraction
(,86,117,O
7.2,86,118,O
),86,121,O
Aspirin,86,123,O
:,86,130,O
increased,86,132,O
nitroglycerin,86,142,O
levels,86,156,O
(,86,163,O
7.3,86,164,O
),86,167,O
Tissue-type,86,169,O
plasminogen,86,181,O
activator,86,193,O
(,86,203,O
t-PA,86,204,O
),86,208,O
:,86,209,O
decreased,86,211,B-SpecificInteraction
thrombolytic,86,211,I-SpecificInteraction
effect,86,211,I-SpecificInteraction
(,86,241,O
7.4,86,242,O
),86,245,O
Heparin,86,247,O
:,86,254,O
anticoagulant,86,256,O
effect,86,270,O
of,86,277,O
heparin,86,280,O
may,86,288,O
be,86,292,O
reduced,86,295,O
.,86,302,O
Plasma,87,0,O
levels,87,7,O
of,87,14,O
t-PA,87,17,O
are,87,22,O
reduced,87,26,O
when,87,34,O
coadministered,87,39,O
with,87,54,O
nitroglycerin,87,59,O
.,87,73,O
The,88,0,O
time,88,4,O
course,88,9,O
and,88,16,O
dose,88,20,O
dependence,88,25,O
of,88,36,O
this,88,39,O
interaction,88,44,O
have,88,56,O
not,88,61,O
been,88,65,O
studied,88,70,O
",",88,77,O
and,88,79,O
use,88,83,O
within,88,87,O
a,88,94,O
few,88,96,O
days,88,100,O
of,88,105,O
one,88,108,O
another,88,112,O
can,88,120,O
not,88,123,O
be,88,127,O
recommended,88,130,O
.,88,141,O
The,89,0,O
use,89,4,O
of,89,8,O
any,89,11,O
form,89,15,O
of,89,20,O
nitroglycerin,89,23,O
during,89,37,O
the,89,44,O
early,89,48,O
days,89,54,O
of,89,59,O
acute,89,62,O
myocardial,89,68,O
infarction,89,79,O
requires,89,90,O
particular,89,99,O
attention,89,110,O
to,89,120,O
hemodynamic,89,123,O
monitoring,89,135,O
and,89,146,O
clinical,89,150,O
status,89,159,O
.,89,165,O
The,90,0,O
vasodilatory,90,4,O
and,90,17,O
hemodynamic,90,21,O
effects,90,33,O
of,90,41,O
nitroglycerin,90,44,O
may,90,58,O
be,90,62,O
enhanced,90,65,O
by,90,74,O
concomitant,90,77,O
administration,90,89,O
of,90,104,O
aspirin,90,107,O
.,90,114,O
Therefore,91,0,O
",",91,10,O
caution,91,12,O
should,91,20,O
be,91,27,O
observed,91,30,O
in,91,39,O
patients,91,42,O
receiving,91,51,O
nitroglycerin,91,61,O
during,91,75,O
t-PA,91,82,O
therapy,91,87,O
.,91,95,O
Therefore,92,0,O
",",92,10,O
patients,92,12,O
receiving,92,21,O
sublingual,92,31,O
nitroglycerin,92,42,O
should,92,56,O
avoid,92,63,O
ergotamine,92,69,O
and,92,80,O
related,92,84,O
drugs,92,92,O
or,92,98,O
be,92,101,O
monitored,92,104,O
for,92,114,O
symptoms,92,118,B-SpecificInteraction
of,92,118,I-SpecificInteraction
ergotism,92,118,I-SpecificInteraction
if,92,139,O
this,92,142,O
is,92,147,O
not,92,150,O
possible,92,154,O
.,92,163,O
Diluted,290,0,O
Remodulin,290,8,O
has,290,18,O
been,290,22,O
shown,290,27,O
to,290,33,O
be,290,36,O
stable,290,39,O
at,290,46,O
ambient,290,49,O
temperature,290,57,O
when,290,69,O
stored,290,74,O
for,290,81,O
up,290,85,O
to,290,88,O
14,290,91,O
days,290,94,O
using,290,99,O
high-pH,290,105,O
glycine,290,113,O
diluent,290,121,O
at,290,129,O
concentrations,290,132,O
as,290,147,O
low,290,150,O
as,290,154,O
0.004,290,157,O
mg/mL,290,163,O
(,290,169,O
"4,000",290,171,O
ng/mL,290,177,O
),290,183,O
.,290,185,O
Increase,291,0,O
the,291,9,O
Remodulin,291,13,O
dose,291,23,O
gradually,291,28,O
as,291,38,O
the,291,41,O
Flolan,291,45,O
dose,291,52,O
is,291,57,O
decreased,291,60,O
",",291,70,O
based,291,72,O
on,291,78,O
constant,291,81,O
observation,291,90,O
of,291,102,O
response,291,105,O
.,291,114,O
Initiate,292,0,O
Remodulin,292,9,O
at,292,19,O
a,292,22,O
recommended,292,24,O
dose,292,36,O
of,292,41,O
10,292,44,O
%,292,47,O
of,292,49,O
the,292,52,O
current,292,56,O
Flolan,292,64,O
dose,292,71,O
",",292,76,O
and,292,78,O
then,292,82,O
escalate,292,87,O
as,292,96,O
the,292,99,O
Flolan,292,103,O
dose,292,110,O
is,292,115,O
decreased,292,118,O
(,292,128,O
see,292,130,O
Table,292,134,O
2,292,140,O
for,292,142,O
recommended,292,146,O
dose,292,158,O
titrations,292,163,O
),292,174,O
.,292,176,O
Patients,293,0,O
are,293,9,O
individually,293,13,O
titrated,293,26,O
to,293,35,O
a,293,38,O
dose,293,40,O
that,293,45,O
allows,293,50,O
transition,293,57,O
from,293,68,O
Flolan,293,73,O
therapy,293,80,O
to,293,88,O
Remodulin,293,91,O
while,293,101,O
balancing,293,107,O
prostacyclin-limiting,293,117,O
adverse,293,139,O
events,293,147,O
.,293,154,O
Remodulin,294,0,O
can,294,10,O
be,294,14,O
administered,294,17,O
without,294,30,O
further,294,38,O
dilution,294,46,O
for,294,55,O
subcutaneous,294,59,O
administration,294,72,O
",",294,87,O
or,294,89,O
diluted,294,92,O
for,294,100,O
intravenous,294,104,O
infusion,294,116,O
with,294,125,O
Sterile,294,130,O
Diluent,294,138,O
for,294,146,O
Remodulin,294,150,O
or,294,160,O
similar,294,163,O
approved,294,171,O
high-pH,294,180,O
glycine,294,188,O
diluent,294,196,O
(,294,204,O
e.g.,294,206,O
Sterile,294,211,O
Diluent,294,219,O
for,294,227,O
Flolan,294,231,O
or,294,238,O
Sterile,294,241,O
Diluent,294,249,O
for,294,257,O
Epoprostenol,294,261,O
Sodium,294,274,O
),294,281,O
",",294,283,O
Sterile,294,285,O
Water,294,293,O
for,294,299,O
Injection,294,303,O
",",294,313,O
or,294,315,O
0.9,294,318,O
%,294,322,O
Sodium,294,326,O
Chloride,294,333,O
Injection,294,342,O
prior,294,352,O
to,294,358,O
administration,294,361,O
.,294,376,O
Transition,295,0,O
from,295,11,O
Flolan,295,16,O
to,295,23,O
Remodulin,295,26,O
is,295,36,O
accomplished,295,39,O
by,295,52,O
initiating,295,55,O
the,295,66,O
infusion,295,70,O
of,295,79,O
Remodulin,295,82,O
and,295,92,O
increasing,295,96,O
it,295,107,O
",",295,110,O
while,295,112,O
simultaneously,295,118,O
reducing,295,133,O
the,295,142,O
dose,295,146,O
of,295,151,O
intravenous,295,154,O
Flolan,295,166,O
.,295,173,O
(,296,0,O
7.2,296,1,O
),296,4,O
Remodulin,296,6,O
dosage,296,16,O
adjustment,296,23,O
may,296,34,O
be,296,38,O
necessary,296,41,O
if,296,51,O
inhibitors,296,54,O
or,296,65,O
inducers,296,68,O
of,296,77,O
CYP2C8,296,80,O
are,296,87,O
added,296,91,O
or,296,97,O
withdrawn,296,100,O
.,296,109,O
(,296,0,O
7.2,296,1,O
),296,4,O
Remodulin,296,6,O
dosage,296,16,O
adjustment,296,23,O
may,296,34,O
be,296,38,O
necessary,296,41,O
if,296,51,O
inhibitors,296,54,O
or,296,65,O
inducers,296,68,O
of,296,77,O
CYP2C8,296,80,O
are,296,87,O
added,296,91,O
or,296,97,O
withdrawn,296,100,O
.,296,109,O
(,297,0,O
7.6,297,1,O
),297,4,O
Concomitant,297,6,O
administration,297,18,O
of,297,33,O
Remodulin,297,36,O
with,297,46,O
diuretics,297,51,O
",",297,60,O
antihypertensive,297,62,O
agents,297,79,O
or,297,86,O
other,297,89,O
vasodilators,297,95,O
may,297,108,O
increase,297,112,O
the,297,121,O
risk,297,125,O
of,297,130,O
symptomatic,297,133,B-SpecificInteraction
hypotension,297,133,I-SpecificInteraction
.,297,156,O
(,297,0,O
7.6,297,1,O
),297,4,O
Concomitant,297,6,O
administration,297,18,O
of,297,33,O
Remodulin,297,36,O
with,297,46,O
diuretics,297,51,O
",",297,60,O
antihypertensive,297,62,O
agents,297,79,O
or,297,86,O
other,297,89,O
vasodilators,297,95,O
may,297,108,O
increase,297,112,O
the,297,121,O
risk,297,125,O
of,297,130,O
symptomatic,297,133,B-SpecificInteraction
hypotension,297,133,I-SpecificInteraction
.,297,156,O
(,297,0,O
7.6,297,1,O
),297,4,O
Concomitant,297,6,O
administration,297,18,O
of,297,33,O
Remodulin,297,36,O
with,297,46,O
diuretics,297,51,O
",",297,60,O
antihypertensive,297,62,O
agents,297,79,O
or,297,86,O
other,297,89,O
vasodilators,297,95,O
may,297,108,O
increase,297,112,O
the,297,121,O
risk,297,125,O
of,297,130,O
symptomatic,297,133,B-SpecificInteraction
hypotension,297,133,I-SpecificInteraction
.,297,156,O
7.6,298,0,O
Effect,298,4,O
of,298,11,O
Cytochrome,298,14,O
P450,298,25,O
Inhibitors,298,30,O
and,298,41,O
Inducers,298,45,O
on,298,54,O
Treprostinil,298,57,O
.,298,70,O
Additionally,299,0,O
",",299,12,O
treprostinil,299,14,O
does,299,27,O
not,299,32,O
induce,299,36,O
cytochrome,299,43,O
P450,299,54,O
isoenzymes,299,59,O
CYP1A2,299,70,O
",",299,76,O
CYP2B6,299,78,O
",",299,84,O
CYP2C9,299,86,O
",",299,92,O
CYP2C19,299,94,O
",",299,101,O
and,299,103,O
CYP3A,299,107,O
.,299,112,O
Co-administration,300,0,O
of,300,18,O
the,300,21,O
CYP2C8,300,25,O
enzyme,300,32,O
inducer,300,39,O
rifampin,300,47,O
decreases,300,56,O
exposure,300,66,O
to,300,75,O
treprostinil,300,78,O
.,300,91,O
Concomitant,301,0,O
administration,301,12,O
of,301,27,O
Remodulin,301,30,O
with,301,40,O
diuretics,301,45,O
",",301,55,O
antihypertensive,301,57,O
agents,301,74,O
or,301,81,O
other,301,84,O
vasodilators,301,90,O
may,301,103,O
increase,301,107,O
the,301,116,O
risk,301,120,O
of,301,125,O
symptomatic,301,128,B-SpecificInteraction
hypotension,301,128,I-SpecificInteraction
.,301,152,O
Concomitant,301,0,O
administration,301,12,O
of,301,27,O
Remodulin,301,30,O
with,301,40,O
diuretics,301,45,O
",",301,55,O
antihypertensive,301,57,O
agents,301,74,O
or,301,81,O
other,301,84,O
vasodilators,301,90,O
may,301,103,O
increase,301,107,O
the,301,116,O
risk,301,120,O
of,301,125,O
symptomatic,301,128,B-SpecificInteraction
hypotension,301,128,I-SpecificInteraction
.,301,152,O
Concomitant,301,0,O
administration,301,12,O
of,301,27,O
Remodulin,301,30,O
with,301,40,O
diuretics,301,45,O
",",301,55,O
antihypertensive,301,57,O
agents,301,74,O
or,301,81,O
other,301,84,O
vasodilators,301,90,O
may,301,103,O
increase,301,107,O
the,301,116,O
risk,301,120,O
of,301,125,O
symptomatic,301,128,B-SpecificInteraction
hypotension,301,128,I-SpecificInteraction
.,301,152,O
Drug,302,0,O
interaction,302,5,O
studies,302,17,O
have,302,25,O
been,302,30,O
carried,302,35,O
out,302,43,O
with,302,47,O
treprostinil,302,52,O
(,302,65,O
oral,302,67,O
or,302,72,O
subcutaneous,302,75,O
),302,88,O
co-administered,302,90,O
with,302,106,O
acetaminophen,302,111,O
(,302,125,O
4,302,127,O
g/day,302,129,O
),302,135,O
",",302,137,O
warfarin,302,139,O
(,302,148,O
25,302,150,O
mg/day,302,153,O
),302,160,O
",",302,162,O
and,302,164,O
fluconazole,302,168,O
(,302,180,O
200,302,182,O
mg/day,302,186,O
),302,193,O
",",302,195,O
respectively,302,197,O
in,302,210,O
healthy,302,213,O
volunteers,302,221,O
.,302,232,O
Human,303,0,O
pharmacokinetic,303,6,O
studies,303,22,O
with,303,30,O
an,303,35,O
oral,303,38,O
formulation,303,43,O
of,303,55,O
treprostinil,303,58,O
(,303,71,O
treprostinil,303,73,O
diethanolamine,303,86,O
),303,101,O
indicated,303,103,O
that,303,113,O
co-administration,303,118,O
of,303,136,O
the,303,139,O
cytochrome,303,143,O
P450,303,154,O
(,303,159,O
CYP,303,161,O
),303,165,O
2C8,303,167,O
enzyme,303,171,O
inhibitor,303,178,O
gemfibrozil,303,188,O
increases,303,200,O
exposure,303,210,O
(,303,219,O
both,303,221,O
Cmax,303,226,O
and,303,231,O
AUC,303,235,O
),303,239,O
to,303,241,O
treprostinil,303,244,O
.,303,257,O
Human,303,0,O
pharmacokinetic,303,6,O
studies,303,22,O
with,303,30,O
an,303,35,O
oral,303,38,O
formulation,303,43,O
of,303,55,O
treprostinil,303,58,O
(,303,71,O
treprostinil,303,73,O
diethanolamine,303,86,O
),303,101,O
indicated,303,103,O
that,303,113,O
co-administration,303,118,O
of,303,136,O
the,303,139,O
cytochrome,303,143,O
P450,303,154,O
(,303,159,O
CYP,303,161,O
),303,165,O
2C8,303,167,O
enzyme,303,171,O
inhibitor,303,178,O
gemfibrozil,303,188,O
increases,303,200,O
exposure,303,210,O
(,303,219,O
both,303,221,O
Cmax,303,226,O
and,303,231,O
AUC,303,235,O
),303,239,O
to,303,241,O
treprostinil,303,244,O
.,303,257,O
Human,303,0,O
pharmacokinetic,303,6,O
studies,303,22,O
with,303,30,O
an,303,35,O
oral,303,38,O
formulation,303,43,O
of,303,55,O
treprostinil,303,58,O
(,303,71,O
treprostinil,303,73,O
diethanolamine,303,86,O
),303,101,O
indicated,303,103,O
that,303,113,O
co-administration,303,118,O
of,303,136,O
the,303,139,O
cytochrome,303,143,O
P450,303,154,O
(,303,159,O
CYP,303,161,O
),303,165,O
2C8,303,167,O
enzyme,303,171,O
inhibitor,303,178,O
gemfibrozil,303,188,O
increases,303,200,O
exposure,303,210,O
(,303,219,O
both,303,221,O
Cmax,303,226,O
and,303,231,O
AUC,303,235,O
),303,239,O
to,303,241,O
treprostinil,303,244,O
.,303,257,O
Human,303,0,O
pharmacokinetic,303,6,O
studies,303,22,O
with,303,30,O
an,303,35,O
oral,303,38,O
formulation,303,43,O
of,303,55,O
treprostinil,303,58,O
(,303,71,O
treprostinil,303,73,O
diethanolamine,303,86,O
),303,101,O
indicated,303,103,O
that,303,113,O
co-administration,303,118,O
of,303,136,O
the,303,139,O
cytochrome,303,143,O
P450,303,154,O
(,303,159,O
CYP,303,161,O
),303,165,O
2C8,303,167,O
enzyme,303,171,O
inhibitor,303,178,O
gemfibrozil,303,188,O
increases,303,200,O
exposure,303,210,O
(,303,219,O
both,303,221,O
Cmax,303,226,O
and,303,231,O
AUC,303,235,O
),303,239,O
to,303,241,O
treprostinil,303,244,O
.,303,257,O
In,304,0,O
a,304,3,O
human,304,5,O
pharmacokinetic,304,11,O
study,304,27,O
conducted,304,33,O
with,304,43,O
bosentan,304,48,O
(,304,57,O
250,304,59,O
mg/day,304,63,O
),304,70,O
and,304,72,O
an,304,76,O
oral,304,79,O
formulation,304,84,O
of,304,96,O
treprostinil,304,99,O
(,304,112,O
treprostinil,304,114,O
diethanolamine,304,127,O
),304,142,O
",",304,144,O
no,304,146,O
pharmacokinetic,304,149,O
interactions,304,165,O
between,304,178,O
treprostinil,304,186,O
and,304,199,O
bosentan,304,203,O
were,304,212,O
observed,304,217,O
.,304,226,O
In,305,0,O
a,305,3,O
human,305,5,O
pharmacokinetic,305,11,O
study,305,27,O
conducted,305,33,O
with,305,43,O
sildenafil,305,48,O
(,305,59,O
60,305,61,O
mg/day,305,64,O
),305,71,O
and,305,73,O
an,305,77,O
oral,305,80,O
formulation,305,85,O
of,305,97,O
treprostinil,305,100,O
(,305,113,O
treprostinil,305,115,O
diethanolamine,305,128,O
),305,143,O
",",305,145,O
no,305,147,O
pharmacokinetic,305,150,O
interactions,305,166,O
between,305,179,O
treprostinil,305,187,O
and,305,200,O
sildenafil,305,204,O
were,305,215,O
observed,305,220,O
.,305,229,O
In,306,0,O
vitro,306,3,O
studies,306,9,O
of,306,17,O
human,306,20,O
hepatic,306,26,O
microsomes,306,34,O
showed,306,45,O
that,306,52,O
treprostinil,306,57,O
does,306,70,O
not,306,75,O
inhibit,306,79,O
cytochrome,306,87,O
P450,306,98,O
(,306,103,O
CYP,306,104,O
),306,107,O
isoenzymes,306,109,O
CYP1A2,306,120,O
",",306,126,O
CYP2A6,306,128,O
",",306,134,O
CYP2C8,306,136,O
",",306,142,O
CYP2C9,306,144,O
",",306,150,O
CYP2C19,306,152,O
",",306,159,O
CYP2D6,306,161,O
",",306,167,O
CYP2E1,306,169,O
and,306,176,O
CYP3A,306,180,O
.,306,185,O
It,307,0,O
has,307,3,O
not,307,7,O
been,307,11,O
determined,307,16,O
if,307,27,O
the,307,30,O
safety,307,34,O
and,307,41,O
efficacy,307,45,O
of,307,54,O
treprostinil,307,57,O
by,307,70,O
the,307,73,O
parenteral,307,77,O
(,307,88,O
subcutaneously,307,90,O
or,307,105,O
intravenously,307,108,O
),307,122,O
route,307,124,O
are,307,130,O
altered,307,134,O
by,307,142,O
inhibitors,307,145,O
or,307,156,O
inducers,307,159,O
of,307,168,O
CYP2C8,307,171,O
see,307,178,O
Warnings,307,182,O
and,307,191,O
Precautions,307,195,O
(,307,207,O
5.4,307,209,O
),307,213,O
.,307,215,O
Pharmacodynamics,308,0,O
Blood,308,17,O
pressure,308,23,O
lowering,308,32,O
drugs,308,41,O
(,308,47,O
e.g.,308,48,O
",",308,52,O
diuretics,308,54,O
",",308,63,O
antihypertensive,308,65,O
agents,308,82,O
",",308,88,O
or,308,90,O
vasodilators,308,93,O
),308,105,O
:,308,106,O
Risk,308,108,O
of,308,113,O
increased,308,116,B-SpecificInteraction
reduction,308,116,I-SpecificInteraction
in,308,116,I-SpecificInteraction
blood,308,116,I-SpecificInteraction
pressure,308,116,I-SpecificInteraction
(,308,154,O
7.1,308,155,O
),308,158,O
Remodulin,308,160,O
inhibits,308,170,O
platelet,308,179,O
aggregation,308,188,O
.,308,199,O
Pharmacodynamics,308,0,O
Blood,308,17,O
pressure,308,23,O
lowering,308,32,O
drugs,308,41,O
(,308,47,O
e.g.,308,48,O
",",308,52,O
diuretics,308,54,O
",",308,63,O
antihypertensive,308,65,O
agents,308,82,O
",",308,88,O
or,308,90,O
vasodilators,308,93,O
),308,105,O
:,308,106,O
Risk,308,108,O
of,308,113,O
increased,308,116,B-SpecificInteraction
reduction,308,116,I-SpecificInteraction
in,308,116,I-SpecificInteraction
blood,308,116,I-SpecificInteraction
pressure,308,116,I-SpecificInteraction
(,308,154,O
7.1,308,155,O
),308,158,O
Remodulin,308,160,O
inhibits,308,170,O
platelet,308,179,O
aggregation,308,188,O
.,308,199,O
Pharmacodynamics,308,0,O
Blood,308,17,O
pressure,308,23,O
lowering,308,32,O
drugs,308,41,O
(,308,47,O
e.g.,308,48,O
",",308,52,O
diuretics,308,54,O
",",308,63,O
antihypertensive,308,65,O
agents,308,82,O
",",308,88,O
or,308,90,O
vasodilators,308,93,O
),308,105,O
:,308,106,O
Risk,308,108,O
of,308,113,O
increased,308,116,B-SpecificInteraction
reduction,308,116,I-SpecificInteraction
in,308,116,I-SpecificInteraction
blood,308,116,I-SpecificInteraction
pressure,308,116,I-SpecificInteraction
(,308,154,O
7.1,308,155,O
),308,158,O
Remodulin,308,160,O
inhibits,308,170,O
platelet,308,179,O
aggregation,308,188,O
.,308,199,O
Pharmacodynamics,308,0,O
Blood,308,17,O
pressure,308,23,O
lowering,308,32,O
drugs,308,41,O
(,308,47,O
e.g.,308,48,O
",",308,52,O
diuretics,308,54,O
",",308,63,O
antihypertensive,308,65,O
agents,308,82,O
",",308,88,O
or,308,90,O
vasodilators,308,93,O
),308,105,O
:,308,106,O
Risk,308,108,O
of,308,113,O
increased,308,116,B-SpecificInteraction
reduction,308,116,I-SpecificInteraction
in,308,116,I-SpecificInteraction
blood,308,116,I-SpecificInteraction
pressure,308,116,I-SpecificInteraction
(,308,154,O
7.1,308,155,O
),308,158,O
Remodulin,308,160,O
inhibits,308,170,O
platelet,308,179,O
aggregation,308,188,O
.,308,199,O
Pharmacokinetic/pharmacodynamic,309,0,O
interaction,309,32,O
studies,309,44,O
have,309,52,O
been,309,57,O
conducted,309,62,O
with,309,72,O
treprostinil,309,77,O
administered,309,90,O
subcutaneously,309,103,O
(,309,118,O
Remodulin,309,119,O
),309,128,O
and,309,130,O
orally,309,134,O
(,309,141,O
treprostinil,309,142,O
diethanolamine,309,155,O
),309,169,O
.,309,170,O
Pharmacokinetics,310,0,O
In,310,17,O
a,310,20,O
human,310,22,O
pharmacokinetic,310,28,O
study,310,44,O
conducted,310,50,O
with,310,60,O
bosentan,310,65,O
(,310,74,O
250,310,75,O
mg/day,310,79,O
),310,85,O
and,310,87,O
an,310,91,O
oral,310,94,O
formulation,310,99,O
of,310,111,O
treprostinil,310,114,O
(,310,127,O
treprostinil,310,128,O
diethanolamine,310,141,O
),310,155,O
",",310,156,O
no,310,158,O
pharmacokinetic,310,161,O
interactions,310,177,O
between,310,190,O
treprostinil,310,198,O
and,310,211,O
bosentan,310,215,O
were,310,224,O
observed,310,229,O
.,310,237,O
Potential,311,0,O
for,311,10,O
increased,311,14,O
risk,311,24,O
of,311,29,O
bleeding,311,32,B-SpecificInteraction
",",311,40,O
particularly,311,42,O
among,311,55,O
patients,311,61,O
on,311,70,O
anticoagulants,311,73,O
.,311,87,O
Remodulin,312,0,O
dosage,312,10,O
adjustment,312,17,O
may,312,28,O
be,312,32,O
necessary,312,35,O
if,312,45,O
inhibitors,312,48,O
or,312,59,O
inducers,312,62,O
of,312,71,O
CYP2C8,312,74,O
are,312,81,O
added,312,85,O
or,312,91,O
withdrawn,312,94,O
.,312,104,O
Remodulin,312,0,O
dosage,312,10,O
adjustment,312,17,O
may,312,28,O
be,312,32,O
necessary,312,35,O
if,312,45,O
inhibitors,312,48,O
or,312,59,O
inducers,312,62,O
of,312,71,O
CYP2C8,312,74,O
are,312,81,O
added,312,85,O
or,312,91,O
withdrawn,312,94,O
.,312,104,O
Remodulin,313,0,O
has,313,10,O
not,313,14,O
been,313,18,O
studied,313,23,O
in,313,31,O
conjunction,313,34,O
with,313,46,O
Flolan,313,51,O
or,313,58,O
Tracleer,313,61,O
(,313,70,O
bosentan,313,72,O
),313,81,O
.,313,83,O
Since,314,0,O
treprostinil,314,6,O
inhibits,314,19,O
platelet,314,28,O
aggregation,314,37,O
",",314,49,O
there,314,51,O
may,314,57,O
be,314,61,O
an,314,64,O
increased,314,67,O
risk,314,77,O
of,314,82,O
bleeding,314,85,B-SpecificInteraction
",",314,94,O
particularly,314,96,O
among,314,109,O
patients,314,115,O
receiving,314,124,O
anticoagulants,314,134,O
.,314,149,O
The,315,0,O
pharmacokinetics,315,4,O
of,315,21,O
R,315,24,O
-,315,26,O
and,315,28,O
S,315,32,O
-,315,34,O
warfarin,315,36,O
and,315,45,O
the,315,49,O
INR,315,53,O
in,315,57,O
healthy,315,60,O
subjects,315,68,O
given,315,77,O
a,315,83,O
single,315,85,O
25,315,92,O
mg,315,95,O
dose,315,98,O
of,315,103,O
warfarin,315,106,O
were,315,115,O
unaffected,315,120,O
by,315,131,O
continuous,315,134,O
subcutaneous,315,145,O
infusion,315,158,O
of,315,167,O
treprostinil,315,170,O
at,315,183,O
an,315,186,O
infusion,315,189,O
rate,315,198,O
of,315,203,O
10,315,206,O
ng/kg/min,315,209,O
.,315,219,O
The,316,0,O
pharmacokinetics,316,4,O
of,316,21,O
R-,316,24,O
and,316,27,O
S-,316,31,O
warfarin,316,34,O
and,316,43,O
the,316,47,O
INR,316,51,O
in,316,55,O
healthy,316,58,O
subjects,316,66,O
given,316,75,O
a,316,81,O
single,316,83,O
25,316,90,O
mg,316,93,O
dose,316,96,O
of,316,101,O
warfarin,316,104,O
were,316,113,O
unaffected,316,118,O
by,316,129,O
continuous,316,132,O
subcutaneous,316,143,O
infusion,316,156,O
of,316,165,O
treprostinil,316,168,O
at,316,181,O
an,316,184,O
infusion,316,187,O
rate,316,196,O
of,316,201,O
10,316,204,O
ng/kg/min,316,207,O
.,316,216,O
These,317,0,O
studies,317,6,O
did,317,14,O
not,317,18,O
show,317,22,O
a,317,27,O
clinically,317,29,O
significant,317,40,O
effect,317,52,O
on,317,59,O
the,317,62,O
pharmacokinetics,317,66,O
of,317,83,O
treprostinil,317,86,O
.,317,98,O
Thus,318,0,O
Remodulin,318,5,O
is,318,15,O
not,318,18,O
expected,318,22,O
to,318,31,O
alter,318,34,O
the,318,40,O
pharmacokinetics,318,44,O
of,318,61,O
compounds,318,64,O
metabolized,318,74,O
by,318,86,O
CYP,318,89,O
enzymes,318,93,O
.,318,100,O
Treprostinil,319,0,O
does,319,13,O
not,319,18,O
affect,319,22,O
the,319,29,O
pharmacokinetics,319,33,O
or,319,50,O
pharmacodynamics,319,53,O
of,319,70,O
warfarin,319,73,O
.,319,82,O
Administration,320,0,O
of,320,15,O
IV,320,18,O
Remodulin,320,21,O
with,320,31,O
a,320,36,O
high,320,38,O
pH,320,43,O
glycine,320,46,O
diluent,320,54,O
has,320,62,O
been,320,66,O
associated,320,71,O
with,320,82,O
a,320,87,O
lower,320,89,O
incidence,320,95,O
of,320,105,O
BSIs,320,108,O
when,320,113,O
compared,320,118,O
to,320,127,O
neutral,320,130,O
diluents,320,138,O
(,320,147,O
sterile,320,149,O
water,320,157,O
",",320,163,O
0.9,320,165,O
%,320,169,O
sodium,320,173,O
chloride,320,180,O
),320,189,O
when,320,191,O
used,320,196,O
along,320,201,O
with,320,207,O
catheter,320,212,O
care,320,221,O
guidelines,320,226,O
.,320,237,O
Co-administration,321,0,O
of,321,18,O
a,321,21,O
CYP2C8,321,23,O
enzyme,321,30,O
inducer,321,37,O
(,321,45,O
e.g.,321,47,O
",",321,52,O
rifampin,321,54,O
),321,63,O
decreases,321,65,O
exposure,321,75,O
to,321,84,O
treprostinil,321,87,O
see,321,100,O
Drug,321,104,O
Interactions,321,109,O
(,321,122,O
7.5,321,124,O
),321,128,O
and,321,130,O
Clinical,321,134,O
Pharmacology,321,143,O
(,321,156,O
12.3,321,158,O
),321,163,O
.,321,165,O
Co-administration,321,0,O
of,321,18,O
a,321,21,O
CYP2C8,321,23,O
enzyme,321,30,O
inducer,321,37,O
(,321,45,O
e.g.,321,47,O
",",321,52,O
rifampin,321,54,O
),321,63,O
decreases,321,65,O
exposure,321,75,O
to,321,84,O
treprostinil,321,87,O
see,321,100,O
Drug,321,104,O
Interactions,321,109,O
(,321,122,O
7.5,321,124,O
),321,128,O
and,321,130,O
Clinical,321,134,O
Pharmacology,321,143,O
(,321,156,O
12.3,321,158,O
),321,163,O
.,321,165,O
Co-administration,322,0,O
of,322,18,O
a,322,21,O
cytochrome,322,23,O
P450,322,34,O
(,322,39,O
CYP,322,41,O
),322,45,O
2C8,322,47,O
enzyme,322,51,O
inhibitor,322,58,O
(,322,68,O
e.g.,322,70,O
",",322,75,O
gemfibrozil,322,77,O
),322,89,O
increases,322,91,O
exposure,322,101,O
(,322,110,O
both,322,112,O
Cmax,322,117,O
and,322,122,O
AUC,322,126,O
),322,130,O
to,322,132,O
treprostinil,322,135,O
.,322,148,O
Co-administration,322,0,O
of,322,18,O
a,322,21,O
cytochrome,322,23,O
P450,322,34,O
(,322,39,O
CYP,322,41,O
),322,45,O
2C8,322,47,O
enzyme,322,51,O
inhibitor,322,58,O
(,322,68,O
e.g.,322,70,O
",",322,75,O
gemfibrozil,322,77,O
),322,89,O
increases,322,91,O
exposure,322,101,O
(,322,110,O
both,322,112,O
Cmax,322,117,O
and,322,122,O
AUC,322,126,O
),322,130,O
to,322,132,O
treprostinil,322,135,O
.,322,148,O
Co-administration,322,0,O
of,322,18,O
a,322,21,O
cytochrome,322,23,O
P450,322,34,O
(,322,39,O
CYP,322,41,O
),322,45,O
2C8,322,47,O
enzyme,322,51,O
inhibitor,322,58,O
(,322,68,O
e.g.,322,70,O
",",322,75,O
gemfibrozil,322,77,O
),322,89,O
increases,322,91,O
exposure,322,101,O
(,322,110,O
both,322,112,O
Cmax,322,117,O
and,322,122,O
AUC,322,126,O
),322,130,O
to,322,132,O
treprostinil,322,135,O
.,322,148,O
Co-administration,322,0,O
of,322,18,O
a,322,21,O
cytochrome,322,23,O
P450,322,34,O
(,322,39,O
CYP,322,41,O
),322,45,O
2C8,322,47,O
enzyme,322,51,O
inhibitor,322,58,O
(,322,68,O
e.g.,322,70,O
",",322,75,O
gemfibrozil,322,77,O
),322,89,O
increases,322,91,O
exposure,322,101,O
(,322,110,O
both,322,112,O
Cmax,322,117,O
and,322,122,O
AUC,322,126,O
),322,130,O
to,322,132,O
treprostinil,322,135,O
.,322,148,O
Co-administration,322,0,O
of,322,18,O
a,322,21,O
cytochrome,322,23,O
P450,322,34,O
(,322,39,O
CYP,322,41,O
),322,45,O
2C8,322,47,O
enzyme,322,51,O
inhibitor,322,58,O
(,322,68,O
e.g.,322,70,O
",",322,75,O
gemfibrozil,322,77,O
),322,89,O
increases,322,91,O
exposure,322,101,O
(,322,110,O
both,322,112,O
Cmax,322,117,O
and,322,122,O
AUC,322,126,O
),322,130,O
to,322,132,O
treprostinil,322,135,O
.,322,148,O
Co-administration,157,0,O
of,157,18,O
SAMSCA,157,21,O
with,157,28,O
inhibitors,157,33,O
of,157,44,O
P-gp,157,47,O
(,157,52,O
e.g.,157,54,O
",",157,59,O
cyclosporine,157,61,O
),157,74,O
may,157,76,O
necessitate,157,80,O
a,157,92,O
decrease,157,94,O
in,157,103,O
SAMSCA,157,106,O
dose,157,113,O
see,157,118,O
Warnings,157,122,O
and,157,131,O
Precautions,157,135,O
(,157,147,O
5.5,157,149,O
),157,153,O
",",157,155,O
Drug,157,157,O
Interactions,157,162,O
(,157,175,O
7.1,157,177,O
),157,181,O
.,157,183,O
Co-administration,157,0,O
of,157,18,O
SAMSCA,157,21,O
with,157,28,O
inhibitors,157,33,O
of,157,44,O
P-gp,157,47,O
(,157,52,O
e.g.,157,54,O
",",157,59,O
cyclosporine,157,61,O
),157,74,O
may,157,76,O
necessitate,157,80,O
a,157,92,O
decrease,157,94,O
in,157,103,O
SAMSCA,157,106,O
dose,157,113,O
see,157,118,O
Warnings,157,122,O
and,157,131,O
Precautions,157,135,O
(,157,147,O
5.5,157,149,O
),157,153,O
",",157,155,O
Drug,157,157,O
Interactions,157,162,O
(,157,175,O
7.1,157,177,O
),157,181,O
.,157,183,O
Co-administration,158,0,O
of,158,18,O
SAMSCA,158,21,O
with,158,28,O
potent,158,33,O
CYP,158,40,O
3A,158,44,O
inducers,158,47,O
(,158,56,O
e.g.,158,58,O
",",158,63,O
rifampin,158,65,O
),158,74,O
reduces,158,76,O
tolvaptan,158,84,O
plasma,158,94,O
concentrations,158,101,O
by,158,116,O
85,158,119,O
%,158,122,O
.,158,124,O
Co-administration,158,0,O
of,158,18,O
SAMSCA,158,21,O
with,158,28,O
potent,158,33,O
CYP,158,40,O
3A,158,44,O
inducers,158,47,O
(,158,56,O
e.g.,158,58,O
",",158,63,O
rifampin,158,65,O
),158,74,O
reduces,158,76,O
tolvaptan,158,84,O
plasma,158,94,O
concentrations,158,101,O
by,158,116,O
85,158,119,O
%,158,122,O
.,158,124,O
Ketoconazole,159,0,O
200,159,13,O
mg,159,17,O
administered,159,20,O
with,159,33,O
tolvaptan,159,38,O
increased,159,48,O
tolvaptan,159,58,O
exposure,159,68,O
by,159,77,O
5-fold,159,80,O
.,159,87,O
There,160,0,O
is,160,6,O
not,160,9,O
adequate,160,13,O
experience,160,22,O
to,160,33,O
define,160,36,O
the,160,43,O
dose,160,47,O
adjustment,160,52,O
that,160,63,O
would,160,68,O
be,160,74,O
needed,160,77,O
to,160,84,O
allow,160,87,O
safe,160,93,O
use,160,98,O
of,160,102,O
tolvaptan,160,105,O
with,160,115,O
strong,160,120,O
CYP,160,127,O
3A,160,131,O
inhibitors,160,134,O
such,160,145,O
as,160,150,O
clarithromycin,160,153,O
",",160,168,O
ketoconazole,160,170,O
",",160,183,O
itraconazole,160,185,O
",",160,198,O
ritonavir,160,200,O
",",160,210,O
indinavir,160,212,O
",",160,222,O
nelfinavir,160,224,O
",",160,235,O
saquinavir,160,237,O
",",160,248,O
nefazodone,160,250,O
",",160,261,O
and,160,263,O
telithromycin,160,267,O
.,160,281,O
A,161,0,O
substantial,161,2,O
increase,161,14,O
in,161,23,O
the,161,26,O
exposure,161,30,O
to,161,39,O
tolvaptan,161,42,O
would,161,52,O
be,161,58,O
expected,161,61,O
when,161,70,O
SAMSCA,161,75,O
is,161,82,O
co-administered,161,85,O
with,161,101,O
moderate,161,106,O
CYP,161,115,O
3A,161,119,O
inhibitors,161,122,O
.,161,132,O
Adverse,162,0,O
reactions,162,8,O
of,162,18,O
hyperkalemia,162,21,B-SpecificInteraction
were,162,34,O
approximately,162,39,O
1-2,162,53,O
%,162,57,O
higher,162,59,O
when,162,66,O
tolvaptan,162,71,O
was,162,81,O
administered,162,85,O
with,162,98,O
angiotensin,162,103,O
receptor,162,115,O
blockers,162,124,O
",",162,133,O
angiotensin,162,135,O
converting,162,147,O
enzyme,162,158,O
inhibitors,162,165,O
and,162,176,O
potassium,162,180,O
sparing,162,190,O
diuretics,162,198,O
compared,162,208,O
to,162,217,O
administration,162,220,O
of,162,235,O
these,162,238,O
medications,162,244,O
with,162,256,O
placebo,162,261,O
.,162,269,O
Adverse,162,0,O
reactions,162,8,O
of,162,18,O
hyperkalemia,162,21,B-SpecificInteraction
were,162,34,O
approximately,162,39,O
1-2,162,53,O
%,162,57,O
higher,162,59,O
when,162,66,O
tolvaptan,162,71,O
was,162,81,O
administered,162,85,O
with,162,98,O
angiotensin,162,103,O
receptor,162,115,O
blockers,162,124,O
",",162,133,O
angiotensin,162,135,O
converting,162,147,O
enzyme,162,158,O
inhibitors,162,165,O
and,162,176,O
potassium,162,180,O
sparing,162,190,O
diuretics,162,198,O
compared,162,208,O
to,162,217,O
administration,162,220,O
of,162,235,O
these,162,238,O
medications,162,244,O
with,162,256,O
placebo,162,261,O
.,162,269,O
Adverse,162,0,O
reactions,162,8,O
of,162,18,O
hyperkalemia,162,21,B-SpecificInteraction
were,162,34,O
approximately,162,39,O
1-2,162,53,O
%,162,57,O
higher,162,59,O
when,162,66,O
tolvaptan,162,71,O
was,162,81,O
administered,162,85,O
with,162,98,O
angiotensin,162,103,O
receptor,162,115,O
blockers,162,124,O
",",162,133,O
angiotensin,162,135,O
converting,162,147,O
enzyme,162,158,O
inhibitors,162,165,O
and,162,176,O
potassium,162,180,O
sparing,162,190,O
diuretics,162,198,O
compared,162,208,O
to,162,217,O
administration,162,220,O
of,162,235,O
these,162,238,O
medications,162,244,O
with,162,256,O
placebo,162,261,O
.,162,269,O
Although,163,0,O
specific,163,9,O
interaction,163,18,O
studies,163,30,O
were,163,38,O
not,163,43,O
performed,163,47,O
",",163,57,O
in,163,59,O
clinical,163,62,O
studies,163,71,O
tolvaptan,163,79,O
was,163,89,O
used,163,93,O
concomitantly,163,98,O
with,163,112,O
beta-blockers,163,117,O
",",163,131,O
angiotensin,163,133,O
receptor,163,145,O
blockers,163,154,O
",",163,163,O
angiotensin,163,165,O
converting,163,177,O
enzyme,163,188,O
inhibitors,163,195,O
and,163,206,O
potassium,163,210,O
sparing,163,220,O
diuretics,163,228,O
.,163,238,O
As,164,0,O
a,164,3,O
V2-receptor,164,5,O
antagonist,164,17,O
",",164,28,O
tolvaptan,164,30,O
may,164,40,O
interfere,164,44,O
with,164,54,O
the,164,59,O
V2-agonist,164,63,O
activity,164,74,O
of,164,83,O
desmopressin,164,86,O
(,164,99,O
dDAVP,164,101,O
),164,107,O
.,164,109,O
Co-administration,165,0,O
of,165,18,O
lovastatin,165,21,O
",",165,32,O
digoxin,165,34,O
",",165,42,O
furosemide,165,44,O
",",165,55,O
and,165,57,O
hydrochlorothiazide,165,61,O
with,165,81,O
SAMSCA,165,86,O
has,165,93,O
no,165,97,O
clinically,165,100,O
relevant,165,111,O
impact,165,120,O
on,165,127,O
the,165,130,O
exposure,165,134,O
to,165,143,O
tolvaptan,165,146,O
.,165,156,O
Co-administration,166,0,O
of,166,18,O
lovastatin,166,21,O
and,166,32,O
SAMSCA,166,36,O
increases,166,43,O
the,166,53,O
exposure,166,57,O
to,166,66,O
lovastatin,166,69,O
and,166,80,O
its,166,84,O
active,166,88,O
metabolite,166,95,O
lovastatin,166,106,O
-,166,117,O
hydroxyacid,166,119,O
by,166,131,O
factors,166,134,O
of,166,142,O
1.4,166,145,O
and,166,149,O
1.3,166,153,O
",",166,157,O
respectively,166,159,O
.,166,172,O
Co-administration,167,0,O
of,167,18,O
rifampin,167,21,O
and,167,30,O
SAMSCA,167,34,O
reduces,167,41,O
exposure,167,49,O
to,167,58,O
tolvaptan,167,61,O
by,167,71,O
85,167,74,O
%,167,77,O
.,167,79,O
Co-administration,168,0,O
of,168,18,O
SAMSCA,168,21,O
and,168,28,O
ketoconazole,168,32,O
200,168,45,O
mg,168,49,O
daily,168,52,O
results,168,58,O
in,168,66,O
a,168,69,O
5-fold,168,71,O
increase,168,78,O
in,168,87,O
exposure,168,90,O
to,168,99,O
tolvaptan,168,102,O
.,168,112,O
Co-administration,169,0,O
of,169,18,O
SAMSCA,169,21,O
and,169,28,O
ketoconazole,169,32,O
200mg,169,45,O
daily,169,51,O
results,169,57,O
in,169,65,O
a,169,68,O
5-fold,169,70,O
increase,169,77,O
in,169,86,O
exposure,169,89,O
to,169,98,O
tolvaptan,169,101,O
.,169,110,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,170,0,O
of,170,18,O
SAMSCA,170,21,O
with,170,28,O
400,170,33,O
mg,170,37,O
ketoconazole,170,40,O
daily,170,53,O
or,170,59,O
with,170,62,O
other,170,67,O
strong,170,73,O
CYP,170,80,O
3A,170,84,O
inhibitors,170,87,O
(,170,98,O
e.g.,170,100,O
",",170,105,O
clarithromycin,170,107,O
",",170,122,O
itraconazole,170,124,O
",",170,137,O
telithromycin,170,139,O
",",170,153,O
saquinavir,170,155,O
",",170,166,O
nelfinavir,170,168,O
",",170,179,O
ritonavir,170,181,O
and,170,191,O
nefazodone,170,195,O
),170,206,O
at,170,208,O
the,170,211,O
highest,170,215,O
labeled,170,223,O
dose,170,231,O
would,170,236,O
be,170,242,O
expected,170,245,O
to,170,254,O
cause,170,257,O
an,170,263,O
even,170,266,O
greater,170,271,O
increase,170,279,O
in,170,288,O
tolvaptan,170,291,O
exposure,170,301,O
.,170,310,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,171,0,O
of,171,18,O
SAMSCA,171,21,O
with,171,28,O
400mg,171,33,O
ketoconazole,171,39,O
daily,171,52,O
or,171,58,O
with,171,61,O
other,171,66,O
strong,171,72,O
CYP,171,79,O
3A,171,83,O
inhibitors,171,86,O
(,171,97,O
e.g.,171,98,O
",",171,102,O
clarithromycin,171,104,O
",",171,118,O
itraconazole,171,120,O
",",171,132,O
telithromycin,171,134,O
",",171,147,O
saquinavir,171,149,O
",",171,159,O
nelfinavir,171,161,O
",",171,171,O
ritonavir,171,173,O
and,171,183,O
nefazodone,171,187,O
),171,197,O
at,171,199,O
the,171,202,O
highest,171,206,O
labeled,171,214,O
dose,171,222,O
would,171,227,O
be,171,233,O
expected,171,236,O
to,171,245,O
cause,171,248,O
an,171,254,O
even,171,257,O
greater,171,262,O
increase,171,270,O
in,171,279,O
tolvaptan,171,282,O
exposure,171,292,O
.,171,300,O
Co-administration,172,0,O
of,172,18,O
SAMSCA,172,21,O
with,172,28,O
digoxin,172,33,O
increased,172,41,O
digoxin,172,51,O
AUC,172,59,O
by,172,63,O
20,172,66,O
%,172,69,O
and,172,71,O
Cmax,172,75,O
by,172,80,O
30,172,83,O
%,172,86,O
.,172,88,O
Co-administration,172,0,O
of,172,18,O
SAMSCA,172,21,O
with,172,28,O
digoxin,172,33,O
increased,172,41,O
digoxin,172,51,O
AUC,172,59,O
by,172,63,O
20,172,66,O
%,172,69,O
and,172,71,O
Cmax,172,75,O
by,172,80,O
30,172,83,O
%,172,86,O
.,172,88,O
Co-administration,173,0,O
of,173,18,O
SAMSCA,173,21,O
with,173,28,O
moderate,173,33,O
CYP3A,173,42,O
inhibitors,173,48,O
should,173,59,O
therefore,173,66,O
generally,173,76,O
be,173,86,O
avoided,173,89,O
see,173,97,O
Dosage,173,101,O
and,173,108,O
Administration,173,112,O
(,173,127,O
2.3,173,129,O
),173,133,O
and,173,135,O
Warnings,173,139,O
and,173,148,O
Precautions,173,152,O
(,173,164,O
5.5,173,166,O
),173,170,O
.,173,172,O
Co-administration,174,0,O
of,174,18,O
tolvaptan,174,21,O
does,174,31,O
not,174,36,O
appear,174,40,O
to,174,47,O
alter,174,50,O
the,174,56,O
pharmacokinetics,174,60,O
of,174,77,O
warfarin,174,80,O
",",174,89,O
furosemide,174,91,O
",",174,102,O
hydrochlorothiazide,174,104,O
",",174,124,O
or,174,126,O
amiodarone,174,129,O
(,174,140,O
or,174,142,O
its,174,145,O
active,174,149,O
metabolite,174,156,O
",",174,167,O
desethylamiodarone,174,169,O
),174,188,O
to,174,190,O
a,174,193,O
clinically,174,195,O
significant,174,206,O
degree,174,218,O
.,174,225,O
Concomitant,175,0,O
administration,175,12,O
of,175,27,O
tolvaptan,175,30,O
with,175,40,O
furosemide,175,45,O
or,175,56,O
hydrochlorothiazide,175,59,O
results,175,79,O
in,175,87,O
a,175,90,O
24,175,92,O
hour,175,95,O
urine,175,100,O
volume/excretion,175,106,O
rate,175,123,O
that,175,128,O
is,175,133,O
similar,175,136,O
to,175,144,O
the,175,147,O
rate,175,151,O
after,175,156,O
tolvaptan,175,162,O
administration,175,172,O
alone,175,187,O
.,175,193,O
CYP,176,0,O
3A,176,4,O
Inducers,176,7,O
Avoid,176,16,O
co-administration,176,22,O
of,176,40,O
CYP,176,43,O
3A,176,47,O
inducers,176,50,O
(,176,59,O
e.g.,176,60,O
",",176,64,O
rifampin,176,66,O
",",176,74,O
rifabutin,176,76,O
",",176,85,O
rifapentin,176,87,O
",",176,97,O
barbiturates,176,99,O
",",176,111,O
phenytoin,176,113,O
",",176,122,O
carbamazepine,176,124,O
",",176,137,O
St.,176,139,O
John,176,143,O
's,176,147,O
Wort,176,150,O
),176,154,O
with,176,156,O
SAMSCA,176,161,O
",",176,167,O
as,176,169,O
this,176,172,O
can,176,177,O
lead,176,181,O
to,176,186,O
a,176,189,O
reduction,176,191,O
in,176,201,O
the,176,204,O
plasma,176,208,O
concentration,176,215,O
of,176,229,O
tolvaptan,176,232,O
and,176,242,O
decreased,176,246,O
effectiveness,176,256,O
of,176,270,O
SAMSCA,176,273,O
treatment,176,280,O
.,176,289,O
CYP,176,0,O
3A,176,4,O
Inducers,176,7,O
Avoid,176,16,O
co-administration,176,22,O
of,176,40,O
CYP,176,43,O
3A,176,47,O
inducers,176,50,O
(,176,59,O
e.g.,176,60,O
",",176,64,O
rifampin,176,66,O
",",176,74,O
rifabutin,176,76,O
",",176,85,O
rifapentin,176,87,O
",",176,97,O
barbiturates,176,99,O
",",176,111,O
phenytoin,176,113,O
",",176,122,O
carbamazepine,176,124,O
",",176,137,O
St.,176,139,O
John,176,143,O
's,176,147,O
Wort,176,150,O
),176,154,O
with,176,156,O
SAMSCA,176,161,O
",",176,167,O
as,176,169,O
this,176,172,O
can,176,177,O
lead,176,181,O
to,176,186,O
a,176,189,O
reduction,176,191,O
in,176,201,O
the,176,204,O
plasma,176,208,O
concentration,176,215,O
of,176,229,O
tolvaptan,176,232,O
and,176,242,O
decreased,176,246,O
effectiveness,176,256,O
of,176,270,O
SAMSCA,176,273,O
treatment,176,280,O
.,176,289,O
CYP,176,0,O
3A,176,4,O
Inducers,176,7,O
Avoid,176,16,O
co-administration,176,22,O
of,176,40,O
CYP,176,43,O
3A,176,47,O
inducers,176,50,O
(,176,59,O
e.g.,176,60,O
",",176,64,O
rifampin,176,66,O
",",176,74,O
rifabutin,176,76,O
",",176,85,O
rifapentin,176,87,O
",",176,97,O
barbiturates,176,99,O
",",176,111,O
phenytoin,176,113,O
",",176,122,O
carbamazepine,176,124,O
",",176,137,O
St.,176,139,O
John,176,143,O
's,176,147,O
Wort,176,150,O
),176,154,O
with,176,156,O
SAMSCA,176,161,O
",",176,167,O
as,176,169,O
this,176,172,O
can,176,177,O
lead,176,181,O
to,176,186,O
a,176,189,O
reduction,176,191,O
in,176,201,O
the,176,204,O
plasma,176,208,O
concentration,176,215,O
of,176,229,O
tolvaptan,176,232,O
and,176,242,O
decreased,176,246,O
effectiveness,176,256,O
of,176,270,O
SAMSCA,176,273,O
treatment,176,280,O
.,176,289,O
CYP,176,0,O
3A,176,4,O
Inducers,176,7,O
Avoid,176,16,O
co-administration,176,22,O
of,176,40,O
CYP,176,43,O
3A,176,47,O
inducers,176,50,O
(,176,59,O
e.g.,176,60,O
",",176,64,O
rifampin,176,66,O
",",176,74,O
rifabutin,176,76,O
",",176,85,O
rifapentin,176,87,O
",",176,97,O
barbiturates,176,99,O
",",176,111,O
phenytoin,176,113,O
",",176,122,O
carbamazepine,176,124,O
",",176,137,O
St.,176,139,O
John,176,143,O
's,176,147,O
Wort,176,150,O
),176,154,O
with,176,156,O
SAMSCA,176,161,O
",",176,167,O
as,176,169,O
this,176,172,O
can,176,177,O
lead,176,181,O
to,176,186,O
a,176,189,O
reduction,176,191,O
in,176,201,O
the,176,204,O
plasma,176,208,O
concentration,176,215,O
of,176,229,O
tolvaptan,176,232,O
and,176,242,O
decreased,176,246,O
effectiveness,176,256,O
of,176,270,O
SAMSCA,176,273,O
treatment,176,280,O
.,176,289,O
CYP,176,0,O
3A,176,4,O
Inducers,176,7,O
Avoid,176,16,O
co-administration,176,22,O
of,176,40,O
CYP,176,43,O
3A,176,47,O
inducers,176,50,O
(,176,59,O
e.g.,176,60,O
",",176,64,O
rifampin,176,66,O
",",176,74,O
rifabutin,176,76,O
",",176,85,O
rifapentin,176,87,O
",",176,97,O
barbiturates,176,99,O
",",176,111,O
phenytoin,176,113,O
",",176,122,O
carbamazepine,176,124,O
",",176,137,O
St.,176,139,O
John,176,143,O
's,176,147,O
Wort,176,150,O
),176,154,O
with,176,156,O
SAMSCA,176,161,O
",",176,167,O
as,176,169,O
this,176,172,O
can,176,177,O
lead,176,181,O
to,176,186,O
a,176,189,O
reduction,176,191,O
in,176,201,O
the,176,204,O
plasma,176,208,O
concentration,176,215,O
of,176,229,O
tolvaptan,176,232,O
and,176,242,O
decreased,176,246,O
effectiveness,176,256,O
of,176,270,O
SAMSCA,176,273,O
treatment,176,280,O
.,176,289,O
CYP,176,0,O
3A,176,4,O
Inducers,176,7,O
Avoid,176,16,O
co-administration,176,22,O
of,176,40,O
CYP,176,43,O
3A,176,47,O
inducers,176,50,O
(,176,59,O
e.g.,176,60,O
",",176,64,O
rifampin,176,66,O
",",176,74,O
rifabutin,176,76,O
",",176,85,O
rifapentin,176,87,O
",",176,97,O
barbiturates,176,99,O
",",176,111,O
phenytoin,176,113,O
",",176,122,O
carbamazepine,176,124,O
",",176,137,O
St.,176,139,O
John,176,143,O
's,176,147,O
Wort,176,150,O
),176,154,O
with,176,156,O
SAMSCA,176,161,O
",",176,167,O
as,176,169,O
this,176,172,O
can,176,177,O
lead,176,181,O
to,176,186,O
a,176,189,O
reduction,176,191,O
in,176,201,O
the,176,204,O
plasma,176,208,O
concentration,176,215,O
of,176,229,O
tolvaptan,176,232,O
and,176,242,O
decreased,176,246,O
effectiveness,176,256,O
of,176,270,O
SAMSCA,176,273,O
treatment,176,280,O
.,176,289,O
CYP,176,0,O
3A,176,4,O
Inducers,176,7,O
Avoid,176,16,O
co-administration,176,22,O
of,176,40,O
CYP,176,43,O
3A,176,47,O
inducers,176,50,O
(,176,59,O
e.g.,176,60,O
",",176,64,O
rifampin,176,66,O
",",176,74,O
rifabutin,176,76,O
",",176,85,O
rifapentin,176,87,O
",",176,97,O
barbiturates,176,99,O
",",176,111,O
phenytoin,176,113,O
",",176,122,O
carbamazepine,176,124,O
",",176,137,O
St.,176,139,O
John,176,143,O
's,176,147,O
Wort,176,150,O
),176,154,O
with,176,156,O
SAMSCA,176,161,O
",",176,167,O
as,176,169,O
this,176,172,O
can,176,177,O
lead,176,181,O
to,176,186,O
a,176,189,O
reduction,176,191,O
in,176,201,O
the,176,204,O
plasma,176,208,O
concentration,176,215,O
of,176,229,O
tolvaptan,176,232,O
and,176,242,O
decreased,176,246,O
effectiveness,176,256,O
of,176,270,O
SAMSCA,176,273,O
treatment,176,280,O
.,176,289,O
CYP,176,0,O
3A,176,4,O
Inducers,176,7,O
Avoid,176,16,O
co-administration,176,22,O
of,176,40,O
CYP,176,43,O
3A,176,47,O
inducers,176,50,O
(,176,59,O
e.g.,176,60,O
",",176,64,O
rifampin,176,66,O
",",176,74,O
rifabutin,176,76,O
",",176,85,O
rifapentin,176,87,O
",",176,97,O
barbiturates,176,99,O
",",176,111,O
phenytoin,176,113,O
",",176,122,O
carbamazepine,176,124,O
",",176,137,O
St.,176,139,O
John,176,143,O
's,176,147,O
Wort,176,150,O
),176,154,O
with,176,156,O
SAMSCA,176,161,O
",",176,167,O
as,176,169,O
this,176,172,O
can,176,177,O
lead,176,181,O
to,176,186,O
a,176,189,O
reduction,176,191,O
in,176,201,O
the,176,204,O
plasma,176,208,O
concentration,176,215,O
of,176,229,O
tolvaptan,176,232,O
and,176,242,O
decreased,176,246,O
effectiveness,176,256,O
of,176,270,O
SAMSCA,176,273,O
treatment,176,280,O
.,176,289,O
CYP,177,0,O
3A,177,4,O
inhibitors,177,7,O
can,177,18,O
lead,177,22,O
to,177,27,O
a,177,30,O
marked,177,32,O
increase,177,39,O
in,177,48,O
tolvaptan,177,51,O
concentrations,177,61,O
[,177,76,O
see,177,77,O
Dosage,177,81,O
and,177,88,O
Administration,177,92,O
(,177,107,O
2.3,177,108,O
),177,111,O
",",177,112,O
Drug,177,114,O
Interactions,177,119,O
(,177,132,O
7.1,177,133,O
),177,136,O
],177,137,O
.,177,138,O
Do,178,0,O
not,178,3,O
use,178,7,O
SAMSCA,178,11,O
with,178,18,O
strong,178,23,O
inhibitors,178,30,O
of,178,41,O
CYP,178,44,O
3A,178,48,O
[,178,51,O
see,178,52,O
Contraindications,178,56,O
(,178,74,O
4.4,178,75,O
),178,78,O
],178,79,O
and,178,81,O
avoid,178,85,O
concomitant,178,91,O
use,178,103,O
with,178,107,O
moderate,178,112,O
CYP,178,121,O
3A,178,125,O
inhibitors,178,128,O
.,178,138,O
Do,178,0,O
not,178,3,O
use,178,7,O
SAMSCA,178,11,O
with,178,18,O
strong,178,23,O
inhibitors,178,30,O
of,178,41,O
CYP,178,44,O
3A,178,48,O
[,178,51,O
see,178,52,O
Contraindications,178,56,O
(,178,74,O
4.4,178,75,O
),178,78,O
],178,79,O
and,178,81,O
avoid,178,85,O
concomitant,178,91,O
use,178,103,O
with,178,107,O
moderate,178,112,O
CYP,178,121,O
3A,178,125,O
inhibitors,178,128,O
.,178,138,O
Grapefruit,179,0,O
Juice,179,11,O
Co-administration,179,17,O
of,179,35,O
grapefruit,179,38,O
juice,179,49,O
and,179,55,O
SAMSCA,179,59,O
results,179,66,O
in,179,74,O
a,179,77,O
1.8-fold,179,79,O
increase,179,88,O
in,179,97,O
exposure,179,100,O
to,179,109,O
tolvaptan,179,112,O
[,179,122,O
see,179,123,O
Dose,179,127,O
and,179,132,O
Administration,179,136,O
(,179,151,O
2.3,179,152,O
),179,155,O
and,179,157,O
Warnings,179,161,O
and,179,170,O
Precautions,179,174,O
(,179,186,O
5.5,179,187,O
),179,190,O
],179,191,O
.,179,192,O
If,180,0,O
co-administered,180,3,O
with,180,19,O
CYP,180,24,O
3A,180,28,O
inducers,180,31,O
",",180,39,O
the,180,41,O
dose,180,45,O
of,180,50,O
SAMSCA,180,53,O
may,180,60,O
need,180,64,O
to,180,69,O
be,180,72,O
increased,180,75,O
[,180,85,O
see,180,86,O
Dosage,180,90,O
and,180,97,O
Administration,180,101,O
(,180,116,O
2.3,180,117,O
),180,120,O
",",180,121,O
Drug,180,123,O
Interactions,180,128,O
(,180,141,O
7.1,180,142,O
),180,145,O
],180,146,O
.,180,147,O
In,181,0,O
a,181,3,O
male,181,5,O
subject,181,10,O
with,181,18,O
mild,181,23,O
Von,181,28,O
Willebrand,181,32,O
(,181,43,O
vW,181,45,O
),181,48,O
disease,181,50,O
",",181,58,O
intravenous,181,60,O
infusion,181,72,O
of,181,81,O
dDAVP,181,84,O
2,181,90,O
hours,181,92,O
after,181,98,O
administration,181,104,O
of,181,119,O
oral,181,122,O
tolvaptan,181,127,O
did,181,137,O
not,181,141,O
produce,181,145,O
the,181,153,O
expected,181,157,O
increases,181,166,O
in,181,176,O
vW,181,179,O
Factor,181,182,O
Antigen,181,189,O
or,181,197,O
Factor,181,200,O
VIII,181,207,O
activity,181,212,O
.,181,221,O
In,182,0,O
a,182,3,O
male,182,5,O
subject,182,10,O
with,182,18,O
mild,182,23,O
Von,182,28,O
Willebrand,182,32,O
(,182,43,O
vW,182,44,O
),182,46,O
disease,182,48,O
",",182,55,O
intravenous,182,57,O
infusion,182,69,O
of,182,78,O
dDAVP,182,81,O
2,182,87,O
hours,182,89,O
after,182,95,O
administration,182,101,O
of,182,116,O
oral,182,119,O
tolvaptan,182,124,O
did,182,134,O
not,182,138,O
produce,182,142,O
the,182,150,O
expected,182,154,O
increases,182,163,O
in,182,173,O
vW,182,176,O
Factor,182,179,O
Antigen,182,186,O
or,182,194,O
Factor,182,197,O
VIII,182,204,O
activity,182,209,O
.,182,217,O
It,183,0,O
is,183,3,O
not,183,6,O
recommended,183,10,O
to,183,22,O
administer,183,25,O
SAMSCA,183,36,O
with,183,43,O
a,183,48,O
V2-agonist,183,50,O
.,183,60,O
Ketoconazole,184,0,O
and,184,13,O
Other,184,17,O
Strong,184,23,O
CYP,184,30,O
3A,184,34,O
Inhibitors,184,37,O
SAMSCA,184,48,O
is,184,55,O
metabolized,184,58,O
primarily,184,70,O
by,184,80,O
CYP,184,83,O
3A,184,87,O
.,184,89,O
Ketoconazole,185,0,O
is,185,13,O
a,185,16,O
strong,185,18,O
inhibitor,185,25,O
of,185,35,O
CYP,185,38,O
3A,185,42,O
and,185,45,O
also,185,49,O
an,185,54,O
inhibitor,185,57,O
of,185,67,O
P-gp,185,70,O
.,185,74,O
Lovastatin,186,0,O
SAMSCA,186,11,O
is,186,18,O
a,186,21,O
weak,186,23,O
inhibitor,186,28,O
of,186,38,O
CYP,186,41,O
3A,186,45,O
.,186,47,O
Lovastatin,187,0,O
",",187,10,O
Digoxin,187,12,O
",",187,19,O
Furosemide,187,21,O
",",187,31,O
and,187,33,O
Hydrochlorothiazide,187,37,O
Co-administration,187,57,O
of,187,75,O
lovastatin,187,78,O
",",187,88,O
digoxin,187,90,O
",",187,97,O
furosemide,187,99,O
",",187,109,O
and,187,111,O
hydrochlorothiazide,187,115,O
with,187,135,O
SAMSCA,187,140,O
has,187,147,O
no,187,151,O
clinically,187,154,O
relevant,187,165,O
impact,187,174,O
on,187,181,O
the,187,184,O
exposure,187,188,O
to,187,197,O
tolvaptan,187,200,O
.,187,209,O
Moderate,188,0,O
CYP,188,9,O
3A,188,13,O
Inhibitors,188,16,O
The,188,27,O
impact,188,31,O
of,188,38,O
moderate,188,41,O
CYP,188,50,O
3A,188,54,O
inhibitors,188,57,O
(,188,68,O
e.g.,188,69,O
",",188,73,O
erythromycin,188,75,O
",",188,87,O
fluconazole,188,89,O
",",188,100,O
aprepitant,188,102,O
",",188,112,O
diltiazem,188,114,O
and,188,124,O
verapamil,188,128,O
),188,137,O
on,188,139,O
the,188,142,O
exposure,188,146,O
to,188,155,O
co-administered,188,158,O
tolvaptan,188,174,O
has,188,184,O
not,188,188,O
been,188,192,O
assessed,188,197,O
.,188,205,O
Other,189,0,O
Drugs,189,6,O
Affecting,189,12,O
Exposure,189,22,O
to,189,31,O
Tolvaptan,189,34,O
CYP,189,44,O
3A,189,48,O
Inhibitors,189,51,O
Tolvaptan,189,62,O
is,189,72,O
a,189,75,O
substrate,189,77,O
of,189,87,O
CYP,189,90,O
3A,189,94,O
.,189,96,O
P-gp,190,0,O
Inhibitors,190,5,O
Reduction,190,16,O
in,190,26,O
the,190,29,O
dose,190,33,O
of,190,38,O
SAMSCA,190,41,O
may,190,48,O
be,190,52,O
required,190,55,O
in,190,64,O
patients,190,67,O
concomitantly,190,76,O
treated,190,90,O
with,190,98,O
P-gp,190,103,O
inhibitors,190,108,O
",",190,118,O
such,190,120,O
as,190,125,O
e.g.,190,128,O
",",190,132,O
cyclosporine,190,134,O
",",190,146,O
based,190,148,O
on,190,154,O
clinical,190,157,O
response,190,166,O
[,190,175,O
see,190,176,O
Dose,190,180,O
and,190,185,O
Administration,190,189,O
(,190,204,O
2.3,190,205,O
),190,208,O
and,190,210,O
Warnings,190,214,O
and,190,223,O
Precautions,190,227,O
(,190,239,O
5.5,190,240,O
),190,243,O
],190,244,O
.,190,245,O
P-gp,190,0,O
Inhibitors,190,5,O
Reduction,190,16,O
in,190,26,O
the,190,29,O
dose,190,33,O
of,190,38,O
SAMSCA,190,41,O
may,190,48,O
be,190,52,O
required,190,55,O
in,190,64,O
patients,190,67,O
concomitantly,190,76,O
treated,190,90,O
with,190,98,O
P-gp,190,103,O
inhibitors,190,108,O
",",190,118,O
such,190,120,O
as,190,125,O
e.g.,190,128,O
",",190,132,O
cyclosporine,190,134,O
",",190,146,O
based,190,148,O
on,190,154,O
clinical,190,157,O
response,190,166,O
[,190,175,O
see,190,176,O
Dose,190,180,O
and,190,185,O
Administration,190,189,O
(,190,204,O
2.3,190,205,O
),190,208,O
and,190,210,O
Warnings,190,214,O
and,190,223,O
Precautions,190,227,O
(,190,239,O
5.5,190,240,O
),190,243,O
],190,244,O
.,190,245,O
P-gp,191,0,O
Inhibitors,191,5,O
The,191,16,O
dose,191,20,O
of,191,25,O
SAMSCA,191,28,O
may,191,35,O
have,191,39,O
to,191,44,O
be,191,47,O
reduced,191,50,O
when,191,58,O
SAMSCA,191,63,O
is,191,70,O
co-administered,191,73,O
with,191,89,O
P-gp,191,94,O
inhibitors,191,99,O
",",191,109,O
e.g.,191,111,O
",",191,115,O
cyclosporine,191,117,O
[,191,130,O
see,191,131,O
Dosage,191,135,O
and,191,142,O
Administration,191,146,O
(,191,161,O
2.3,191,162,O
),191,165,O
",",191,166,O
Drug,191,168,O
Interactions,191,173,O
(,191,186,O
7.1,191,187,O
),191,190,O
],191,191,O
.,191,192,O
P-gp,191,0,O
Inhibitors,191,5,O
The,191,16,O
dose,191,20,O
of,191,25,O
SAMSCA,191,28,O
may,191,35,O
have,191,39,O
to,191,44,O
be,191,47,O
reduced,191,50,O
when,191,58,O
SAMSCA,191,63,O
is,191,70,O
co-administered,191,73,O
with,191,89,O
P-gp,191,94,O
inhibitors,191,99,O
",",191,109,O
e.g.,191,111,O
",",191,115,O
cyclosporine,191,117,O
[,191,130,O
see,191,131,O
Dosage,191,135,O
and,191,142,O
Administration,191,146,O
(,191,161,O
2.3,191,162,O
),191,165,O
",",191,166,O
Drug,191,168,O
Interactions,191,173,O
(,191,186,O
7.1,191,187,O
),191,190,O
],191,191,O
.,191,192,O
Pharmacodynamic,192,0,O
Interactions,192,16,O
Tolvaptan,192,29,O
produces,192,39,O
a,192,48,O
greater,192,50,O
24hour,192,58,O
urine,192,65,O
volume/excretion,192,71,O
rate,192,88,O
than,192,93,O
does,192,98,O
furosemide,192,103,O
or,192,114,O
hydrochlorothiazide,192,117,O
.,192,136,O
Reduction,193,0,O
in,193,10,O
the,193,13,O
dose,193,17,O
of,193,22,O
SAMSCA,193,25,O
may,193,32,O
be,193,36,O
required,193,39,O
in,193,48,O
patients,193,51,O
concomitantly,193,60,O
treated,193,74,O
with,193,82,O
P-gp,193,87,O
inhibitors,193,92,O
",",193,103,O
such,193,105,O
as,193,110,O
e.g.,193,113,O
",",193,118,O
cyclosporine,193,120,O
",",193,133,O
based,193,135,O
on,193,141,O
clinical,193,144,O
response,193,153,O
see,193,162,O
Dose,193,166,O
and,193,171,O
Administration,193,175,O
(,193,190,O
2.3,193,192,O
),193,196,O
and,193,198,O
Warnings,193,202,O
and,193,211,O
Precautions,193,215,O
(,193,227,O
5.5,193,229,O
),193,233,O
.,193,235,O
Reduction,193,0,O
in,193,10,O
the,193,13,O
dose,193,17,O
of,193,22,O
SAMSCA,193,25,O
may,193,32,O
be,193,36,O
required,193,39,O
in,193,48,O
patients,193,51,O
concomitantly,193,60,O
treated,193,74,O
with,193,82,O
P-gp,193,87,O
inhibitors,193,92,O
",",193,103,O
such,193,105,O
as,193,110,O
e.g.,193,113,O
",",193,118,O
cyclosporine,193,120,O
",",193,133,O
based,193,135,O
on,193,141,O
clinical,193,144,O
response,193,153,O
see,193,162,O
Dose,193,166,O
and,193,171,O
Administration,193,175,O
(,193,190,O
2.3,193,192,O
),193,196,O
and,193,198,O
Warnings,193,202,O
and,193,211,O
Precautions,193,215,O
(,193,227,O
5.5,193,229,O
),193,233,O
.,193,235,O
Rifampin,194,0,O
and,194,9,O
Other,194,13,O
CYP,194,19,O
3A,194,23,O
Inducers,194,26,O
Rifampin,194,35,O
is,194,44,O
an,194,47,O
inducer,194,50,O
of,194,58,O
CYP,194,61,O
3A,194,65,O
and,194,68,O
P-gp,194,72,O
.,194,76,O
Serum,195,0,O
potassium,195,6,O
levels,195,16,O
should,195,23,O
be,195,30,O
monitored,195,33,O
during,195,43,O
concomitant,195,50,O
drug,195,62,O
therapy,195,67,O
.,195,74,O
The,196,0,O
dose,196,4,O
of,196,9,O
SAMSCA,196,12,O
may,196,19,O
have,196,23,O
to,196,28,O
be,196,31,O
increased,196,34,O
[,196,44,O
Dosage,196,45,O
and,196,52,O
Administration,196,56,O
(,196,71,O
2.3,196,72,O
),196,75,O
and,196,77,O
Warnings,196,81,O
and,196,90,O
Precautions,196,94,O
(,196,106,O
5.5,196,107,O
),196,110,O
],196,111,O
.,196,112,O
The,197,0,O
impact,197,4,O
of,197,11,O
moderate,197,14,O
CYP,197,23,O
3A,197,27,O
inhibitors,197,30,O
(,197,41,O
e.g.,197,43,O
",",197,48,O
erythromycin,197,50,O
",",197,63,O
fluconazole,197,65,O
",",197,77,O
aprepitant,197,79,O
",",197,90,O
diltiazem,197,92,O
and,197,102,O
verapamil,197,106,O
),197,116,O
on,197,118,O
the,197,121,O
exposure,197,125,O
to,197,134,O
co-administered,197,137,O
tolvaptan,197,153,O
has,197,163,O
not,197,167,O
been,197,171,O
assessed,197,176,O
.,197,185,O
Therefore,198,0,O
",",198,10,O
the,198,12,O
expected,198,16,O
clinical,198,25,O
effects,198,34,O
of,198,42,O
SAMSCA,198,45,O
in,198,52,O
the,198,55,O
presence,198,59,O
of,198,68,O
rifampin,198,71,O
and,198,80,O
other,198,84,O
inducers,198,90,O
(,198,99,O
e.g.,198,101,O
",",198,106,O
rifabutin,198,108,O
",",198,118,O
rifapentin,198,120,O
",",198,131,O
barbiturates,198,133,O
",",198,146,O
phenytoin,198,148,O
",",198,158,O
carbamazepine,198,160,O
and,198,174,O
St.,198,178,O
John,198,184,O
's,198,189,O
Wort,198,194,O
),198,199,O
may,198,201,O
not,198,205,O
be,198,209,O
observed,198,212,O
at,198,221,O
the,198,224,O
usual,198,228,O
dose,198,234,O
levels,198,239,O
of,198,246,O
SAMSCA,198,249,O
.,198,256,O
Therefore,198,0,O
",",198,10,O
the,198,12,O
expected,198,16,O
clinical,198,25,O
effects,198,34,O
of,198,42,O
SAMSCA,198,45,O
in,198,52,O
the,198,55,O
presence,198,59,O
of,198,68,O
rifampin,198,71,O
and,198,80,O
other,198,84,O
inducers,198,90,O
(,198,99,O
e.g.,198,101,O
",",198,106,O
rifabutin,198,108,O
",",198,118,O
rifapentin,198,120,O
",",198,131,O
barbiturates,198,133,O
",",198,146,O
phenytoin,198,148,O
",",198,158,O
carbamazepine,198,160,O
and,198,174,O
St.,198,178,O
John,198,184,O
's,198,189,O
Wort,198,194,O
),198,199,O
may,198,201,O
not,198,205,O
be,198,209,O
observed,198,212,O
at,198,221,O
the,198,224,O
usual,198,228,O
dose,198,234,O
levels,198,239,O
of,198,246,O
SAMSCA,198,249,O
.,198,256,O
Therefore,198,0,O
",",198,10,O
the,198,12,O
expected,198,16,O
clinical,198,25,O
effects,198,34,O
of,198,42,O
SAMSCA,198,45,O
in,198,52,O
the,198,55,O
presence,198,59,O
of,198,68,O
rifampin,198,71,O
and,198,80,O
other,198,84,O
inducers,198,90,O
(,198,99,O
e.g.,198,101,O
",",198,106,O
rifabutin,198,108,O
",",198,118,O
rifapentin,198,120,O
",",198,131,O
barbiturates,198,133,O
",",198,146,O
phenytoin,198,148,O
",",198,158,O
carbamazepine,198,160,O
and,198,174,O
St.,198,178,O
John,198,184,O
's,198,189,O
Wort,198,194,O
),198,199,O
may,198,201,O
not,198,205,O
be,198,209,O
observed,198,212,O
at,198,221,O
the,198,224,O
usual,198,228,O
dose,198,234,O
levels,198,239,O
of,198,246,O
SAMSCA,198,249,O
.,198,256,O
Therefore,198,0,O
",",198,10,O
the,198,12,O
expected,198,16,O
clinical,198,25,O
effects,198,34,O
of,198,42,O
SAMSCA,198,45,O
in,198,52,O
the,198,55,O
presence,198,59,O
of,198,68,O
rifampin,198,71,O
and,198,80,O
other,198,84,O
inducers,198,90,O
(,198,99,O
e.g.,198,101,O
",",198,106,O
rifabutin,198,108,O
",",198,118,O
rifapentin,198,120,O
",",198,131,O
barbiturates,198,133,O
",",198,146,O
phenytoin,198,148,O
",",198,158,O
carbamazepine,198,160,O
and,198,174,O
St.,198,178,O
John,198,184,O
's,198,189,O
Wort,198,194,O
),198,199,O
may,198,201,O
not,198,205,O
be,198,209,O
observed,198,212,O
at,198,221,O
the,198,224,O
usual,198,228,O
dose,198,234,O
levels,198,239,O
of,198,246,O
SAMSCA,198,249,O
.,198,256,O
Therefore,198,0,O
",",198,10,O
the,198,12,O
expected,198,16,O
clinical,198,25,O
effects,198,34,O
of,198,42,O
SAMSCA,198,45,O
in,198,52,O
the,198,55,O
presence,198,59,O
of,198,68,O
rifampin,198,71,O
and,198,80,O
other,198,84,O
inducers,198,90,O
(,198,99,O
e.g.,198,101,O
",",198,106,O
rifabutin,198,108,O
",",198,118,O
rifapentin,198,120,O
",",198,131,O
barbiturates,198,133,O
",",198,146,O
phenytoin,198,148,O
",",198,158,O
carbamazepine,198,160,O
and,198,174,O
St.,198,178,O
John,198,184,O
's,198,189,O
Wort,198,194,O
),198,199,O
may,198,201,O
not,198,205,O
be,198,209,O
observed,198,212,O
at,198,221,O
the,198,224,O
usual,198,228,O
dose,198,234,O
levels,198,239,O
of,198,246,O
SAMSCA,198,249,O
.,198,256,O
Therefore,198,0,O
",",198,10,O
the,198,12,O
expected,198,16,O
clinical,198,25,O
effects,198,34,O
of,198,42,O
SAMSCA,198,45,O
in,198,52,O
the,198,55,O
presence,198,59,O
of,198,68,O
rifampin,198,71,O
and,198,80,O
other,198,84,O
inducers,198,90,O
(,198,99,O
e.g.,198,101,O
",",198,106,O
rifabutin,198,108,O
",",198,118,O
rifapentin,198,120,O
",",198,131,O
barbiturates,198,133,O
",",198,146,O
phenytoin,198,148,O
",",198,158,O
carbamazepine,198,160,O
and,198,174,O
St.,198,178,O
John,198,184,O
's,198,189,O
Wort,198,194,O
),198,199,O
may,198,201,O
not,198,205,O
be,198,209,O
observed,198,212,O
at,198,221,O
the,198,224,O
usual,198,228,O
dose,198,234,O
levels,198,239,O
of,198,246,O
SAMSCA,198,249,O
.,198,256,O
Therefore,198,0,O
",",198,10,O
the,198,12,O
expected,198,16,O
clinical,198,25,O
effects,198,34,O
of,198,42,O
SAMSCA,198,45,O
in,198,52,O
the,198,55,O
presence,198,59,O
of,198,68,O
rifampin,198,71,O
and,198,80,O
other,198,84,O
inducers,198,90,O
(,198,99,O
e.g.,198,101,O
",",198,106,O
rifabutin,198,108,O
",",198,118,O
rifapentin,198,120,O
",",198,131,O
barbiturates,198,133,O
",",198,146,O
phenytoin,198,148,O
",",198,158,O
carbamazepine,198,160,O
and,198,174,O
St.,198,178,O
John,198,184,O
's,198,189,O
Wort,198,194,O
),198,199,O
may,198,201,O
not,198,205,O
be,198,209,O
observed,198,212,O
at,198,221,O
the,198,224,O
usual,198,228,O
dose,198,234,O
levels,198,239,O
of,198,246,O
SAMSCA,198,249,O
.,198,256,O
Therefore,198,0,O
",",198,10,O
the,198,12,O
expected,198,16,O
clinical,198,25,O
effects,198,34,O
of,198,42,O
SAMSCA,198,45,O
in,198,52,O
the,198,55,O
presence,198,59,O
of,198,68,O
rifampin,198,71,O
and,198,80,O
other,198,84,O
inducers,198,90,O
(,198,99,O
e.g.,198,101,O
",",198,106,O
rifabutin,198,108,O
",",198,118,O
rifapentin,198,120,O
",",198,131,O
barbiturates,198,133,O
",",198,146,O
phenytoin,198,148,O
",",198,158,O
carbamazepine,198,160,O
and,198,174,O
St.,198,178,O
John,198,184,O
's,198,189,O
Wort,198,194,O
),198,199,O
may,198,201,O
not,198,205,O
be,198,209,O
observed,198,212,O
at,198,221,O
the,198,224,O
usual,198,228,O
dose,198,234,O
levels,198,239,O
of,198,246,O
SAMSCA,198,249,O
.,198,256,O
This,199,0,O
is,199,5,O
not,199,8,O
a,199,12,O
clinically,199,14,O
relevant,199,25,O
change,199,34,O
.,199,40,O
Thus,200,0,O
",",200,4,O
SAMSCA,200,6,O
and,200,13,O
strong,200,17,O
CYP,200,24,O
3A,200,28,O
inhibitors,200,31,O
should,200,42,O
not,200,49,O
be,200,53,O
co-administered,200,56,O
[,200,72,O
see,200,73,O
Dosage,200,77,O
and,200,84,O
Administration,200,88,O
(,200,103,O
2.3,200,104,O
),200,107,O
and,200,109,O
Contraindications,200,113,O
(,200,131,O
4.4,200,132,O
),200,135,O
],200,136,O
.,200,137,O
Tolvaptan,201,0,O
produces,201,10,O
a,201,19,O
greater,201,21,O
24,201,29,O
hour,201,32,O
urine,201,37,O
volume/excretion,201,43,O
rate,201,60,O
than,201,65,O
does,201,70,O
furosemide,201,75,O
or,201,86,O
hydrochlorothiazide,201,89,O
.,201,109,O
Warfarin,202,0,O
",",202,8,O
Amiodarone,202,10,O
",",202,20,O
Furosemide,202,22,O
",",202,32,O
and,202,34,O
Hydrochlorothiazide,202,38,O
Co-administration,202,58,O
of,202,76,O
tolvaptan,202,79,O
does,202,89,O
not,202,94,O
appear,202,98,O
to,202,105,O
alter,202,108,O
the,202,114,O
pharmacokinetics,202,118,O
of,202,135,O
warfarin,202,138,O
",",202,146,O
furosemide,202,148,O
",",202,158,O
hydrochlorothiazide,202,160,O
",",202,179,O
or,202,181,O
amiodarone,202,184,O
(,202,195,O
or,202,196,O
its,202,199,O
active,202,203,O
metabolite,202,210,O
",",202,220,O
desethylamiodarone,202,222,O
),202,240,O
to,202,242,O
a,202,245,O
clinically,202,247,O
significant,202,258,O
degree,202,270,O
.,202,276,O
Avoid,203,0,O
co-administration,203,6,O
of,203,24,O
CYP,203,27,O
3A,203,31,O
inducers,203,34,O
(,203,43,O
e.g.,203,45,O
",",203,50,O
rifampin,203,52,O
",",203,61,O
rifabutin,203,63,O
",",203,73,O
rifapentin,203,75,O
",",203,86,O
barbiturates,203,88,O
",",203,101,O
phenytoin,203,103,O
",",203,113,O
carbamazepine,203,115,O
",",203,129,O
St.,203,131,O
John,203,137,O
's,203,142,O
Wort,203,147,O
),203,152,O
with,203,154,O
SAMSCA,203,159,O
",",203,166,O
as,203,168,O
this,203,171,O
can,203,176,O
lead,203,180,O
to,203,185,O
a,203,188,O
reduction,203,190,O
in,203,200,O
the,203,203,O
plasma,203,207,O
concentration,203,214,O
of,203,228,O
tolvaptan,203,231,O
and,203,241,O
decreased,203,245,O
effectiveness,203,255,O
of,203,269,O
SAMSCA,203,272,O
treatment,203,279,O
.,203,289,O
Avoid,203,0,O
co-administration,203,6,O
of,203,24,O
CYP,203,27,O
3A,203,31,O
inducers,203,34,O
(,203,43,O
e.g.,203,45,O
",",203,50,O
rifampin,203,52,O
",",203,61,O
rifabutin,203,63,O
",",203,73,O
rifapentin,203,75,O
",",203,86,O
barbiturates,203,88,O
",",203,101,O
phenytoin,203,103,O
",",203,113,O
carbamazepine,203,115,O
",",203,129,O
St.,203,131,O
John,203,137,O
's,203,142,O
Wort,203,147,O
),203,152,O
with,203,154,O
SAMSCA,203,159,O
",",203,166,O
as,203,168,O
this,203,171,O
can,203,176,O
lead,203,180,O
to,203,185,O
a,203,188,O
reduction,203,190,O
in,203,200,O
the,203,203,O
plasma,203,207,O
concentration,203,214,O
of,203,228,O
tolvaptan,203,231,O
and,203,241,O
decreased,203,245,O
effectiveness,203,255,O
of,203,269,O
SAMSCA,203,272,O
treatment,203,279,O
.,203,289,O
Avoid,203,0,O
co-administration,203,6,O
of,203,24,O
CYP,203,27,O
3A,203,31,O
inducers,203,34,O
(,203,43,O
e.g.,203,45,O
",",203,50,O
rifampin,203,52,O
",",203,61,O
rifabutin,203,63,O
",",203,73,O
rifapentin,203,75,O
",",203,86,O
barbiturates,203,88,O
",",203,101,O
phenytoin,203,103,O
",",203,113,O
carbamazepine,203,115,O
",",203,129,O
St.,203,131,O
John,203,137,O
's,203,142,O
Wort,203,147,O
),203,152,O
with,203,154,O
SAMSCA,203,159,O
",",203,166,O
as,203,168,O
this,203,171,O
can,203,176,O
lead,203,180,O
to,203,185,O
a,203,188,O
reduction,203,190,O
in,203,200,O
the,203,203,O
plasma,203,207,O
concentration,203,214,O
of,203,228,O
tolvaptan,203,231,O
and,203,241,O
decreased,203,245,O
effectiveness,203,255,O
of,203,269,O
SAMSCA,203,272,O
treatment,203,279,O
.,203,289,O
Avoid,203,0,O
co-administration,203,6,O
of,203,24,O
CYP,203,27,O
3A,203,31,O
inducers,203,34,O
(,203,43,O
e.g.,203,45,O
",",203,50,O
rifampin,203,52,O
",",203,61,O
rifabutin,203,63,O
",",203,73,O
rifapentin,203,75,O
",",203,86,O
barbiturates,203,88,O
",",203,101,O
phenytoin,203,103,O
",",203,113,O
carbamazepine,203,115,O
",",203,129,O
St.,203,131,O
John,203,137,O
's,203,142,O
Wort,203,147,O
),203,152,O
with,203,154,O
SAMSCA,203,159,O
",",203,166,O
as,203,168,O
this,203,171,O
can,203,176,O
lead,203,180,O
to,203,185,O
a,203,188,O
reduction,203,190,O
in,203,200,O
the,203,203,O
plasma,203,207,O
concentration,203,214,O
of,203,228,O
tolvaptan,203,231,O
and,203,241,O
decreased,203,245,O
effectiveness,203,255,O
of,203,269,O
SAMSCA,203,272,O
treatment,203,279,O
.,203,289,O
Avoid,203,0,O
co-administration,203,6,O
of,203,24,O
CYP,203,27,O
3A,203,31,O
inducers,203,34,O
(,203,43,O
e.g.,203,45,O
",",203,50,O
rifampin,203,52,O
",",203,61,O
rifabutin,203,63,O
",",203,73,O
rifapentin,203,75,O
",",203,86,O
barbiturates,203,88,O
",",203,101,O
phenytoin,203,103,O
",",203,113,O
carbamazepine,203,115,O
",",203,129,O
St.,203,131,O
John,203,137,O
's,203,142,O
Wort,203,147,O
),203,152,O
with,203,154,O
SAMSCA,203,159,O
",",203,166,O
as,203,168,O
this,203,171,O
can,203,176,O
lead,203,180,O
to,203,185,O
a,203,188,O
reduction,203,190,O
in,203,200,O
the,203,203,O
plasma,203,207,O
concentration,203,214,O
of,203,228,O
tolvaptan,203,231,O
and,203,241,O
decreased,203,245,O
effectiveness,203,255,O
of,203,269,O
SAMSCA,203,272,O
treatment,203,279,O
.,203,289,O
Avoid,203,0,O
co-administration,203,6,O
of,203,24,O
CYP,203,27,O
3A,203,31,O
inducers,203,34,O
(,203,43,O
e.g.,203,45,O
",",203,50,O
rifampin,203,52,O
",",203,61,O
rifabutin,203,63,O
",",203,73,O
rifapentin,203,75,O
",",203,86,O
barbiturates,203,88,O
",",203,101,O
phenytoin,203,103,O
",",203,113,O
carbamazepine,203,115,O
",",203,129,O
St.,203,131,O
John,203,137,O
's,203,142,O
Wort,203,147,O
),203,152,O
with,203,154,O
SAMSCA,203,159,O
",",203,166,O
as,203,168,O
this,203,171,O
can,203,176,O
lead,203,180,O
to,203,185,O
a,203,188,O
reduction,203,190,O
in,203,200,O
the,203,203,O
plasma,203,207,O
concentration,203,214,O
of,203,228,O
tolvaptan,203,231,O
and,203,241,O
decreased,203,245,O
effectiveness,203,255,O
of,203,269,O
SAMSCA,203,272,O
treatment,203,279,O
.,203,289,O
Avoid,203,0,O
co-administration,203,6,O
of,203,24,O
CYP,203,27,O
3A,203,31,O
inducers,203,34,O
(,203,43,O
e.g.,203,45,O
",",203,50,O
rifampin,203,52,O
",",203,61,O
rifabutin,203,63,O
",",203,73,O
rifapentin,203,75,O
",",203,86,O
barbiturates,203,88,O
",",203,101,O
phenytoin,203,103,O
",",203,113,O
carbamazepine,203,115,O
",",203,129,O
St.,203,131,O
John,203,137,O
's,203,142,O
Wort,203,147,O
),203,152,O
with,203,154,O
SAMSCA,203,159,O
",",203,166,O
as,203,168,O
this,203,171,O
can,203,176,O
lead,203,180,O
to,203,185,O
a,203,188,O
reduction,203,190,O
in,203,200,O
the,203,203,O
plasma,203,207,O
concentration,203,214,O
of,203,228,O
tolvaptan,203,231,O
and,203,241,O
decreased,203,245,O
effectiveness,203,255,O
of,203,269,O
SAMSCA,203,272,O
treatment,203,279,O
.,203,289,O
Avoid,203,0,O
co-administration,203,6,O
of,203,24,O
CYP,203,27,O
3A,203,31,O
inducers,203,34,O
(,203,43,O
e.g.,203,45,O
",",203,50,O
rifampin,203,52,O
",",203,61,O
rifabutin,203,63,O
",",203,73,O
rifapentin,203,75,O
",",203,86,O
barbiturates,203,88,O
",",203,101,O
phenytoin,203,103,O
",",203,113,O
carbamazepine,203,115,O
",",203,129,O
St.,203,131,O
John,203,137,O
's,203,142,O
Wort,203,147,O
),203,152,O
with,203,154,O
SAMSCA,203,159,O
",",203,166,O
as,203,168,O
this,203,171,O
can,203,176,O
lead,203,180,O
to,203,185,O
a,203,188,O
reduction,203,190,O
in,203,200,O
the,203,203,O
plasma,203,207,O
concentration,203,214,O
of,203,228,O
tolvaptan,203,231,O
and,203,241,O
decreased,203,245,O
effectiveness,203,255,O
of,203,269,O
SAMSCA,203,272,O
treatment,203,279,O
.,203,289,O
In,204,0,O
patients,204,3,O
receiving,204,12,O
SAMSCA,204,22,O
who,204,29,O
develop,204,33,O
medically,204,41,O
significant,204,51,O
signs,204,63,O
or,204,69,O
symptoms,204,72,O
of,204,81,O
hypovolemia,204,84,O
",",204,96,O
interrupt,204,98,O
or,204,108,O
discontinue,204,111,O
SAMSCA,204,123,O
therapy,204,130,O
and,204,138,O
provide,204,142,O
supportive,204,150,O
care,204,161,O
with,204,166,O
careful,204,171,O
management,204,179,O
of,204,190,O
vital,204,193,O
signs,204,199,O
",",204,205,O
fluid,204,207,O
balance,204,213,O
and,204,221,O
electrolytes,204,225,O
.,204,238,O
The,205,0,O
dose,205,4,O
of,205,9,O
SAMSCA,205,12,O
may,205,19,O
have,205,23,O
to,205,28,O
be,205,31,O
reduced,205,34,O
when,205,42,O
SAMSCA,205,47,O
is,205,54,O
co-administered,205,57,O
with,205,73,O
P-gp,205,78,O
inhibitors,205,83,O
",",205,94,O
e.g.,205,96,O
",",205,101,O
cyclosporine,205,103,O
see,205,116,O
Dosage,205,120,O
and,205,127,O
Administration,205,131,O
(,205,146,O
2.3,205,148,O
),205,152,O
",",205,154,O
Drug,205,156,O
Interactions,205,161,O
(,205,174,O
7.1,205,176,O
),205,180,O
.,205,182,O
The,205,0,O
dose,205,4,O
of,205,9,O
SAMSCA,205,12,O
may,205,19,O
have,205,23,O
to,205,28,O
be,205,31,O
reduced,205,34,O
when,205,42,O
SAMSCA,205,47,O
is,205,54,O
co-administered,205,57,O
with,205,73,O
P-gp,205,78,O
inhibitors,205,83,O
",",205,94,O
e.g.,205,96,O
",",205,101,O
cyclosporine,205,103,O
see,205,116,O
Dosage,205,120,O
and,205,127,O
Administration,205,131,O
(,205,146,O
2.3,205,148,O
),205,152,O
",",205,154,O
Drug,205,156,O
Interactions,205,161,O
(,205,174,O
7.1,205,176,O
),205,180,O
.,205,182,O
Do,366,0,O
not,366,3,O
use,366,7,O
aliskiren,366,11,O
with,366,21,O
ARBs,366,26,O
or,366,31,O
ACEIs,366,34,O
in,366,40,O
patients,366,43,O
with,366,52,O
diabetes,366,57,O
see,366,66,O
Warnings,366,70,O
and,366,79,O
Precautions,366,83,O
(,366,95,O
5.2,366,97,O
),366,101,O
and,366,103,O
Clinical,366,107,O
Studies,366,116,O
(,366,124,O
14.3,366,126,O
),366,131,O
.,366,133,O
Do,366,0,O
not,366,3,O
use,366,7,O
aliskiren,366,11,O
with,366,21,O
ARBs,366,26,O
or,366,31,O
ACEIs,366,34,O
in,366,40,O
patients,366,43,O
with,366,52,O
diabetes,366,57,O
see,366,66,O
Warnings,366,70,O
and,366,79,O
Precautions,366,83,O
(,366,95,O
5.2,366,97,O
),366,101,O
and,366,103,O
Clinical,366,107,O
Studies,366,116,O
(,366,124,O
14.3,366,126,O
),366,131,O
.,366,133,O
(,367,0,O
5.7,367,1,O
",",367,4,O
7,367,6,O
",",367,7,O
12.3,367,9,O
),367,13,O
Nonsteroidal,367,15,O
Anti-Inflammatory,367,28,O
Drugs,367,46,O
(,367,52,O
NSAIDs,367,53,O
),367,59,O
Increased,367,61,O
risk,367,71,O
of,367,76,O
renal,367,79,O
impairment,367,85,O
and,367,96,O
loss,367,100,O
of,367,105,O
antihypertensive,367,108,O
effect,367,125,O
.,367,131,O
Cyclosporine,368,0,O
:,368,13,O
Avoid,368,15,O
coadministration,368,21,O
of,368,38,O
cyclosporine,368,41,O
with,368,54,O
aliskiren,368,59,O
see,368,69,O
Warnings,368,73,O
and,368,82,O
Precautions,368,86,O
(,368,98,O
5.7,368,100,O
),368,104,O
and,368,106,O
Clinical,368,110,O
Pharmacology,368,119,O
(,368,132,O
12.3,368,134,O
),368,139,O
.,368,141,O
Cyclosporine,369,0,O
or,369,13,O
Itraconazole,369,16,O
:,369,28,O
Avoid,369,30,O
concomitant,369,36,O
use,369,48,O
.,369,51,O
Cyclosporine,369,0,O
or,369,13,O
Itraconazole,369,16,O
:,369,28,O
Avoid,369,30,O
concomitant,369,36,O
use,369,48,O
.,369,51,O
Dual,370,0,O
Blockade,370,5,O
of,370,14,O
the,370,17,O
Renin-Angiotensin-Aldosterone,370,21,O
System,370,51,O
(,370,58,O
RAAS,370,59,O
),370,63,O
:,370,64,O
The,370,66,O
concomitant,370,70,O
use,370,82,O
of,370,86,O
aliskiren,370,89,O
with,370,99,O
other,370,104,O
agents,370,110,O
acting,370,117,O
on,370,124,O
the,370,127,O
RAAS,370,131,O
such,370,136,O
as,370,141,O
ACEIs,370,144,O
or,370,150,O
ARBs,370,153,O
is,370,158,O
associated,370,161,O
with,370,172,O
an,370,177,O
increased,370,180,O
risk,370,190,O
of,370,195,O
hypotension,370,198,B-SpecificInteraction
",",370,209,O
hyperkalemia,370,211,B-SpecificInteraction
",",370,223,O
and,370,225,O
changes,370,229,B-SpecificInteraction
in,370,229,I-SpecificInteraction
renal,370,229,I-SpecificInteraction
function,370,229,I-SpecificInteraction
(,370,255,O
including,370,256,O
acute,370,266,B-SpecificInteraction
renal,370,266,I-SpecificInteraction
failure,370,266,I-SpecificInteraction
),370,285,O
compared,370,287,O
to,370,296,O
monotherapy,370,299,O
.,370,310,O
Dual,370,0,O
Blockade,370,5,O
of,370,14,O
the,370,17,O
Renin-Angiotensin-Aldosterone,370,21,O
System,370,51,O
(,370,58,O
RAAS,370,59,O
),370,63,O
:,370,64,O
The,370,66,O
concomitant,370,70,O
use,370,82,O
of,370,86,O
aliskiren,370,89,O
with,370,99,O
other,370,104,O
agents,370,110,O
acting,370,117,O
on,370,124,O
the,370,127,O
RAAS,370,131,O
such,370,136,O
as,370,141,O
ACEIs,370,144,O
or,370,150,O
ARBs,370,153,O
is,370,158,O
associated,370,161,O
with,370,172,O
an,370,177,O
increased,370,180,O
risk,370,190,O
of,370,195,O
hypotension,370,198,B-SpecificInteraction
",",370,209,O
hyperkalemia,370,211,B-SpecificInteraction
",",370,223,O
and,370,225,O
changes,370,229,B-SpecificInteraction
in,370,229,I-SpecificInteraction
renal,370,229,I-SpecificInteraction
function,370,229,I-SpecificInteraction
(,370,255,O
including,370,256,O
acute,370,266,B-SpecificInteraction
renal,370,266,I-SpecificInteraction
failure,370,266,I-SpecificInteraction
),370,285,O
compared,370,287,O
to,370,296,O
monotherapy,370,299,O
.,370,310,O
Dual,370,0,O
Blockade,370,5,O
of,370,14,O
the,370,17,O
Renin-Angiotensin-Aldosterone,370,21,O
System,370,51,O
(,370,58,O
RAAS,370,59,O
),370,63,O
:,370,64,O
The,370,66,O
concomitant,370,70,O
use,370,82,O
of,370,86,O
aliskiren,370,89,O
with,370,99,O
other,370,104,O
agents,370,110,O
acting,370,117,O
on,370,124,O
the,370,127,O
RAAS,370,131,O
such,370,136,O
as,370,141,O
ACEIs,370,144,O
or,370,150,O
ARBs,370,153,O
is,370,158,O
associated,370,161,O
with,370,172,O
an,370,177,O
increased,370,180,O
risk,370,190,O
of,370,195,O
hypotension,370,198,B-SpecificInteraction
",",370,209,O
hyperkalemia,370,211,B-SpecificInteraction
",",370,223,O
and,370,225,O
changes,370,229,B-SpecificInteraction
in,370,229,I-SpecificInteraction
renal,370,229,I-SpecificInteraction
function,370,229,I-SpecificInteraction
(,370,255,O
including,370,256,O
acute,370,266,B-SpecificInteraction
renal,370,266,I-SpecificInteraction
failure,370,266,I-SpecificInteraction
),370,285,O
compared,370,287,O
to,370,296,O
monotherapy,370,299,O
.,370,310,O
Furosemide,371,0,O
:,371,11,O
Oral,371,13,O
coadministration,371,18,O
of,371,35,O
aliskiren,371,38,O
and,371,48,O
furosemide,371,52,O
reduced,371,63,O
exposure,371,71,O
to,371,80,O
furosemide,371,83,O
.,371,94,O
In,372,0,O
general,372,3,O
",",372,11,O
avoid,372,13,O
combined,372,19,O
use,372,28,O
of,372,32,O
aliskiren,372,35,O
with,372,45,O
ACE,372,50,O
inhibitors,372,54,O
or,372,65,O
ARBs,372,68,O
",",372,73,O
particularly,372,75,O
in,372,88,O
patients,372,91,O
with,372,100,O
CrCl,372,105,O
less,372,110,O
than,372,115,O
60,372,120,O
mL/min,372,123,O
.,372,130,O
In,372,0,O
general,372,3,O
",",372,11,O
avoid,372,13,O
combined,372,19,O
use,372,28,O
of,372,32,O
aliskiren,372,35,O
with,372,45,O
ACE,372,50,O
inhibitors,372,54,O
or,372,65,O
ARBs,372,68,O
",",372,73,O
particularly,372,75,O
in,372,88,O
patients,372,91,O
with,372,100,O
CrCl,372,105,O
less,372,110,O
than,372,115,O
60,372,120,O
mL/min,372,123,O
.,372,130,O
Itraconazole,373,0,O
:,373,13,O
Avoid,373,15,O
coadministration,373,21,O
of,373,38,O
itraconazole,373,41,O
with,373,54,O
aliskiren,373,59,O
see,373,69,O
Warnings,373,73,O
and,373,82,O
Precautions,373,86,O
(,373,98,O
5.7,373,100,O
),373,104,O
and,373,106,O
Clinical,373,110,O
Pharmacology,373,119,O
(,373,132,O
12.3,373,134,O
),373,139,O
.,373,141,O
Monitor,374,0,O
blood,374,8,O
pressure,374,14,O
",",374,23,O
renal,374,25,O
function,374,31,O
",",374,40,O
and,374,42,O
electrolytes,374,46,O
in,374,59,O
patients,374,62,O
taking,374,71,O
aliskiren,374,78,O
and,374,88,O
other,374,92,O
agents,374,98,O
that,374,105,O
affect,374,110,O
the,374,117,O
RAAS,374,121,O
see,374,126,O
Warnings,374,130,O
and,374,139,O
Precautions,374,143,O
(,374,155,O
5.4,374,157,O
",",374,161,O
5.5,374,163,O
",",374,167,O
5.6,374,169,O
),374,173,O
.,374,175,O
Monitor,375,0,O
diuretic,375,8,O
effects,375,17,O
when,375,25,O
furosemide,375,30,O
is,375,41,O
coadministered,375,44,O
with,375,59,O
aliskiren,375,64,O
.,375,74,O
Monitor,376,0,O
renal,376,8,O
function,376,14,O
periodically,376,23,O
in,376,36,O
patients,376,39,O
receiving,376,48,O
aliskiren,376,58,O
and,376,68,O
NSAID,376,72,O
therapy,376,78,O
.,376,86,O
Most,377,0,O
patients,377,5,O
receiving,377,14,O
the,377,24,O
combination,377,28,O
of,377,40,O
two,377,43,O
drugs,377,47,O
that,377,53,O
inhibit,377,58,O
the,377,66,O
renin-angiotensin,377,70,O
system,377,88,O
do,377,95,O
not,377,98,O
obtain,377,102,O
any,377,109,O
additional,377,113,O
benefit,377,124,O
compared,377,132,O
to,377,141,O
monotherapy,377,144,O
.,377,155,O
Nonsteroidal,378,0,O
Anti-Inflammatory,378,13,O
Drugs,378,31,O
(,378,37,O
NSAIDs,378,39,O
),378,46,O
including,378,48,O
selective,378,58,O
Cyclooxygenase-2,378,68,O
inhibitors,378,85,O
(,378,96,O
COX-2,378,98,O
inhibitors,378,104,O
),378,115,O
:,378,117,O
In,378,119,O
patients,378,122,O
who,378,131,O
are,378,135,O
elderly,378,139,O
",",378,147,O
volume-depleted,378,149,O
(,378,165,O
including,378,167,O
those,378,177,O
on,378,183,O
diuretic,378,186,O
therapy,378,195,O
),378,203,O
",",378,205,O
or,378,207,O
with,378,210,O
compromised,378,215,O
renal,378,227,O
function,378,233,O
",",378,242,O
coadministration,378,244,O
of,378,261,O
NSAIDs,378,264,O
",",378,271,O
including,378,273,O
selective,378,283,O
COX-2,378,293,O
inhibitors,378,299,O
with,378,310,O
agents,378,315,O
that,378,322,O
affect,378,327,O
the,378,334,O
RAAS,378,338,O
",",378,343,O
including,378,345,O
aliskiren,378,355,O
",",378,365,O
may,378,367,O
result,378,371,O
in,378,378,O
deterioration,378,381,B-SpecificInteraction
of,378,381,I-SpecificInteraction
renal,378,381,I-SpecificInteraction
function,378,381,I-SpecificInteraction
",",378,413,O
including,378,415,O
possible,378,425,O
acute,378,434,B-SpecificInteraction
renal,378,434,I-SpecificInteraction
failure,378,434,I-SpecificInteraction
.,378,454,O
Nonsteroidal,378,0,O
Anti-Inflammatory,378,13,O
Drugs,378,31,O
(,378,37,O
NSAIDs,378,39,O
),378,46,O
including,378,48,O
selective,378,58,O
Cyclooxygenase-2,378,68,O
inhibitors,378,85,O
(,378,96,O
COX-2,378,98,O
inhibitors,378,104,O
),378,115,O
:,378,117,O
In,378,119,O
patients,378,122,O
who,378,131,O
are,378,135,O
elderly,378,139,O
",",378,147,O
volume-depleted,378,149,O
(,378,165,O
including,378,167,O
those,378,177,O
on,378,183,O
diuretic,378,186,O
therapy,378,195,O
),378,203,O
",",378,205,O
or,378,207,O
with,378,210,O
compromised,378,215,O
renal,378,227,O
function,378,233,O
",",378,242,O
coadministration,378,244,O
of,378,261,O
NSAIDs,378,264,O
",",378,271,O
including,378,273,O
selective,378,283,O
COX-2,378,293,O
inhibitors,378,299,O
with,378,310,O
agents,378,315,O
that,378,322,O
affect,378,327,O
the,378,334,O
RAAS,378,338,O
",",378,343,O
including,378,345,O
aliskiren,378,355,O
",",378,365,O
may,378,367,O
result,378,371,O
in,378,378,O
deterioration,378,381,B-SpecificInteraction
of,378,381,I-SpecificInteraction
renal,378,381,I-SpecificInteraction
function,378,381,I-SpecificInteraction
",",378,413,O
including,378,415,O
possible,378,425,O
acute,378,434,B-SpecificInteraction
renal,378,434,I-SpecificInteraction
failure,378,434,I-SpecificInteraction
.,378,454,O
Nonsteroidal,379,0,O
Anti-Inflammatory,379,13,O
Drugs,379,31,O
(,379,37,O
NSAIDs,379,38,O
),379,44,O
including,379,46,O
selective,379,56,O
Cyclooxygenase-2,379,66,O
inhibitors,379,83,O
(,379,94,O
COX-2,379,95,O
inhibitors,379,101,O
),379,111,O
:,379,112,O
In,379,114,O
patients,379,117,O
who,379,126,O
are,379,130,O
elderly,379,134,O
",",379,141,O
volume-depleted,379,143,O
(,379,159,O
including,379,160,O
those,379,170,O
on,379,176,O
diuretic,379,179,O
therapy,379,188,O
),379,195,O
",",379,196,O
or,379,198,O
with,379,201,O
compromised,379,206,O
renal,379,218,O
function,379,224,O
",",379,232,O
coadministration,379,234,O
of,379,251,O
NSAIDs,379,254,O
",",379,260,O
including,379,262,O
selective,379,272,O
COX-2,379,282,O
inhibitors,379,288,O
with,379,299,O
agents,379,304,O
that,379,311,O
affect,379,316,O
the,379,323,O
RAAS,379,327,O
",",379,331,O
including,379,333,O
aliskiren,379,343,O
",",379,352,O
may,379,354,O
result,379,358,O
in,379,365,O
deterioration,379,368,B-SpecificInteraction
of,379,368,I-SpecificInteraction
renal,379,368,I-SpecificInteraction
function,379,368,I-SpecificInteraction
",",379,399,O
including,379,401,O
possible,379,411,O
acute,379,420,B-SpecificInteraction
renal,379,420,I-SpecificInteraction
failure,379,420,I-SpecificInteraction
.,379,439,O
Nonsteroidal,379,0,O
Anti-Inflammatory,379,13,O
Drugs,379,31,O
(,379,37,O
NSAIDs,379,38,O
),379,44,O
including,379,46,O
selective,379,56,O
Cyclooxygenase-2,379,66,O
inhibitors,379,83,O
(,379,94,O
COX-2,379,95,O
inhibitors,379,101,O
),379,111,O
:,379,112,O
In,379,114,O
patients,379,117,O
who,379,126,O
are,379,130,O
elderly,379,134,O
",",379,141,O
volume-depleted,379,143,O
(,379,159,O
including,379,160,O
those,379,170,O
on,379,176,O
diuretic,379,179,O
therapy,379,188,O
),379,195,O
",",379,196,O
or,379,198,O
with,379,201,O
compromised,379,206,O
renal,379,218,O
function,379,224,O
",",379,232,O
coadministration,379,234,O
of,379,251,O
NSAIDs,379,254,O
",",379,260,O
including,379,262,O
selective,379,272,O
COX-2,379,282,O
inhibitors,379,288,O
with,379,299,O
agents,379,304,O
that,379,311,O
affect,379,316,O
the,379,323,O
RAAS,379,327,O
",",379,331,O
including,379,333,O
aliskiren,379,343,O
",",379,352,O
may,379,354,O
result,379,358,O
in,379,365,O
deterioration,379,368,B-SpecificInteraction
of,379,368,I-SpecificInteraction
renal,379,368,I-SpecificInteraction
function,379,368,I-SpecificInteraction
",",379,399,O
including,379,401,O
possible,379,411,O
acute,379,420,B-SpecificInteraction
renal,379,420,I-SpecificInteraction
failure,379,420,I-SpecificInteraction
.,379,439,O
Nonsteroidal,379,0,O
Anti-Inflammatory,379,13,O
Drugs,379,31,O
(,379,37,O
NSAIDs,379,38,O
),379,44,O
including,379,46,O
selective,379,56,O
Cyclooxygenase-2,379,66,O
inhibitors,379,83,O
(,379,94,O
COX-2,379,95,O
inhibitors,379,101,O
),379,111,O
:,379,112,O
In,379,114,O
patients,379,117,O
who,379,126,O
are,379,130,O
elderly,379,134,O
",",379,141,O
volume-depleted,379,143,O
(,379,159,O
including,379,160,O
those,379,170,O
on,379,176,O
diuretic,379,179,O
therapy,379,188,O
),379,195,O
",",379,196,O
or,379,198,O
with,379,201,O
compromised,379,206,O
renal,379,218,O
function,379,224,O
",",379,232,O
coadministration,379,234,O
of,379,251,O
NSAIDs,379,254,O
",",379,260,O
including,379,262,O
selective,379,272,O
COX-2,379,282,O
inhibitors,379,288,O
with,379,299,O
agents,379,304,O
that,379,311,O
affect,379,316,O
the,379,323,O
RAAS,379,327,O
",",379,331,O
including,379,333,O
aliskiren,379,343,O
",",379,352,O
may,379,354,O
result,379,358,O
in,379,365,O
deterioration,379,368,B-SpecificInteraction
of,379,368,I-SpecificInteraction
renal,379,368,I-SpecificInteraction
function,379,368,I-SpecificInteraction
",",379,399,O
including,379,401,O
possible,379,411,O
acute,379,420,B-SpecificInteraction
renal,379,420,I-SpecificInteraction
failure,379,420,I-SpecificInteraction
.,379,439,O
Nonsteroidal,379,0,O
Anti-Inflammatory,379,13,O
Drugs,379,31,O
(,379,37,O
NSAIDs,379,38,O
),379,44,O
including,379,46,O
selective,379,56,O
Cyclooxygenase-2,379,66,O
inhibitors,379,83,O
(,379,94,O
COX-2,379,95,O
inhibitors,379,101,O
),379,111,O
:,379,112,O
In,379,114,O
patients,379,117,O
who,379,126,O
are,379,130,O
elderly,379,134,O
",",379,141,O
volume-depleted,379,143,O
(,379,159,O
including,379,160,O
those,379,170,O
on,379,176,O
diuretic,379,179,O
therapy,379,188,O
),379,195,O
",",379,196,O
or,379,198,O
with,379,201,O
compromised,379,206,O
renal,379,218,O
function,379,224,O
",",379,232,O
coadministration,379,234,O
of,379,251,O
NSAIDs,379,254,O
",",379,260,O
including,379,262,O
selective,379,272,O
COX-2,379,282,O
inhibitors,379,288,O
with,379,299,O
agents,379,304,O
that,379,311,O
affect,379,316,O
the,379,323,O
RAAS,379,327,O
",",379,331,O
including,379,333,O
aliskiren,379,343,O
",",379,352,O
may,379,354,O
result,379,358,O
in,379,365,O
deterioration,379,368,B-SpecificInteraction
of,379,368,I-SpecificInteraction
renal,379,368,I-SpecificInteraction
function,379,368,I-SpecificInteraction
",",379,399,O
including,379,401,O
possible,379,411,O
acute,379,420,B-SpecificInteraction
renal,379,420,I-SpecificInteraction
failure,379,420,I-SpecificInteraction
.,379,439,O
The,380,0,O
antihypertensive,380,4,O
effect,380,21,O
of,380,28,O
aliskiren,380,31,O
may,380,41,O
be,380,45,O
attenuated,380,48,O
by,380,59,O
NSAIDs,380,62,O
.,380,69,O
The,381,0,O
concomitant,381,4,O
use,381,16,O
of,381,20,O
aliskiren,381,23,O
with,381,33,O
an,381,38,O
ARB,381,41,O
or,381,45,O
an,381,48,O
ACEI,381,51,O
in,381,56,O
diabetic,381,59,O
patients,381,68,O
is,381,77,O
contraindicated,381,80,O
[,381,96,O
see,381,97,O
Contraindications,381,101,O
(,381,119,O
4,381,120,O
),381,121,O
],381,122,O
.,381,123,O
The,381,0,O
concomitant,381,4,O
use,381,16,O
of,381,20,O
aliskiren,381,23,O
with,381,33,O
an,381,38,O
ARB,381,41,O
or,381,45,O
an,381,48,O
ACEI,381,51,O
in,381,56,O
diabetic,381,59,O
patients,381,68,O
is,381,77,O
contraindicated,381,80,O
[,381,96,O
see,381,97,O
Contraindications,381,101,O
(,381,119,O
4,381,120,O
),381,121,O
],381,122,O
.,381,123,O
Avoid,382,0,O
concomitant,382,6,O
use,382,18,O
of,382,22,O
aliskiren,382,25,O
with,382,35,O
cyclosporine,382,40,O
or,382,53,O
itraconazole,382,56,O
see,382,69,O
Drug,382,73,O
Interactions,382,78,O
(,382,91,O
7,382,93,O
),382,95,O
.,382,97,O
Avoid,382,0,O
concomitant,382,6,O
use,382,18,O
of,382,22,O
aliskiren,382,25,O
with,382,35,O
cyclosporine,382,40,O
or,382,53,O
itraconazole,382,56,O
see,382,69,O
Drug,382,73,O
Interactions,382,78,O
(,382,91,O
7,382,93,O
),382,95,O
.,382,97,O
In,383,0,O
general,383,3,O
",",383,11,O
avoid,383,13,O
combined,383,19,O
use,383,28,O
of,383,32,O
aliskiren,383,35,O
with,383,45,O
ACE,383,50,O
inhibitors,383,54,O
or,383,65,O
ARBs,383,68,O
",",383,73,O
particularly,383,75,O
in,383,88,O
patients,383,91,O
with,383,100,O
creatinine,383,105,O
clearance,383,116,O
(,383,126,O
CrCl,383,128,O
),383,133,O
less,383,135,O
than,383,140,O
60,383,145,O
mL/min,383,148,O
see,383,155,O
Contraindications,383,159,O
(,383,177,O
4,383,179,O
),383,181,O
",",383,183,O
Drug,383,185,O
Interactions,383,190,O
(,383,203,O
7,383,205,O
),383,207,O
and,383,209,O
Clinical,383,213,O
Studies,383,222,O
(,383,230,O
14.3,383,232,O
),383,237,O
.,383,239,O
In,383,0,O
general,383,3,O
",",383,11,O
avoid,383,13,O
combined,383,19,O
use,383,28,O
of,383,32,O
aliskiren,383,35,O
with,383,45,O
ACE,383,50,O
inhibitors,383,54,O
or,383,65,O
ARBs,383,68,O
",",383,73,O
particularly,383,75,O
in,383,88,O
patients,383,91,O
with,383,100,O
creatinine,383,105,O
clearance,383,116,O
(,383,126,O
CrCl,383,128,O
),383,133,O
less,383,135,O
than,383,140,O
60,383,145,O
mL/min,383,148,O
see,383,155,O
Contraindications,383,159,O
(,383,177,O
4,383,179,O
),383,181,O
",",383,183,O
Drug,383,185,O
Interactions,383,190,O
(,383,203,O
7,383,205,O
),383,207,O
and,383,209,O
Clinical,383,213,O
Studies,383,222,O
(,383,230,O
14.3,383,232,O
),383,237,O
.,383,239,O
Patients,384,0,O
whose,384,9,O
renal,384,15,O
function,384,21,O
may,384,30,O
depend,384,34,O
in,384,41,O
part,384,44,O
on,384,49,O
the,384,52,O
activity,384,56,O
of,384,65,O
the,384,68,O
RAAS,384,72,O
(,384,77,O
e.g.,384,79,O
",",384,84,O
patients,384,86,O
with,384,95,O
renal,384,100,O
artery,384,106,O
stenosis,384,113,O
",",384,122,O
severe,384,124,O
heart,384,131,O
failure,384,137,O
",",384,145,O
post-myocardial,384,147,O
infarction,384,163,O
or,384,174,O
volume,384,177,O
depletion,384,184,O
),384,194,O
or,384,196,O
patients,384,199,O
receiving,384,208,O
ARB,384,218,O
",",384,222,O
ACEI,384,224,O
or,384,229,O
nonsteroidal,384,232,O
anti-inflammatory,384,245,O
drug,384,263,O
(,384,268,O
NSAID,384,270,O
),384,276,O
",",384,278,O
including,384,280,O
selective,384,290,O
Cyclooxygenase-2,384,300,O
inhibitors,384,317,O
(,384,328,O
COX-2,384,330,O
inhibitors,384,336,O
),384,347,O
",",384,349,O
therapy,384,351,O
may,384,359,O
be,384,363,O
at,384,366,O
particular,384,369,O
risk,384,380,O
for,384,385,O
developing,384,389,O
acute,384,400,B-SpecificInteraction
renal,384,400,I-SpecificInteraction
failure,384,400,I-SpecificInteraction
on,384,420,O
Tekturna,384,423,O
see,384,432,O
Warnings,384,436,O
and,384,445,O
Precautions,384,449,O
(,384,461,O
5.2,384,463,O
Drug,384,467,O
Interactions,384,472,O
(,384,485,O
7,384,487,O
),384,489,O
",",384,491,O
and,384,493,O
Use,384,497,O
in,384,501,O
Specific,384,504,O
Populations,384,513,O
(,384,525,O
8.7,384,527,O
),384,531,O
and,384,533,O
Clinical,384,537,O
Studies,384,546,O
(,384,554,O
14.3,384,556,O
),384,561,O
.,384,563,O
Patients,384,0,O
whose,384,9,O
renal,384,15,O
function,384,21,O
may,384,30,O
depend,384,34,O
in,384,41,O
part,384,44,O
on,384,49,O
the,384,52,O
activity,384,56,O
of,384,65,O
the,384,68,O
RAAS,384,72,O
(,384,77,O
e.g.,384,79,O
",",384,84,O
patients,384,86,O
with,384,95,O
renal,384,100,O
artery,384,106,O
stenosis,384,113,O
",",384,122,O
severe,384,124,O
heart,384,131,O
failure,384,137,O
",",384,145,O
post-myocardial,384,147,O
infarction,384,163,O
or,384,174,O
volume,384,177,O
depletion,384,184,O
),384,194,O
or,384,196,O
patients,384,199,O
receiving,384,208,O
ARB,384,218,O
",",384,222,O
ACEI,384,224,O
or,384,229,O
nonsteroidal,384,232,O
anti-inflammatory,384,245,O
drug,384,263,O
(,384,268,O
NSAID,384,270,O
),384,276,O
",",384,278,O
including,384,280,O
selective,384,290,O
Cyclooxygenase-2,384,300,O
inhibitors,384,317,O
(,384,328,O
COX-2,384,330,O
inhibitors,384,336,O
),384,347,O
",",384,349,O
therapy,384,351,O
may,384,359,O
be,384,363,O
at,384,366,O
particular,384,369,O
risk,384,380,O
for,384,385,O
developing,384,389,O
acute,384,400,B-SpecificInteraction
renal,384,400,I-SpecificInteraction
failure,384,400,I-SpecificInteraction
on,384,420,O
Tekturna,384,423,O
see,384,432,O
Warnings,384,436,O
and,384,445,O
Precautions,384,449,O
(,384,461,O
5.2,384,463,O
Drug,384,467,O
Interactions,384,472,O
(,384,485,O
7,384,487,O
),384,489,O
",",384,491,O
and,384,493,O
Use,384,497,O
in,384,501,O
Specific,384,504,O
Populations,384,513,O
(,384,525,O
8.7,384,527,O
),384,531,O
and,384,533,O
Clinical,384,537,O
Studies,384,546,O
(,384,554,O
14.3,384,556,O
),384,561,O
.,384,563,O
Patients,384,0,O
whose,384,9,O
renal,384,15,O
function,384,21,O
may,384,30,O
depend,384,34,O
in,384,41,O
part,384,44,O
on,384,49,O
the,384,52,O
activity,384,56,O
of,384,65,O
the,384,68,O
RAAS,384,72,O
(,384,77,O
e.g.,384,79,O
",",384,84,O
patients,384,86,O
with,384,95,O
renal,384,100,O
artery,384,106,O
stenosis,384,113,O
",",384,122,O
severe,384,124,O
heart,384,131,O
failure,384,137,O
",",384,145,O
post-myocardial,384,147,O
infarction,384,163,O
or,384,174,O
volume,384,177,O
depletion,384,184,O
),384,194,O
or,384,196,O
patients,384,199,O
receiving,384,208,O
ARB,384,218,O
",",384,222,O
ACEI,384,224,O
or,384,229,O
nonsteroidal,384,232,O
anti-inflammatory,384,245,O
drug,384,263,O
(,384,268,O
NSAID,384,270,O
),384,276,O
",",384,278,O
including,384,280,O
selective,384,290,O
Cyclooxygenase-2,384,300,O
inhibitors,384,317,O
(,384,328,O
COX-2,384,330,O
inhibitors,384,336,O
),384,347,O
",",384,349,O
therapy,384,351,O
may,384,359,O
be,384,363,O
at,384,366,O
particular,384,369,O
risk,384,380,O
for,384,385,O
developing,384,389,O
acute,384,400,B-SpecificInteraction
renal,384,400,I-SpecificInteraction
failure,384,400,I-SpecificInteraction
on,384,420,O
Tekturna,384,423,O
see,384,432,O
Warnings,384,436,O
and,384,445,O
Precautions,384,449,O
(,384,461,O
5.2,384,463,O
Drug,384,467,O
Interactions,384,472,O
(,384,485,O
7,384,487,O
),384,489,O
",",384,491,O
and,384,493,O
Use,384,497,O
in,384,501,O
Specific,384,504,O
Populations,384,513,O
(,384,525,O
8.7,384,527,O
),384,531,O
and,384,533,O
Clinical,384,537,O
Studies,384,546,O
(,384,554,O
14.3,384,556,O
),384,561,O
.,384,563,O
Patients,384,0,O
whose,384,9,O
renal,384,15,O
function,384,21,O
may,384,30,O
depend,384,34,O
in,384,41,O
part,384,44,O
on,384,49,O
the,384,52,O
activity,384,56,O
of,384,65,O
the,384,68,O
RAAS,384,72,O
(,384,77,O
e.g.,384,79,O
",",384,84,O
patients,384,86,O
with,384,95,O
renal,384,100,O
artery,384,106,O
stenosis,384,113,O
",",384,122,O
severe,384,124,O
heart,384,131,O
failure,384,137,O
",",384,145,O
post-myocardial,384,147,O
infarction,384,163,O
or,384,174,O
volume,384,177,O
depletion,384,184,O
),384,194,O
or,384,196,O
patients,384,199,O
receiving,384,208,O
ARB,384,218,O
",",384,222,O
ACEI,384,224,O
or,384,229,O
nonsteroidal,384,232,O
anti-inflammatory,384,245,O
drug,384,263,O
(,384,268,O
NSAID,384,270,O
),384,276,O
",",384,278,O
including,384,280,O
selective,384,290,O
Cyclooxygenase-2,384,300,O
inhibitors,384,317,O
(,384,328,O
COX-2,384,330,O
inhibitors,384,336,O
),384,347,O
",",384,349,O
therapy,384,351,O
may,384,359,O
be,384,363,O
at,384,366,O
particular,384,369,O
risk,384,380,O
for,384,385,O
developing,384,389,O
acute,384,400,B-SpecificInteraction
renal,384,400,I-SpecificInteraction
failure,384,400,I-SpecificInteraction
on,384,420,O
Tekturna,384,423,O
see,384,432,O
Warnings,384,436,O
and,384,445,O
Precautions,384,449,O
(,384,461,O
5.2,384,463,O
Drug,384,467,O
Interactions,384,472,O
(,384,485,O
7,384,487,O
),384,489,O
",",384,491,O
and,384,493,O
Use,384,497,O
in,384,501,O
Specific,384,504,O
Populations,384,513,O
(,384,525,O
8.7,384,527,O
),384,531,O
and,384,533,O
Clinical,384,537,O
Studies,384,546,O
(,384,554,O
14.3,384,556,O
),384,561,O
.,384,563,O
Patients,384,0,O
whose,384,9,O
renal,384,15,O
function,384,21,O
may,384,30,O
depend,384,34,O
in,384,41,O
part,384,44,O
on,384,49,O
the,384,52,O
activity,384,56,O
of,384,65,O
the,384,68,O
RAAS,384,72,O
(,384,77,O
e.g.,384,79,O
",",384,84,O
patients,384,86,O
with,384,95,O
renal,384,100,O
artery,384,106,O
stenosis,384,113,O
",",384,122,O
severe,384,124,O
heart,384,131,O
failure,384,137,O
",",384,145,O
post-myocardial,384,147,O
infarction,384,163,O
or,384,174,O
volume,384,177,O
depletion,384,184,O
),384,194,O
or,384,196,O
patients,384,199,O
receiving,384,208,O
ARB,384,218,O
",",384,222,O
ACEI,384,224,O
or,384,229,O
nonsteroidal,384,232,O
anti-inflammatory,384,245,O
drug,384,263,O
(,384,268,O
NSAID,384,270,O
),384,276,O
",",384,278,O
including,384,280,O
selective,384,290,O
Cyclooxygenase-2,384,300,O
inhibitors,384,317,O
(,384,328,O
COX-2,384,330,O
inhibitors,384,336,O
),384,347,O
",",384,349,O
therapy,384,351,O
may,384,359,O
be,384,363,O
at,384,366,O
particular,384,369,O
risk,384,380,O
for,384,385,O
developing,384,389,O
acute,384,400,B-SpecificInteraction
renal,384,400,I-SpecificInteraction
failure,384,400,I-SpecificInteraction
on,384,420,O
Tekturna,384,423,O
see,384,432,O
Warnings,384,436,O
and,384,445,O
Precautions,384,449,O
(,384,461,O
5.2,384,463,O
Drug,384,467,O
Interactions,384,472,O
(,384,485,O
7,384,487,O
),384,489,O
",",384,491,O
and,384,493,O
Use,384,497,O
in,384,501,O
Specific,384,504,O
Populations,384,513,O
(,384,525,O
8.7,384,527,O
),384,531,O
and,384,533,O
Clinical,384,537,O
Studies,384,546,O
(,384,554,O
14.3,384,556,O
),384,561,O
.,384,563,O
Patients,384,0,O
whose,384,9,O
renal,384,15,O
function,384,21,O
may,384,30,O
depend,384,34,O
in,384,41,O
part,384,44,O
on,384,49,O
the,384,52,O
activity,384,56,O
of,384,65,O
the,384,68,O
RAAS,384,72,O
(,384,77,O
e.g.,384,79,O
",",384,84,O
patients,384,86,O
with,384,95,O
renal,384,100,O
artery,384,106,O
stenosis,384,113,O
",",384,122,O
severe,384,124,O
heart,384,131,O
failure,384,137,O
",",384,145,O
post-myocardial,384,147,O
infarction,384,163,O
or,384,174,O
volume,384,177,O
depletion,384,184,O
),384,194,O
or,384,196,O
patients,384,199,O
receiving,384,208,O
ARB,384,218,O
",",384,222,O
ACEI,384,224,O
or,384,229,O
nonsteroidal,384,232,O
anti-inflammatory,384,245,O
drug,384,263,O
(,384,268,O
NSAID,384,270,O
),384,276,O
",",384,278,O
including,384,280,O
selective,384,290,O
Cyclooxygenase-2,384,300,O
inhibitors,384,317,O
(,384,328,O
COX-2,384,330,O
inhibitors,384,336,O
),384,347,O
",",384,349,O
therapy,384,351,O
may,384,359,O
be,384,363,O
at,384,366,O
particular,384,369,O
risk,384,380,O
for,384,385,O
developing,384,389,O
acute,384,400,B-SpecificInteraction
renal,384,400,I-SpecificInteraction
failure,384,400,I-SpecificInteraction
on,384,420,O
Tekturna,384,423,O
see,384,432,O
Warnings,384,436,O
and,384,445,O
Precautions,384,449,O
(,384,461,O
5.2,384,463,O
Drug,384,467,O
Interactions,384,472,O
(,384,485,O
7,384,487,O
),384,489,O
",",384,491,O
and,384,493,O
Use,384,497,O
in,384,501,O
Specific,384,504,O
Populations,384,513,O
(,384,525,O
8.7,384,527,O
),384,531,O
and,384,533,O
Clinical,384,537,O
Studies,384,546,O
(,384,554,O
14.3,384,556,O
),384,561,O
.,384,563,O
When,385,0,O
aliskiren,385,5,O
was,385,15,O
given,385,19,O
with,385,25,O
cyclosporine,385,30,O
or,385,43,O
itraconazole,385,46,O
",",385,59,O
the,385,61,O
blood,385,65,O
concentrations,385,71,O
of,385,86,O
aliskiren,385,89,O
were,385,99,O
significantly,385,104,O
increased,385,118,O
.,385,128,O
When,385,0,O
aliskiren,385,5,O
was,385,15,O
given,385,19,O
with,385,25,O
cyclosporine,385,30,O
or,385,43,O
itraconazole,385,46,O
",",385,59,O
the,385,61,O
blood,385,65,O
concentrations,385,71,O
of,385,86,O
aliskiren,385,89,O
were,385,99,O
significantly,385,104,O
increased,385,118,O
.,385,128,O
The,386,0,O
recommended,386,4,O
initial,386,16,O
dose,386,24,O
of,386,29,O
Tenex,386,32,O
(,386,38,O
guanfacine,386,40,O
hydrochloride,386,51,O
),386,65,O
when,386,67,O
given,386,72,O
alone,386,78,O
or,386,84,O
in,386,87,O
combination,386,90,O
with,386,102,O
another,386,107,O
antihypertensive,386,115,O
drug,386,132,O
is,386,137,O
1,386,140,O
mg,386,142,O
daily,386,145,O
given,386,151,O
at,386,157,O
bedtime,386,160,O
to,386,168,O
minimize,386,171,O
somnolence,386,180,O
.,386,191,O
Anticoagulants,387,0,O
Ten,387,15,O
patients,387,19,O
who,387,28,O
were,387,32,O
stabilized,387,37,O
on,387,48,O
oral,387,51,O
anticoagulants,387,56,O
were,387,71,O
given,387,76,O
guanfacine,387,82,O
",",387,92,O
1,387,94,O
-,387,96,O
2,387,98,O
mg/day,387,100,O
",",387,106,O
for,387,108,O
4,387,112,O
weeks,387,114,O
.,387,119,O
Further,388,0,O
",",388,7,O
if,388,9,O
guanfacine,388,12,O
is,388,23,O
to,388,26,O
be,388,29,O
discontinued,388,32,O
in,388,45,O
such,388,48,O
patients,388,53,O
",",388,61,O
careful,388,63,O
tapering,388,71,O
of,388,80,O
the,388,83,O
dosage,388,87,O
may,388,94,O
be,388,98,O
necessary,388,101,O
in,388,111,O
order,388,114,O
to,388,120,O
avoid,388,123,O
rebound,388,129,O
phenomena,388,137,O
(,388,147,O
see,388,148,O
Rebound,388,152,O
above,388,160,O
),388,165,O
.,388,166,O
In,389,0,O
several,389,3,O
well-controlled,389,11,O
studies,389,27,O
",",389,35,O
guanfacine,389,37,O
was,389,48,O
administered,389,52,O
together,389,65,O
with,389,74,O
diuretics,389,79,O
with,389,89,O
no,389,94,O
drug,389,97,O
interactions,389,102,O
reported,389,115,O
.,389,124,O
In,390,0,O
such,390,3,O
cases,390,8,O
",",390,13,O
therefore,390,15,O
",",390,24,O
more,390,26,O
frequent,390,31,O
dosing,390,40,O
may,390,47,O
be,390,51,O
required,390,54,O
to,390,63,O
achieve,390,66,O
or,390,74,O
maintain,390,77,O
the,390,86,O
desired,390,90,O
hypotensive,390,98,O
response,390,110,O
.,390,118,O
In,391,0,O
the,391,3,O
long-term,391,7,O
safety,391,17,O
studies,391,24,O
",",391,31,O
Tenex,391,33,O
was,391,39,O
given,391,43,O
concomitantly,391,49,O
with,391,63,O
many,391,68,O
drugs,391,73,O
without,391,79,O
evidence,391,87,O
of,391,96,O
any,391,99,O
interactions,391,103,O
.,391,115,O
No,392,0,O
changes,392,3,O
were,392,11,O
observed,392,16,O
in,392,25,O
the,392,28,O
degree,392,32,O
of,392,39,O
anticoagulation,392,42,O
.,392,57,O
Ten,393,0,O
patients,393,4,O
who,393,13,O
were,393,17,O
stabilized,393,22,O
on,393,33,O
oral,393,36,O
anticoagulants,393,41,O
were,393,56,O
given,393,61,O
guanfacine,393,67,O
",",393,78,O
1,393,80,O
-,393,82,O
2,393,84,O
mg/day,393,86,O
",",393,93,O
for,393,95,O
4,393,99,O
weeks,393,101,O
.,393,107,O
The,394,0,O
administration,394,4,O
of,394,19,O
guanfacine,394,22,O
concomitantly,394,33,O
with,394,47,O
a,394,52,O
known,394,54,O
microsomal,394,60,O
enzyme,394,71,O
inducer,394,78,O
(,394,86,O
phenobarbital,394,88,O
or,394,102,O
phenytoin,394,105,O
),394,115,O
to,394,117,O
two,394,120,O
patients,394,124,O
with,394,133,O
renal,394,138,O
impairment,394,144,O
reportedly,394,155,O
resulted,394,166,O
in,394,175,O
significant,394,178,O
reductions,394,190,O
in,394,201,O
elimination,394,204,O
half-life,394,216,O
and,394,226,O
plasma,394,230,O
concentration,394,237,O
.,394,251,O
The,394,0,O
administration,394,4,O
of,394,19,O
guanfacine,394,22,O
concomitantly,394,33,O
with,394,47,O
a,394,52,O
known,394,54,O
microsomal,394,60,O
enzyme,394,71,O
inducer,394,78,O
(,394,86,O
phenobarbital,394,88,O
or,394,102,O
phenytoin,394,105,O
),394,115,O
to,394,117,O
two,394,120,O
patients,394,124,O
with,394,133,O
renal,394,138,O
impairment,394,144,O
reportedly,394,155,O
resulted,394,166,O
in,394,175,O
significant,394,178,O
reductions,394,190,O
in,394,201,O
elimination,394,204,O
half-life,394,216,O
and,394,226,O
plasma,394,230,O
concentration,394,237,O
.,394,251,O
The,394,0,O
administration,394,4,O
of,394,19,O
guanfacine,394,22,O
concomitantly,394,33,O
with,394,47,O
a,394,52,O
known,394,54,O
microsomal,394,60,O
enzyme,394,71,O
inducer,394,78,O
(,394,86,O
phenobarbital,394,88,O
or,394,102,O
phenytoin,394,105,O
),394,115,O
to,394,117,O
two,394,120,O
patients,394,124,O
with,394,133,O
renal,394,138,O
impairment,394,144,O
reportedly,394,155,O
resulted,394,166,O
in,394,175,O
significant,394,178,O
reductions,394,190,O
in,394,201,O
elimination,394,204,O
half-life,394,216,O
and,394,226,O
plasma,394,230,O
concentration,394,237,O
.,394,251,O
The,394,0,O
administration,394,4,O
of,394,19,O
guanfacine,394,22,O
concomitantly,394,33,O
with,394,47,O
a,394,52,O
known,394,54,O
microsomal,394,60,O
enzyme,394,71,O
inducer,394,78,O
(,394,86,O
phenobarbital,394,88,O
or,394,102,O
phenytoin,394,105,O
),394,115,O
to,394,117,O
two,394,120,O
patients,394,124,O
with,394,133,O
renal,394,138,O
impairment,394,144,O
reportedly,394,155,O
resulted,394,166,O
in,394,175,O
significant,394,178,O
reductions,394,190,O
in,394,201,O
elimination,394,204,O
half-life,394,216,O
and,394,226,O
plasma,394,230,O
concentration,394,237,O
.,394,251,O
The,394,0,O
administration,394,4,O
of,394,19,O
guanfacine,394,22,O
concomitantly,394,33,O
with,394,47,O
a,394,52,O
known,394,54,O
microsomal,394,60,O
enzyme,394,71,O
inducer,394,78,O
(,394,86,O
phenobarbital,394,88,O
or,394,102,O
phenytoin,394,105,O
),394,115,O
to,394,117,O
two,394,120,O
patients,394,124,O
with,394,133,O
renal,394,138,O
impairment,394,144,O
reportedly,394,155,O
resulted,394,166,O
in,394,175,O
significant,394,178,O
reductions,394,190,O
in,394,201,O
elimination,394,204,O
half-life,394,216,O
and,394,226,O
plasma,394,230,O
concentration,394,237,O
.,394,251,O
The,394,0,O
administration,394,4,O
of,394,19,O
guanfacine,394,22,O
concomitantly,394,33,O
with,394,47,O
a,394,52,O
known,394,54,O
microsomal,394,60,O
enzyme,394,71,O
inducer,394,78,O
(,394,86,O
phenobarbital,394,88,O
or,394,102,O
phenytoin,394,105,O
),394,115,O
to,394,117,O
two,394,120,O
patients,394,124,O
with,394,133,O
renal,394,138,O
impairment,394,144,O
reportedly,394,155,O
resulted,394,166,O
in,394,175,O
significant,394,178,O
reductions,394,190,O
in,394,201,O
elimination,394,204,O
half-life,394,216,O
and,394,226,O
plasma,394,230,O
concentration,394,237,O
.,394,251,O
The,395,0,O
potential,395,4,O
for,395,14,O
increased,395,18,B-SpecificInteraction
sedation,395,18,I-SpecificInteraction
when,395,37,O
Tenex,395,42,O
is,395,48,O
given,395,51,O
with,395,57,O
other,395,62,O
CNS-depressant,395,68,O
drugs,395,83,O
should,395,89,O
be,395,96,O
appreciated,395,99,O
.,395,111,O
The,396,0,O
principal,396,4,O
drugs,396,14,O
given,396,20,O
(,396,26,O
number,396,27,O
of,396,34,O
patients,396,37,O
in,396,46,O
parentheses,396,49,O
),396,60,O
were,396,62,O
:,396,66,O
cardiac,396,68,O
glycosides,396,76,O
(,396,87,O
115,396,88,O
),396,91,O
",",396,92,O
sedatives,396,94,O
and,396,104,O
hypnotics,396,108,O
(,396,118,O
103,396,119,O
),396,122,O
",",396,123,O
coronary,396,125,O
vasodilators,396,134,O
(,396,147,O
52,396,148,O
),396,150,O
",",396,151,O
oral,396,153,O
hypoglycemics,396,158,O
(,396,172,O
45,396,173,O
),396,175,O
",",396,176,O
cough,396,178,O
and,396,184,O
cold,396,188,O
preparations,396,193,O
(,396,206,O
45,396,207,O
),396,209,O
",",396,210,O
NSAIDs,396,212,O
(,396,219,O
38,396,220,O
),396,222,O
",",396,223,O
antihyperlipidemics,396,225,O
(,396,245,O
29,396,246,O
),396,248,O
",",396,249,O
antigout,396,251,O
drugs,396,260,O
(,396,266,O
24,396,267,O
),396,269,O
",",396,270,O
oral,396,272,O
contraceptives,396,277,O
(,396,292,O
18,396,293,O
),396,295,O
",",396,296,O
bronchodilators,396,298,O
(,396,314,O
13,396,315,O
),396,317,O
",",396,318,O
insulin,396,320,O
(,396,328,O
10,396,329,O
),396,331,O
",",396,332,O
and,396,334,O
beta,396,338,O
blockers,396,343,O
(,396,352,O
10,396,353,O
),396,355,O
.,396,356,O
Like,397,0,O
other,397,5,O
antihypertensive,397,11,O
agents,397,28,O
",",397,35,O
Tenex,397,37,O
(,397,43,O
guanfacine,397,45,O
hydrochloride,397,56,O
),397,70,O
should,397,72,O
be,397,79,O
used,397,82,O
with,397,87,O
caution,397,92,O
in,397,100,O
patients,397,103,O
with,397,112,O
severe,397,117,O
coronary,397,124,O
insufficiency,397,133,O
",",397,147,O
recent,397,149,O
myocardial,397,156,O
infarction,397,167,O
",",397,178,O
cerebrovascular,397,180,O
disease,397,196,O
",",397,204,O
or,397,206,O
chronic,397,209,O
renal,397,217,O
or,397,223,O
hepatic,397,226,O
failure,397,234,O
.,397,242,O
Tenex,398,0,O
",",398,6,O
like,398,8,O
other,398,13,O
orally,398,19,O
active,398,26,O
central,398,33,O
2-adrenergic,398,41,O
agonists,398,54,O
",",398,63,O
causes,398,65,O
sedation,398,72,O
or,398,81,O
drowsiness,398,84,O
",",398,95,O
especially,398,97,O
when,398,108,O
beginning,398,113,O
therapy,398,123,O
.,398,131,O
When,399,0,O
Tenex,399,5,O
is,399,11,O
used,399,14,O
with,399,19,O
other,399,24,O
centrally,399,30,O
active,399,40,O
depressants,399,47,O
(,399,59,O
such,399,61,O
as,399,66,O
phenothiazines,399,69,O
",",399,84,O
barbiturates,399,86,O
",",399,99,O
or,399,101,O
benzodiazepines,399,104,O
),399,120,O
",",399,122,O
the,399,124,O
potential,399,128,O
for,399,138,O
additive,399,142,B-SpecificInteraction
sedative,399,142,I-SpecificInteraction
effects,399,142,I-SpecificInteraction
should,399,168,O
be,399,175,O
considered,399,178,O
.,399,189,O
When,399,0,O
Tenex,399,5,O
is,399,11,O
used,399,14,O
with,399,19,O
other,399,24,O
centrally,399,30,O
active,399,40,O
depressants,399,47,O
(,399,59,O
such,399,61,O
as,399,66,O
phenothiazines,399,69,O
",",399,84,O
barbiturates,399,86,O
",",399,99,O
or,399,101,O
benzodiazepines,399,104,O
),399,120,O
",",399,122,O
the,399,124,O
potential,399,128,O
for,399,138,O
additive,399,142,B-SpecificInteraction
sedative,399,142,I-SpecificInteraction
effects,399,142,I-SpecificInteraction
should,399,168,O
be,399,175,O
considered,399,178,O
.,399,189,O
When,399,0,O
Tenex,399,5,O
is,399,11,O
used,399,14,O
with,399,19,O
other,399,24,O
centrally,399,30,O
active,399,40,O
depressants,399,47,O
(,399,59,O
such,399,61,O
as,399,66,O
phenothiazines,399,69,O
",",399,84,O
barbiturates,399,86,O
",",399,99,O
or,399,101,O
benzodiazepines,399,104,O
),399,120,O
",",399,122,O
the,399,124,O
potential,399,128,O
for,399,138,O
additive,399,142,B-SpecificInteraction
sedative,399,142,I-SpecificInteraction
effects,399,142,I-SpecificInteraction
should,399,168,O
be,399,175,O
considered,399,178,O
.,399,189,O
When,399,0,O
Tenex,399,5,O
is,399,11,O
used,399,14,O
with,399,19,O
other,399,24,O
centrally,399,30,O
active,399,40,O
depressants,399,47,O
(,399,59,O
such,399,61,O
as,399,66,O
phenothiazines,399,69,O
",",399,84,O
barbiturates,399,86,O
",",399,99,O
or,399,101,O
benzodiazepines,399,104,O
),399,120,O
",",399,122,O
the,399,124,O
potential,399,128,O
for,399,138,O
additive,399,142,B-SpecificInteraction
sedative,399,142,I-SpecificInteraction
effects,399,142,I-SpecificInteraction
should,399,168,O
be,399,175,O
considered,399,178,O
.,399,189,O
Hormonal,323,0,O
contraceptives,323,9,O
",",323,24,O
including,323,26,O
oral,323,36,O
",",323,41,O
injectable,323,43,O
",",323,54,O
transdermal,323,56,O
",",323,68,O
and,323,70,O
implantable,323,74,O
contraceptives,323,86,O
should,323,101,O
not,323,108,O
be,323,112,O
used,323,115,O
as,323,120,O
the,323,123,O
sole,323,127,O
means,323,132,O
of,323,138,O
contraception,323,141,O
because,323,155,O
these,323,163,O
may,323,169,O
not,323,173,O
be,323,177,O
effective,323,180,O
in,323,190,O
patients,323,193,O
receiving,323,202,O
Tracleer,323,212,O
see,323,221,O
Drug,323,225,O
Interactions,323,230,O
(,323,243,O
7.2,323,245,O
),323,249,O
.,323,251,O
After,324,0,O
at,324,6,O
least,324,9,O
10,324,15,O
days,324,18,O
following,324,23,O
the,324,33,O
initiation,324,37,O
of,324,48,O
ritonavir,324,51,O
",",324,61,O
resume,324,63,O
Tracleer,324,70,O
at,324,79,O
the,324,82,O
recommended,324,86,O
initial,324,98,O
dose,324,106,O
once,324,111,O
daily,324,116,O
or,324,122,O
every,324,125,O
other,324,131,O
day,324,137,O
based,324,141,O
upon,324,147,O
individual,324,152,O
tolerability,324,163,O
see,324,176,O
Cytochrome,324,180,O
P450,324,191,O
Drug,324,196,O
Interactions,324,201,O
(,324,214,O
7.1,324,216,O
),324,220,O
.,324,222,O
Co-administration,325,0,O
of,325,18,O
Ritonavir,325,21,O
in,325,31,O
Patients,325,34,O
on,325,43,O
Tracleer,325,46,O
.,325,55,O
Co-administration,326,0,O
of,326,18,O
Tracleer,326,21,O
in,326,30,O
Patients,326,33,O
on,326,42,O
Ritonavir,326,45,O
.,326,55,O
Discontinue,327,0,O
use,327,12,O
of,327,16,O
Tracleer,327,19,O
at,327,28,O
least,327,31,O
36,327,37,O
hours,327,40,O
prior,327,46,O
to,327,52,O
initiation,327,55,O
of,327,66,O
ritonavir,327,69,O
.,327,79,O
In,328,0,O
patients,328,3,O
who,328,12,O
have,328,16,O
been,328,21,O
receiving,328,26,O
ritonavir,328,36,O
for,328,46,O
at,328,50,O
least,328,53,O
10,328,59,O
days,328,62,O
",",328,67,O
start,328,69,O
Tracleer,328,75,O
at,328,84,O
the,328,87,O
recommended,328,91,O
initial,328,103,O
dose,328,111,O
once,328,116,O
daily,328,121,O
or,328,127,O
every,328,130,O
other,328,136,O
day,328,142,O
based,328,146,O
upon,328,152,O
individual,328,157,O
tolerability,328,168,O
see,328,181,O
Cytochrome,328,185,O
P450,328,196,O
Drug,328,201,O
Interactions,328,206,O
(,328,219,O
7.1,328,221,O
),328,225,O
.,328,227,O
An,329,0,O
increased,329,3,O
risk,329,13,O
of,329,18,O
liver,329,21,B-SpecificInteraction
enzyme,329,21,I-SpecificInteraction
elevations,329,21,I-SpecificInteraction
was,329,45,O
observed,329,49,O
in,329,58,O
patients,329,61,O
receiving,329,70,O
glyburide,329,80,O
concomitantly,329,90,O
with,329,104,O
bosentan,329,109,O
.,329,118,O
Co-administration,330,0,O
of,330,18,O
cyclosporine,330,21,O
A,330,34,O
and,330,36,O
bosentan,330,40,O
resulted,330,49,O
in,330,58,O
markedly,330,61,O
increased,330,70,O
plasma,330,80,O
concentrations,330,87,O
of,330,102,O
bosentan,330,105,O
.,330,114,O
Therefore,331,0,O
",",331,10,O
concomitant,331,12,O
use,331,24,O
of,331,28,O
Tracleer,331,31,O
and,331,40,O
cyclosporine,331,44,O
A,331,57,O
is,331,59,O
contraindicated,331,62,O
see,331,78,O
Cytochrome,331,82,O
P450,331,93,O
Drug,331,98,O
Interactions,331,103,O
(,331,116,O
7.1,331,118,O
),331,122,O
.,331,124,O
Therefore,332,0,O
co-administration,332,10,O
of,332,28,O
glyburide,332,31,O
and,332,41,O
Tracleer,332,45,O
is,332,54,O
contraindicated,332,57,O
see,332,73,O
Cytochrome,332,77,O
P450,332,88,O
Drug,332,93,O
Interactions,332,98,O
(,332,111,O
7.1,332,113,O
),332,117,O
.,332,119,O
An,333,0,O
interaction,333,3,O
study,333,15,O
demonstrated,333,21,O
that,333,34,O
co-administration,333,39,O
of,333,57,O
bosentan,333,60,O
and,333,69,O
a,333,73,O
combination,333,75,O
oral,333,87,O
hormonal,333,92,O
contraceptive,333,101,O
produced,333,115,O
average,333,124,O
decreases,333,132,O
of,333,142,O
norethindrone,333,145,O
and,333,159,O
ethinyl,333,163,O
estradiol,333,171,O
levels,333,181,O
of,333,188,O
14,333,191,O
%,333,194,O
and,333,196,O
31,333,200,O
%,333,203,O
",",333,205,O
respectively,333,207,O
.,333,220,O
Bosentan,334,0,O
had,334,9,O
no,334,13,O
relevant,334,16,O
inhibitory,334,25,O
effect,334,36,O
on,334,43,O
any,334,46,O
CYP,334,50,O
isozyme,334,54,O
in,334,62,O
vitro,334,65,O
(,334,71,O
CYP1A2,334,72,O
",",334,78,O
CYP2C9,334,80,O
",",334,86,O
CYP2C19,334,88,O
",",334,95,O
CYP2D6,334,97,O
",",334,103,O
CYP3A,334,105,O
),334,110,O
.,334,111,O
Bosentan,335,0,O
is,335,9,O
an,335,12,O
inducer,335,15,O
of,335,23,O
CYP3A,335,26,O
and,335,32,O
CYP2C9,335,36,O
.,335,42,O
Bosentan,336,0,O
is,336,9,O
metabolized,336,12,O
by,336,24,O
CYP2C9,336,27,O
and,336,34,O
CYP3A,336,38,O
.,336,43,O
Co-administration,337,0,O
of,337,18,O
such,337,21,O
combinations,337,26,O
of,337,39,O
a,337,42,O
CYP2C9,337,44,O
inhibitor,337,51,O
plus,337,61,O
a,337,66,O
strong,337,68,O
or,337,75,O
moderate,337,78,O
CYP3A,337,87,O
inhibitor,337,93,O
with,337,103,O
Tracleer,337,108,O
is,337,117,O
not,337,120,O
recommended,337,124,O
.,337,135,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Concomitant,338,0,O
administration,338,12,O
of,338,27,O
both,338,30,O
a,338,35,O
CYP2C9,338,37,O
inhibitor,338,44,O
(,338,54,O
such,338,56,O
as,338,61,O
fluconazole,338,64,O
or,338,76,O
amiodarone,338,79,O
),338,90,O
and,338,92,O
a,338,96,O
strong,338,98,O
CYP3A,338,105,O
inhibitor,338,111,O
(,338,121,O
e.g.,338,123,O
",",338,128,O
ketoconazole,338,130,O
",",338,143,O
itraconazole,338,145,O
),338,158,O
or,338,160,O
a,338,163,O
moderate,338,165,O
CYP3A,338,174,O
inhibitor,338,180,O
(,338,190,O
e.g.,338,192,O
",",338,197,O
amprenavir,338,199,O
",",338,210,O
erythromycin,338,212,O
",",338,225,O
fluconazole,338,227,O
",",338,239,O
diltiazem,338,241,O
),338,251,O
with,338,253,O
Tracleer,338,258,O
will,338,267,O
likely,338,272,O
lead,338,279,O
to,338,284,O
large,338,287,O
increases,338,293,O
in,338,303,O
plasma,338,306,O
concentrations,338,313,O
of,338,328,O
bosentan,338,331,O
.,338,340,O
Consequently,339,0,O
plasma,339,13,O
concentrations,339,20,O
of,339,35,O
drugs,339,38,O
metabolized,339,44,O
by,339,56,O
these,339,59,O
two,339,65,O
isozymes,339,69,O
will,339,78,O
be,339,83,O
decreased,339,86,O
when,339,96,O
Tracleer,339,101,O
is,339,110,O
co-administered,339,113,O
.,339,128,O
Consequently,340,0,O
",",340,12,O
Tracleer,340,14,O
is,340,23,O
not,340,26,O
expected,340,30,O
to,340,39,O
increase,340,42,O
the,340,51,O
plasma,340,55,O
concentrations,340,62,O
of,340,77,O
drugs,340,80,O
metabolized,340,86,O
by,340,98,O
these,340,101,O
enzymes,340,107,O
.,340,114,O
CYP3A,341,0,O
induction-mediated,341,6,O
effect,341,25,O
of,341,32,O
bosentan,341,35,O
on,341,44,O
other,341,47,O
drugs,341,53,O
.,341,59,O
Cytochrome,342,0,O
P450,342,11,O
:,342,15,O
Coadministration,342,17,O
of,342,34,O
Tracleer,342,37,O
with,342,46,O
drugs,342,51,O
metabolized,342,57,O
by,342,69,O
CYP2C9,342,72,O
and,342,79,O
CYP3A,342,83,O
can,342,89,O
increase,342,93,O
exposure,342,102,O
to,342,111,O
Tracleer,342,114,O
and/or,342,123,O
the,342,130,O
coadministered,342,134,O
drug,342,149,O
(,342,154,O
4.2,342,155,O
",",342,158,O
4.3,342,160,O
",",342,163,O
7.1,342,165,O
),342,168,O
Hormonal,342,170,O
contraceptives,342,179,O
:,342,193,O
Tracleer,342,195,O
use,342,204,O
decreases,342,208,O
contraceptive,342,218,O
exposure,342,232,O
and,342,241,O
reduces,342,245,O
effectiveness,342,253,O
(,342,267,O
7.2,342,268,O
),342,271,O
.,342,272,O
Cytochrome,342,0,O
P450,342,11,O
:,342,15,O
Coadministration,342,17,O
of,342,34,O
Tracleer,342,37,O
with,342,46,O
drugs,342,51,O
metabolized,342,57,O
by,342,69,O
CYP2C9,342,72,O
and,342,79,O
CYP3A,342,83,O
can,342,89,O
increase,342,93,O
exposure,342,102,O
to,342,111,O
Tracleer,342,114,O
and/or,342,123,O
the,342,130,O
coadministered,342,134,O
drug,342,149,O
(,342,154,O
4.2,342,155,O
",",342,158,O
4.3,342,160,O
",",342,163,O
7.1,342,165,O
),342,168,O
Hormonal,342,170,O
contraceptives,342,179,O
:,342,193,O
Tracleer,342,195,O
use,342,204,O
decreases,342,208,O
contraceptive,342,218,O
exposure,342,232,O
and,342,241,O
reduces,342,245,O
effectiveness,342,253,O
(,342,267,O
7.2,342,268,O
),342,271,O
.,342,272,O
Cytochrome,342,0,O
P450,342,11,O
:,342,15,O
Coadministration,342,17,O
of,342,34,O
Tracleer,342,37,O
with,342,46,O
drugs,342,51,O
metabolized,342,57,O
by,342,69,O
CYP2C9,342,72,O
and,342,79,O
CYP3A,342,83,O
can,342,89,O
increase,342,93,O
exposure,342,102,O
to,342,111,O
Tracleer,342,114,O
and/or,342,123,O
the,342,130,O
coadministered,342,134,O
drug,342,149,O
(,342,154,O
4.2,342,155,O
",",342,158,O
4.3,342,160,O
",",342,163,O
7.1,342,165,O
),342,168,O
Hormonal,342,170,O
contraceptives,342,179,O
:,342,193,O
Tracleer,342,195,O
use,342,204,O
decreases,342,208,O
contraceptive,342,218,O
exposure,342,232,O
and,342,241,O
reduces,342,245,O
effectiveness,342,253,O
(,342,267,O
7.2,342,268,O
),342,271,O
.,342,272,O
Cytochrome,342,0,O
P450,342,11,O
:,342,15,O
Coadministration,342,17,O
of,342,34,O
Tracleer,342,37,O
with,342,46,O
drugs,342,51,O
metabolized,342,57,O
by,342,69,O
CYP2C9,342,72,O
and,342,79,O
CYP3A,342,83,O
can,342,89,O
increase,342,93,O
exposure,342,102,O
to,342,111,O
Tracleer,342,114,O
and/or,342,123,O
the,342,130,O
coadministered,342,134,O
drug,342,149,O
(,342,154,O
4.2,342,155,O
",",342,158,O
4.3,342,160,O
",",342,163,O
7.1,342,165,O
),342,168,O
Hormonal,342,170,O
contraceptives,342,179,O
:,342,193,O
Tracleer,342,195,O
use,342,204,O
decreases,342,208,O
contraceptive,342,218,O
exposure,342,232,O
and,342,241,O
reduces,342,245,O
effectiveness,342,253,O
(,342,267,O
7.2,342,268,O
),342,271,O
.,342,272,O
Cytochrome,342,0,O
P450,342,11,O
:,342,15,O
Coadministration,342,17,O
of,342,34,O
Tracleer,342,37,O
with,342,46,O
drugs,342,51,O
metabolized,342,57,O
by,342,69,O
CYP2C9,342,72,O
and,342,79,O
CYP3A,342,83,O
can,342,89,O
increase,342,93,O
exposure,342,102,O
to,342,111,O
Tracleer,342,114,O
and/or,342,123,O
the,342,130,O
coadministered,342,134,O
drug,342,149,O
(,342,154,O
4.2,342,155,O
",",342,158,O
4.3,342,160,O
",",342,163,O
7.1,342,165,O
),342,168,O
Hormonal,342,170,O
contraceptives,342,179,O
:,342,193,O
Tracleer,342,195,O
use,342,204,O
decreases,342,208,O
contraceptive,342,218,O
exposure,342,232,O
and,342,241,O
reduces,342,245,O
effectiveness,342,253,O
(,342,267,O
7.2,342,268,O
),342,271,O
.,342,272,O
Effect,343,0,O
of,343,7,O
other,343,10,O
drugs,343,16,O
on,343,22,O
bosentan,343,25,O
Figure,343,34,O
1,343,41,O
Figure,343,43,O
2,343,50,O
Hormonal,343,52,O
contraceptives,343,61,O
",",343,75,O
including,343,77,O
oral,343,87,O
",",343,91,O
injectable,343,93,O
",",343,103,O
transdermal,343,105,O
",",343,116,O
and,343,118,O
implantable,343,122,O
forms,343,134,O
",",343,139,O
may,343,141,O
not,343,145,O
be,343,149,O
reliable,343,152,O
when,343,161,O
Tracleer,343,166,O
is,343,175,O
co-administered,343,178,O
.,343,193,O
Females,344,0,O
should,344,8,O
practice,344,15,O
additional,344,24,O
methods,344,35,O
of,344,43,O
contraception,344,46,O
and,344,60,O
not,344,64,O
rely,344,68,O
on,344,73,O
hormonal,344,76,O
contraception,344,85,O
alone,344,99,O
when,344,105,O
taking,344,110,O
Tracleer,344,117,O
[,344,126,O
see,344,127,O
Use,344,131,O
in,344,135,O
Specific,344,138,O
Populations,344,147,O
(,344,159,O
8.3,344,160,O
),344,163,O
],344,164,O
.,344,165,O
Hormonal,345,0,O
contraceptives,345,9,O
",",345,24,O
including,345,26,O
oral,345,36,O
",",345,41,O
injectable,345,43,O
",",345,54,O
transdermal,345,56,O
",",345,68,O
and,345,70,O
implantable,345,74,O
forms,345,86,O
",",345,92,O
may,345,94,O
not,345,98,O
be,345,102,O
reliable,345,105,O
when,345,114,O
Tracleer,345,119,O
is,345,128,O
co-administered,345,131,O
.,345,147,O
Hormonal,346,0,O
contraceptives,346,9,O
:,346,24,O
Tracleer,346,26,O
use,346,35,O
decreases,346,39,O
contraceptive,346,49,O
exposure,346,63,O
and,346,72,O
reduces,346,76,O
effectiveness,346,84,O
(,346,98,O
7.2,346,100,O
),346,104,O
.,346,106,O
However,347,0,O
",",347,7,O
decreases,347,9,O
in,347,19,O
exposure,347,22,O
were,347,31,O
as,347,36,O
much,347,39,O
as,347,44,O
56,347,47,O
%,347,49,O
and,347,51,O
66,347,55,O
%,347,57,O
",",347,58,O
respectively,347,60,O
",",347,72,O
in,347,74,O
individual,347,77,O
subjects,347,88,O
.,347,96,O
Inhibition,348,0,O
of,348,11,O
these,348,14,O
enzymes,348,20,O
may,348,28,O
increase,348,32,O
the,348,41,O
plasma,348,45,O
concentration,348,52,O
of,348,66,O
bosentan,348,69,O
[,348,78,O
see,348,79,O
Pharmacokinetics,348,83,O
(,348,100,O
12.3,348,101,O
),348,105,O
],348,106,O
.,348,107,O
Peripheral,349,0,O
edema,349,11,O
is,349,17,O
a,349,20,O
known,349,22,O
clinical,349,28,O
consequence,349,37,O
of,349,49,O
PAH,349,52,O
and,349,56,O
worsening,349,60,O
PAH,349,70,O
and,349,74,O
is,349,78,O
also,349,81,O
a,349,86,O
known,349,88,O
effect,349,94,O
of,349,101,O
Tracleer,349,104,O
and,349,113,O
other,349,117,O
endothelin,349,123,O
receptor,349,134,O
antagonists,349,143,O
.,349,155,O
Preclinical,350,0,O
data,350,12,O
also,350,17,O
suggest,350,22,O
that,350,30,O
Tracleer,350,35,O
",",350,44,O
similar,350,46,O
to,350,54,O
other,350,57,O
endothelin,350,63,O
receptor,350,74,O
antagonists,350,83,O
",",350,95,O
may,350,97,O
have,350,101,O
an,350,106,O
adverse,350,109,O
effect,350,117,O
on,350,124,O
spermatogenesis,350,127,O
see,350,143,O
Adverse,350,147,O
Reactions,350,155,O
(,350,165,O
6.1,350,167,O
),350,171,O
",",350,173,O
Nonclinical,350,175,O
Toxicology,350,187,O
(,350,198,O
13.1,350,200,O
),350,205,O
.,350,207,O
Add,102,0,O
50,102,4,O
mL,102,7,O
of,102,10,O
Bicitra,102,13,O
Registered,102,21,O
trademark,102,32,O
of,102,42,O
Alza,102,45,O
Corporation,102,50,O
to,102,62,O
a,102,65,O
polyethylene,102,67,O
terephthalate,102,80,O
(,102,94,O
PET,102,96,O
),102,100,O
bottle,102,102,O
containing,102,109,O
ten,102,120,O
20,102,124,O
mg,102,127,O
tablets,102,130,O
of,102,138,O
VASOTEC,102,141,O
and,102,149,O
shake,102,153,O
for,102,159,O
at,102,163,O
least,102,166,O
2,102,172,O
minutes,102,174,O
.,102,182,O
Concomitant,103,0,O
administration,103,12,O
of,103,27,O
VASOTEC,103,30,O
with,103,38,O
potassium,103,43,O
supplements,103,53,O
",",103,65,O
potassium,103,67,O
salt,103,77,O
substitutes,103,82,O
",",103,94,O
or,103,96,O
potassium-sparing,103,99,O
diuretics,103,117,O
may,103,127,O
lead,103,131,O
to,103,136,O
increases,103,139,B-SpecificInteraction
of,103,139,I-SpecificInteraction
serum,103,139,I-SpecificInteraction
potassium,103,139,I-SpecificInteraction
(,103,168,O
see,103,170,O
PRECAUTIONS,103,174,O
),103,186,O
.,103,188,O
Concomitant,103,0,O
administration,103,12,O
of,103,27,O
VASOTEC,103,30,O
with,103,38,O
potassium,103,43,O
supplements,103,53,O
",",103,65,O
potassium,103,67,O
salt,103,77,O
substitutes,103,82,O
",",103,94,O
or,103,96,O
potassium-sparing,103,99,O
diuretics,103,117,O
may,103,127,O
lead,103,131,O
to,103,136,O
increases,103,139,B-SpecificInteraction
of,103,139,I-SpecificInteraction
serum,103,139,I-SpecificInteraction
potassium,103,139,I-SpecificInteraction
(,103,168,O
see,103,170,O
PRECAUTIONS,103,174,O
),103,186,O
.,103,188,O
Concomitant,103,0,O
administration,103,12,O
of,103,27,O
VASOTEC,103,30,O
with,103,38,O
potassium,103,43,O
supplements,103,53,O
",",103,65,O
potassium,103,67,O
salt,103,77,O
substitutes,103,82,O
",",103,94,O
or,103,96,O
potassium-sparing,103,99,O
diuretics,103,117,O
may,103,127,O
lead,103,131,O
to,103,136,O
increases,103,139,B-SpecificInteraction
of,103,139,I-SpecificInteraction
serum,103,139,I-SpecificInteraction
potassium,103,139,I-SpecificInteraction
(,103,168,O
see,103,170,O
PRECAUTIONS,103,174,O
),103,186,O
.,103,188,O
If,104,0,O
blood,104,3,O
pressure,104,9,O
is,104,18,O
not,104,21,O
controlled,104,25,O
with,104,36,O
VASOTEC,104,41,O
alone,104,49,O
",",104,55,O
a,104,57,O
diuretic,104,59,O
may,104,68,O
be,104,72,O
added,104,75,O
.,104,81,O
In,105,0,O
patients,105,3,O
who,105,12,O
are,105,16,O
currently,105,20,O
being,105,30,O
treated,105,36,O
with,105,44,O
a,105,49,O
diuretic,105,51,O
",",105,60,O
symptomatic,105,62,B-SpecificInteraction
hypotension,105,62,I-SpecificInteraction
occasionally,105,86,O
may,105,99,O
occur,105,103,O
following,105,109,O
the,105,119,O
initial,105,123,O
dose,105,131,O
of,105,136,O
VASOTEC,105,139,O
.,105,147,O
The,106,0,O
diuretic,106,4,O
should,106,13,O
",",106,20,O
if,106,22,O
possible,106,25,O
",",106,34,O
be,106,36,O
discontinued,106,39,O
for,106,52,O
two,106,56,O
to,106,60,O
three,106,63,O
days,106,69,O
before,106,74,O
beginning,106,81,O
therapy,106,91,O
with,106,99,O
VASOTEC,106,104,O
to,106,112,O
reduce,106,115,O
the,106,122,O
likelihood,106,126,O
of,106,137,O
hypotension,106,140,B-SpecificInteraction
(,106,152,O
see,106,154,O
WARNINGS,106,158,O
),106,167,O
.,106,169,O
VASOTEC,107,0,O
is,107,8,O
indicated,107,11,O
for,107,21,O
the,107,25,O
treatment,107,29,O
of,107,39,O
symptomatic,107,42,O
heart,107,54,O
failure,107,60,O
",",107,68,O
usually,107,70,O
in,107,78,O
combination,107,81,O
with,107,93,O
diuretics,107,98,O
and,107,108,O
digitalis,107,112,O
.,107,122,O
Do,108,0,O
not,108,3,O
administer,108,7,O
VASOTEC,108,18,O
within,108,26,O
36,108,33,O
hours,108,36,O
of,108,42,O
switching,108,45,O
to,108,55,O
or,108,58,O
from,108,61,O
sacubitril/valsartan,108,66,O
",",108,87,O
a,108,89,O
neprilysin,108,91,O
inhibitor,108,102,O
(,108,112,O
see,108,114,O
WARNINGS,108,118,O
),108,127,O
.,108,129,O
Do,108,0,O
not,108,3,O
administer,108,7,O
VASOTEC,108,18,O
within,108,26,O
36,108,33,O
hours,108,36,O
of,108,42,O
switching,108,45,O
to,108,55,O
or,108,58,O
from,108,61,O
sacubitril/valsartan,108,66,O
",",108,87,O
a,108,89,O
neprilysin,108,91,O
inhibitor,108,102,O
(,108,112,O
see,108,114,O
WARNINGS,108,118,O
),108,127,O
.,108,129,O
Do,109,0,O
not,109,3,O
coadminister,109,7,O
aliskiren,109,20,O
with,109,30,O
VASOTEC,109,35,O
in,109,43,O
patients,109,46,O
with,109,55,O
diabetes,109,60,O
(,109,69,O
see,109,71,O
PRECAUTIONS,109,75,O
",",109,87,O
Drug,109,89,O
Interactions,109,94,O
),109,107,O
.,109,109,O
VASOTEC,110,0,O
is,110,8,O
contraindicated,110,11,O
in,110,27,O
combination,110,30,O
with,110,42,O
a,110,47,O
neprilysin,110,49,O
inhibitor,110,60,O
(,110,70,O
e.g.,110,72,O
",",110,77,O
sacubitril,110,79,O
),110,90,O
.,110,92,O
VASOTEC,110,0,O
is,110,8,O
contraindicated,110,11,O
in,110,27,O
combination,110,30,O
with,110,42,O
a,110,47,O
neprilysin,110,49,O
inhibitor,110,60,O
(,110,70,O
e.g.,110,72,O
",",110,77,O
sacubitril,110,79,O
),110,90,O
.,110,92,O
VASOTEC,111,0,O
is,111,8,O
contraindicated,111,11,O
in,111,27,O
patients,111,30,O
who,111,39,O
are,111,43,O
hypersensitive,111,47,O
to,111,62,O
this,111,65,O
product,111,70,O
and,111,78,O
in,111,82,O
patients,111,85,O
with,111,94,O
a,111,99,O
history,111,101,O
of,111,109,O
angioedema,111,112,O
related,111,123,O
to,111,131,O
previous,111,134,O
treatment,111,143,O
with,111,153,O
an,111,158,O
angiotensin,111,161,O
converting,111,173,O
enzyme,111,184,O
inhibitor,111,191,O
and,111,201,O
in,111,205,O
patients,111,208,O
with,111,217,O
hereditary,111,222,O
or,111,233,O
idiopathic,111,236,O
angioedema,111,247,O
.,111,258,O
Angioedema,112,0,O
of,112,11,O
the,112,14,O
face,112,18,O
",",112,23,O
extremities,112,25,O
",",112,37,O
lips,112,39,O
",",112,44,O
tongue,112,46,O
",",112,53,O
glottis,112,55,O
and/or,112,63,O
larynx,112,70,O
has,112,77,O
been,112,81,O
reported,112,86,O
in,112,95,O
patients,112,98,O
treated,112,107,O
with,112,115,O
angiotensin,112,120,O
converting,112,132,O
enzyme,112,143,O
inhibitors,112,150,O
",",112,161,O
including,112,163,O
VASOTEC,112,173,O
.,112,181,O
If,113,0,O
symptomatic,113,3,B-SpecificInteraction
hypotension,113,3,I-SpecificInteraction
develops,113,27,O
",",113,36,O
a,113,38,O
dose,113,40,O
reduction,113,45,O
or,113,55,O
discontinuation,113,58,O
of,113,74,O
VASOTEC,113,77,O
or,113,85,O
concomitant,113,88,O
diuretic,113,100,O
may,113,109,O
be,113,113,O
necessary,113,116,O
.,113,126,O
In,114,0,O
patients,114,3,O
at,114,12,O
risk,114,15,O
for,114,20,O
excessive,114,24,O
hypotension,114,34,O
",",114,46,O
therapy,114,48,O
should,114,56,O
be,114,63,O
started,114,66,O
under,114,74,O
very,114,80,O
close,114,85,O
medical,114,91,O
supervision,114,99,O
and,114,111,O
such,114,115,O
patients,114,120,O
should,114,129,O
be,114,136,O
followed,114,139,O
closely,114,148,O
for,114,156,O
the,114,160,O
first,114,164,O
two,114,170,O
weeks,114,174,O
of,114,180,O
treatment,114,183,O
and,114,193,O
whenever,114,197,O
the,114,206,O
dose,114,210,O
of,114,215,O
enalapril,114,218,O
and/or,114,228,O
diuretic,114,235,O
is,114,244,O
increased,114,247,O
.,114,257,O
It,115,0,O
may,115,3,O
be,115,7,O
advisable,115,10,O
to,115,20,O
eliminate,115,23,O
the,115,33,O
diuretic,115,37,O
(,115,46,O
except,115,48,O
in,115,55,O
patients,115,58,O
with,115,67,O
heart,115,72,O
failure,115,78,O
),115,86,O
",",115,88,O
reduce,115,90,O
the,115,97,O
diuretic,115,101,O
dose,115,110,O
or,115,115,O
increase,115,118,O
salt,115,127,O
intake,115,132,O
cautiously,115,139,O
before,115,150,O
initiating,115,157,O
therapy,115,168,O
with,115,176,O
VASOTEC,115,181,O
in,115,189,O
patients,115,192,O
at,115,201,O
risk,115,204,O
for,115,209,O
excessive,115,213,O
hypotension,115,223,O
who,115,235,O
are,115,239,O
able,115,243,O
to,115,248,O
tolerate,115,251,O
such,115,260,O
adjustments,115,265,O
(,115,277,O
see,115,279,O
PRECAUTIONS,115,283,O
",",115,295,O
Drug,115,297,O
Interactions,115,302,O
and,115,315,O
ADVERSE,115,319,O
REACTIONS,115,327,O
),115,337,O
.,115,339,O
Presumably,116,0,O
because,116,11,O
angiotensin-converting,116,19,O
enzyme,116,42,O
inhibitors,116,49,O
affect,116,60,O
the,116,67,O
metabolism,116,71,O
of,116,82,O
eicosanoids,116,85,O
and,116,97,O
polypeptides,116,101,O
",",116,114,O
including,116,116,O
endogenous,116,126,O
bradykinin,116,137,O
",",116,148,O
patients,116,150,O
receiving,116,159,O
ACE,116,169,O
inhibitors,116,173,O
(,116,184,O
including,116,186,O
VASOTEC,116,196,O
),116,204,O
may,116,206,O
be,116,210,O
subject,116,213,O
to,116,221,O
a,116,224,O
variety,116,226,O
of,116,234,O
adverse,116,237,O
reactions,116,245,O
",",116,255,O
some,116,257,O
of,116,262,O
them,116,265,O
serious,116,270,O
.,116,278,O
Presumably,116,0,O
because,116,11,O
angiotensin-converting,116,19,O
enzyme,116,42,O
inhibitors,116,49,O
affect,116,60,O
the,116,67,O
metabolism,116,71,O
of,116,82,O
eicosanoids,116,85,O
and,116,97,O
polypeptides,116,101,O
",",116,114,O
including,116,116,O
endogenous,116,126,O
bradykinin,116,137,O
",",116,148,O
patients,116,150,O
receiving,116,159,O
ACE,116,169,O
inhibitors,116,173,O
(,116,184,O
including,116,186,O
VASOTEC,116,196,O
),116,204,O
may,116,206,O
be,116,210,O
subject,116,213,O
to,116,221,O
a,116,224,O
variety,116,226,O
of,116,234,O
adverse,116,237,O
reactions,116,245,O
",",116,255,O
some,116,257,O
of,116,262,O
them,116,265,O
serious,116,270,O
.,116,278,O
Presumably,116,0,O
because,116,11,O
angiotensin-converting,116,19,O
enzyme,116,42,O
inhibitors,116,49,O
affect,116,60,O
the,116,67,O
metabolism,116,71,O
of,116,82,O
eicosanoids,116,85,O
and,116,97,O
polypeptides,116,101,O
",",116,114,O
including,116,116,O
endogenous,116,126,O
bradykinin,116,137,O
",",116,148,O
patients,116,150,O
receiving,116,159,O
ACE,116,169,O
inhibitors,116,173,O
(,116,184,O
including,116,186,O
VASOTEC,116,196,O
),116,204,O
may,116,206,O
be,116,210,O
subject,116,213,O
to,116,221,O
a,116,224,O
variety,116,226,O
of,116,234,O
adverse,116,237,O
reactions,116,245,O
",",116,255,O
some,116,257,O
of,116,262,O
them,116,265,O
serious,116,270,O
.,116,278,O
(,117,0,O
see,117,1,O
WARNINGS,117,5,O
),117,13,O
Dual,117,15,O
blockade,117,20,O
of,117,29,O
the,117,32,O
RAS,117,36,O
with,117,40,O
angiotensin,117,45,O
receptor,117,57,O
blockers,117,66,O
",",117,74,O
ACE,117,76,O
inhibitors,117,80,O
",",117,90,O
or,117,92,O
aliskiren,117,95,O
is,117,105,O
associated,117,108,O
with,117,119,O
increased,117,124,O
risks,117,134,O
of,117,140,O
hypotension,117,143,B-SpecificInteraction
",",117,154,O
hyperkalemia,117,156,B-SpecificInteraction
",",117,168,O
and,117,170,O
changes,117,174,B-SpecificInteraction
in,117,174,I-SpecificInteraction
renal,117,174,I-SpecificInteraction
function,117,174,I-SpecificInteraction
(,117,174,I-SpecificInteraction
including,117,174,I-SpecificInteraction
acute,117,174,I-SpecificInteraction
renal,117,174,I-SpecificInteraction
failure,117,174,I-SpecificInteraction
),117,174,I-SpecificInteraction
compared,117,232,O
to,117,241,O
monotherapy,117,244,O
.,117,255,O
(,117,0,O
see,117,1,O
WARNINGS,117,5,O
),117,13,O
Dual,117,15,O
blockade,117,20,O
of,117,29,O
the,117,32,O
RAS,117,36,O
with,117,40,O
angiotensin,117,45,O
receptor,117,57,O
blockers,117,66,O
",",117,74,O
ACE,117,76,O
inhibitors,117,80,O
",",117,90,O
or,117,92,O
aliskiren,117,95,O
is,117,105,O
associated,117,108,O
with,117,119,O
increased,117,124,O
risks,117,134,O
of,117,140,O
hypotension,117,143,B-SpecificInteraction
",",117,154,O
hyperkalemia,117,156,B-SpecificInteraction
",",117,168,O
and,117,170,O
changes,117,174,B-SpecificInteraction
in,117,174,I-SpecificInteraction
renal,117,174,I-SpecificInteraction
function,117,174,I-SpecificInteraction
(,117,174,I-SpecificInteraction
including,117,174,I-SpecificInteraction
acute,117,174,I-SpecificInteraction
renal,117,174,I-SpecificInteraction
failure,117,174,I-SpecificInteraction
),117,174,I-SpecificInteraction
compared,117,232,O
to,117,241,O
monotherapy,117,244,O
.,117,255,O
(,117,0,O
see,117,1,O
WARNINGS,117,5,O
),117,13,O
Dual,117,15,O
blockade,117,20,O
of,117,29,O
the,117,32,O
RAS,117,36,O
with,117,40,O
angiotensin,117,45,O
receptor,117,57,O
blockers,117,66,O
",",117,74,O
ACE,117,76,O
inhibitors,117,80,O
",",117,90,O
or,117,92,O
aliskiren,117,95,O
is,117,105,O
associated,117,108,O
with,117,119,O
increased,117,124,O
risks,117,134,O
of,117,140,O
hypotension,117,143,B-SpecificInteraction
",",117,154,O
hyperkalemia,117,156,B-SpecificInteraction
",",117,168,O
and,117,170,O
changes,117,174,B-SpecificInteraction
in,117,174,I-SpecificInteraction
renal,117,174,I-SpecificInteraction
function,117,174,I-SpecificInteraction
(,117,174,I-SpecificInteraction
including,117,174,I-SpecificInteraction
acute,117,174,I-SpecificInteraction
renal,117,174,I-SpecificInteraction
failure,117,174,I-SpecificInteraction
),117,174,I-SpecificInteraction
compared,117,232,O
to,117,241,O
monotherapy,117,244,O
.,117,255,O
Agents,118,0,O
Causing,118,7,O
Renin,118,15,O
Release,118,21,O
:,118,28,O
The,118,30,O
antihypertensive,118,34,B-SpecificInteraction
effect,118,34,I-SpecificInteraction
of,118,58,O
VASOTEC,118,61,O
is,118,69,O
augmented,118,72,O
by,118,82,O
antihypertensive,118,85,O
agents,118,102,O
that,118,109,O
cause,118,114,O
renin,118,120,O
release,118,126,O
(,118,134,O
e.g.,118,135,O
",",118,139,O
diuretics,118,141,O
),118,150,O
.,118,151,O
Agents,118,0,O
Causing,118,7,O
Renin,118,15,O
Release,118,21,O
:,118,28,O
The,118,30,O
antihypertensive,118,34,B-SpecificInteraction
effect,118,34,I-SpecificInteraction
of,118,58,O
VASOTEC,118,61,O
is,118,69,O
augmented,118,72,O
by,118,82,O
antihypertensive,118,85,O
agents,118,102,O
that,118,109,O
cause,118,114,O
renin,118,120,O
release,118,126,O
(,118,134,O
e.g.,118,135,O
",",118,139,O
diuretics,118,141,O
),118,150,O
.,118,151,O
Agents,118,0,O
Causing,118,7,O
Renin,118,15,O
Release,118,21,O
:,118,28,O
The,118,30,O
antihypertensive,118,34,B-SpecificInteraction
effect,118,34,I-SpecificInteraction
of,118,58,O
VASOTEC,118,61,O
is,118,69,O
augmented,118,72,O
by,118,82,O
antihypertensive,118,85,O
agents,118,102,O
that,118,109,O
cause,118,114,O
renin,118,120,O
release,118,126,O
(,118,134,O
e.g.,118,135,O
",",118,139,O
diuretics,118,141,O
),118,150,O
.,118,151,O
Agents,119,0,O
Increasing,119,7,O
Serum,119,18,O
Potassium,119,24,O
:,119,33,O
VASOTEC,119,35,O
attenuates,119,43,B-SpecificInteraction
potassium,119,43,I-SpecificInteraction
loss,119,43,I-SpecificInteraction
caused,119,69,O
by,119,76,O
thiazide-type,119,79,O
diuretics,119,93,O
.,119,102,O
Drug,120,0,O
Interactions,120,5,O
Neprilysin,120,18,O
Inhibitors,120,29,O
:,120,39,O
Patients,120,41,O
taking,120,50,O
concomitant,120,57,O
neprilysin,120,69,O
inhibitors,120,80,O
may,120,91,O
be,120,95,O
at,120,98,O
increased,120,101,O
risk,120,111,O
for,120,116,O
angioedema,120,120,B-SpecificInteraction
.,120,130,O
Gold,121,0,O
:,121,4,O
Nitritoid,121,6,B-SpecificInteraction
reactions,121,6,I-SpecificInteraction
(,121,26,O
symptoms,121,27,O
include,121,36,O
facial,121,44,B-SpecificInteraction
flushing,121,44,I-SpecificInteraction
",",121,59,O
nausea,121,61,B-SpecificInteraction
",",121,67,O
vomiting,121,69,B-SpecificInteraction
and,121,78,O
hypotension,121,82,B-SpecificInteraction
),121,93,O
have,121,95,O
been,121,100,O
reported,121,105,O
rarely,121,114,O
in,121,121,O
patients,121,124,O
on,121,133,O
therapy,121,136,O
with,121,144,O
injectable,121,149,O
gold,121,160,O
(,121,165,O
sodium,121,166,O
aurothiomalate,121,173,O
),121,187,O
and,121,189,O
concomitant,121,193,O
ACE,121,205,O
inhibitor,121,209,O
therapy,121,219,O
including,121,227,O
VASOTEC.,121,237,O
mTOR,121,246,O
(,121,251,O
mammalian,121,252,O
target,121,262,O
of,121,269,O
rapamycin,121,272,O
),121,281,O
inhibitors,121,283,O
:,121,293,O
Patients,121,295,O
receiving,121,304,O
coadministration,121,314,O
of,121,331,O
ACE,121,334,O
inhibitor,121,338,O
and,121,348,O
mTOR,121,352,O
inhibitor,121,357,O
(,121,367,O
e.g.,121,368,O
",",121,372,O
temsirolimus,121,374,O
",",121,386,O
sirolimus,121,388,O
",",121,397,O
everolimus,121,399,O
),121,409,O
therapy,121,411,O
may,121,419,O
be,121,423,O
at,121,426,O
increased,121,429,O
risk,121,439,O
for,121,444,O
angioedema,121,448,B-SpecificInteraction
(,121,459,O
see,121,460,O
WARNINGS,121,464,O
),121,472,O
.,121,473,O
Gold,121,0,O
:,121,4,O
Nitritoid,121,6,B-SpecificInteraction
reactions,121,6,I-SpecificInteraction
(,121,26,O
symptoms,121,27,O
include,121,36,O
facial,121,44,B-SpecificInteraction
flushing,121,44,I-SpecificInteraction
",",121,59,O
nausea,121,61,B-SpecificInteraction
",",121,67,O
vomiting,121,69,B-SpecificInteraction
and,121,78,O
hypotension,121,82,B-SpecificInteraction
),121,93,O
have,121,95,O
been,121,100,O
reported,121,105,O
rarely,121,114,O
in,121,121,O
patients,121,124,O
on,121,133,O
therapy,121,136,O
with,121,144,O
injectable,121,149,O
gold,121,160,O
(,121,165,O
sodium,121,166,O
aurothiomalate,121,173,O
),121,187,O
and,121,189,O
concomitant,121,193,O
ACE,121,205,O
inhibitor,121,209,O
therapy,121,219,O
including,121,227,O
VASOTEC.,121,237,O
mTOR,121,246,O
(,121,251,O
mammalian,121,252,O
target,121,262,O
of,121,269,O
rapamycin,121,272,O
),121,281,O
inhibitors,121,283,O
:,121,293,O
Patients,121,295,O
receiving,121,304,O
coadministration,121,314,O
of,121,331,O
ACE,121,334,O
inhibitor,121,338,O
and,121,348,O
mTOR,121,352,O
inhibitor,121,357,O
(,121,367,O
e.g.,121,368,O
",",121,372,O
temsirolimus,121,374,O
",",121,386,O
sirolimus,121,388,O
",",121,397,O
everolimus,121,399,O
),121,409,O
therapy,121,411,O
may,121,419,O
be,121,423,O
at,121,426,O
increased,121,429,O
risk,121,439,O
for,121,444,O
angioedema,121,448,B-SpecificInteraction
(,121,459,O
see,121,460,O
WARNINGS,121,464,O
),121,472,O
.,121,473,O
Gold,121,0,O
:,121,4,O
Nitritoid,121,6,B-SpecificInteraction
reactions,121,6,I-SpecificInteraction
(,121,26,O
symptoms,121,27,O
include,121,36,O
facial,121,44,B-SpecificInteraction
flushing,121,44,I-SpecificInteraction
",",121,59,O
nausea,121,61,B-SpecificInteraction
",",121,67,O
vomiting,121,69,B-SpecificInteraction
and,121,78,O
hypotension,121,82,B-SpecificInteraction
),121,93,O
have,121,95,O
been,121,100,O
reported,121,105,O
rarely,121,114,O
in,121,121,O
patients,121,124,O
on,121,133,O
therapy,121,136,O
with,121,144,O
injectable,121,149,O
gold,121,160,O
(,121,165,O
sodium,121,166,O
aurothiomalate,121,173,O
),121,187,O
and,121,189,O
concomitant,121,193,O
ACE,121,205,O
inhibitor,121,209,O
therapy,121,219,O
including,121,227,O
VASOTEC.,121,237,O
mTOR,121,246,O
(,121,251,O
mammalian,121,252,O
target,121,262,O
of,121,269,O
rapamycin,121,272,O
),121,281,O
inhibitors,121,283,O
:,121,293,O
Patients,121,295,O
receiving,121,304,O
coadministration,121,314,O
of,121,331,O
ACE,121,334,O
inhibitor,121,338,O
and,121,348,O
mTOR,121,352,O
inhibitor,121,357,O
(,121,367,O
e.g.,121,368,O
",",121,372,O
temsirolimus,121,374,O
",",121,386,O
sirolimus,121,388,O
",",121,397,O
everolimus,121,399,O
),121,409,O
therapy,121,411,O
may,121,419,O
be,121,423,O
at,121,426,O
increased,121,429,O
risk,121,439,O
for,121,444,O
angioedema,121,448,B-SpecificInteraction
(,121,459,O
see,121,460,O
WARNINGS,121,464,O
),121,472,O
.,121,473,O
Gold,121,0,O
:,121,4,O
Nitritoid,121,6,B-SpecificInteraction
reactions,121,6,I-SpecificInteraction
(,121,26,O
symptoms,121,27,O
include,121,36,O
facial,121,44,B-SpecificInteraction
flushing,121,44,I-SpecificInteraction
",",121,59,O
nausea,121,61,B-SpecificInteraction
",",121,67,O
vomiting,121,69,B-SpecificInteraction
and,121,78,O
hypotension,121,82,B-SpecificInteraction
),121,93,O
have,121,95,O
been,121,100,O
reported,121,105,O
rarely,121,114,O
in,121,121,O
patients,121,124,O
on,121,133,O
therapy,121,136,O
with,121,144,O
injectable,121,149,O
gold,121,160,O
(,121,165,O
sodium,121,166,O
aurothiomalate,121,173,O
),121,187,O
and,121,189,O
concomitant,121,193,O
ACE,121,205,O
inhibitor,121,209,O
therapy,121,219,O
including,121,227,O
VASOTEC.,121,237,O
mTOR,121,246,O
(,121,251,O
mammalian,121,252,O
target,121,262,O
of,121,269,O
rapamycin,121,272,O
),121,281,O
inhibitors,121,283,O
:,121,293,O
Patients,121,295,O
receiving,121,304,O
coadministration,121,314,O
of,121,331,O
ACE,121,334,O
inhibitor,121,338,O
and,121,348,O
mTOR,121,352,O
inhibitor,121,357,O
(,121,367,O
e.g.,121,368,O
",",121,372,O
temsirolimus,121,374,O
",",121,386,O
sirolimus,121,388,O
",",121,397,O
everolimus,121,399,O
),121,409,O
therapy,121,411,O
may,121,419,O
be,121,423,O
at,121,426,O
increased,121,429,O
risk,121,439,O
for,121,444,O
angioedema,121,448,B-SpecificInteraction
(,121,459,O
see,121,460,O
WARNINGS,121,464,O
),121,472,O
.,121,473,O
Gold,121,0,O
:,121,4,O
Nitritoid,121,6,B-SpecificInteraction
reactions,121,6,I-SpecificInteraction
(,121,26,O
symptoms,121,27,O
include,121,36,O
facial,121,44,B-SpecificInteraction
flushing,121,44,I-SpecificInteraction
",",121,59,O
nausea,121,61,B-SpecificInteraction
",",121,67,O
vomiting,121,69,B-SpecificInteraction
and,121,78,O
hypotension,121,82,B-SpecificInteraction
),121,93,O
have,121,95,O
been,121,100,O
reported,121,105,O
rarely,121,114,O
in,121,121,O
patients,121,124,O
on,121,133,O
therapy,121,136,O
with,121,144,O
injectable,121,149,O
gold,121,160,O
(,121,165,O
sodium,121,166,O
aurothiomalate,121,173,O
),121,187,O
and,121,189,O
concomitant,121,193,O
ACE,121,205,O
inhibitor,121,209,O
therapy,121,219,O
including,121,227,O
VASOTEC.,121,237,O
mTOR,121,246,O
(,121,251,O
mammalian,121,252,O
target,121,262,O
of,121,269,O
rapamycin,121,272,O
),121,281,O
inhibitors,121,283,O
:,121,293,O
Patients,121,295,O
receiving,121,304,O
coadministration,121,314,O
of,121,331,O
ACE,121,334,O
inhibitor,121,338,O
and,121,348,O
mTOR,121,352,O
inhibitor,121,357,O
(,121,367,O
e.g.,121,368,O
",",121,372,O
temsirolimus,121,374,O
",",121,386,O
sirolimus,121,388,O
",",121,397,O
everolimus,121,399,O
),121,409,O
therapy,121,411,O
may,121,419,O
be,121,423,O
at,121,426,O
increased,121,429,O
risk,121,439,O
for,121,444,O
angioedema,121,448,B-SpecificInteraction
(,121,459,O
see,121,460,O
WARNINGS,121,464,O
),121,472,O
.,121,473,O
However,122,0,O
",",122,7,O
reports,122,9,O
suggest,122,17,O
that,122,25,O
NSAIDs,122,30,O
may,122,37,O
diminish,122,41,O
the,122,50,O
antihypertensive,122,54,O
effect,122,71,O
of,122,78,O
ACE,122,81,O
inhibitors,122,85,O
.,122,95,O
Hypotension,123,0,O
Patients,123,13,O
on,123,22,O
Diuretic,123,25,O
Therapy,123,34,O
:,123,41,O
Patients,123,43,O
on,123,52,O
diuretics,123,55,O
and,123,65,O
especially,123,69,O
those,123,80,O
in,123,86,O
whom,123,89,O
diuretic,123,94,O
therapy,123,103,O
was,123,111,O
recently,123,115,O
instituted,123,124,O
",",123,134,O
may,123,136,O
occasionally,123,140,O
experience,123,153,O
an,123,164,O
excessive,123,167,B-SpecificInteraction
reduction,123,167,I-SpecificInteraction
of,123,167,I-SpecificInteraction
blood,123,167,I-SpecificInteraction
pressure,123,167,I-SpecificInteraction
after,123,205,O
initiation,123,211,O
of,123,222,O
therapy,123,225,O
with,123,233,O
enalapril,123,238,O
.,123,247,O
If,124,0,O
it,124,3,O
is,124,6,O
necessary,124,9,O
to,124,19,O
continue,124,22,O
the,124,31,O
diuretic,124,35,O
",",124,43,O
provide,124,45,O
close,124,53,O
medical,124,59,O
supervision,124,67,O
after,124,79,O
the,124,85,O
initial,124,89,O
dose,124,97,O
for,124,102,O
at,124,106,O
least,124,109,O
two,124,115,O
hours,124,119,O
and,124,125,O
until,124,129,O
blood,124,135,O
pressure,124,141,O
has,124,150,O
stabilized,124,154,O
for,124,165,O
at,124,169,O
least,124,172,O
an,124,178,O
additional,124,181,O
hour,124,192,O
(,124,197,O
see,124,198,O
WARNINGS,124,202,O
and,124,211,O
DOSAGE,124,215,O
AND,124,222,O
ADMINISTRATION,124,226,O
),124,241,O
.,124,242,O
In,125,0,O
general,125,3,O
",",125,10,O
avoid,125,12,O
combined,125,18,O
use,125,27,O
of,125,31,O
RAS,125,34,O
inhibitors,125,38,O
.,125,48,O
Lithium,126,0,O
:,126,7,O
Lithium,126,9,O
toxicity,126,17,O
has,126,26,O
been,126,30,O
reported,126,35,O
in,126,44,O
patients,126,47,O
receiving,126,56,O
lithium,126,66,O
concomitantly,126,74,O
with,126,88,O
drugs,126,93,O
which,126,99,O
cause,126,105,O
elimination,126,111,O
of,126,123,O
sodium,126,126,O
",",126,132,O
including,126,134,O
ACE,126,144,O
inhibitors,126,148,O
.,126,158,O
Most,127,0,O
patients,127,5,O
receiving,127,14,O
the,127,24,O
combination,127,28,O
of,127,40,O
two,127,43,O
RAS,127,47,O
inhibitors,127,51,O
do,127,62,O
not,127,65,O
obtain,127,69,O
any,127,76,O
additional,127,80,O
benefit,127,91,O
compared,127,99,O
to,127,108,O
monotherapy,127,111,O
.,127,122,O
Non-Steroidal,128,0,O
Anti-Inflammatory,128,14,O
Agents,128,32,O
including,128,39,O
Selective,128,49,O
Cyclooxygenase-2,128,59,O
Inhibitors,128,76,O
(,128,87,O
COX-2,128,88,O
Inhibitors,128,94,O
),128,104,O
:,128,105,O
In,128,107,O
patients,128,110,O
who,128,119,O
are,128,123,O
elderly,128,127,O
",",128,134,O
volume-depleted,128,136,O
(,128,152,O
including,128,153,O
those,128,163,O
on,128,169,O
diuretic,128,172,O
therapy,128,181,O
),128,188,O
",",128,189,O
or,128,191,O
with,128,194,O
compromised,128,199,O
renal,128,211,O
function,128,217,O
",",128,225,O
coadministration,128,227,O
of,128,244,O
NSAIDs,128,247,O
",",128,253,O
including,128,255,O
selective,128,265,O
COX-2,128,275,O
inhibitors,128,281,O
",",128,291,O
with,128,293,O
ACE,128,298,O
inhibitors,128,302,O
",",128,312,O
including,128,314,O
enalapril,128,324,O
",",128,333,O
may,128,335,O
result,128,339,O
in,128,346,O
deterioration,128,349,B-SpecificInteraction
of,128,349,I-SpecificInteraction
renal,128,349,I-SpecificInteraction
function,128,349,I-SpecificInteraction
",",128,380,O
including,128,382,O
possible,128,392,O
acute,128,401,B-SpecificInteraction
renal,128,401,I-SpecificInteraction
failure,128,401,I-SpecificInteraction
.,128,420,O
Non-Steroidal,128,0,O
Anti-Inflammatory,128,14,O
Agents,128,32,O
including,128,39,O
Selective,128,49,O
Cyclooxygenase-2,128,59,O
Inhibitors,128,76,O
(,128,87,O
COX-2,128,88,O
Inhibitors,128,94,O
),128,104,O
:,128,105,O
In,128,107,O
patients,128,110,O
who,128,119,O
are,128,123,O
elderly,128,127,O
",",128,134,O
volume-depleted,128,136,O
(,128,152,O
including,128,153,O
those,128,163,O
on,128,169,O
diuretic,128,172,O
therapy,128,181,O
),128,188,O
",",128,189,O
or,128,191,O
with,128,194,O
compromised,128,199,O
renal,128,211,O
function,128,217,O
",",128,225,O
coadministration,128,227,O
of,128,244,O
NSAIDs,128,247,O
",",128,253,O
including,128,255,O
selective,128,265,O
COX-2,128,275,O
inhibitors,128,281,O
",",128,291,O
with,128,293,O
ACE,128,298,O
inhibitors,128,302,O
",",128,312,O
including,128,314,O
enalapril,128,324,O
",",128,333,O
may,128,335,O
result,128,339,O
in,128,346,O
deterioration,128,349,B-SpecificInteraction
of,128,349,I-SpecificInteraction
renal,128,349,I-SpecificInteraction
function,128,349,I-SpecificInteraction
",",128,380,O
including,128,382,O
possible,128,392,O
acute,128,401,B-SpecificInteraction
renal,128,401,I-SpecificInteraction
failure,128,401,I-SpecificInteraction
.,128,420,O
Other,129,0,O
Cardiovascular,129,6,O
Agents,129,21,O
:,129,27,O
VASOTEC,129,29,O
has,129,37,O
been,129,41,O
used,129,46,O
concomitantly,129,51,O
with,129,65,O
beta,129,70,O
adrenergic-blocking,129,75,O
agents,129,95,O
",",129,101,O
methyldopa,129,103,O
",",129,113,O
nitrates,129,115,O
",",129,123,O
calcium-blocking,129,125,O
agents,129,142,O
",",129,148,O
hydralazine,129,150,O
",",129,161,O
prazosin,129,163,O
and,129,172,O
digoxin,129,176,O
without,129,184,O
evidence,129,192,O
of,129,201,O
clinically,129,204,O
significant,129,215,O
adverse,129,227,O
interactions,129,235,O
.,129,247,O
Potassium-sparing,130,0,O
diuretics,130,18,O
(,130,28,O
e.g.,130,29,O
",",130,33,O
spironolactone,130,35,O
",",130,49,O
triamterene,130,51,O
",",130,62,O
or,130,64,O
amiloride,130,67,O
),130,76,O
",",130,77,O
potassium,130,79,O
supplements,130,89,O
",",130,100,O
or,130,102,O
potassium-containing,130,105,O
salt,130,126,O
substitutes,130,131,O
may,130,143,O
lead,130,147,O
to,130,152,O
significant,130,155,O
increases,130,167,B-SpecificInteraction
in,130,167,I-SpecificInteraction
serum,130,167,I-SpecificInteraction
potassium,130,167,I-SpecificInteraction
.,130,195,O
Potassium-sparing,130,0,O
diuretics,130,18,O
(,130,28,O
e.g.,130,29,O
",",130,33,O
spironolactone,130,35,O
",",130,49,O
triamterene,130,51,O
",",130,62,O
or,130,64,O
amiloride,130,67,O
),130,76,O
",",130,77,O
potassium,130,79,O
supplements,130,89,O
",",130,100,O
or,130,102,O
potassium-containing,130,105,O
salt,130,126,O
substitutes,130,131,O
may,130,143,O
lead,130,147,O
to,130,152,O
significant,130,155,O
increases,130,167,B-SpecificInteraction
in,130,167,I-SpecificInteraction
serum,130,167,I-SpecificInteraction
potassium,130,167,I-SpecificInteraction
.,130,195,O
Potassium-sparing,130,0,O
diuretics,130,18,O
(,130,28,O
e.g.,130,29,O
",",130,33,O
spironolactone,130,35,O
",",130,49,O
triamterene,130,51,O
",",130,62,O
or,130,64,O
amiloride,130,67,O
),130,76,O
",",130,77,O
potassium,130,79,O
supplements,130,89,O
",",130,100,O
or,130,102,O
potassium-containing,130,105,O
salt,130,126,O
substitutes,130,131,O
may,130,143,O
lead,130,147,O
to,130,152,O
significant,130,155,O
increases,130,167,B-SpecificInteraction
in,130,167,I-SpecificInteraction
serum,130,167,I-SpecificInteraction
potassium,130,167,I-SpecificInteraction
.,130,195,O
Potassium-sparing,130,0,O
diuretics,130,18,O
(,130,28,O
e.g.,130,29,O
",",130,33,O
spironolactone,130,35,O
",",130,49,O
triamterene,130,51,O
",",130,62,O
or,130,64,O
amiloride,130,67,O
),130,76,O
",",130,77,O
potassium,130,79,O
supplements,130,89,O
",",130,100,O
or,130,102,O
potassium-containing,130,105,O
salt,130,126,O
substitutes,130,131,O
may,130,143,O
lead,130,147,O
to,130,152,O
significant,130,155,O
increases,130,167,B-SpecificInteraction
in,130,167,I-SpecificInteraction
serum,130,167,I-SpecificInteraction
potassium,130,167,I-SpecificInteraction
.,130,195,O
Potassium-sparing,130,0,O
diuretics,130,18,O
(,130,28,O
e.g.,130,29,O
",",130,33,O
spironolactone,130,35,O
",",130,49,O
triamterene,130,51,O
",",130,62,O
or,130,64,O
amiloride,130,67,O
),130,76,O
",",130,77,O
potassium,130,79,O
supplements,130,89,O
",",130,100,O
or,130,102,O
potassium-containing,130,105,O
salt,130,126,O
substitutes,130,131,O
may,130,143,O
lead,130,147,O
to,130,152,O
significant,130,155,O
increases,130,167,B-SpecificInteraction
in,130,167,I-SpecificInteraction
serum,130,167,I-SpecificInteraction
potassium,130,167,I-SpecificInteraction
.,130,195,O
Potassium-sparing,130,0,O
diuretics,130,18,O
(,130,28,O
e.g.,130,29,O
",",130,33,O
spironolactone,130,35,O
",",130,49,O
triamterene,130,51,O
",",130,62,O
or,130,64,O
amiloride,130,67,O
),130,76,O
",",130,77,O
potassium,130,79,O
supplements,130,89,O
",",130,100,O
or,130,102,O
potassium-containing,130,105,O
salt,130,126,O
substitutes,130,131,O
may,130,143,O
lead,130,147,O
to,130,152,O
significant,130,155,O
increases,130,167,B-SpecificInteraction
in,130,167,I-SpecificInteraction
serum,130,167,I-SpecificInteraction
potassium,130,167,I-SpecificInteraction
.,130,195,O
Therefore,131,0,O
",",131,9,O
if,131,11,O
concomitant,131,14,O
use,131,26,O
of,131,30,O
these,131,33,O
agents,131,39,O
is,131,46,O
indicated,131,49,O
because,131,59,O
of,131,67,O
demonstrated,131,70,O
hypokalemia,131,83,O
",",131,94,O
they,131,96,O
should,131,101,O
be,131,108,O
used,131,111,O
with,131,116,O
caution,131,121,O
and,131,129,O
with,131,133,O
frequent,131,138,O
monitoring,131,147,O
of,131,158,O
serum,131,161,O
potassium,131,167,O
.,131,176,O
A,132,0,O
few,132,2,O
cases,132,6,O
of,132,12,O
lithium,132,15,O
toxicity,132,23,O
have,132,32,O
been,132,37,O
reported,132,42,O
in,132,51,O
patients,132,54,O
receiving,132,63,O
concomitant,132,73,O
VASOTEC,132,85,O
and,132,93,O
lithium,132,97,O
and,132,105,O
were,132,109,O
reversible,132,114,O
upon,132,125,O
discontinuation,132,130,O
of,132,146,O
both,132,149,O
drugs,132,154,O
.,132,160,O
Angioedema,133,0,O
",",133,11,O
including,133,13,O
laryngeal,133,23,O
edema,133,33,O
",",133,39,O
may,133,41,O
occur,133,45,O
at,133,51,O
any,133,54,O
time,133,58,O
during,133,63,O
treatment,133,70,O
with,133,80,O
angiotensin,133,85,O
converting,133,97,O
enzyme,133,108,O
inhibitors,133,115,O
",",133,126,O
including,133,128,O
enalapril,133,138,O
.,133,148,O
Antihypertensive,134,0,O
effects,134,17,O
of,134,25,O
VASOTEC,134,28,O
have,134,36,O
been,134,41,O
established,134,46,O
in,134,58,O
hypertensive,134,61,O
pediatric,134,74,O
patients,134,84,O
age,134,93,O
1,134,97,O
month,134,99,O
to,134,105,O
16,134,108,O
years,134,111,O
.,134,117,O
As,135,0,O
with,135,3,O
all,135,8,O
vasodilators,135,12,O
",",135,25,O
enalapril,135,27,O
should,135,37,O
be,135,44,O
given,135,47,O
with,135,53,O
caution,135,58,O
to,135,66,O
patients,135,69,O
with,135,78,O
obstruction,135,83,O
in,135,95,O
the,135,98,O
outflow,135,102,O
tract,135,110,O
of,135,116,O
the,135,119,O
left,135,123,O
ventricle,135,128,O
.,135,138,O
Avoid,136,0,O
use,136,6,O
of,136,10,O
aliskiren,136,13,O
with,136,23,O
VASOTEC,136,28,O
in,136,36,O
patients,136,39,O
with,136,48,O
renal,136,53,O
impairment,136,59,O
(,136,70,O
GFR,136,72,O
60,136,76,O
mL/min,136,79,O
),136,86,O
.,136,88,O
Closely,137,0,O
monitor,137,8,O
blood,137,16,O
pressure,137,22,O
",",137,31,O
renal,137,33,O
function,137,39,O
",",137,48,O
and,137,50,O
electrolytes,137,54,O
in,137,67,O
patients,137,70,O
on,137,79,O
VASOTEC,137,82,O
and,137,90,O
other,137,94,O
agents,137,100,O
that,137,107,O
affect,137,112,O
the,137,119,O
RAS,137,123,O
.,137,127,O
Do,138,0,O
not,138,3,O
coadminister,138,7,O
aliskiren,138,20,O
with,138,30,O
VASOTEC,138,35,O
in,138,43,O
patients,138,46,O
with,138,55,O
diabetes,138,60,O
.,138,69,O
Dosage,139,0,O
reduction,139,7,O
and/or,139,17,O
discontinuation,139,24,O
of,139,40,O
the,139,43,O
diuretic,139,47,O
and/or,139,56,O
VASOTEC,139,63,O
may,139,71,O
be,139,75,O
required,139,78,O
.,139,87,O
Enalapril,140,0,O
and,140,10,O
enalaprilat,140,14,O
have,140,26,O
been,140,31,O
detected,140,36,O
in,140,45,O
human,140,48,O
breast,140,54,O
milk,140,61,O
.,140,66,O
In,141,0,O
a,141,3,O
clinical,141,5,O
pharmacology,141,14,O
study,141,27,O
",",141,33,O
indomethacin,141,35,O
or,141,48,O
sulindac,141,51,O
was,141,60,O
administered,141,64,O
to,141,77,O
hypertensive,141,80,O
patients,141,93,O
receiving,141,102,O
VASOTEC,141,112,O
.,141,120,O
In,142,0,O
patients,142,3,O
undergoing,142,12,O
major,142,23,O
surgery,142,29,O
or,142,37,O
during,142,40,O
anesthesia,142,47,O
with,142,58,O
agents,142,63,O
that,142,70,O
produce,142,75,O
hypotension,142,83,O
",",142,95,O
enalapril,142,97,O
may,142,107,O
block,142,111,O
angiotensin,142,117,O
II,142,129,O
formation,142,132,O
secondary,142,142,O
to,142,152,O
compensatory,142,155,O
renin,142,168,O
release,142,174,O
.,142,182,O
In,143,0,O
patients,143,3,O
who,143,12,O
are,143,16,O
elderly,143,20,O
",",143,28,O
volume-depleted,143,30,O
(,143,46,O
including,143,48,O
those,143,58,O
on,143,64,O
diuretic,143,67,O
therapy,143,76,O
),143,84,O
",",143,86,O
or,143,88,O
with,143,91,O
compromised,143,96,O
renal,143,108,O
function,143,114,O
",",143,123,O
coadministration,143,125,O
of,143,142,O
NSAIDs,143,145,O
",",143,152,O
including,143,154,O
selective,143,164,O
COX-2,143,174,O
inhibitors,143,180,O
",",143,191,O
with,143,193,O
ACE,143,198,O
inhibitors,143,202,O
",",143,213,O
including,143,215,O
enalapril,143,225,O
",",143,235,O
may,143,237,O
result,143,241,O
in,143,248,O
deterioration,143,251,B-SpecificInteraction
of,143,251,I-SpecificInteraction
renal,143,251,I-SpecificInteraction
function,143,251,I-SpecificInteraction
",",143,283,O
including,143,285,O
possible,143,295,O
acute,143,304,B-SpecificInteraction
renal,143,304,I-SpecificInteraction
failure,143,304,I-SpecificInteraction
.,143,324,O
In,143,0,O
patients,143,3,O
who,143,12,O
are,143,16,O
elderly,143,20,O
",",143,28,O
volume-depleted,143,30,O
(,143,46,O
including,143,48,O
those,143,58,O
on,143,64,O
diuretic,143,67,O
therapy,143,76,O
),143,84,O
",",143,86,O
or,143,88,O
with,143,91,O
compromised,143,96,O
renal,143,108,O
function,143,114,O
",",143,123,O
coadministration,143,125,O
of,143,142,O
NSAIDs,143,145,O
",",143,152,O
including,143,154,O
selective,143,164,O
COX-2,143,174,O
inhibitors,143,180,O
",",143,191,O
with,143,193,O
ACE,143,198,O
inhibitors,143,202,O
",",143,213,O
including,143,215,O
enalapril,143,225,O
",",143,235,O
may,143,237,O
result,143,241,O
in,143,248,O
deterioration,143,251,B-SpecificInteraction
of,143,251,I-SpecificInteraction
renal,143,251,I-SpecificInteraction
function,143,251,I-SpecificInteraction
",",143,283,O
including,143,285,O
possible,143,295,O
acute,143,304,B-SpecificInteraction
renal,143,304,I-SpecificInteraction
failure,143,304,I-SpecificInteraction
.,143,324,O
In,144,0,O
patients,144,3,O
with,144,12,O
severe,144,17,O
heart,144,24,O
failure,144,30,O
whose,144,38,O
renal,144,44,O
function,144,50,O
may,144,59,O
depend,144,63,O
on,144,70,O
the,144,73,O
activity,144,77,O
of,144,86,O
the,144,89,O
renin-angiotensin-aldosterone,144,93,O
system,144,123,O
",",144,130,O
treatment,144,132,O
with,144,142,O
angiotensin,144,147,O
converting,144,159,O
enzyme,144,170,O
inhibitors,144,177,O
",",144,188,O
including,144,190,O
VASOTEC,144,200,O
",",144,208,O
may,144,210,O
be,144,214,O
associated,144,217,O
with,144,228,O
oliguria,144,233,O
and/or,144,242,O
progressive,144,249,O
azotemia,144,261,O
and,144,270,O
rarely,144,274,O
with,144,281,O
acute,144,286,O
renal,144,292,O
failure,144,298,O
and/or,144,306,O
death,144,313,O
(,144,319,O
see,144,321,O
PRECAUTIONS,144,325,O
",",144,337,O
Drug,144,339,O
Interactions,144,344,O
),144,357,O
.,144,359,O
In,145,0,O
this,145,3,O
study,145,8,O
there,145,14,O
was,145,20,O
no,145,24,O
evidence,145,27,O
of,145,36,O
a,145,39,O
blunting,145,41,O
of,145,50,O
the,145,53,O
antihypertensive,145,57,O
action,145,74,O
of,145,81,O
VASOTEC,145,84,O
.,145,92,O
It,146,0,O
is,146,3,O
recommended,146,6,O
that,146,18,O
serum,146,23,O
lithium,146,29,O
levels,146,37,O
be,146,44,O
monitored,146,47,O
frequently,146,57,O
if,146,68,O
enalapril,146,71,O
is,146,81,O
administered,146,84,O
concomitantly,146,97,O
with,146,111,O
lithium,146,116,O
.,146,124,O
Monitor,147,0,O
renal,147,8,O
function,147,14,O
periodically,147,23,O
in,147,36,O
patients,147,39,O
receiving,147,48,O
enalapril,147,58,O
and,147,68,O
NSAID,147,72,O
therapy,147,78,O
.,147,86,O
Nitritoid,148,0,B-SpecificInteraction
reactions,148,0,I-SpecificInteraction
(,148,20,O
symptoms,148,22,O
include,148,31,O
facial,148,39,B-SpecificInteraction
flushing,148,39,I-SpecificInteraction
",",148,55,O
nausea,148,57,B-SpecificInteraction
",",148,64,O
vomiting,148,66,B-SpecificInteraction
and,148,75,O
hypotension,148,79,B-SpecificInteraction
),148,91,O
have,148,93,O
been,148,98,O
reported,148,103,O
rarely,148,112,O
in,148,119,O
patients,148,122,O
on,148,131,O
therapy,148,134,O
with,148,142,O
injectable,148,147,O
gold,148,158,O
(,148,163,O
sodium,148,165,O
aurothiomalate,148,172,O
),148,187,O
and,148,189,O
concomitant,148,193,O
ACE,148,205,O
inhibitor,148,209,O
therapy,148,219,O
including,148,227,O
VASOTEC,148,237,O
.,148,245,O
Nitritoid,148,0,B-SpecificInteraction
reactions,148,0,I-SpecificInteraction
(,148,20,O
symptoms,148,22,O
include,148,31,O
facial,148,39,B-SpecificInteraction
flushing,148,39,I-SpecificInteraction
",",148,55,O
nausea,148,57,B-SpecificInteraction
",",148,64,O
vomiting,148,66,B-SpecificInteraction
and,148,75,O
hypotension,148,79,B-SpecificInteraction
),148,91,O
have,148,93,O
been,148,98,O
reported,148,103,O
rarely,148,112,O
in,148,119,O
patients,148,122,O
on,148,131,O
therapy,148,134,O
with,148,142,O
injectable,148,147,O
gold,148,158,O
(,148,163,O
sodium,148,165,O
aurothiomalate,148,172,O
),148,187,O
and,148,189,O
concomitant,148,193,O
ACE,148,205,O
inhibitor,148,209,O
therapy,148,219,O
including,148,227,O
VASOTEC,148,237,O
.,148,245,O
Patients,149,0,O
on,149,9,O
diuretics,149,12,O
and,149,22,O
especially,149,26,O
those,149,37,O
in,149,43,O
whom,149,46,O
diuretic,149,51,O
therapy,149,60,O
was,149,68,O
recently,149,72,O
instituted,149,81,O
",",149,92,O
may,149,94,O
occasionally,149,98,O
experience,149,111,O
an,149,122,O
excessive,149,125,O
reduction,149,135,B-SpecificInteraction
of,149,135,I-SpecificInteraction
blood,149,135,I-SpecificInteraction
pressure,149,135,I-SpecificInteraction
after,149,163,O
initiation,149,169,O
of,149,180,O
therapy,149,183,O
with,149,191,O
enalapril,149,196,O
.,149,206,O
Potassium-sparing,150,0,O
agents,150,18,O
should,150,25,O
generally,150,32,O
not,150,42,O
be,150,46,O
used,150,49,O
in,150,54,O
patients,150,57,O
with,150,66,O
heart,150,71,O
failure,150,77,O
receiving,150,85,O
VASOTEC,150,95,O
.,150,103,O
Risk,151,0,O
factors,151,5,O
for,151,13,O
the,151,17,O
development,151,21,O
of,151,33,O
hyperkalemia,151,36,B-SpecificInteraction
include,151,49,O
renal,151,57,O
insufficiency,151,63,O
",",151,77,O
diabetes,151,79,O
mellitus,151,88,O
",",151,97,O
and,151,99,O
the,151,103,O
concomitant,151,107,O
use,151,119,O
of,151,123,O
potassium-sparing,151,126,O
diuretics,151,144,O
",",151,154,O
potassium,151,156,O
supplements,151,166,O
and/or,151,178,O
potassium-containing,151,185,O
salt,151,206,O
substitutes,151,211,O
",",151,223,O
which,151,225,O
should,151,231,O
be,151,238,O
used,151,241,O
cautiously,151,246,O
",",151,257,O
if,151,259,O
at,151,262,O
all,151,265,O
",",151,269,O
with,151,271,O
VASOTEC,151,276,O
(,151,284,O
see,151,286,O
Drug,151,290,O
Interactions,151,295,O
),151,308,O
.,151,310,O
Risk,151,0,O
factors,151,5,O
for,151,13,O
the,151,17,O
development,151,21,O
of,151,33,O
hyperkalemia,151,36,B-SpecificInteraction
include,151,49,O
renal,151,57,O
insufficiency,151,63,O
",",151,77,O
diabetes,151,79,O
mellitus,151,88,O
",",151,97,O
and,151,99,O
the,151,103,O
concomitant,151,107,O
use,151,119,O
of,151,123,O
potassium-sparing,151,126,O
diuretics,151,144,O
",",151,154,O
potassium,151,156,O
supplements,151,166,O
and/or,151,178,O
potassium-containing,151,185,O
salt,151,206,O
substitutes,151,211,O
",",151,223,O
which,151,225,O
should,151,231,O
be,151,238,O
used,151,241,O
cautiously,151,246,O
",",151,257,O
if,151,259,O
at,151,262,O
all,151,265,O
",",151,269,O
with,151,271,O
VASOTEC,151,276,O
(,151,284,O
see,151,286,O
Drug,151,290,O
Interactions,151,295,O
),151,308,O
.,151,310,O
Risk,151,0,O
factors,151,5,O
for,151,13,O
the,151,17,O
development,151,21,O
of,151,33,O
hyperkalemia,151,36,B-SpecificInteraction
include,151,49,O
renal,151,57,O
insufficiency,151,63,O
",",151,77,O
diabetes,151,79,O
mellitus,151,88,O
",",151,97,O
and,151,99,O
the,151,103,O
concomitant,151,107,O
use,151,119,O
of,151,123,O
potassium-sparing,151,126,O
diuretics,151,144,O
",",151,154,O
potassium,151,156,O
supplements,151,166,O
and/or,151,178,O
potassium-containing,151,185,O
salt,151,206,O
substitutes,151,211,O
",",151,223,O
which,151,225,O
should,151,231,O
be,151,238,O
used,151,241,O
cautiously,151,246,O
",",151,257,O
if,151,259,O
at,151,262,O
all,151,265,O
",",151,269,O
with,151,271,O
VASOTEC,151,276,O
(,151,284,O
see,151,286,O
Drug,151,290,O
Interactions,151,295,O
),151,308,O
.,151,310,O
Some,152,0,O
patients,152,5,O
with,152,14,O
hypertension,152,19,O
or,152,32,O
heart,152,35,O
failure,152,41,O
with,152,49,O
no,152,54,O
apparent,152,57,O
pre-existing,152,66,O
renal,152,79,O
vascular,152,85,O
disease,152,94,O
have,152,102,O
developed,152,107,O
increases,152,117,O
in,152,127,O
blood,152,130,O
urea,152,136,O
and,152,141,O
serum,152,145,O
creatinine,152,151,O
",",152,162,O
usually,152,164,O
minor,152,172,O
and,152,178,O
transient,152,182,O
",",152,192,O
especially,152,194,O
when,152,205,O
VASOTEC,152,210,O
has,152,218,O
been,152,222,O
given,152,227,O
concomitantly,152,233,O
with,152,247,O
a,152,252,O
diuretic,152,254,O
.,152,263,O
The,153,0,O
antihypertensive,153,4,O
effect,153,21,O
of,153,28,O
VASOTEC,153,31,O
is,153,39,O
augmented,153,42,O
by,153,52,O
antihypertensive,153,55,O
agents,153,72,O
that,153,79,O
cause,153,84,O
renin,153,90,O
release,153,96,O
(,153,104,O
e.g.,153,106,O
",",153,111,O
diuretics,153,113,O
),153,123,O
.,153,125,O
The,153,0,O
antihypertensive,153,4,O
effect,153,21,O
of,153,28,O
VASOTEC,153,31,O
is,153,39,O
augmented,153,42,O
by,153,52,O
antihypertensive,153,55,O
agents,153,72,O
that,153,79,O
cause,153,84,O
renin,153,90,O
release,153,96,O
(,153,104,O
e.g.,153,106,O
",",153,111,O
diuretics,153,113,O
),153,123,O
.,153,125,O
The,154,0,O
possibility,154,4,O
of,154,16,O
hypotensive,154,19,B-SpecificInteraction
effects,154,19,I-SpecificInteraction
with,154,39,O
enalapril,154,44,O
can,154,54,O
be,154,58,O
minimized,154,61,O
by,154,71,O
either,154,74,O
discontinuing,154,81,O
the,154,95,O
diuretic,154,99,O
or,154,108,O
increasing,154,111,O
the,154,122,O
salt,154,126,O
intake,154,131,O
prior,154,138,O
to,154,144,O
initiation,154,147,O
of,154,158,O
treatment,154,161,O
with,154,171,O
enalapril,154,176,O
.,154,186,O
VASOTEC,155,0,O
attenuates,155,8,B-SpecificInteraction
potassium,155,8,I-SpecificInteraction
loss,155,8,I-SpecificInteraction
caused,155,34,O
by,155,41,O
thiazide-type,155,44,O
diuretics,155,58,O
.,155,68,O
VASOTEC,156,0,O
has,156,8,O
been,156,12,O
used,156,17,O
concomitantly,156,22,O
with,156,36,O
beta,156,41,O
adrenergic-blocking,156,46,O
agents,156,66,O
",",156,73,O
methyldopa,156,75,O
",",156,86,O
nitrates,156,88,O
",",156,97,O
calcium-blocking,156,99,O
agents,156,116,O
",",156,123,O
hydralazine,156,125,O
",",156,137,O
prazosin,156,139,O
and,156,148,O
digoxin,156,152,O
without,156,160,O
evidence,156,168,O
of,156,177,O
clinically,156,180,O
significant,156,191,O
adverse,156,203,O
interactions,156,211,O
.,156,224,O
Acetylsalicylic,417,0,O
acid,417,16,O
did,417,21,O
not,417,25,O
alter,417,29,O
the,417,35,O
clearance,417,39,O
(,417,49,O
pharmacokinetics,417,51,O
),417,68,O
of,417,70,O
iloprost,417,73,O
.,417,82,O
Although,418,0,O
clinical,418,9,O
studies,418,18,O
have,418,26,O
not,418,31,O
been,418,35,O
conducted,418,40,O
with,418,50,O
Ventavis,418,55,O
(,418,64,O
inhaled,418,65,O
iloprost,418,73,O
),418,81,O
",",418,82,O
in,418,84,O
vitro,418,87,O
studies,418,93,O
of,418,101,O
iloprost,418,104,O
indicate,418,113,O
that,418,122,O
no,418,127,O
relevant,418,130,O
inhibition,418,139,O
of,418,150,O
cytochrome,418,153,O
P450,418,164,O
drug,418,169,O
metabolism,418,174,O
would,418,185,O
be,418,191,O
expected,418,194,O
.,418,202,O
During,419,0,O
clinical,419,7,O
trials,419,16,O
",",419,23,O
iloprost,419,25,O
was,419,34,O
used,419,38,O
concurrently,419,43,O
with,419,56,O
anticoagulants,419,61,O
",",419,76,O
diuretics,419,78,O
",",419,88,O
cardiac,419,90,O
glycosides,419,98,O
",",419,109,O
calcium,419,111,O
channel,419,119,O
blockers,419,127,O
",",419,136,O
analgesics,419,138,O
",",419,149,O
antipyretics,419,151,O
",",419,164,O
nonsteroidal,419,166,O
anti-inflammatory,419,179,O
drugs,419,197,O
",",419,203,O
corticosteroids,419,205,O
",",419,221,O
and,419,223,O
other,419,227,O
medications,419,233,O
.,419,245,O
However,420,0,O
",",420,8,O
Ventavis,420,10,O
has,420,19,O
the,420,23,O
potential,420,27,O
to,420,37,O
increase,420,40,B-SpecificInteraction
the,420,40,I-SpecificInteraction
hypotensive,420,40,I-SpecificInteraction
effect,420,40,I-SpecificInteraction
of,420,72,O
vasodilators,420,75,O
and,420,88,O
antihypertensive,420,92,O
agents,420,109,O
.,420,116,O
However,420,0,O
",",420,8,O
Ventavis,420,10,O
has,420,19,O
the,420,23,O
potential,420,27,O
to,420,37,O
increase,420,40,B-SpecificInteraction
the,420,40,I-SpecificInteraction
hypotensive,420,40,I-SpecificInteraction
effect,420,40,I-SpecificInteraction
of,420,72,O
vasodilators,420,75,O
and,420,88,O
antihypertensive,420,92,O
agents,420,109,O
.,420,116,O
In,421,0,O
studies,421,3,O
in,421,11,O
normal,421,14,O
subjects,421,21,O
",",421,30,O
there,421,32,O
was,421,38,O
no,421,42,O
pharmacodynamic,421,45,O
interaction,421,61,O
between,421,73,O
intravenous,421,81,O
iloprost,421,93,O
and,421,102,O
either,421,106,O
nifedipine,421,113,O
",",421,124,O
diltiazem,421,126,O
",",421,136,O
or,421,138,O
captopril,421,141,O
.,421,151,O
Intravenous,422,0,O
infusion,422,12,O
of,422,21,O
iloprost,422,24,O
had,422,33,O
no,422,37,O
effect,422,40,O
on,422,47,O
the,422,50,O
pharmacokinetics,422,54,O
of,422,71,O
digoxin,422,74,O
.,422,81,O
Since,423,0,O
Ventavis,423,6,O
inhibits,423,15,O
platelet,423,24,O
function,423,33,O
",",423,42,O
there,423,44,O
is,423,50,O
a,423,53,O
potential,423,55,O
for,423,65,O
increased,423,69,O
risk,423,79,O
of,423,84,O
bleeding,423,87,B-SpecificInteraction
",",423,96,O
particularly,423,98,O
in,423,111,O
patients,423,114,O
maintained,423,123,O
on,423,134,O
anticoagulants,423,137,O
or,423,152,O
platelet,423,155,O
inhibitors,423,164,O
.,423,175,O
Since,423,0,O
Ventavis,423,6,O
inhibits,423,15,O
platelet,423,24,O
function,423,33,O
",",423,42,O
there,423,44,O
is,423,50,O
a,423,53,O
potential,423,55,O
for,423,65,O
increased,423,69,O
risk,423,79,O
of,423,84,O
bleeding,423,87,B-SpecificInteraction
",",423,96,O
particularly,423,98,O
in,423,111,O
patients,423,114,O
maintained,423,123,O
on,423,134,O
anticoagulants,423,137,O
or,423,152,O
platelet,423,155,O
inhibitors,423,164,O
.,423,175,O
There,424,0,O
is,424,6,O
a,424,9,O
potential,424,11,O
for,424,21,O
increased,424,25,O
risk,424,35,O
of,424,40,O
bleeding,424,43,B-SpecificInteraction
",",424,51,O
particularly,424,53,O
in,424,66,O
patients,424,69,O
maintained,424,78,O
on,424,89,O
anticoagulants,424,92,O
(,424,107,O
7.3,424,108,O
),424,111,O
.,424,112,O
Ventavis,425,0,O
has,425,9,O
the,425,13,O
potential,425,17,O
to,425,27,O
increase,425,30,B-SpecificInteraction
the,425,30,I-SpecificInteraction
hypotensive,425,30,I-SpecificInteraction
effect,425,30,I-SpecificInteraction
of,425,62,O
vasodilators,425,65,O
and,425,78,O
antihypertensive,425,82,O
agents,425,99,O
(,425,106,O
7.2,425,108,O
),425,112,O
.,425,114,O
Ventavis,425,0,O
has,425,9,O
the,425,13,O
potential,425,17,O
to,425,27,O
increase,425,30,B-SpecificInteraction
the,425,30,I-SpecificInteraction
hypotensive,425,30,I-SpecificInteraction
effect,425,30,I-SpecificInteraction
of,425,62,O
vasodilators,425,65,O
and,425,78,O
antihypertensive,425,82,O
agents,425,99,O
(,425,106,O
7.2,425,108,O
),425,112,O
.,425,114,O
Epidural,36,0,O
or,36,9,O
spinal,36,12,O
hematomas,36,19,O
have,36,29,O
occurred,36,34,O
in,36,43,O
patients,36,46,O
treated,36,55,O
with,36,63,O
XARELTO,36,68,O
who,36,76,O
are,36,80,O
receiving,36,84,O
neuraxial,36,94,O
anesthesia,36,104,O
or,36,115,O
undergoing,36,118,O
spinal,36,129,O
puncture,36,136,O
.,36,145,O
Premature,37,0,O
discontinuation,37,10,O
of,37,26,O
any,37,29,O
oral,37,33,O
anticoagulant,37,38,O
",",37,52,O
including,37,54,O
XARELTO,37,64,O
",",37,72,O
increases,37,74,O
the,37,84,O
risk,37,88,O
of,37,93,O
thrombotic,37,96,O
events,37,107,O
.,37,114,O
use,38,0,O
of,38,4,O
indwelling,38,7,O
epiduralcatheters,38,18,O
.,38,36,O
concomitant,38,38,O
use,38,50,O
of,38,54,O
other,38,57,O
drugs,38,63,O
that,38,69,O
affect,38,74,O
hemostasis,38,81,O
",",38,92,O
such,38,94,O
as,38,99,O
nnon-steroidal,38,102,O
anti-inflammatory,38,117,O
drugs,38,135,O
(,38,141,O
NSAIDs,38,143,O
),38,150,O
",",38,152,O
platelet,38,154,O
inhibitors,38,163,O
",",38,174,O
other,38,176,O
anticoagulants,38,182,O
.,38,197,O
a,38,199,O
history,38,201,O
of,38,209,O
traumatic,38,212,O
or,38,222,O
repeated,38,225,O
epidural,38,234,O
or,38,243,O
spinal,38,246,O
punctures,38,253,O
.,38,263,O
a,38,265,O
history,38,267,O
of,38,275,O
spinal,38,278,O
deformity,38,285,O
or,38,295,O
spinal,38,298,O
surgery,38,305,O
.,38,313,O
optimal,38,315,O
timing,38,323,O
between,38,330,O
the,38,338,O
administration,38,342,O
of,38,357,O
XXARELTOand,38,360,O
neuraxial,38,372,O
procedures,38,382,O
is,38,393,O
not,38,396,O
known,38,400,O
.,38,406,O
see,38,408,O
Warnings,38,412,O
and,38,421,O
Precautions,38,425,O
(,38,437,O
5.2,38,439,O
",",38,443,O
5.3,38,445,O
),38,449,O
and,38,451,O
Adverse,38,455,O
Reactions,38,463,O
(,38,473,O
6.2,38,475,O
),38,479,O
.,38,481,O
For,39,0,O
unfractionated,39,4,O
heparin,39,19,O
being,39,27,O
administered,39,33,O
by,39,46,O
continuous,39,49,O
infusion,39,60,O
",",39,69,O
stop,39,71,O
the,39,76,O
infusion,39,80,O
and,39,89,O
start,39,93,O
XARELTO,39,99,O
at,39,107,O
the,39,110,O
same,39,114,O
time,39,119,O
.,39,124,O
One,40,0,O
approach,40,4,O
is,40,13,O
to,40,16,O
discontinue,40,19,O
XARELTO,40,31,O
and,40,39,O
begin,40,43,O
both,40,49,O
a,40,54,O
parenteral,40,56,O
anticoagulant,40,67,O
and,40,81,O
warfarin,40,85,O
at,40,94,O
the,40,97,O
time,40,101,O
the,40,106,O
next,40,110,O
dose,40,115,O
of,40,120,O
XARELTO,40,123,O
would,40,131,O
have,40,137,O
been,40,142,O
taken,40,147,O
.,40,153,O
Switching,41,0,O
from,41,10,O
Anticoagulants,41,15,O
other,41,30,O
than,41,36,O
Warfarin,41,41,O
to,41,50,O
XARELTO,41,53,O
-,41,61,O
For,41,63,O
patients,41,67,O
currently,41,76,O
receiving,41,86,O
an,41,96,O
anticoagulant,41,99,O
other,41,113,O
than,41,119,O
warfarin,41,124,O
",",41,133,O
start,41,135,O
XARELTO,41,141,O
0,41,149,O
to,41,151,O
2,41,154,O
hours,41,156,O
prior,41,162,O
to,41,168,O
the,41,171,O
next,41,175,O
scheduled,41,180,O
evening,41,190,O
administration,41,198,O
of,41,213,O
the,41,216,O
drug,41,220,O
(,41,225,O
e.g.,41,227,O
",",41,232,O
low,41,234,O
molecular,41,238,O
weight,41,248,O
heparin,41,255,O
or,41,263,O
non-warfarin,41,266,O
oral,41,279,O
anticoagulant,41,284,O
),41,298,O
and,41,300,O
omit,41,304,O
administration,41,309,O
of,41,324,O
the,41,327,O
other,41,331,O
anticoagulant,41,337,O
.,41,351,O
Switching,42,0,O
from,42,10,O
Warfarin,42,15,O
to,42,24,O
XARELTO,42,27,O
-,42,35,O
When,42,37,O
switching,42,42,O
patients,42,52,O
from,42,61,O
warfarin,42,66,O
to,42,75,O
XARELTO,42,78,O
",",42,86,O
discontinue,42,88,O
warfarin,42,100,O
and,42,109,O
start,42,113,O
XARELTO,42,119,O
as,42,127,O
soon,42,130,O
as,42,135,O
the,42,138,O
International,42,142,O
Normalized,42,156,O
Ratio,42,167,O
(,42,173,O
INR,42,175,O
),42,179,O
is,42,181,O
below,42,184,O
3.0,42,190,O
to,42,194,O
avoid,42,197,O
periods,42,203,O
of,42,211,O
inadequate,42,214,O
anticoagulation,42,225,O
.,42,241,O
Switching,43,0,O
from,43,10,O
XARELTO,43,15,O
to,43,23,O
Anticoagulants,43,26,O
other,43,41,O
than,43,47,O
Warfarin,43,52,O
-,43,61,O
For,43,63,O
patients,43,67,O
currently,43,76,O
taking,43,86,O
XARELTO,43,93,O
and,43,101,O
transitioning,43,105,O
to,43,119,O
an,43,122,O
anticoagulant,43,125,O
with,43,139,O
rapid,43,144,O
onset,43,150,O
",",43,156,O
discontinue,43,158,O
XARELTO,43,170,O
and,43,178,O
give,43,182,O
the,43,187,O
first,43,191,O
dose,43,197,O
of,43,202,O
the,43,205,O
other,43,209,O
anticoagulant,43,215,O
(,43,229,O
oral,43,231,O
or,43,236,O
parenteral,43,239,O
),43,250,O
at,43,252,O
the,43,255,O
time,43,259,O
that,43,264,O
the,43,269,O
next,43,273,O
XARELTO,43,278,O
dose,43,286,O
would,43,291,O
have,43,297,O
been,43,302,O
taken,43,307,O
see,43,313,O
Drug,43,317,O
Interactions,43,322,O
(,43,335,O
7.4,43,337,O
),43,341,O
.,43,343,O
Switching,44,0,O
from,44,10,O
XARELTO,44,15,O
to,44,23,O
Warfarin,44,26,O
-,44,35,O
No,44,37,O
clinical,44,40,O
trial,44,49,O
data,44,55,O
are,44,60,O
available,44,64,O
to,44,74,O
guide,44,77,O
converting,44,83,O
patients,44,94,O
from,44,103,O
XARELTO,44,108,O
to,44,116,O
warfarin,44,119,O
.,44,128,O
The,45,0,O
recommended,45,4,O
dose,45,16,O
of,45,21,O
XARELTO,45,24,O
for,45,32,O
the,45,36,O
reduction,45,40,O
in,45,50,O
the,45,53,O
risk,45,57,O
of,45,62,O
recurrence,45,65,O
of,45,76,O
DVT,45,79,O
and/or,45,83,O
PE,45,90,O
after,45,93,O
at,45,99,O
least,45,102,O
6,45,108,O
months,45,110,O
of,45,117,O
standard,45,120,O
anticoagulant,45,129,O
treatment,45,143,O
in,45,153,O
patients,45,156,O
at,45,165,O
continued,45,168,O
risk,45,178,O
of,45,183,O
DVT,45,186,O
and/or,45,190,O
PE,45,197,O
is,45,200,O
10,45,203,O
mg,45,206,O
taken,45,209,O
orally,45,215,O
once,45,222,O
daily,45,227,O
with,45,233,O
or,45,238,O
without,45,241,O
food,45,249,O
see,45,254,O
Clinical,45,258,O
Studies,45,267,O
(,45,275,O
14.3,45,277,O
),45,282,O
.,45,284,O
XARELTO,46,0,O
affects,46,8,O
INR,46,16,O
",",46,20,O
so,46,22,O
INR,46,25,O
measurements,46,29,O
made,46,42,O
during,46,47,O
coadministration,46,54,O
with,46,71,O
warfarin,46,76,O
may,46,85,O
not,46,89,O
be,46,93,O
useful,46,96,O
for,46,103,O
determining,46,107,O
the,46,119,O
appropriate,46,123,O
dose,46,135,O
of,46,140,O
warfarin,46,143,O
.,46,152,O
Although,47,0,O
clarithromycin,47,9,O
is,47,24,O
a,47,27,O
combined,47,29,O
P-gp,47,38,O
and,47,43,O
strong,47,47,O
CYP3A4,47,54,O
inhibitor,47,61,O
",",47,71,O
pharmacokinetic,47,73,O
data,47,89,O
suggests,47,94,O
that,47,103,O
no,47,108,O
precautions,47,111,O
are,47,123,O
necessary,47,127,O
with,47,137,O
concomitant,47,142,O
administration,47,154,O
with,47,169,O
XARELTO,47,174,O
as,47,182,O
the,47,185,O
change,47,189,O
in,47,196,O
exposure,47,199,O
is,47,208,O
unlikely,47,211,O
to,47,220,O
affect,47,223,O
the,47,230,O
bleeding,47,234,O
risk,47,243,O
see,47,248,O
Clinical,47,252,O
Pharmacology,47,261,O
(,47,274,O
12.3,47,276,O
),47,281,O
.,47,283,O
Avoid,48,0,O
concomitant,48,6,O
administration,48,18,O
of,48,33,O
XARELTO,48,36,O
with,48,44,O
known,48,49,O
combined,48,55,O
P-gp,48,64,O
and,48,69,O
strong,48,73,O
CYP3A4,48,80,O
inhibitors,48,87,O
(,48,98,O
e.g.,48,100,O
",",48,105,O
ketoconazole,48,107,O
and,48,120,O
ritonavir,48,124,O
),48,134,O
see,48,136,O
Warnings,48,140,O
and,48,149,O
Precautions,48,153,O
(,48,165,O
5.6,48,167,O
),48,171,O
and,48,173,O
Clinical,48,177,O
Pharmacology,48,186,O
(,48,199,O
12.3,48,201,O
),48,206,O
.,48,208,O
Avoid,48,0,O
concomitant,48,6,O
administration,48,18,O
of,48,33,O
XARELTO,48,36,O
with,48,44,O
known,48,49,O
combined,48,55,O
P-gp,48,64,O
and,48,69,O
strong,48,73,O
CYP3A4,48,80,O
inhibitors,48,87,O
(,48,98,O
e.g.,48,100,O
",",48,105,O
ketoconazole,48,107,O
and,48,120,O
ritonavir,48,124,O
),48,134,O
see,48,136,O
Warnings,48,140,O
and,48,149,O
Precautions,48,153,O
(,48,165,O
5.6,48,167,O
),48,171,O
and,48,173,O
Clinical,48,177,O
Pharmacology,48,186,O
(,48,199,O
12.3,48,201,O
),48,206,O
.,48,208,O
Avoid,48,0,O
concomitant,48,6,O
administration,48,18,O
of,48,33,O
XARELTO,48,36,O
with,48,44,O
known,48,49,O
combined,48,55,O
P-gp,48,64,O
and,48,69,O
strong,48,73,O
CYP3A4,48,80,O
inhibitors,48,87,O
(,48,98,O
e.g.,48,100,O
",",48,105,O
ketoconazole,48,107,O
and,48,120,O
ritonavir,48,124,O
),48,134,O
see,48,136,O
Warnings,48,140,O
and,48,149,O
Precautions,48,153,O
(,48,165,O
5.6,48,167,O
),48,171,O
and,48,173,O
Clinical,48,177,O
Pharmacology,48,186,O
(,48,199,O
12.3,48,201,O
),48,206,O
.,48,208,O
Avoid,48,0,O
concomitant,48,6,O
administration,48,18,O
of,48,33,O
XARELTO,48,36,O
with,48,44,O
known,48,49,O
combined,48,55,O
P-gp,48,64,O
and,48,69,O
strong,48,73,O
CYP3A4,48,80,O
inhibitors,48,87,O
(,48,98,O
e.g.,48,100,O
",",48,105,O
ketoconazole,48,107,O
and,48,120,O
ritonavir,48,124,O
),48,134,O
see,48,136,O
Warnings,48,140,O
and,48,149,O
Precautions,48,153,O
(,48,165,O
5.6,48,167,O
),48,171,O
and,48,173,O
Clinical,48,177,O
Pharmacology,48,186,O
(,48,199,O
12.3,48,201,O
),48,206,O
.,48,208,O
Avoid,49,0,O
concomitant,49,6,O
use,49,18,O
of,49,22,O
XARELTO,49,25,O
with,49,33,O
drugs,49,38,O
that,49,44,O
are,49,49,O
combined,49,53,O
P-gp,49,62,O
and,49,67,O
strong,49,71,O
CYP3A4,49,78,O
inducers,49,85,O
(,49,94,O
e.g.,49,96,O
",",49,101,O
carbamazepine,49,103,O
",",49,117,O
phenytoin,49,119,O
",",49,129,O
rifampin,49,131,O
",",49,140,O
St.,49,142,O
John,49,148,O
's,49,153,O
wort,49,158,O
),49,163,O
see,49,165,O
Warnings,49,169,O
and,49,178,O
Precautions,49,182,O
(,49,194,O
5.6,49,196,O
),49,200,O
and,49,202,O
Clinical,49,206,O
Pharmacology,49,215,O
(,49,228,O
12.3,49,230,O
),49,235,O
.,49,237,O
Avoid,49,0,O
concomitant,49,6,O
use,49,18,O
of,49,22,O
XARELTO,49,25,O
with,49,33,O
drugs,49,38,O
that,49,44,O
are,49,49,O
combined,49,53,O
P-gp,49,62,O
and,49,67,O
strong,49,71,O
CYP3A4,49,78,O
inducers,49,85,O
(,49,94,O
e.g.,49,96,O
",",49,101,O
carbamazepine,49,103,O
",",49,117,O
phenytoin,49,119,O
",",49,129,O
rifampin,49,131,O
",",49,140,O
St.,49,142,O
John,49,148,O
's,49,153,O
wort,49,158,O
),49,163,O
see,49,165,O
Warnings,49,169,O
and,49,178,O
Precautions,49,182,O
(,49,194,O
5.6,49,196,O
),49,200,O
and,49,202,O
Clinical,49,206,O
Pharmacology,49,215,O
(,49,228,O
12.3,49,230,O
),49,235,O
.,49,237,O
Avoid,49,0,O
concomitant,49,6,O
use,49,18,O
of,49,22,O
XARELTO,49,25,O
with,49,33,O
drugs,49,38,O
that,49,44,O
are,49,49,O
combined,49,53,O
P-gp,49,62,O
and,49,67,O
strong,49,71,O
CYP3A4,49,78,O
inducers,49,85,O
(,49,94,O
e.g.,49,96,O
",",49,101,O
carbamazepine,49,103,O
",",49,117,O
phenytoin,49,119,O
",",49,129,O
rifampin,49,131,O
",",49,140,O
St.,49,142,O
John,49,148,O
's,49,153,O
wort,49,158,O
),49,163,O
see,49,165,O
Warnings,49,169,O
and,49,178,O
Precautions,49,182,O
(,49,194,O
5.6,49,196,O
),49,200,O
and,49,202,O
Clinical,49,206,O
Pharmacology,49,215,O
(,49,228,O
12.3,49,230,O
),49,235,O
.,49,237,O
Avoid,49,0,O
concomitant,49,6,O
use,49,18,O
of,49,22,O
XARELTO,49,25,O
with,49,33,O
drugs,49,38,O
that,49,44,O
are,49,49,O
combined,49,53,O
P-gp,49,62,O
and,49,67,O
strong,49,71,O
CYP3A4,49,78,O
inducers,49,85,O
(,49,94,O
e.g.,49,96,O
",",49,101,O
carbamazepine,49,103,O
",",49,117,O
phenytoin,49,119,O
",",49,129,O
rifampin,49,131,O
",",49,140,O
St.,49,142,O
John,49,148,O
's,49,153,O
wort,49,158,O
),49,163,O
see,49,165,O
Warnings,49,169,O
and,49,178,O
Precautions,49,182,O
(,49,194,O
5.6,49,196,O
),49,200,O
and,49,202,O
Clinical,49,206,O
Pharmacology,49,215,O
(,49,228,O
12.3,49,230,O
),49,235,O
.,49,237,O
Avoid,49,0,O
concomitant,49,6,O
use,49,18,O
of,49,22,O
XARELTO,49,25,O
with,49,33,O
drugs,49,38,O
that,49,44,O
are,49,49,O
combined,49,53,O
P-gp,49,62,O
and,49,67,O
strong,49,71,O
CYP3A4,49,78,O
inducers,49,85,O
(,49,94,O
e.g.,49,96,O
",",49,101,O
carbamazepine,49,103,O
",",49,117,O
phenytoin,49,119,O
",",49,129,O
rifampin,49,131,O
",",49,140,O
St.,49,142,O
John,49,148,O
's,49,153,O
wort,49,158,O
),49,163,O
see,49,165,O
Warnings,49,169,O
and,49,178,O
Precautions,49,182,O
(,49,194,O
5.6,49,196,O
),49,200,O
and,49,202,O
Clinical,49,206,O
Pharmacology,49,215,O
(,49,228,O
12.3,49,230,O
),49,235,O
.,49,237,O
Avoid,49,0,O
concomitant,49,6,O
use,49,18,O
of,49,22,O
XARELTO,49,25,O
with,49,33,O
drugs,49,38,O
that,49,44,O
are,49,49,O
combined,49,53,O
P-gp,49,62,O
and,49,67,O
strong,49,71,O
CYP3A4,49,78,O
inducers,49,85,O
(,49,94,O
e.g.,49,96,O
",",49,101,O
carbamazepine,49,103,O
",",49,117,O
phenytoin,49,119,O
",",49,129,O
rifampin,49,131,O
",",49,140,O
St.,49,142,O
John,49,148,O
's,49,153,O
wort,49,158,O
),49,163,O
see,49,165,O
Warnings,49,169,O
and,49,178,O
Precautions,49,182,O
(,49,194,O
5.6,49,196,O
),49,200,O
and,49,202,O
Clinical,49,206,O
Pharmacology,49,215,O
(,49,228,O
12.3,49,230,O
),49,235,O
.,49,237,O
Avoid,50,0,O
concurrent,50,6,O
use,50,17,O
of,50,21,O
XARELTO,50,24,O
with,50,32,O
other,50,37,O
anticoagulants,50,43,O
due,50,58,O
to,50,62,O
increased,50,65,B-SpecificInteraction
bleeding,50,65,I-SpecificInteraction
risk,50,65,I-SpecificInteraction
unless,50,89,O
benefit,50,96,O
outweighs,50,104,O
risk,50,114,O
.,50,119,O
Coadministration,51,0,O
of,51,17,O
enoxaparin,51,20,O
",",51,30,O
warfarin,51,32,O
",",51,40,O
aspirin,51,42,O
",",51,49,O
clopidogrel,51,51,O
and,51,63,O
chronic,51,67,O
NSAID,51,75,O
use,51,81,O
may,51,85,O
increase,51,89,O
the,51,98,O
risk,51,102,O
of,51,107,O
bleeding,51,110,B-SpecificInteraction
[,51,119,O
see,51,120,O
Clinical,51,124,O
Pharmacology,51,133,O
(,51,146,O
12.3,51,147,O
),51,151,O
],51,152,O
.,51,153,O
Coadministration,51,0,O
of,51,17,O
enoxaparin,51,20,O
",",51,30,O
warfarin,51,32,O
",",51,40,O
aspirin,51,42,O
",",51,49,O
clopidogrel,51,51,O
and,51,63,O
chronic,51,67,O
NSAID,51,75,O
use,51,81,O
may,51,85,O
increase,51,89,O
the,51,98,O
risk,51,102,O
of,51,107,O
bleeding,51,110,B-SpecificInteraction
[,51,119,O
see,51,120,O
Clinical,51,124,O
Pharmacology,51,133,O
(,51,146,O
12.3,51,147,O
),51,151,O
],51,152,O
.,51,153,O
Coadministration,51,0,O
of,51,17,O
enoxaparin,51,20,O
",",51,30,O
warfarin,51,32,O
",",51,40,O
aspirin,51,42,O
",",51,49,O
clopidogrel,51,51,O
and,51,63,O
chronic,51,67,O
NSAID,51,75,O
use,51,81,O
may,51,85,O
increase,51,89,O
the,51,98,O
risk,51,102,O
of,51,107,O
bleeding,51,110,B-SpecificInteraction
[,51,119,O
see,51,120,O
Clinical,51,124,O
Pharmacology,51,133,O
(,51,146,O
12.3,51,147,O
),51,151,O
],51,152,O
.,51,153,O
Coadministration,51,0,O
of,51,17,O
enoxaparin,51,20,O
",",51,30,O
warfarin,51,32,O
",",51,40,O
aspirin,51,42,O
",",51,49,O
clopidogrel,51,51,O
and,51,63,O
chronic,51,67,O
NSAID,51,75,O
use,51,81,O
may,51,85,O
increase,51,89,O
the,51,98,O
risk,51,102,O
of,51,107,O
bleeding,51,110,B-SpecificInteraction
[,51,119,O
see,51,120,O
Clinical,51,124,O
Pharmacology,51,133,O
(,51,146,O
12.3,51,147,O
),51,151,O
],51,152,O
.,51,153,O
Coadministration,51,0,O
of,51,17,O
enoxaparin,51,20,O
",",51,30,O
warfarin,51,32,O
",",51,40,O
aspirin,51,42,O
",",51,49,O
clopidogrel,51,51,O
and,51,63,O
chronic,51,67,O
NSAID,51,75,O
use,51,81,O
may,51,85,O
increase,51,89,O
the,51,98,O
risk,51,102,O
of,51,107,O
bleeding,51,110,B-SpecificInteraction
[,51,119,O
see,51,120,O
Clinical,51,124,O
Pharmacology,51,133,O
(,51,146,O
12.3,51,147,O
),51,151,O
],51,152,O
.,51,153,O
Combined,52,0,O
P-gp,52,9,O
and,52,14,O
strong,52,18,O
CYP3A4,52,25,O
inducers,52,32,O
decrease,52,41,O
exposure,52,50,O
to,52,59,O
rivaroxaban,52,62,O
and,52,74,O
may,52,78,O
increase,52,82,O
the,52,91,O
risk,52,95,O
of,52,100,O
thromboembolic,52,103,B-SpecificInteraction
events,52,103,I-SpecificInteraction
.,52,125,O
Combined,52,0,O
P-gp,52,9,O
and,52,14,O
strong,52,18,O
CYP3A4,52,25,O
inducers,52,32,O
decrease,52,41,O
exposure,52,50,O
to,52,59,O
rivaroxaban,52,62,O
and,52,74,O
may,52,78,O
increase,52,82,O
the,52,91,O
risk,52,95,O
of,52,100,O
thromboembolic,52,103,B-SpecificInteraction
events,52,103,I-SpecificInteraction
.,52,125,O
Combined,52,0,O
P-gp,52,9,O
and,52,14,O
strong,52,18,O
CYP3A4,52,25,O
inducers,52,32,O
decrease,52,41,O
exposure,52,50,O
to,52,59,O
rivaroxaban,52,62,O
and,52,74,O
may,52,78,O
increase,52,82,O
the,52,91,O
risk,52,95,O
of,52,100,O
thromboembolic,52,103,B-SpecificInteraction
events,52,103,I-SpecificInteraction
.,52,125,O
Combined,52,0,O
P-gp,52,9,O
and,52,14,O
strong,52,18,O
CYP3A4,52,25,O
inducers,52,32,O
decrease,52,41,O
exposure,52,50,O
to,52,59,O
rivaroxaban,52,62,O
and,52,74,O
may,52,78,O
increase,52,82,O
the,52,91,O
risk,52,95,O
of,52,100,O
thromboembolic,52,103,B-SpecificInteraction
events,52,103,I-SpecificInteraction
.,52,125,O
Combined,53,0,O
P-gp,53,9,O
and,53,14,O
strong,53,18,O
CYP3A4,53,25,O
inhibitors,53,32,O
and,53,43,O
inducers,53,47,O
:,53,55,O
Avoid,53,57,O
concomitant,53,63,O
use,53,75,O
(,53,79,O
7.2,53,80,O
",",53,83,O
7.3,53,85,O
),53,88,O
Anticoagulants,53,90,O
:,53,104,O
Avoid,53,106,O
concomitant,53,112,O
use,53,124,O
(,53,128,O
7.4,53,129,O
),53,132,O
Rivaroxaban,53,134,O
is,53,146,O
a,53,149,O
substrate,53,151,O
of,53,161,O
CYP3A4/5,53,164,O
",",53,172,O
CYP2J2,53,174,O
",",53,180,O
and,53,182,O
the,53,186,O
P-gp,53,190,O
and,53,195,O
ATP-binding,53,199,O
cassette,53,211,O
G2,53,220,O
(,53,223,O
ABCG2,53,224,O
),53,229,O
transporters,53,231,O
.,53,243,O
Combined,53,0,O
P-gp,53,9,O
and,53,14,O
strong,53,18,O
CYP3A4,53,25,O
inhibitors,53,32,O
and,53,43,O
inducers,53,47,O
:,53,55,O
Avoid,53,57,O
concomitant,53,63,O
use,53,75,O
(,53,79,O
7.2,53,80,O
",",53,83,O
7.3,53,85,O
),53,88,O
Anticoagulants,53,90,O
:,53,104,O
Avoid,53,106,O
concomitant,53,112,O
use,53,124,O
(,53,128,O
7.4,53,129,O
),53,132,O
Rivaroxaban,53,134,O
is,53,146,O
a,53,149,O
substrate,53,151,O
of,53,161,O
CYP3A4/5,53,164,O
",",53,172,O
CYP2J2,53,174,O
",",53,180,O
and,53,182,O
the,53,186,O
P-gp,53,190,O
and,53,195,O
ATP-binding,53,199,O
cassette,53,211,O
G2,53,220,O
(,53,223,O
ABCG2,53,224,O
),53,229,O
transporters,53,231,O
.,53,243,O
Combined,53,0,O
P-gp,53,9,O
and,53,14,O
strong,53,18,O
CYP3A4,53,25,O
inhibitors,53,32,O
and,53,43,O
inducers,53,47,O
:,53,55,O
Avoid,53,57,O
concomitant,53,63,O
use,53,75,O
(,53,79,O
7.2,53,80,O
",",53,83,O
7.3,53,85,O
),53,88,O
Anticoagulants,53,90,O
:,53,104,O
Avoid,53,106,O
concomitant,53,112,O
use,53,124,O
(,53,128,O
7.4,53,129,O
),53,132,O
Rivaroxaban,53,134,O
is,53,146,O
a,53,149,O
substrate,53,151,O
of,53,161,O
CYP3A4/5,53,164,O
",",53,172,O
CYP2J2,53,174,O
",",53,180,O
and,53,182,O
the,53,186,O
P-gp,53,190,O
and,53,195,O
ATP-binding,53,199,O
cassette,53,211,O
G2,53,220,O
(,53,223,O
ABCG2,53,224,O
),53,229,O
transporters,53,231,O
.,53,243,O
Combined,53,0,O
P-gp,53,9,O
and,53,14,O
strong,53,18,O
CYP3A4,53,25,O
inhibitors,53,32,O
and,53,43,O
inducers,53,47,O
:,53,55,O
Avoid,53,57,O
concomitant,53,63,O
use,53,75,O
(,53,79,O
7.2,53,80,O
",",53,83,O
7.3,53,85,O
),53,88,O
Anticoagulants,53,90,O
:,53,104,O
Avoid,53,106,O
concomitant,53,112,O
use,53,124,O
(,53,128,O
7.4,53,129,O
),53,132,O
Rivaroxaban,53,134,O
is,53,146,O
a,53,149,O
substrate,53,151,O
of,53,161,O
CYP3A4/5,53,164,O
",",53,172,O
CYP2J2,53,174,O
",",53,180,O
and,53,182,O
the,53,186,O
P-gp,53,190,O
and,53,195,O
ATP-binding,53,199,O
cassette,53,211,O
G2,53,220,O
(,53,223,O
ABCG2,53,224,O
),53,229,O
transporters,53,231,O
.,53,243,O
Combined,53,0,O
P-gp,53,9,O
and,53,14,O
strong,53,18,O
CYP3A4,53,25,O
inhibitors,53,32,O
and,53,43,O
inducers,53,47,O
:,53,55,O
Avoid,53,57,O
concomitant,53,63,O
use,53,75,O
(,53,79,O
7.2,53,80,O
",",53,83,O
7.3,53,85,O
),53,88,O
Anticoagulants,53,90,O
:,53,104,O
Avoid,53,106,O
concomitant,53,112,O
use,53,124,O
(,53,128,O
7.4,53,129,O
),53,132,O
Rivaroxaban,53,134,O
is,53,146,O
a,53,149,O
substrate,53,151,O
of,53,161,O
CYP3A4/5,53,164,O
",",53,172,O
CYP2J2,53,174,O
",",53,180,O
and,53,182,O
the,53,186,O
P-gp,53,190,O
and,53,195,O
ATP-binding,53,199,O
cassette,53,211,O
G2,53,220,O
(,53,223,O
ABCG2,53,224,O
),53,229,O
transporters,53,231,O
.,53,243,O
Combined,54,0,O
P-gp,54,9,O
and,54,14,O
strong,54,18,O
CYP3A4,54,25,O
inhibitors,54,32,O
increase,54,43,O
exposure,54,52,O
to,54,61,O
rivaroxaban,54,64,O
and,54,76,O
may,54,80,O
increase,54,84,O
the,54,93,O
risk,54,97,O
of,54,102,O
bleeding,54,105,B-SpecificInteraction
.,54,114,O
Combined,54,0,O
P-gp,54,9,O
and,54,14,O
strong,54,18,O
CYP3A4,54,25,O
inhibitors,54,32,O
increase,54,43,O
exposure,54,52,O
to,54,61,O
rivaroxaban,54,64,O
and,54,76,O
may,54,80,O
increase,54,84,O
the,54,93,O
risk,54,97,O
of,54,102,O
bleeding,54,105,B-SpecificInteraction
.,54,114,O
Combined,54,0,O
P-gp,54,9,O
and,54,14,O
strong,54,18,O
CYP3A4,54,25,O
inhibitors,54,32,O
increase,54,43,O
exposure,54,52,O
to,54,61,O
rivaroxaban,54,64,O
and,54,76,O
may,54,80,O
increase,54,84,O
the,54,93,O
risk,54,97,O
of,54,102,O
bleeding,54,105,B-SpecificInteraction
.,54,114,O
Combined,54,0,O
P-gp,54,9,O
and,54,14,O
strong,54,18,O
CYP3A4,54,25,O
inhibitors,54,32,O
increase,54,43,O
exposure,54,52,O
to,54,61,O
rivaroxaban,54,64,O
and,54,76,O
may,54,80,O
increase,54,84,O
the,54,93,O
risk,54,97,O
of,54,102,O
bleeding,54,105,B-SpecificInteraction
.,54,114,O
Interaction,55,0,O
with,55,12,O
Combined,55,17,O
P-gp,55,26,O
and,55,31,O
Moderate,55,35,O
CYP3A4,55,44,O
Inhibitors,55,51,O
in,55,62,O
Patients,55,65,O
with,55,74,O
Renal,55,79,O
Impairment,55,85,O
XARELTO,55,96,O
should,55,104,O
not,55,111,O
be,55,115,O
used,55,118,O
in,55,123,O
patients,55,126,O
with,55,135,O
CrCl,55,140,O
15,55,145,O
to,55,148,O
<,55,151,O
80,55,152,O
mL/min,55,155,O
who,55,162,O
are,55,166,O
receiving,55,170,O
concomitant,55,180,O
combined,55,192,O
P-gp,55,201,O
and,55,206,O
moderate,55,210,O
CYP3A4,55,219,O
inhibitors,55,226,O
(,55,237,O
e.g.,55,238,O
",",55,242,O
erythromycin,55,244,O
),55,256,O
unless,55,258,O
the,55,265,O
potential,55,269,O
benefit,55,279,O
justifies,55,287,O
the,55,297,O
potential,55,301,O
risk,55,311,O
[,55,316,O
see,55,317,O
Warnings,55,321,O
and,55,330,O
Precautions,55,334,O
(,55,346,O
5.4,55,347,O
),55,350,O
and,55,352,O
Clinical,55,356,O
Pharmacology,55,365,O
(,55,378,O
12.3,55,379,O
),55,383,O
],55,384,O
.,55,385,O
Interaction,55,0,O
with,55,12,O
Combined,55,17,O
P-gp,55,26,O
and,55,31,O
Moderate,55,35,O
CYP3A4,55,44,O
Inhibitors,55,51,O
in,55,62,O
Patients,55,65,O
with,55,74,O
Renal,55,79,O
Impairment,55,85,O
XARELTO,55,96,O
should,55,104,O
not,55,111,O
be,55,115,O
used,55,118,O
in,55,123,O
patients,55,126,O
with,55,135,O
CrCl,55,140,O
15,55,145,O
to,55,148,O
<,55,151,O
80,55,152,O
mL/min,55,155,O
who,55,162,O
are,55,166,O
receiving,55,170,O
concomitant,55,180,O
combined,55,192,O
P-gp,55,201,O
and,55,206,O
moderate,55,210,O
CYP3A4,55,219,O
inhibitors,55,226,O
(,55,237,O
e.g.,55,238,O
",",55,242,O
erythromycin,55,244,O
),55,256,O
unless,55,258,O
the,55,265,O
potential,55,269,O
benefit,55,279,O
justifies,55,287,O
the,55,297,O
potential,55,301,O
risk,55,311,O
[,55,316,O
see,55,317,O
Warnings,55,321,O
and,55,330,O
Precautions,55,334,O
(,55,346,O
5.4,55,347,O
),55,350,O
and,55,352,O
Clinical,55,356,O
Pharmacology,55,365,O
(,55,378,O
12.3,55,379,O
),55,383,O
],55,384,O
.,55,385,O
Interaction,55,0,O
with,55,12,O
Combined,55,17,O
P-gp,55,26,O
and,55,31,O
Moderate,55,35,O
CYP3A4,55,44,O
Inhibitors,55,51,O
in,55,62,O
Patients,55,65,O
with,55,74,O
Renal,55,79,O
Impairment,55,85,O
XARELTO,55,96,O
should,55,104,O
not,55,111,O
be,55,115,O
used,55,118,O
in,55,123,O
patients,55,126,O
with,55,135,O
CrCl,55,140,O
15,55,145,O
to,55,148,O
<,55,151,O
80,55,152,O
mL/min,55,155,O
who,55,162,O
are,55,166,O
receiving,55,170,O
concomitant,55,180,O
combined,55,192,O
P-gp,55,201,O
and,55,206,O
moderate,55,210,O
CYP3A4,55,219,O
inhibitors,55,226,O
(,55,237,O
e.g.,55,238,O
",",55,242,O
erythromycin,55,244,O
),55,256,O
unless,55,258,O
the,55,265,O
potential,55,269,O
benefit,55,279,O
justifies,55,287,O
the,55,297,O
potential,55,301,O
risk,55,311,O
[,55,316,O
see,55,317,O
Warnings,55,321,O
and,55,330,O
Precautions,55,334,O
(,55,346,O
5.4,55,347,O
),55,350,O
and,55,352,O
Clinical,55,356,O
Pharmacology,55,365,O
(,55,378,O
12.3,55,379,O
),55,383,O
],55,384,O
.,55,385,O
Interaction,56,0,O
with,56,12,O
Combined,56,17,O
P-gp,56,26,O
and,56,31,O
Strong,56,35,O
CYP3A4,56,42,O
Inhibitors,56,49,O
Avoid,56,60,O
concomitant,56,66,O
administration,56,78,O
of,56,93,O
XARELTO,56,96,O
with,56,104,O
known,56,109,O
combined,56,115,O
P-gp,56,124,O
and,56,129,O
strong,56,133,O
CYP3A4,56,140,O
inhibitors,56,147,O
(,56,158,O
e.g.,56,159,O
",",56,163,O
ketoconazole,56,165,O
and,56,178,O
ritonavir,56,182,O
),56,191,O
[,56,193,O
see,56,194,O
Warnings,56,198,O
and,56,207,O
Precautions,56,211,O
(,56,223,O
5.6,56,224,O
),56,227,O
and,56,229,O
Clinical,56,233,O
Pharmacology,56,242,O
(,56,255,O
12.3,56,256,O
),56,260,O
],56,261,O
.,56,262,O
Interaction,56,0,O
with,56,12,O
Combined,56,17,O
P-gp,56,26,O
and,56,31,O
Strong,56,35,O
CYP3A4,56,42,O
Inhibitors,56,49,O
Avoid,56,60,O
concomitant,56,66,O
administration,56,78,O
of,56,93,O
XARELTO,56,96,O
with,56,104,O
known,56,109,O
combined,56,115,O
P-gp,56,124,O
and,56,129,O
strong,56,133,O
CYP3A4,56,140,O
inhibitors,56,147,O
(,56,158,O
e.g.,56,159,O
",",56,163,O
ketoconazole,56,165,O
and,56,178,O
ritonavir,56,182,O
),56,191,O
[,56,193,O
see,56,194,O
Warnings,56,198,O
and,56,207,O
Precautions,56,211,O
(,56,223,O
5.6,56,224,O
),56,227,O
and,56,229,O
Clinical,56,233,O
Pharmacology,56,242,O
(,56,255,O
12.3,56,256,O
),56,260,O
],56,261,O
.,56,262,O
Interaction,56,0,O
with,56,12,O
Combined,56,17,O
P-gp,56,26,O
and,56,31,O
Strong,56,35,O
CYP3A4,56,42,O
Inhibitors,56,49,O
Avoid,56,60,O
concomitant,56,66,O
administration,56,78,O
of,56,93,O
XARELTO,56,96,O
with,56,104,O
known,56,109,O
combined,56,115,O
P-gp,56,124,O
and,56,129,O
strong,56,133,O
CYP3A4,56,140,O
inhibitors,56,147,O
(,56,158,O
e.g.,56,159,O
",",56,163,O
ketoconazole,56,165,O
and,56,178,O
ritonavir,56,182,O
),56,191,O
[,56,193,O
see,56,194,O
Warnings,56,198,O
and,56,207,O
Precautions,56,211,O
(,56,223,O
5.6,56,224,O
),56,227,O
and,56,229,O
Clinical,56,233,O
Pharmacology,56,242,O
(,56,255,O
12.3,56,256,O
),56,260,O
],56,261,O
.,56,262,O
Interaction,56,0,O
with,56,12,O
Combined,56,17,O
P-gp,56,26,O
and,56,31,O
Strong,56,35,O
CYP3A4,56,42,O
Inhibitors,56,49,O
Avoid,56,60,O
concomitant,56,66,O
administration,56,78,O
of,56,93,O
XARELTO,56,96,O
with,56,104,O
known,56,109,O
combined,56,115,O
P-gp,56,124,O
and,56,129,O
strong,56,133,O
CYP3A4,56,140,O
inhibitors,56,147,O
(,56,158,O
e.g.,56,159,O
",",56,163,O
ketoconazole,56,165,O
and,56,178,O
ritonavir,56,182,O
),56,191,O
[,56,193,O
see,56,194,O
Warnings,56,198,O
and,56,207,O
Precautions,56,211,O
(,56,223,O
5.6,56,224,O
),56,227,O
and,56,229,O
Clinical,56,233,O
Pharmacology,56,242,O
(,56,255,O
12.3,56,256,O
),56,260,O
],56,261,O
.,56,262,O
Promptly,57,0,O
evaluate,57,9,O
any,57,18,O
signs,57,22,O
or,57,28,O
symptoms,57,31,O
of,57,40,O
blood,57,43,B-SpecificInteraction
loss,57,43,I-SpecificInteraction
if,57,54,O
patients,57,57,O
are,57,66,O
treated,57,70,O
concomitantly,57,78,O
with,57,92,O
aspirin,57,97,O
",",57,104,O
other,57,106,O
platelet,57,112,O
aggregation,57,121,O
inhibitors,57,133,O
",",57,143,O
or,57,145,O
NSAIDs,57,148,O
[,57,155,O
see,57,156,O
Warnings,57,160,O
and,57,169,O
Precautions,57,173,O
(,57,185,O
5.2,57,186,O
),57,189,O
],57,190,O
.,57,191,O
Promptly,57,0,O
evaluate,57,9,O
any,57,18,O
signs,57,22,O
or,57,28,O
symptoms,57,31,O
of,57,40,O
blood,57,43,B-SpecificInteraction
loss,57,43,I-SpecificInteraction
if,57,54,O
patients,57,57,O
are,57,66,O
treated,57,70,O
concomitantly,57,78,O
with,57,92,O
aspirin,57,97,O
",",57,104,O
other,57,106,O
platelet,57,112,O
aggregation,57,121,O
inhibitors,57,133,O
",",57,143,O
or,57,145,O
NSAIDs,57,148,O
[,57,155,O
see,57,156,O
Warnings,57,160,O
and,57,169,O
Precautions,57,173,O
(,57,185,O
5.2,57,186,O
),57,189,O
],57,190,O
.,57,191,O
Promptly,57,0,O
evaluate,57,9,O
any,57,18,O
signs,57,22,O
or,57,28,O
symptoms,57,31,O
of,57,40,O
blood,57,43,B-SpecificInteraction
loss,57,43,I-SpecificInteraction
if,57,54,O
patients,57,57,O
are,57,66,O
treated,57,70,O
concomitantly,57,78,O
with,57,92,O
aspirin,57,97,O
",",57,104,O
other,57,106,O
platelet,57,112,O
aggregation,57,121,O
inhibitors,57,133,O
",",57,143,O
or,57,145,O
NSAIDs,57,148,O
[,57,155,O
see,57,156,O
Warnings,57,160,O
and,57,169,O
Precautions,57,173,O
(,57,185,O
5.2,57,186,O
),57,189,O
],57,190,O
.,57,191,O
XARELTO,58,0,O
should,58,8,O
not,58,15,O
be,58,19,O
used,58,22,O
in,58,27,O
patients,58,30,O
with,58,39,O
CrCl,58,44,O
15,58,49,O
to,58,52,O
80,58,55,O
mL/min,58,58,O
who,58,65,O
are,58,69,O
receiving,58,73,O
concomitant,58,83,O
combined,58,95,O
P-gp,58,104,O
and,58,109,O
moderate,58,113,O
CYP3A4,58,122,O
inhibitors,58,129,O
(,58,140,O
e.g.,58,142,O
",",58,147,O
erythromycin,58,149,O
),58,162,O
unless,58,164,O
the,58,171,O
potential,58,175,O
benefit,58,185,O
justifies,58,193,O
the,58,203,O
potential,58,207,O
risk,58,217,O
see,58,222,O
Warnings,58,226,O
and,58,235,O
Precautions,58,239,O
(,58,251,O
5.4,58,253,O
),58,257,O
and,58,259,O
Clinical,58,263,O
Pharmacology,58,272,O
(,58,285,O
12.3,58,287,O
),58,292,O
.,58,294,O
XARELTO,58,0,O
should,58,8,O
not,58,15,O
be,58,19,O
used,58,22,O
in,58,27,O
patients,58,30,O
with,58,39,O
CrCl,58,44,O
15,58,49,O
to,58,52,O
80,58,55,O
mL/min,58,58,O
who,58,65,O
are,58,69,O
receiving,58,73,O
concomitant,58,83,O
combined,58,95,O
P-gp,58,104,O
and,58,109,O
moderate,58,113,O
CYP3A4,58,122,O
inhibitors,58,129,O
(,58,140,O
e.g.,58,142,O
",",58,147,O
erythromycin,58,149,O
),58,162,O
unless,58,164,O
the,58,171,O
potential,58,175,O
benefit,58,185,O
justifies,58,193,O
the,58,203,O
potential,58,207,O
risk,58,217,O
see,58,222,O
Warnings,58,226,O
and,58,235,O
Precautions,58,239,O
(,58,251,O
5.4,58,253,O
),58,257,O
and,58,259,O
Clinical,58,263,O
Pharmacology,58,272,O
(,58,285,O
12.3,58,287,O
),58,292,O
.,58,294,O
XARELTO,58,0,O
should,58,8,O
not,58,15,O
be,58,19,O
used,58,22,O
in,58,27,O
patients,58,30,O
with,58,39,O
CrCl,58,44,O
15,58,49,O
to,58,52,O
80,58,55,O
mL/min,58,58,O
who,58,65,O
are,58,69,O
receiving,58,73,O
concomitant,58,83,O
combined,58,95,O
P-gp,58,104,O
and,58,109,O
moderate,58,113,O
CYP3A4,58,122,O
inhibitors,58,129,O
(,58,140,O
e.g.,58,142,O
",",58,147,O
erythromycin,58,149,O
),58,162,O
unless,58,164,O
the,58,171,O
potential,58,175,O
benefit,58,185,O
justifies,58,193,O
the,58,203,O
potential,58,207,O
risk,58,217,O
see,58,222,O
Warnings,58,226,O
and,58,235,O
Precautions,58,239,O
(,58,251,O
5.4,58,253,O
),58,257,O
and,58,259,O
Clinical,58,263,O
Pharmacology,58,272,O
(,58,285,O
12.3,58,287,O
),58,292,O
.,58,294,O
A,59,0,O
specific,59,2,O
antidote,59,11,O
for,59,20,O
rivaroxaban,59,24,O
is,59,36,O
not,59,39,O
available,59,43,O
.,59,53,O
An,60,0,O
increased,60,3,O
rate,60,13,O
of,60,18,O
stroke,60,21,O
was,60,28,O
observed,60,32,O
during,60,41,O
the,60,48,O
transition,60,52,O
from,60,63,O
XARELTO,60,68,O
to,60,76,O
warfarin,60,79,O
in,60,88,O
clinical,60,91,O
trials,60,100,O
in,60,107,O
atrial,60,110,O
fibrillation,60,117,O
patients,60,130,O
.,60,139,O
Avoid,61,0,O
concomitant,61,6,O
use,61,18,O
of,61,22,O
XARELTO,61,25,O
with,61,33,O
drugs,61,38,O
that,61,44,O
are,61,49,O
known,61,53,O
combined,61,59,O
P-gp,61,68,O
and,61,73,O
strong,61,77,O
CYP3A4,61,84,O
inducers,61,91,O
see,61,100,O
Drug,61,104,O
Interactions,61,109,O
(,61,122,O
7.3,61,124,O
),61,128,O
.,61,130,O
Avoid,61,0,O
concomitant,61,6,O
use,61,18,O
of,61,22,O
XARELTO,61,25,O
with,61,33,O
drugs,61,38,O
that,61,44,O
are,61,49,O
known,61,53,O
combined,61,59,O
P-gp,61,68,O
and,61,73,O
strong,61,77,O
CYP3A4,61,84,O
inducers,61,91,O
see,61,100,O
Drug,61,104,O
Interactions,61,109,O
(,61,122,O
7.3,61,124,O
),61,128,O
.,61,130,O
Avoid,62,0,O
concomitant,62,6,O
use,62,18,O
of,62,22,O
XARELTO,62,25,O
with,62,33,O
known,62,38,O
combined,62,44,O
P-gp,62,53,O
and,62,58,O
strong,62,62,O
CYP3A4,62,69,O
inhibitors,62,76,O
see,62,87,O
Drug,62,91,O
Interactions,62,96,O
(,62,109,O
7.2,62,111,O
),62,115,O
.,62,117,O
Avoid,62,0,O
concomitant,62,6,O
use,62,18,O
of,62,22,O
XARELTO,62,25,O
with,62,33,O
known,62,38,O
combined,62,44,O
P-gp,62,53,O
and,62,58,O
strong,62,62,O
CYP3A4,62,69,O
inhibitors,62,76,O
see,62,87,O
Drug,62,91,O
Interactions,62,96,O
(,62,109,O
7.2,62,111,O
),62,115,O
.,62,117,O
Concomitant,63,0,O
use,63,12,O
of,63,16,O
drugs,63,19,O
that,63,25,O
are,63,30,O
known,63,34,O
combined,63,40,O
P-gp,63,49,O
and,63,54,O
strong,63,58,O
CYP3A4,63,65,O
inhibitors,63,72,O
increases,63,83,O
rivaroxaban,63,93,O
exposure,63,105,O
and,63,114,O
may,63,118,O
increase,63,122,O
bleeding,63,131,O
risk,63,140,O
see,63,145,O
Drug,63,149,O
Interactions,63,154,O
(,63,167,O
7.2,63,169,O
),63,173,O
.,63,175,O
Concomitant,63,0,O
use,63,12,O
of,63,16,O
drugs,63,19,O
that,63,25,O
are,63,30,O
known,63,34,O
combined,63,40,O
P-gp,63,49,O
and,63,54,O
strong,63,58,O
CYP3A4,63,65,O
inhibitors,63,72,O
increases,63,83,O
rivaroxaban,63,93,O
exposure,63,105,O
and,63,114,O
may,63,118,O
increase,63,122,O
bleeding,63,131,O
risk,63,140,O
see,63,145,O
Drug,63,149,O
Interactions,63,154,O
(,63,167,O
7.2,63,169,O
),63,173,O
.,63,175,O
Initiation,64,0,O
of,64,11,O
XARELTO,64,14,O
is,64,22,O
not,64,25,O
recommended,64,29,O
acutely,64,41,O
as,64,49,O
an,64,52,O
alternative,64,55,O
to,64,67,O
unfractionated,64,70,O
heparin,64,85,O
in,64,93,O
patients,64,96,O
with,64,105,O
pulmonary,64,110,O
embolism,64,120,O
who,64,129,O
present,64,133,O
with,64,141,O
hemodynamic,64,146,O
instability,64,158,O
or,64,170,O
who,64,173,O
may,64,177,O
receive,64,181,O
thrombolysis,64,189,O
or,64,202,O
pulmonary,64,205,O
embolectomy,64,215,O
.,64,227,O
Premature,65,0,O
discontinuation,65,10,O
of,65,26,O
any,65,29,O
oral,65,33,O
anticoagulant,65,38,O
",",65,52,O
including,65,54,O
XARELTO,65,64,O
",",65,72,O
in,65,74,O
the,65,77,O
absence,65,81,O
of,65,89,O
adequate,65,92,O
alternative,65,101,O
anticoagulation,65,113,O
increases,65,129,O
the,65,139,O
risk,65,143,O
of,65,148,O
thrombotic,65,151,O
events,65,162,O
.,65,169,O
Protamine,66,0,O
sulfate,66,10,O
and,66,18,O
vitamin,66,22,O
K,66,30,O
are,66,32,O
not,66,36,O
expected,66,40,O
to,66,49,O
affect,66,52,O
the,66,59,O
anticoagulant,66,63,O
activity,66,77,O
of,66,86,O
rivaroxaban,66,89,O
.,66,101,O
